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Stem	   cell	   derived	   endothelial	   cells	   have	   a	   growing	   number	   of	   applications	   in	   clinical	  
medicine	  and	  biomedical	  research	  and	  will	  be	  critical	  in	  any	  organ	  regeneration	  programme.	  
Endothelial	   cells	   can	   now	   be	   derived	   from	   a	   number	   of	   distinct	   stem	   cell	   populations	  
including	   embryonic	   stem	   cells,	   blood	   progenitors	   and	   induced	   pluripotent	   stem	   cells.	   In	  
order	   for	  stem	  cell	  derived	  endothelial	  cells	   to	  be	  used	  optimally	   it	   is	   important	   that	   they	  
are	  fully	  assessed	  for	  the	  cardinal	  characteristics	  of	  endothelial	  cells	  on	  mature	  vessels.	  	  
	  
With	  this	   in	  mind,	   in	  my	  thesis	   I	  have	  assessed	  the	  ability	  of	  stem	  cell	  derived	  endothelial	  
cells	   to	   display	   hallmarks	   of	   authentic	   endothelial	   cells	   from	   vessels	   including,	   alignment	  
under	   shear	   stress,	   responses	   to	   pathogen	   stimuli	   and	   vasoactive	   hormone	   release.	   My	  
group	  has	  previously	  shown	  that	  endothelial	  cells	  from	  human	  embryonic	  stem	  cells	  did	  not	  
respond	  to	  agonists	  of	  toll-­‐like	  receptor-­‐4	  (TLR4).	  TLR4	  is	  important	  to	  allow	  endothelial	  cells	  
to	  sense	   infection,	  but	   is	  also	  associated	  with	  cardiovascular	  disease.	   In	  my	  PhD,	   I	  showed	  
that,	  whilst	   these	  cells	  have	  no	  TLR4	   they	  have	  a	   fully	   functional	  NOD1	   receptor	  pathway	  
which	  allows	   the	  cells	   to	   sense	  Gram-­‐negative	  bacteria.	  This	  may	  be	   relevant	   to	   their	  use	  
therapeutically	   and	  allowed	  me	   to	   speculate	   that	   these	   cells	   are	   immune	   competent,	   but	  
through	  lack	  of	  TLR4	  might	  be	  protected	  from	  vascular	  inflammation.	  In	  order	  for	  stem	  cell	  
derived	  endothelial	   cells	   to	  be	  useful	   in	   in	   vitro	   assays	  however,	   it	   is	   important	   that	   they	  
express	  all	  the	  key	  hallmarks	  of	  endothelial	  cells	  from	  vessels.	  Endothelial	  cells	  grown	  from	  
blood	   progenitors	   or	   from	   induced	   pluripotent	   stem	   cells	   did	   have	   TLR4	   responses	   and	  
released	  vasoactive	  hormones	  at	  levels	  comparable	  to	  endothelial	  cells	  from	  vessels.	  
	  
In	  the	  later	  part	  of	  my	  PhD,	  I	  applied	  endothelial	  cells	  derived	  from	  blood	  progenitor	  cells	  to	  
key	   assays	   to	   study	   endothelial	   cell	   biology	   and	   pharmacology.	   This	   included	   an	   assay	   to	  
detect	   cytokine	   storm	   reactions	   to	   drugs,	   which	   currently	   limits	   the	   development	   of	  
biological	   drugs.	   This	   assay,	   employing	   cells	   derived	   from	  stem	  cells	   of	   individual	  patients	  
also	  has	  applications	  in	  personalised	  medicine.	  In	  my	  final	  chapter,	  I	  was	  able	  to	  grow	  BOEC	  
from	  a	  patient	  with	  a	  homozygous	  mutation	  that	  results	   in	   loss	  of	   function	  of	  the	  enzyme	  
cPLA2,	  which	   is	   thought	   to	   be	   critical	   to	   prostaglandin	   and	   prostacyclin	   release,	   and	   used	  
these	  cells	  to	  study	  this	  pathway.	  I	  showed	  that	  cPLA2α	  is	  the	  dominant	  isoform	  responsible	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for	  the	  release	  of	  prostacyclin	  from	  endothelial	  cells	  and	  provided	  a	  proof-­‐of-­‐concept	  that	  
BOEC	  can	  be	  used	  to	  phenotype	  patients.	  
	  
In	  summary,	  my	  thesis	   includes	  characterisation	  of	  stem	  cell	  derived	  endothelial	  cells,	  and	  
includes	  applications	  of	  adult	  progenitor	  derived	  cells	  in	  assays	  to	  study	  pharmacology	  and	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  culture.	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  derived	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   cell-­‐derived	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   from	   different	   stem	   cell-­‐derived	   endothelial	   cells	   versus	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(left)	   and	  human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   (right)	   in	   response	   to	   TLR4	   and	  
NOD1	  agonist	  
Figure	  4.5	  IL-­‐12p70	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐
EC)	  (left)	  and	  human	  umbilical	  vein	  endothelial	  cells	  (HUVEC)	  (right)	  in	  response	  to	  TLR4	  and	  
NOD1	  agonist	  
Figure	  4.6	  IL-­‐1β	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC)	  
(left)	   and	  human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   (right)	   in	   response	   to	   TLR4	   and	  
NOD1	  agonist	  
Figure	  4.7	  IL-­‐2	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC)	  




Figure	  4.8	  IL-­‐6	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  derived	  endothelial	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Figure	  4.10	  TLR4	  and	  NOD1	  expression	   in	  human	  embryonic	  stem	  cell	  derived	  endothelial	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   targeting	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  autologous	  
peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  on	  responses	  to	  pathogen	  associated	  molecular	  
patterns	  (PAMPs).	  
Figure	  5.2	  Response	  of	  same	  donor	  blood	  outgrowth	  endothelial	  cell	  (BOEC)	  and	  peripheral	  
blood	  mononuclear	  cell	  (PBMC)	  co-­‐culture	  assays	  to	  biologics.	  
Figure	  5.3	  Proliferative	  response	  of	  same	  donor	  blood	  outgrowth	  endothelial	  cell	  (BOEC)	  and	  
peripheral	  blood	  mononuclear	  cell	   (PBMC)	  co-­‐culture	  assays	  to	  TGN1412-­‐like	  anti-­‐CD28	  SA	  
(ANC28).	  
Figure	  5.4	  TNFα,	  CXCL8	  and	  IL-­‐2	  release	  from	  blood	  outgrowth	  endothelial	  cell	  (BOEC)	  and	  
peripheral	  blood	  mononuclear	   cell	   (PBMC)	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1.1 	  OVERVIEW	  
Endothelial	   cells	   line	   the	   surface	   of	   every	   vessel	   in	   the	   body.	   Through	   the	   release	   of	  
vasoactive	   mediators	   and	   other	   important	   functions,	   including	   sensing	   of	   pathogens,	  
endothelial	  cells	  are	  important	  for	  the	  health	  of	  almost	  every	  organ	  in	  the	  body.	  In	  line	  with	  
this,	  endothelial	  cells	  derived	  from	  stem	  cells	  have	  been	  considered	  as	  therapies	  and	  tools	  
for	  cardiovascular	  research,	  and	  will	  be	  important	  to	  integrate	  organs	  engineered	  from	  stem	  
cells	   with	   host	   vasculature.	   In	   this	   introduction,	   I	   describe	   these	   key	   endothelial	   cell	  
functions	   in	  detail	  and	  develop	  the	   idea	  of	  stem	  cell	  derived	  endothelial	  cells	  as	   therapies	  
and	   as	   in	   vitro	   tools	   in	   pharmacological	   bioassays	   to	   study	   cardiovascular	   pathways	   and	  
develop	  and	  test	  new	  therapies.	  
	  
1.2	  ENDOTHELIAL	  CELL	  FUNCTION	  
Endothelial	   cells	   are	   critical	   regulators	  of	   the	   cardiovascular	   system.	  Endothelial	   cells,	   and	  
indeed	   the	   term	   endothelium,	   were	   first	   introduced	   in	   the	   1800s.	   Lord	   Florey	   described	  
endothelial	   cells	   as	   ‘a	   sheet	   of	   nucleated	   cellophane’	   wrap	   for	   the	   blood	   vessel	   (Florey,	  
1966).	   This	   view	  changed	  dramatically	   in	  1973	  with	   the	   isolation	  of	  endothelial	   cells	   from	  
human	  umbilical	  vein,	  which	  formed	  the	  basis	  of	  two	  seminal	  research	  papers	  by	  Jaffe	  and	  
co-­‐workers	   (Jaffe	   et	   al.,	   1973a;	   Jaffe	   et	   al.,	   1973b).	   The	   anatomical	   location	   of	   the	  
endothelial	  cell	  layer	  in	  vessels	  as	  well	  as	  the	  appearance	  of	  these	  cells	  in	  culture	  is	  shown	  in	  
Figure	   1.1.	   The	   ensuing	   study	   of	   endothelial	   cells	   from	   human	   umbilical	   vein	   (Nachman,	  
2012)	  as	  well	  as	  other	  sources	  has	  meant	  that	  we	  now	  know	  endothelial	  cells	  represent	  a	  






Figure	  1.1	  (A)	  Cross	  section	  of	  structure	  of	  human	  arteriole.	  (B)	  Cobblestone	  morphology	  of	  
human	  umbilical	  vein	  endothelial	  cells	   (HUVEC)	   in	  culture.	   Image	  from	  Nachman	  and	  Jaffe	  
















1.1.1 Barrier	  function	  
One	   of	   the	  most	   important	   functions	   of	   endothelial	   cells	   is	   to	   provide	   a	   restrictive	   semi-­‐
permeable	  physical	  barrier	  between	  the	  blood	  and	  the	  vessel	  wall.	  Endothelial	  cells	  fulfil	  this	  
function	   by	   forming	   a	   universal	   monolayer	   that	   covers	   the	   luminal	   surface	   of	   the	   entire	  
vascular	  tree.	  	  Connections	  between	  endothelial	  cells	  are	  strengthened	  with	  tight	  junctions	  
between	   cells.	   Proteins	   involved	   in	   the	   formation	   of	   these	   junctions	   include	   vascular	  
endothelial-­‐cadherin	   (VE-­‐cadherin	   or	   CD144),	   which	   can	   also	   be	   used	   as	   a	   marker	   of	  
endothelial	  cell	  membranes.	  	  Whilst	  providing	  a	  barrier,	  the	  endothelium	  must	  also	  permit	  
the	   transport	  of	  molecules,	  and	  cells	   from	  the	   luminal	   to	   the	  abluminal	   side	  of	   the	  vessel	  
wall.	  Molecules	   and	   cells	   can	   pass	   between	   (paracellular	   permeability)	   cells	   and	   selected	  
molecules	  can	  also	  pass	  through	  (intracellular	  permeability)	  cells.	  
	  
Paracellular	   permeability	   of	   the	   endothelial	   monolayer	   can	   be	   increased	   or	   decreased	  
depending	  on	  external	  stimuli	  (Komarova	  and	  Malik,	  2010;	  Konstantoulaki	  et	  al.,	  2003).	  The	  
leakiness	  of	  the	  endothelial	  cell	  monolayer	  to	  molecules	  and	  cells	  in	  this	  regard	  is	  regulated	  
in	  two	  ways:	  (i)	  by	  phosphorylation	  of	  cadherin	  proteins	  which	  result	  in	  internalisation	  and	  
(ii)	   by	  actin	   rearrangement	  which	  break	  apart	   the	   junctions	  between	   the	   cells.	   These	   two	  
pathways	   can	   be	   activated	   by	   a	   range	   of	   stimuli	   including	   VEGF,	   thrombin	   and	   histamine	  
which	   typically	   increase	   intracellular	   Ca2+	   and	   activate	   protein	   kinase	   C.	   Transcellular	  
permeability	   allows	   the	   transport	   of	   selected	   macromolecules	   through	   cells.	   This	   energy	  
dependent	  process	  requires	  trafficking	  of	  vesicles	  called	  caveloae.	  Caveloae	  are	  cholesterol	  
rich	  pits	  present	  both	  on	  the	  endothelial	  cell	  surface	  and	  as	  free	  vesicles	  in	  the	  cytoplasm.	  
The	   assembly	   of	   these	   vesicles,	   and	   subsequent	   transport,	   is	   regulated	   by	   the	   structural	  
protein	  caveolin-­‐1.	  Both	  paracelluar	  and	  intracellular	  pathways	  are	  important	  to	  endothelial	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cell	  barrier	  function	  and	  are	  thought	  to	  cross-­‐talk	  to	  regulate	  over	  barrier	  function	  in	  health	  
and	  disease	  (Komarova	  and	  Malik,	  2010).	  
	  
1.1.2 Endothelial	  cells	  and	  shear	  stress	  
In	   vessels,	   endothelial	   cells	   exist	   in	   a	   dynamic	   environment	   that	   includes	   not	   only	  
interactions	  with	  cells,	  but	  also	  physical	  forces.	  These	  include	  cyclic	  stretch,	  due	  to	  pulsatile	  
nature	  of	  blood	  flow,	  and	  shear	  stress,	  which	  is	  the	  frictional	  force	  of	  the	  blood	  flow	  on	  the	  
endothelial	  cell	  surface.	  The	  degree	  and	  direction	  of	  shear	  stress	  that	  endothelial	  cells	  are	  
exposed	  to	  is	  thought	  to	  have	  profound	  effects	  on	  both	  morphology,	  function,	  sensitivity	  to	  
inflammation	   and	   the	   development	   of	   atherosclerosis	   (Dai	   et	   al.,	   2004;	   Wasserman	   and	  
Topper,	  2004).	   This	  phenomenon	   is	  well	   illustrated	   in	   the	  endothelium	  of	   the	  aortic	   arch.	  
Cells	  lining	  the	  greater	  curvature	  of	  the	  arch	  are	  exposed	  to	  directional,	  also	  referred	  to	  as	  
laminar,	   shear	   stress	   are	   elongated	   and	   aligned	   in	   the	   direction	   of	   the	   blood	   flow.	  
Endothelial	  cells	  in	  regions	  of	  directional	  shear	  stress	  are	  protected	  from	  inflammation	  and	  
atherosclerosis.	  By	   contrast,	  endothelial	   cells	   lining	   the	   lesser	   curvature	  of	   the	  aortic	  arch	  
are	  exposed	  to	  non-­‐directional,	  also	  referred	  to	  as	  oscillatory	  or	  turbulent,	  shear	  stress	  are	  
of	   a	   cobblestone	   appearance	   and	   are	   primed	   for	   inflammation	   (Hajra	   et	   al.,	   2000)	   and	  
atherosclerosis	  (Cheng	  et	  al.,	  2006;	  Dai	  et	  al.,	  2004;	  Dai	  et	  al.,	  2007).	  This	  phenomenon	  can	  
be	  modelled	   in	  vitro	  using	  a	  number	  of	  approaches	  (Gimbrone	  et	  al.,	  2000).	  Our	  group	  has	  
adopted	  a	   simple	   approach	  where	   complex	   shear	   stress	  patterns	   can	  be	   applied	  easily	   to	  
endothelial	  cell	  cells	   in	  regular	  plastic	  culture	  plates	  placed	  on	  an	  orbital	  shaker	  (Potter	  et	  
al.,	  2011).	  The	  different	  phenotypes	  of	  endothelial	  cells	  that	  occur	  at	  different	  regions	  of	  the	  





Figure	  1.2	   Schematic	   representation	  of	  endothelial	   cell	  morphology	  and	  phenotype	   in	   the	  
greater	  curvature	  and	  lesser	  curvature	  of	  the	  aortic	  arch.	  	  
	  
	  
1.1.3	  	   Endothelial	  cells	  and	  vasoactive	  hormones	  
In	  addition	  to	  a	  physical	  barrier	  endothelial	  cells	  also	  form	  a	  metabolic	  barrier.	  In	  this	  regard	  
endothelial	  cells	  have	  the	  capacity	  to	  metabolise	  and	  convert	  circulating	  hormones,	  such	  as	  
angiotensin	  and	  bradykinin	  via	  angiotensin	  converting	  enzyme.	  Endothelial	  cells	  also	  release	  
three	  key	  vasoactive	  hormones,	  which	  act	  to	  regulate	  vascular	  tone	  and	  platelet	  reactivity.	  
These	  are	  (i)	  prostacyclin	  (Moncada	  et	  al.,	  1976)	  (ii)	  nitric	  oxide	  (Palmer	  et	  al.,	  1987)	  and	  (iii)	  
endothelin	  (ET)-­‐1	  (Yanagisawa	  et	  al.,	  1988).	  During	  the	  course	  of	  my	  PhD	  thesis	  I	  have	  used	  














have	  therefore	  included	  more	  detail	  below	  on	  the	  background	  of	  NO,	  prostacyclin	  and	  ET-­‐1	  
in	  the	  vasculature.	  
	  
1.1.4 Prostacyclin	  	  	  
Receptor	  pathways	  utilised	  by	  prostacyclin	  
Prostacyclin	   belongs	   to	   a	   family	   of	  mediators	   known	   as	   the	   prostaglandins,	  which	   have	   a	  
range	  of	  effects	  on	  human	  physiology.	   It	  was	  pioneering	  work	  by	  Sir	   John	  R	  Vane’s	  group	  
that	   identified	   prostacyclin	   as	   a	   molecule	   secreted	   by	   endothelial	   cells	   (Moncada	   et	   al.,	  
1976).	   Prostacyclin	   has	   a	   myriad	   of	   protective	   effects	   on	   the	   cardiovascular	   system	  
including;	  vasodilation,	   inhibition	  of	  platelet	  aggregation	  and	  inhibition	  of	  vascular	  smooth	  
muscle	   proliferation.	   Prostacyclin	   mediates	   these	   actions	   via	   ligating	   two	   receptors;	   IP	  
receptors	   which	   are	   expressed	   on	   the	   cell	   surface	   and	   peroxisome	   proliferator	   activated	  
receptor-­‐β	   (PPARβ)	  which	   is	  a	  cytosolic	   receptor	   (Ali	  et	  al.,	  2006;	  Mitchell	  et	  al.,	  2008).	   IP	  
receptors	   belong	   the	   seven	   transmembrane	  domain	   receptor	   family	   of	  G-­‐protein	   coupled	  
receptors	   (GPCRs)	  and	  are	  expressed	  on	  vascular	  smooth	  muscle	  and	  platelets	   (Stitham	  et	  
al.,	   2007)	   (Figure	   1.3).	   Activation	   of	   IP	   receptors,	   which	   are	   coupled	   to	   Gs,	   results	   in	  
activation	   of	   adenylate	   cyclase	   and	   thus	   a	   rise	   in	   intracellular	   levels	   of	   the	   second	  
messenger,	   cyclic	   adenosine	  monophosphate	   (cAMP)	  which	   leads	   to	   activation	   of	   protein	  
kinase	  A.	  Activated	  protein	  kinase	  A	  phosphorylates	  Ca2+	  channels	  leading	  to	  rapid	  reduction	  
in	   intracellular	   Ca2+	   concentration	   in	   vascular	   smooth	   muscle	   cells.	   PPARβ	   is	   a	   nuclear	  
receptor	  that	  mediates	  the	  effects	  of	  prostacyclin,	  along	  with	  other	  biologically	  active	  lipids,	  
in	  a	  least	  three	  ways.	  Firstly	  activation	  of	  PPARβ	  releases	  bound	  and	  repressed	  BCL6.	  Once	  
released	  BCL6	   is	   free	  to	  act	  as	  a	  transcriptional	  repressor	  of	  genes	  encoding	   inflammatory	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proteins	   including	   MCP-­‐1	   (Lee	   et	   al.,	   2003).	   Secondly	   PPARβ	   acts	   to	   regulate	   the	  
transcription	   of	   target	   genes,	   including	   CD36	   and	   AGNP4	   via	   binding	   to	   specific	   response	  
elements.	  Finally,	  PPARβ	  can	  act	  as	  an	  repressor	  of	  PKCα	  through	  a	  direct	  interaction	  (Ali	  et	  
al.,	  2009).	  
	  
Synthesis	  of	  prostacyclin	  
Prostacyclin	   synthesis	   is	   mediated	   by	   the	   concerted	   actions	   of	   three	   enzymes.	   Firstly	  
phospholipase	   A2	   (PLA2)	   liberates	   the	   substrate,	   arachidonic	   acid,	   from	   membrane	  
phospholipids.	  Due	  to	  the	  potent	  biological	  actions	  of	  mediators	  derived	  from	  arachidonic	  
acid	   levels	   are	   actively	   kept	   low	   within	   the	   cell	   and	   once	   PLA2	   activity	   has	   declined	  
arachidonic	   acid	   is	   rapidly	   re-­‐acetylated	   back	   to	   the	   plasma	   membrane.	   Secondly,	  
cyclooxygenase	  (COX)	  metabolises	  arachidonic	  acid	  in	  at	  two-­‐step	  process,	  first	  	  to	  PGG2	  and	  
then	  PGH2.	   Finally	  PGH2	   is	  metabolised	  by	  prostacyclin	   synthase	   (PGIS)	   to	  prostacyclin.	  As	  
part	   of	   my	   thesis,	   I	   have	   had	   the	   opportunity	   to	   grow	   endothelial	   cells	   from	   blood	  
progenitors	   from	   a	   unique	   patient	   with	   a	   homozygous	   polymorphism	   in	   the	   gene	   that	  
regulates	   cPLA2	   (cPLA2α).	   In	   light	   of	   this	   I	   have	   introduced	   PLA2	   in	   some	   additional	   detail	  
below.	  
	  
Phospholipase	  A2	  (PLA2)	  
PLA2	  was	  first	  identified	  in	  the	  1800s	  as	  a	  component	  of	  snake	  venom	  (Stephens	  et	  al.,	  1898)	  
and	  later	  identified	  as	  an	  enzyme	  present	  in	  mammalian	  fluids	  (Seilhamer	  et	  al.,	  1989).	  We	  
now	  know	  that	  there	  are	  numerous	  individual	  isoforms	  of	  PLA2	  that	  are	  categorised	  into	  (i)	  
cytosolic	  PLA2	   (cPLA2),	   (ii)	  calcium-­‐independent	  PLA2	   (iPLA2)	  and	  (iii)	   secreted	  PLA2	   (sPLA2).	  	  
SPLA2	  and	  cPLA2	  are	  calcium	  dependent	  enzymes.	  The	  concentration	  of	  calcium	  required	  for	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activation	  of	  sPLA2	  often	  depends	  on	  the	  substrate	  phospholipid	  (Lambeau	  and	  Gelb,	  2008)	  
whereas	   cPLA2	   can	   be	   activated	   by	   low	   levels	   of	   Ca2+	   in	   cells	   and	   is	   sensitive	   to	   short-­‐
duration	   transient	   changes	   in	   intracellular	   Ca2+	   (Evans	   et	   al.,	   2001;	   Leslie,	   1997).	   The	  
classification	  of	  PLA2	  enzymes	  is	  complex	  and	  has	  recently	  been	  revised	  giving	  11	  groups	  in	  
total	  based	  on	  protein	  structure	  and	  covering	  plants	  and	  animals	  (Six	  and	  Dennis,	  2000).	  
	  
Group	   II,	   V,	   X	   (sPLA2),	   Group	   IV	   (cPLA2)	   and	   Group	   VI	   (iPLA2)	   are	   the	   most	   relevant	   in	  
humans.	  As	  mentioned	  above	  cPLA2	  is	  activated	  by	  increases	  in	  cytosolic	  calcium.	  As	  such	  it	  
is	   thought	   that	   this	   isoform	   is	   responsible	   for	   arachidonic	   acid	   release	   and	   subsequent	  
eicosanoid	   biosynthesis	   in	   response	   to	   a	   range	   of	   agonists	   that	   cause	   increases	   in	  
intracellular	   Ca2+	   (Leslie,	   1997).	   In	   line	  with	   this	   recent	  work	   from	   our	   group	   using	   blood	  
from	  a	  patient	  with	  a	   rare	   condition,	   cryptogenic	  multifocal	  ulcerating	   stenosing	  enteritis,	  
and	  a	  homozygous	  mutation	  in	  	  the	  PLA2G4A	  gene	  which	  results	  in	  a	  complete	  loss	  of	  cPLA2α	  
activity,	   demonstrated	   that	   this	   isoform	   is	   responsible	   for	   prostaglandin	   release	   from	  
platelets	   stimulated	  with	   collagen	   (Brooke	   et	   al.,	   2012).	   In	   the	   course	   of	  my	   PhD	   thesis	   I	  
have	   grown	   endothelial	   cells	   from	   progenitors	   in	   this	   patients’	   blood	   and	   used	   them	   to	  
investigate	   the	   role	   of	   cPLA2α	   in	   prostacyclin	   release	   by	   endothelial	   cells	   (see	   Chapter	   6).	  	  
This	   was	   particularly	   important	   to	   do	   since	   others	   have	   suggested	   that	   that	   the	   calcium	  
independent	   form	   of	   PLA2	   (iPLA2)	   mediates	   prostacyclin	   release	   from	   endothelial	   cells	  
stimulated	   with	   thrombin	   (Sharma	   et	   al.,	   2011).	   A	   fuller	   description	   of	   the	   clinical	  
manifestations	  and	  the	  genetic	  profiling	  data	  that	  defines	  this	  patient	  and	  their	  relatives	  is	  






The	   conversion	   of	   arachidonic	   acid	   to	   PGH2	   occurs	   as	   a	   two-­‐step	   process;	   the	   first	   step	  
occurs	  via	  formation	  of	  an	  unstable	  cyclic	  endoperoxide,	  PGG2.	  This	  is	  then	  reduced	  to	  PGH2.	  
PGH2	   is	   then	   converted	   by	   various	   isomerase	   and	   synthase,	   enzymes	   to	   a	   range	   of	  
prostanoids.	  This	  process	  is	  catalysed	  by	  the	  enzyme	  COX.	  It	   is	  the	  expression	  of	  particular	  
isomerase	  and	  synthase	  enzymes	  which	   then	  determines	  which	   specific	  prostanoids	  a	   cell	  
will	  produce.	  In	  the	  case	  of	  endothelial	  cells,	  prostacyclin	  synthase	  (PGIS)	  is	  highly	  expressed	  
resulting	  in	  prostacyclin	  being	  the	  predominant	  COX	  product	  released	  by	  endothelial	  cells.	  
	  
Two	   distinct	   isoforms	   of	   COX	   exist	   and	   these	   arise	   from	   separate	   genes.	   COX-­‐1,	  which	   is	  
constitutively	   expressed,	   and	   COX-­‐2,	   which	   is	   inducible	   under	   inflammatory	   conditions	  
(Kujubu	   et	   al.,	   1991;	   Xie	   et	   al.,	   1991).	   Since	   COX-­‐2	   is	   induced	   in	   inflammation	   it	   is	   the	  
therapeutic	   target	   for	   common	   anti-­‐inflammatory	   medications	   of	   the	   non-­‐steroidal	   anti-­‐
inflammatory	  drugs	  (NSAIDs)	  class.	  These	  include	  ibuprofen	  and	  diclofenac.	  However,	  these	  
drugs	  also	  inhibit	  COX-­‐1	  resulting	  in	  increased	  risk	  of	  gastrointestinal	  side	  effects	  (Wallace	  et	  
al.,	  1998).	  COX-­‐2	  selective	  drugs	  such	  as	  celecoxib	  and	  rofecoxib	  were	  introduced	  to	  spare	  
COX-­‐1	   and	   therefore	   have	   reduced	   gastrointestinal	   side	   effects	   (Mitchell	   et	   al.,	   1993).	  
However,	   inhibition	   of	   COX-­‐2	   by	   selective	   drugs	   such	   as	   celecoxib	   and	   rofecoxib	   or	  
traditional	   anti-­‐inflammatory	   drugs	   such	   as	   diclofenac	   and	   ibuprofen	  has	   been	   associated	  
with	   increased	   risk	   of	   cardiovascular	   events.	   The	   mechanism	   explaining	   these	   increased	  
cardiovascular	  events	  is	  not	  clear	  although	  it	  has	  been	  suggested	  by	  some	  that	  COX-­‐2	  is	  the	  
principle	   isoform	   that	  drives	  prostacyclin	   release	   in	   the	   vasculature	  and	   that	   its	   inhibition	  
removes	   a	   cardioprotective	   brake	   (Funk	   and	   FitzGerald,	   2007;	   Yu	   et	   al.,	   2012).	   However,	  
direct	  evidence	  to	  support	  this	  is	  difficult	  to	  find.	  Instead	  where	  directly	  investigated	  COX-­‐1	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appears	   to	   be	   the	   principal	   isoform	   that	   drives	   prostacyclin	   release	   in	   vitro	   and	   in	   vivo	  
(Kirkby	  et	  al.,	  2012).	  COX-­‐2	  is	  also	  expressed	  in	  the	  kidney(Harris,	  2006)	  where	  its	  inhibition	  
leads	  to	   increases	   in	  blood	  pressure	  (Krum	  et	  al.,	  2006).	  Effects	  of	  COX-­‐2	   inhibitors	  on	  the	  
kidney	  may	  therefore	  also	  explain	  the	  increased	  cardiovascular	  events	  associated	  with	  anti-­‐
inflammatory	  drugs.	  
	  
1.1.5 Nitric	  Oxide	  (NO)	  
NO	   and	   prostacyclin	   are	   co-­‐released	   by	   endothelial	   cells,	   and	   in	   partnership,	   regulate	  
vascular	   tone,	   platelet	   function	   and	   VSMC	   dilation	   and	   proliferation.	   NO	   release	   by	  
endothelial	   cells	   is	   regulated	   by	   NO	   synthase	   (NOS)	   (Pollock	   et	   al.,	   1991)	   of	   which	   three	  
isoforms	  exist;	  NOSI,	  expressed	  in	  neurons,	  and	  also	  referred	  to	  as	  nNOS;	  NOSII,	  expressed	  
under	   inflammatory	   conditions	   and	   also	   known	   as	   iNOS;	   and	   NOSIII,	   expressed	   in	  
endothelial	   cells,	   also	   referred	   to	   as	   eNOS.	   eNOS	   and	   nNOS	   are	   both	   calcium/calmodulin	  
dependent	   isoforms	  whilst	   iNOS	   activity	   is	   calcium	   independent	   due	   to	   calcium	   activated	  
calmodulin	  being	  bound	  to	  it	  shortly	  after	  translation.	  eNOS	  is	  a	  membrane	  bound	  isoform	  
thought	   to	   be	   associated	   with	   calveolin	   in	   lipid	   rafts	   whist	   nNOS	   and	   iNOS	   are	   cytosolic	  
isoforms.	  
	  
The	  key	  sensor	  pathway	  in	  cells	  of	  NO	  is	  guanyl	  cyclase	  (Hanafy	  et	  al.,	  2001).	  Guanyl	  cyclase	  
catalyses	   the	   conversion	   of	   guanosine	   triphosphate	   (GTP)	   to	   cyclic	   guanosine	  
monophosphate	   (cGMP)	   which	   acting	   as	   a	   classical	   second	   messenger,	   activates	   protein	  
kinase	   G.	   Activated	   protein	   kinase	   G,	   as	   with	   protein	   kinase	   A,	   phosphorylates	   calcium	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channels	  leading	  to	  rapid	  reduction	  in	  intracellular	  calcium	  levels	  which	  leads	  to	  an	  overall	  
reduction	  in	  intracellular	  Ca2+	  and	  vasodilation.	  
	  
1.1.6 Endothelin-­‐1	  (ET-­‐1)	  
As	  a	  constrictor,	  ET-­‐1	  release	  by	  the	  endothelium	  is	  in	  balance	  with	  prostacyclin	  and	  NO	  to	  
maintain	  cardiovascular	  homeostasis.	  Even	  prior	  to	  the	  full	  identification	  and	  isolation	  of	  ET-­‐
1	   it	   was	   known	   that	   endothelial	   cells	   release	   a	   vasoconstrictor	  molecule	   (De	  Mey	   et	   al.,	  
1982).	   Then	   in	   1988	   the	   sequence	   of	   a	   potent	   vasoconstrictor	   peptide	   termed	   ET-­‐1	   was	  
published	   (Yanagisawa	  et	  al.,	  1988).	  ET-­‐1	   is	  a	  21	  amino	  acid	  peptide	   released	  primarily	  by	  
endothelial	   cells,	   although	   other	   cell	   types	   can	   make	   it,	   particularly	   under	   inflammatory	  
conditions	  (Lüscher	  and	  Barton,	  2000).	  ET-­‐1	  is	  the	  dominant	  cardiovascular	  isoform.	  ET-­‐1	  is	  
generated	   from	   immature	   precursors	   via	   a	   two-­‐step	   proteolytic	   pathway.	   The	   ET-­‐1	   gene	  
liberates	  prepro-­‐ET-­‐1	  mRNA	  which	  encodes	  a	  212	  amino	  acid	  peptide.	  Once	  transcribed	  the	  
immature	  protein	   is	  secreted	   in	  to	  the	  cytoplasm	  as	  pro-­‐ET-­‐1	  (Inoue	  et	  al.,	  1989)	  where	   it	  
undergoes	  proteolytic	  cleavage	  by	  a	  furin-­‐like	  endopeptidase	  to	  liberate	  BIG-­‐ET-­‐1.	  The	  final,	  
and	  rate	  limiting	  step	  involves	  cleavage	  of	  BIG-­‐ET-­‐1	  by	  endothelin	  converting	  enzymes	  (ECE)	  
to	  liberate	  ET-­‐1.	  	  
	  











Figure	   1.3.	   Summary	   of	   endothelial	   hormone	   pathways.	   Endothelial	   cells	   release	   nitric	  
oxide,	  prostacyclin	  and	  endothelin-­‐1,	  which	  are	  regulated	  by	  signalling	  pathways	  (including	  
GATA-­‐3,	   HIF1α	   and	  NF-­‐κB	  mediated	   gene	   transcription)	   and	   the	   concerted	   actions	   of	   key	  
enzymes.	   Abbreviations:	   G-­‐protein	   coupled	   receptors	   (GPCRs),	   acetylcholine	   (Ach),	  
phospholipase-­‐Cγ	   (PLCγ),	   Phosphatidylinositol	   4,5-­‐bisphosphate	   (PIP2),	   inositol	   1,4,5-­‐
trisphosphate	   (IP3),	   diacylglycerol	   (DAG),	   cytosolic	   Ca2+-­‐dependent	   PLA2	   (cPLA2),	  
cycloxgenase	   (COX),	   arachidonic	   acid	   (AA),	   prostacyclin	   synthase	   (PGIS),	   Ca2+-­‐calmodulin	  
(Ca2+-­‐CAM),	  endothelial	  nitric	  oxide	  synthase	  (eNOS),	  endothelin	  converting	  enzyme	  (ECE),	  
endothelin-­‐1	  (ET-­‐1),	  hypoxia	  inducible	  factor	  (HIF).	  
	  
	  
1.1.7	  	   Endothelial	  cells	  and	  innate	  immunity	  	  
Another	   important	   function	   of	   endothelial	   cells	   is	   their	   critical	   role	   in	   innate	   immunity.	  
Endothelial	   cells	   are	   the	   interface	   between	   pathogens	   and	   circulating	   leukocytes.	   Thus,	  
endothelial	   cells	   need	   to	   be	   able	   to	   sense	   pathogens	   and	   in	   response	   to	   this	   release	  
chemokines	   and	   express	   adhesion	   receptors	   to	   recruit	   leukocytes	   to	   the	   site	   of	   infection.	  
The	  sensing	  of	  pathogens	  is	  mediated	  by	  a	  group	  of	  receptors	  known	  as	  ‘pattern	  recognition	  




































receptors’	  (PRRs)	  that	  respond	  to	  unique	  molecular	  motifs	  in	  pathogens.	  	  The	  best	  studied	  
of	  these	  are	  the	  Toll	  like	  receptors	  (TLRs)	  and	  the	  nucleotide	  oligomerisation	  domain	  (NOD)	  
receptors,	  many	   of	   which	   are	   expressed	   and	   functional	   on	   endothelial	   cells	   (Opitz	   et	   al.,	  
2009).	   In	   my	   thesis	   I	   have	   studied	   the	   pharmacology	   of	   TLRs	   and	   NOD	   receptors	   in	  
endothelial	  cells	  derived	  from	  stem	  cells	  and	  their	  role	  in	  infection	  with	  live	  bacteria.	  In	  this	  
section	  of	   the	   introduction	   I	  will	   therefore	   include	  some	  general	  details	  of	  PRRs	  and	   their	  




















1.3	  INNATE	  IMMUNITY	  AND	  PATTERN	  RECOGNITION	  RECEPTORS	  (PRR)	  
Until	   recently	   it	  was	   thought	   that	   the	   initial	   response	  of	   tissues,	   so	   called	   innate	   immune	  
responses,	  was	  non-­‐specific	  and	  of	  little	  importance	  in	  human	  immunity.	  Prior	  to	  pioneering	  
work	  by	  Charles	  Janeway,	  explaining	  the	  requirement	  for	  co-­‐stimulation,	  it	  was	  thought	  the	  
adaptive	   immune	  system	  was	  wholly	  sufficient	   for	  host	  defense	  (Janeway,	  1989).	   Janeway	  
proposed	   that	   mobilisation	   of	   adaptive	   immunity	   in	   fact	   relied	   on	   the	   activation	   of	   an	  
innate,	   evolutionary	   preserved	   family	   of	   receptors	   that	   could	   sense	   pathogens	   and	  
orchestrate	   adaptive	   immune	   pathways.	   Crucially,	   it	   was	   shown	   that	   T-­‐cells	   could	   not	  
respond	   to	   a	   specific	   antigen	  without	   co-­‐stimulation	  with	   lipopolysaccharide	   (LPS),	   which	  
represents	   a	   small	  molecular	  motif	   found	   in	  Gram-­‐negative	   bacterial	   cell	  membranes	   (Liu	  
and	  Janeway,	  1991).	  LPS	  and	  other	  molecular	  motifs	  unique	  to	  pathogens	  are	  referred	  to	  as	  
pathogen	  associated	  molecular	  patterns	  (PAMPs).	  
	  
Work	   subsequently	  began	  on	   the	   receptors	   responsible	   for	   the	   recognition	  of	  PAMPs;	   so-­‐
called	   pattern	   recognition	   receptors	   (PRR).	   The	   first	  work	   on	   PRRs	  was	   done	   on	   immune	  
responses	  in	  the	  fruit	  fly	  Drosophilia	  melanogaster.	  In	  1996,	  Jules	  Hoffmann	  demonstrated	  
for	   the	   first	   time	   that	   the	   immune	   response	  of	   the	  Drosophilia	   fly	   to	   fungal	   infection	  was	  
obliterated	  in	  the	  presence	  of	   loss	  of	  function	  mutations	   in	  a	  gene	  called	  Toll	   (Lemaitre	  et	  
al.,	   1996).	   The	   toll	   gene	   had	   been	   characterised	   previously	   as	   essential	   in	   dorsal-­‐ventral	  
patterning	   (Anderson	   et	   al.,	   1985;	  Nüsslein-­‐Volhard	   et	   al.,	   1980)	   and	  was	   known	   to	   have	  
encoded	   a	   receptor	   with	   an	   intracellular	   domain	   similar	   to	   human	   interleukin	   (IL)-­‐1	  
receptors	  (Gay	  and	  Keith,	  1991).	  At	  the	  same	  time,	  a	  human	  homologue	  of	  the	  Toll	  receptor	  
found	  in	  Drosophila	  was	  cloned.	  This	  receptor	  contained	  a	  leucine	  rich	  receptor	  (LRR)	  and	  an	  
intracellular	  domain	  similar	   to	  Toll	  and	   IL-­‐1	   receptors,	  now	  termed	  Toll/IL-­‐R	   (TIR)	  domains	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(Medzhitov	   et	   al.,	   1997).	   This	   TIR	   domain	   was	   subsequently	   shown	   to	   activate	   the	  
transcription	   factor	   NF-­‐κB	   and	   so	   regulate	   inflammatory	   genes,	   and	   that	   this	   activation	  
provided	   the	   co-­‐stimulatory	   signal	   for	   T-­‐cell	   activation	   (Medzhitov	   et	   al.,	   1997).	   The	  
significance	  therefore	  of	  innate	  immune	  pathways	  in	  human	  immunity	  was	  thus	  established.	  
The	  family	  of	  human	  Toll	  receptor	  homologues	  were	  named	  Toll-­‐like	  receptors.	  In	  parallel	  to	  
work	   in	  human	  systems	  two	  groups	  working	   independently	  showed	  that	  TLR4	  in	  mice	  was	  
the	   critical	   receptor	   that	  mediates	   the	   effects	   of	   LPS	   (Kawai	   et	   al.,	   1999;	   Poltorak	   et	   al.,	  
1998).	  In	  light	  of	  this	  pioneering	  work,	  Bruce	  Beutler	  and	  Jules	  Hoffmann	  were	  awarded	  the	  
Nobel	  Prize	  in	  2011	  for	  their	  observation	  that	  TLR4	  is	  the	  LPS	  receptor.	  	  
	  
1.3.1	  	   Toll-­‐like	  receptors	  
After	  the	  discovery	  of	  the	  LPS	  receptor,	  TLR4,	  a	  number	  of	  additional	  receptors	  with	  shared	  
sequence	  homology,	  and	  their	  agonists,	  were	  subsequently	  identified	  and	  characterised.	  To	  
date,	  10	  functional	  TLRs	  have	  been	  identified	  with	  PAMPs	  identified	  for	  9	  of	  them.	  Selective	  
TLR	  expression	  and	  activation	  enables	  cells	   to	   respond	  to	  an	  array	  of	  PAMPs	  on	  or	  within	  
bacteria,	  viruses	  and	  fungi.	  Agonists	  of	  PRRs	  and	  their	  specific	  receptors	  are	  listed	  in	  Chapter	  
2	  in	  Table	  2.3	  
	  
TLRs	  are	  type	  I	  membrane	  bound	  receptors,	  expressed	  either	  on	  the	  cell	  membrane	  (TLR1,	  
TLR2,	  TLR4,	  TLR5,	  TLR6)	  or	  the	  endoplasmic	  reticulum	  membrane	  (TLR3,	  TLR7,	  TLR8,	  TLR9)	  
(Akira	  and	  Takeda,	  2004).	  A	  summary	  of	  TLR	  signalling	  is	  shown	  in	  Figure	  1.4.	  TLRs	  expressed	  
on	  the	  cell	  surface	  are	  typically	  responsive	  to	  bacteria	  and	  PAMPs	  on,	  or	  contained	  within,	  
bacteria,	  whilst	  endosomal	  TLRs	  respond	  to	  nucleic	  acids	  in	  invading	  viruses.	  The	  function	  of	  
TLR10	   in	   humans	   is	   unknown.	   TLRs	   are	   activated	   by	   ligands	   as	   either	   homo-­‐	   or	   hetero	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dimers.	   TLR6	   forms	   heterodimers	   with	   TLR2	   and	   TLR1	   whilst	   TLR3,	   4	   and	   5	   form	  
homodimers.	  TLR8	  can	  also	  form	  dimers	  with	  TLR7	  and	  TLR9.	  
	  
TLRs	   signal	   via	   recruitment	   of	   the	   adapter	   proteins	  MyD88	   (with	   or	   without	   the	   adaptor	  
protein	   Mal)	   and/or	   TIR-­‐domain-­‐containing	   adapter-­‐inducing	   interferon-­‐β	   (TRIF)	   (with	   or	  
without	   the	   adapter	   protein	   TRAM)	   that	   results	   in	   downstream	   activation	   transcription	  
factors	  associated	  with	   innate	   immunity	  and	   inflammation.	  For	  TLRs,	  MyD88	  and	  TRIF	  are	  
the	  two	  main	  adapter	  protein	  pathways	  and	  are	  described	  in	  more	  detail	  below.	  	  
	  
MyD88	  signalling	  
MyD88	   was	   first	   identified	   as	   a	   differentiating	   factor	   in	   myeloid	   cells.	   In	   1999	   it	   was	  
demonstrated	   in	  MyD88	   (-­‐/-­‐)	  mice	   that	   responses	   to	   ligands	   of	   TLR2,	   4,	   5,	   7	   and	   9	  were	  
completely	   abrogated	   (Kawai	   et	   al.,	   1999).	   Activation	   of	   MyD88	   leads	   to	   activation	   of	   a	  
complex	  of	  IL-­‐1	  receptor	  associated	  proteins	  (IRAK)	  and	  activation	  of	  tumour	  necrosis	  factor	  
(TNF)	  receptor	  associated	  factor-­‐6	  (TRAF-­‐6)	  (Cao	  et	  al.,	  1996).	  The	  interaction	  between	  TLRs	  
and	  MyD88	  occurs	  via	  a	  TIR	  to	  TIR	  domain	  interaction	  and	  between	  MyD88	  and	  IRAK	  via	  a	  
DD-­‐domain	   interaction.	   MyD88	   therefore	   provides	   a	   critical	   link	   between	   TLRs	   and	   their	  
associated	  downstream	  pathways.	  Another	  adapter	  protein,	  MAL	  (or	  TIRAP)	  acts	  a	  bridging	  
protein	  to	  anchor	  MyD88	  to	  TIR	  domains	  on	  TLR2	  and	  TLR4	  since	  in	  mice	  deficient	   in	  MAL	  
responses	   to	   TLR2	   activation	   is	   absent,	   and	   	   to	   TLR4	   activation	   delayed	   (Fitzgerald	   et	   al.,	  
2001).	  TRAF-­‐6,	  through	  association	  with	  TGF-­‐β-­‐activated	  kinases	  (TAK)	  and	  a	  series	  of	  TAK-­‐
binding	  proteins	   (TAB),	  provides	  a	  signal	   for	  phosphorylation	  of	   inhibitor	  of	  NF-­‐κB	  kinases	  
(IKKs)	  (Kanayama	  et	  al.,	  2004).	  IKKs	  in	  turn	  phosphorylate	  the	  NF-­‐κB	  inhibitor,	  IκB,	  resulting	  
in	  its	  degradation.	  NF-­‐κB	  can	  then	  translocate	  to	  the	  nucleus	  and	  activate	  target	  genes.	  IKKs	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can	   also	   activate	  NF-­‐κB	   independently	   of	   IκB	   via	   phosphorylation	   of	   co-­‐activator	   proteins	  
such	   as	   CBP/p300,	   which	   interact	   with	   NF-­‐κB	   in	   the	   nucleus	   or	   via	   phosphorylation,	   and	  
inhibition	  of	  repressor	  proteins	  such	  as	  SMRT	  (Ghosh	  and	  Hayden,	  2008).	  	  
	  
TLR	   mediated	   activation	   of	   NF-­‐κB	   is	   now	   know	   to	   extend	   beyond	   innate	   and	   adaptive	  
immunity,	  suggesting	  new	  roles	  for	  PRRs	   in	  human	  cell	  signaling	  and	  physiology.	  TAK1,	  for	  
example,	  may	  also	  activate	  a	  mitogen	  activated	  protein	  kinase	   (MAPK)	  cascade	   leading	   to	  
activation	  of	  JNK,	  p38	  MAPK,	  ERK,	  AP-­‐1	  that	  also	  regulate	  immunity	  and	  inflammatory	  genes	  
(Wang	  et	  al.,	  2001).	  	  	  
	  
TRIF	  signalling	  
The	   TIR	   domain	   of	   TLRs	   can	   also	   interact	   with	   the	   adaptor	   protein	   TRIF.	   TRIF	   was	   first	  
identified	   as	   a	   requirement	   for	   TLR3	   signalling	   and	   activation	   of	   the	   IFNβ	   promoter	   in	  
response	   to	   poly(I:C)	   which	   mimics	   viral	   dsRNA	   (Yamamoto	   et	   al.,	   2002)	   and	   to	   viral	  
infection	   (Hoebe	  et	  al.,	  2003).	   In	   fact,	  TLR3	  signals	  exclusively	   through	  TRIF	  since	  cytokine	  
release	  is	  abolished	  in	  macrophages	  harbouring	  the	  germline	  mutation	  Lps2	  which	  results	  in	  
a	   frameshift	   error	   in	   TRIF	   (Hoebe	   et	   al.,	   2003).	   In	   macrophages	   harbouring	   the	   same	  
mutation,	   responses	   to	  LPS	  are	  also	   truncated	   (Hoebe	  et	  al.,	  2003).	  This	   indicates	   that	   for	  
TLR4	  signalling	  in	  response	  to	  LPS,	  both	  MyD88	  and	  TRIF	  pathways	  have	  important	  roles	  to	  
play.	  
	  
Importantly,	  TRIF	  results	  predominantly	   in	  activation	  of	  the	  IFN-­‐β	  promoter	  (Yamamoto	  et	  
al.,	  2002)	  via	   IRF	   transcription	   factors.	  This	   induces	   the	  expression	  of	  cytokines	  associated	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with	   viral	   immunity	   including	   IFNs	   and	   IFN	   related	   protein-­‐10	   (IP10)	   (Akira	   and	   Takeda,	  
2004;	  Paul-­‐Clark	  et	  al.,	  2012).	  	  
	  
These	  pathways	  are	  summarised	  in	  Figure	  1.4	  
	  
1.3.2	  	   TLR4,	  endothelial	  cells	  and	  cardiovascular	  disease	  
TLR4	  has	  also	  been	  directly	  associated	  with	  cardiovascular	  diseases	  such	  as	  atherosclerosis	  
where	   increased	   TLR4	   activation	   and	   expression	   are	   reported	   (Edfeldt	   et	   al.,	   2002;	  
Michelsen	   et	   al.,	   2004a).	   	   Indeed,	   TLR4-­‐/-­‐(Michelsen	   et	   al.,	   2004b),	   TLR2-­‐/-­‐(Mullick	   et	   al.,	  
2008)	   and	  MyD88-­‐/-­‐(Michelsen	   et	   al.,	   2004b)	  mice	   are	   protected	   against	   atherosclerosis.	  	  
The	   development	   and	   use	   of	   TLR	   knockout	   mice	   models	   help	   to	   explain	   early	   studies	  
conducted	   in	   the	   late	   1980s	   and	   early	   1990s	   implicating	   a	   role	   for	   subclinical	   bacterial	  
infection	  in	  atherosclerosis	  (Saikku	  et	  al.,	  1988;	  Thom	  et	  al.,	  1992).	  Specifically,	  a	  number	  of	  
papers	   have	   shown	   that	   Gram-­‐negative	   Chlamydia,	   which	   activates	   TLR4,	   is	   present	   in	  
atherosclerotic	   lesions	   (Libby	   et	   al.,	   1997).	   These	   papers	   paved	   the	   way	   for	   early	   clinical	  
trials	   designed	   to	   assess	   the	   potential	   preventive	   benefits	   of	   antibiotic	   therapy	   in	  
atherosclerosis	   (Andraws	   et	   al.,	   2005).	   Whilst,	   on	   the	   whole,	   the	   clinical	   trials	   with	  
antibiotics	   were	   not	   successful	   in	   preventing	   cardiovascular	   disease,	   the	   link	   between	  
pathogens	  and	  atherosclerosis	  has	  continued	  to	  be	  investigated.	  	  
	  
TLR4	  can	  also	  be	  activated	  by	  endogenous	  ligands	  that	  are	  associated	  with	  atherosclerosis,	  
including	  oxidised	  LDL	   (Xu	  et	  al.,	   2001)	  and	  heat	   shock	  protein-­‐90	   (Sasu	  et	  al.,	   2001)	  high	  
levels	   of	  which	   can	  drive	   vascular	   inflammation	   and	   atherosclerosis	   (Salonen	  et	   al.,	   1992;	  
Wick,	  2006).	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Single	  nucleotide	  polymorphisms	   in	  genes	  encoding	  TLRs	  are	  also	  associated	  with	  diseases	  
(Paul-­‐Clark	  et	  al.,	  2012).	  The	  role	  of	  mutation	  in	  TLR	  function	  is	  typified	  by	  the	  well-­‐studied	  
polymorphism	   in	   the	   TLR4	   gene	   which	   results	   in	   Asp-­‐Gly	   substitution	   at	   position	   299.	  
Asp299Gly	   in	   fact	   confers	   hyporesponsiveness	   to	   LPS	   and	   results	   in	   reduced	   risk	   of	  
atherosclerosis	   (Kiechl	   et	   al.,	   2002)	   although	   in	   2012	   a	   meta-­‐analysis	   found	   a	   lack	   of	  
association	   between	   this	   polymorphism	   and	   atherosclerosis	   was	   reported	   (Zhang	   et	   al.,	  
2012).	   Nonetheless,	   increases	   in	   TLR4	   activation	   and	   expression	   on	   endothelial	   cells	   and	  
macrophages	  in	  atherosclerosis	  is	  clear	  (Edfeldt	  et	  al.,	  2002).	  
	  
Atherosclerosis	   can	   also	   occur	   after	   transplant	   and	   is	   a	  major	   clinical	   limitation	   of	   organ	  
transplant	  surgery	  (Rahmani	  et	  al.,	  2006).	  Interestingly,	  a	  2005	  study	  evaluating	  the	  role	  of	  
TLR4	   is	   atherosclerosis	   in	   patients	   following	   kidney	   transplant	   found	   that	   patients	   with	  
Asp299Gly	  had	  reduced	  risk	  of	  post-­‐transplant	  atherosclerosis	  but	   increased	  risk	  of	  severe	  
infection	   (Ducloux	   et	   al.,	   2005).	   The	   role	   of	   TLR4	   in	   disease	   is	   very	  much	   a	   double-­‐edged	  
sword,	   and	   in	   the	   context	   of	   vessel	   and	   organ	   regeneration	   this	   deserves	   careful	  
consideration.	  
	  
1.3.3	  	   Nucleotide-­‐binding	  leucine	  rich	  repeat	  (NLR)	  receptors	  
Another,	   more	   recently	   discovered	   family	   of	   PRRs	   are	   the	   NLR	   receptors.	   This	   family	   of	  
receptors	  was	  identified	  from	  studies	  in	  plants	  (van	  der	  Biezen	  and	  Jones,	  1998),	  which	  have	  
no	  adaptive	  immune	  system	  and	  thus	  rely	  solely	  on	  innate	  immunity	  to	  overcome	  infection.	  
In	  plants,	  NLRs	  are	  associated	  with	  resistance	  to	  disease.	  Screening	  of	  the	  human	  genome	  
has	   led	   to	   the	   identification	   of	   NLR	   containing	   receptors	   in	   humans.	   These	   include	   the	  
caspase	   recruitment	   domain-­‐4	   (CARD4)	   or	   NOD1	   receptor	   and	   the	   CARD15	   or	   NOD2	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receptor	   (Harton	  et	  al.,	   2002).	  Whilst	  TLRs	  use	  TIR	  domains	   to	   interact	  with	   their	  adapter	  
proteins,	   NLRs	   typically	   use	   CARD	   domains	   to	   interact	   with	   other	   adapter/signalling	  
proteins,	  the	  best	  studied	  of	  these	  being	  RIP2.	  	  
	  
NOD1-­‐RIP2	  signalling	  
The	   authors	   that	   first	   demonstrated	   that	   NOD1	   and	   NOD2	   activate	   NF-­‐κB(Inohara	   et	   al.,	  
1999)	   	   also	   demonstrated	   that	   they	   require	   the	   then	   recently	   identified	   CARD	   domain	  
containing	   serine/threonine	   kinase,	   receptor	   interacting	   protein-­‐2	   (RIP2)	   (Inohara	   et	   al.,	  
1998).	  
	  
NOD1	   receptors	  are	  known	   to	  be	  activated	  by	  a	  muropeptide	   (L-­‐Ala-­‐G-­‐Glu-­‐meso-­‐diamino-­‐
pimelate	   (DAP))	   found	  uniquely	   in	  Gram	  negative	   bacterial	   peptidoglycan.	  Once	   activated	  
NOD1	   binds	   the	   RIP2	   via	   a	   CARD-­‐CARD	   domain	   interaction.	   RIP2	   then	   carries	   out	   a	  
polyubiquitination	  which	  allows	  recruitment	  of	  the	  TAB-­‐TAK	  complex	  described	  above	  and	  
subsequent	  activation	  of	  NF-­‐κB	  and	  other	  downstream	   transcription	   factors	   (Hasegawa	  et	  
al.,	  2008).	  NOD2	  receptors	  are	  activated	  by	  muramyl	  dipeptides,	  which	  are	  expressed	  in	  the	  
peptidoglycan	   structures	   of	   some	   Gram-­‐positive	   and	   Gram-­‐negative	   bacteria	   and	   are	  
reviewed	  by	  Opitz.	  et	  al	  (Opitz	  et	  al.,	  2009)	  .	  The	  NOD1	  pathway	  is	  summarised	  in	  Figure	  1.4	  
	  
After	   the	  characterisation	  of	  NOD1	  and	  NOD2	  the	  existence	  of	  many	  more	  NLRs	  emerged	  
(Becker	   and	   O'Neill,	   2007).	   All	   NLRs	   comprise	   a	   central	   nucleotide	   binding	   domain,	   a	   C-­‐
terminal	  LRR	  domain	  and	  a	  variable	  N-­‐terminal	  effector	  domain.	  To	  date,	  four	  key	  families	  
have	   been	   identified,	   and	   their	   N-­‐terminal	   effector	   domains	   define	   these.	   The	   four	   NLR	  
families	   are	   defined	   as	   those	   that	   express	   an	   acid	   transactivation	   domain	   (NLRA),	   a	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baculovirus	   inhibitor	   domain	   (NLRB),	   a	   CARD	  domain	   (NLRC)	   or	   a	   pyrin	   domain	   (NLRP).	   A	  
subclass	  of	  NLRs	  has	  been	  reported	  and	  is	  localised	  to	  the	  mitochondria,	  capable	  of	  inducing	  
NF-­‐κB	  and	  JNK-­‐1	  and	  is	  included	  in	  the	  nomenclature	  as	  the	  NLRX	  family.	  These	  families	  are	  
further	  sub-­‐divided	  in	  to	  individual	  NLRs	  expressed	  in	  a	  variety	  of	  tissues.	  Unlike	  TLRs,	  NLRs	  
are	   intracellular	   receptors	   wherein	   they	   respond	   to	   a	   range	   of	   PAMPs	   as	   well	   as	   host	  
ligands,	  or	  danger	  associated	  molecular	  patterns	  (DAMPs)(Becker	  and	  O'Neill,	  2007)	  
	  
1.3.4	  	   NOD	  receptors,	  endothelial	  cells	  and	  disease	  
In	  contrast	  to	  TLRs,	  NOD	  function	  in	  the	  vasculature	  is	  less	  explored.	  Evidence	  for	  a	  function	  
of	   NOD1	   in	   endothelial	   cells	   emerged	   in	   2005.	   Using	   a	   NOD1-­‐siRNA	   knockdown	   in	  
endothelial	  cells,	  it	  was	  shown	  that	  inflammatory	  responses	  of	  endothelial	  cells	  to	  the	  Gram	  
negative	   bacteria,	  Chlamydia	   pneumoniae	   and	   Listeria	  monocytogenes	  were	  NOD1	   driven	  
(Opitz	  et	  al.,	  2005;	  Opitz	  et	  al.,	  2006).	  As	  the	  presence	  of	  Chlamydia	  pneumoniae	  has	  been	  
reported	  in	  atherosclerotic	  plaques	  in	  humans	  (Kuo	  et	  al.,	  1993),	  it	  is	  possible	  therefore	  that	  
NOD1	  contributes	  to	  vascular	  inflammation	  and	  dysfunction.	  However,	  the	  role	  of	  NOD1	  in	  
atherosclerosis	  has	  not	  been	  studied	  directly.	  By	  contrast,	  our	  group	  has	  shown	  a	  clear	  role	  
for	   NOD1	   in	   vascular	   dysfunction,	   and	   cardiovascular	   collapse	   in	   sepsis	   has	   been	  
demonstrated	  where	  effects	  were	  seen	  to	  be	  more	  severe	  than	  those	  induced	  by	  the	  TLR4	  
agonists	   LPS	   (Cartwright	   et	   al.,	   2007).	  We	  have	   gone	   on	   to	   show	   that	   human	   endothelial	  
cells	   express	   distinct	   and	   discernable	   TLR4	   and	   NOD1	   pathways	   via	   separate	   signalling	  
pathways	  which	  can	  be	  targeted	  selectively	  with	  pharmacological	  antagonists	   (Gatheral	  et	  
al.,	   2012).	   Other	   NLRs,	   included	  NLRP3	   have	   been	   associated	  with	   cardiovascular	   disease	  
(Duewell	   et	   al.,	   2010;	   Mallat	   et	   al.,	   2001).	   The	   study	   of	   NLR	   biology	   and	   function	   in	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cardiovascular	  cells	  and	  tissues	  thus	  represents	  an	  active	  area	  of	  research	  that	  could	  yield	  
new	  insights	  in	  to	  disease	  pathophysiology	  and	  new	  targets	  for	  therapy.	  
	  
	  
Figure	  1.4	  Summary	  of	  Toll-­‐like	  receptor	  (TLR)	  and	  nucleotide	  oligomerisation	  domain	  (NOD)	  
signalling.	   Abbreviations:	   myeloid	   differentiation	   factor-­‐88	   (MyD88),	   Mitogen	   activated	  
protein	  kinase-­‐3	  (MAP3K),	  Receptor	  interacting	  protein	  (RIP),	  Tumour	  necrosis	  factor-­‐alpha	  
(TNFα)	  receptor	  associated	  factor	  (TRAF)-­‐3/6.	  Transforming	  growth	  factor	  β	  activated	  kinase	  
(TAK),	   TAK-­‐1	   binding	   protein	   (TAB),	   TIR-­‐containing	   adaptor	   protein	   inducing	   interferon-­‐β	  
(TRIF),	   TRIF	   related	   adaptor	   molecule	   (TRAM),	   Interferon	   (IFN)	   regulatory	   factor	   (IRF),	  
Nuclear	   factor	   kappa	  B	   (NF-­‐κB),	   C-­‐jun	  N-­‐terminal	   kinase	   (JNK),	   extracullar	   signal	   activated	  
kinase	   (ERK),	   Interleukin	   (IL)-­‐1	   receptor	   associated	   kinase	   (IRAK),	   IκB	   kinase	   (IKK),	   TAK-­‐


































































1.4	  STEM	  CELLS	  AND	  REGENERATIVE	  MEDICINE	  
Regenerative	  medicine	   and	   stem	   cell	   biology	   are	   offering	   significant	   advances	   in	   how	  we	  
treat	  disease.	  Stem	  cells	  can	  now	  be	  isolated,	  engineered	  in	  vitro	  and	  used	  to	  regrow	  and/or	  
repair	  tissues	  damaged	  by	  disease.	  These	  stem	  cell	  technologies	  can	  also	  be	  used	  to	  develop	  
in	  vitro	  assays	  to	  test	  efficacy	  and	  toxicity	  of	  drugs,	  this	  is	  particularly	  relevant	  to	  the	  testing	  
of	  biological	  drugs	  designed	  for	  a	  personalised	  medicine	  approach.	  In	  my	  PhD	  thesis	  I	  have	  
studied	   the	  morphology	   and	   function	   of	   endothelial	   cells	   derived	   from	   various	   stem	   cell	  
sources.	  I	  have	  gone	  on	  to	  use	  stem	  cells	  in	  the	  specific	  application	  of	  bioassays	  for	  testing	  
side	  effects	  of	  drugs	  like	  the	  CD28	  superagonist	  TGN1412.	  I	  will	  therefore	  introduce	  in	  some	  
detail	  the	  general	  area	  of	  stem	  cell	  biology,	  the	  specific	  application	  and	  usefulness	  of	  this	  in	  
terms	  of	   the	  endothelium	  and,	   finally,	   the	  area	  of	  human	   tissue	  bioassays	  and	  associated	  
limitations.	  
	  
Stem	  cells	  are	  cells	   that	  have	  the	  capacity	  to	  self-­‐renew	  an	  unlimited	  number	  of	  times,	  or	  
differentiate	   in	  any	  number	  of	  specialised	  cell	   types	   in	   the	  body.	  Stem	  cells	   that	  can	   form	  
any	  cell	   type	   in	  the	  body	  are	  defined	  as	  pluripotent	  whereas	  cells	  that	   form	  a	  pre-­‐defined	  
lineage	   of	   cells	   are	   defined	   as	   multipotent.	   Multipotent	   progenitors	   can	   arise	   from	  
pluripotent	   stem	   cells	   but	   this	   is	   not	   always	   the	   case.	   For	   the	  purpose	  of	  my	   thesis	   I	  will	  
specifically	   introduce	   the	   area	   of	   (i)	   embryonic	   stem	   cells,	   (ii),	   adult	   stem	   cells	   and	   (iii)	  




1.4.1	  	   Early	  studies	  on	  rodent,	  primate	  and	  human	  embryonic	  stem	  cells	  	  
The	   term	   stem	   cell	   was	   introduced	   based	   on	   analysis	   of	   embryo	   development,	   where	   it	  
seemed	  logical	  that	  all	  cells	  in	  the	  body	  must	  ‘stem’	  from	  a	  special	  group	  of	  cells.	  Knowledge	  
on	  the	  mechanisms	  by	  which	  stem	  cells	  differentiate,	  and	  their	  proliferative	  potential	  came	  
from	  studies	  on	  spermatogenesis	  (Oakberg,	  1971).	  True	  embryonic	  stem	  cells	  however	  are	  
obtained	  from	  pre-­‐implantation	  blastocysts.	  The	  first	  successful	  isolation	  of	  stem	  cells	  from	  
embryos	  was	  performed	  in	  mice	  (Martin,	  1981).	  However,	  we	  now	  have	  the	  technology	  to	  
isolate	  and	  study	  stem	  cells	   from	  human	  embryos.	  This	  was	  pioneered	  by	  James	  Thomson	  
and	   colleagues	   at	   the	   University	   of	   Wisconsin	   (Thomson	   et	   al.,	   1998).	   Indeed,	   James	  
Thomson	  was	  recognised	  by	  Time	  Magazine	  as	  ‘the	  man	  who	  brought	  you	  stem	  cells’	  	  (Time	  
Magazine,	   August	   20th,	   2001).	   For	   ethical	   and	   technical	   reasons	   at	   the	   time,	   early	   work	  
leading	   to	   the	   ultimate	   isolation	   of	   stem	   cells	   from	   human	   embryos	   was	   carried	   in	   non-­‐
human	  primates,	  specifically	  two	  species	  of	  rhesus	  monkey	  (Macaca	  mulatta	  and	  Callithrix	  
jacchus).	   In	   order	   to	   draw	   conclusions	   on	   how	   closely	   these	   primate	   stem	   cells	   might	  
resemble	   human	   stem	   cells,	   Thomsons	   group	   used	   human	   embryonal	   carcinoma	   cells	   as	  
comparators	   (Thomson	   et	   al.,	   1995).	   Human	   embryonal	   carcinoma	   cells	   are	   derived	   from	  
teratomas	   and	   express	   stage	   specific	   embryonic	   antigen	   (SSEA)-­‐3,	   SSEA-­‐4,	   TRA-­‐1-­‐60	   and	  
TRA-­‐1-­‐81	  (Andrews	  et	  al.,	  1984).	  Positive	  expression	  of	  each	  of	  these	  were	  found	  in	  the	  cells	  
isolated	   from	  monkey	  embryo	  and	  allowed	   for	   the	   reasonable	  conclusion	   that	   these	  stem	  
cells	  were	   closely	   related	   to	   human	  embryonic	   stem	   cells.	   Thus,	   primate	   embryonic	   stem	  
cells	   were	   thought	   to	   be	   a	   superior	   tool	   to	   mouse	   embryonic	   stem	   cells	   and	   embryonal	  
carcinoma	  cells	   for	   their	   closer	   relationship	   to	  human	  cells,	   and	   in	   the	   case	  of	   embryonal	  




However,	   in	   1998,	   pioneering	   research	   demonstrated	   that	   human	   embryonic	   stem	   cells	  
could	  be	   isolated	  from	  human	  embryos	  surplus	  to	   in	  vitro	   fertilisation	  programs.	  Fourteen	  
inner	   cell	  masses	  were	   isolated	   from	   five	  pre-­‐implantation	  blastocysts	   in	   this	   study.	   From	  
these,	   five	   human	   embryonic	   stem	   cell	   lines	   (hESC)	  were	   derived	   (Thomson	   et	   al.,	   1998).	  
These	  cells	  were	  also	  shown	  to	  express	  SSEA-­‐3	  and	  4,	  TRA-­‐1-­‐60	  and	  TRA-­‐1-­‐81	  and	  fulfilled	  
the	   criteria	   set	   by	   Thomason	   in	   primate	   embryonic	   stem	   cells.	   These	   cell	   lines	   were	  
subsequently	   cryopreserved	   and	   have	   been	   used	   extensively	   to	   study	   developmental	  
biology,	  model	   human	  disease,	   applied	   to	   in	   vitro	   assays	   and	  organ	   engineering.	  Notably,	  
the	  first	  clinical	  trial	  of	  hESC	  differentiated	  to	  nerve	  cells	  was	  commenced	  in	  2009	  and,	  after	  
delay,	  is	  ongoing.	  A	  further	  clinical	  trial	  using	  hESC-­‐derived	  retinal	  pigmented	  epithelial	  cells	  
and	  early	  data	  indicates	  safety	  of	  the	  approach	  (Schwartz	  et	  al.,	  2012).	  
	  
	  1.4.2	  	   Adult	  stem	  cells	  
Knowledge	  that	  a	  population	  of	  cells	  existed	  in	  the	  bone	  marrow	  emerged	  from	  two	  ground	  
breaking	  studies	  in	  mice.	  In	  1949	  Leon	  Jacobson	  demonstrated	  that	  mice	  could	  be	  protected	  
from	   lethal	   ionising	   radiation	  by	  shielding	   the	   femur	   (Jacobson	  et	  al.,	  1949).	  Then	   in	  1951	  
another	  group	  demonstrated	  that	  intravenous	  infusions	  of	  bone	  marrow	  in	  mice	  could	  also	  
protect	  against	  radiation	  (LORENZ	  et	  al.,	  1951).	  These	  data	  suggested	  that	  the	  bone	  marrow	  
was	  a	  source	  of	  circulating	  cells,	  and	  it	  was	  Barnes	  and	  Louitt	  who	  first	  suggested	  that	  these	  
effects	  of	  femur	  shielding,	  were	  a	  result	  of	  the	  protection	  of	  stem	  cells	  in	  the	  bone	  marrow	  
(BARNES	   and	   LOUTIT,	   1955).	   This	   provided	   the	   first	   evidence	   of	   adult	   stem	   cells	   beyond	  
those	   involved	   in	   spermatogenesis	   and	  provided	   the	   foundations	   for	   cell	   therapy	   and	   the	  
first	   bone	  marrow	   transplants	   (THOMAS	   et	   al.,	   1959).	   These	   adult	   stem	   cells	   circulate	   in	  
blood	  and	  reside	  in	  tissues	  of	  the	  body.	  These	  cells	  are	  typically	  multipotent,	  which	  means	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they	  act	  as	  ‘progenitors’	  or	  ‘precursors’	  to	  many	  but	  not	  all	  differentiated	  cell	  types.	  Adult	  
stem	   cells	   were	   in	   fact	   the	   first	   type	   of	   stem	   cell	   to	   be	   isolated	   and	   expanded	   from	  
peripheral	  blood	  of	  mice	   in	  the	   lab	  (GOODMAN	  and	  HODGSON,	  1962).	  These	  cells	  derived	  
from	   bone	  marrow	   and	   peripheral	   blood,	   and	   in	   line	  with	   data	   from	   early	   bone	  marrow	  
transplants	  in	  humans,	  have	  been	  studied	  in	  relation	  to	  cancer	  (Metcalf	  and	  Moore,	  1970)	  
and	  can	  now	  be	  isolated	  and	  preserved	  for	  use	  in	  bone	  marrow	  transplants	  and	  cell	  therapy	  
for	  cancer	  	  (Goldman	  et	  al.,	  1978).	  
	  
Indeed,	   adult	   stem	   cell	   approaches	   and	   their	   role	   in	   human	   physiology	   continue	   to	   be	  
studied	   and	   pioneered	   today.	   It	   is	   now	   known	   that	  many	   populations	   of	   adult	   stem	   cells	  
exist	  and	   these	  cells	  participate	   in	  endogenous	   repair	  of	  organs	  and	   tissues	   in	   the	  human	  
body.	  In	  fact,	  it	  is	  now	  possible	  to	  view	  many	  diseases,	  including	  cardiovascular	  disease,	  as	  
‘diseases	  of	   failed	   repair’.	   That	   is	   to	   say,	  patients	  who	  develop	  disease	  or	   those	  at	  higher	  
risk,	   have	   progenitor	   cells	  with	   reduced	  or	   damaged	   capacity	   to	   repair	   tissues	   (Hill	   et	   al.,	  
2003).	  Whether	  this	  is	  true,	  and	  reductions	  or	  increases	  in	  adult	  progenitor	  cells	  are	  reactive	  
or	  causative	  is	  unclear.	  To	  illustrate	  this,	  I	  will	  take	  endothelial	  progenitor	  cells	  (EPCs)	  as	  an	  
example	  which	  epitomise	  the	  current	  thinking	  on	  the	  role	  of	  adult	  progenitor	  cells	  in	  human	  
biology	  and	  disease.	  
	  
Endothelial	  Progenitor	  Cells	  (EPCs)	  	  
EPCs	  were	   first	   defined	   in	   1997	   by	   Asahara	   et	   al	   (Asahara	   et	   al.,	   1997).	   These	   cells	  were	  
initially	  defined	  as	  CD34+,	  CD133+,	  VEGFR+	  circulating	  progenitor	  cells	  that	  were	  involved	  in	  
vessel	  homeostasis	  and	  post-­‐natal	  angiogenesis.	  This	  marked	  a	  substantial	  paradigm	  shift	  in	  
how	  we	  think	  about	  stem	  cells	  and	  vascular	  biology.	  A	  great	  number	  of	  studies	  followed	  that	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aimed	   to	   further	   define	   this	   novel	   cell	   population	   and	   these	   are	   discussed	   later	   in	   the	  
context	   of	   other	   stem	   cell	   derived	   endothelial	   cells.	   An	   early	   clinical	   study	   on	   circulating	  
levels	   of	   EPCs	   demonstrated	   that	   EPC	   numbers	   in	   the	   peripheral	   blood	   were	   lower	   in	  
patients	  with	  cardiovascular	  disease,	  and	  that	  this	  correlated	  with	  severity	  of	  disease	  (Hill	  et	  
al.,	   2003).	   This	   led	   to	   the	   suggestion	   that	   EPCs	   are	   involved	   in	   a	   protective	   endogenous	  
repair	  system,	  and	  if	  the	  performance	  of	  this	  repair	  is	  reduced,	  disease	  can	  result.	  In	  further	  
support	  of	   this,	  Xu	  et	  al.	   illustrated	  that	   the	  endothelial	  cells	   found	  on	  vein	   isografts	   from	  
wild	  type	  mice	  in	  TIE2-­‐LacZ	  mice	  were	  negative	  for	  β-­‐gal	  staining,	  and	  therefore	  suggested	  
that	  these	  were	  derived	  from	  a	  recipient	  progenitor	  cell	  (Xu	  et	  al.,	  2003).	  They	  went	  on	  to	  
show	  that	  these	  recipient	  cells	  were	  derived	  in	  part	  from	  a	  bone	  marrow	  population	  of	  cells	  
and	  that	  this	  function	  was	  reduced	  in	  ApoE(-­‐/-­‐)	  hyperlipidaemic	  mice.	  
	  
In	  line	  with	  the	  apparent	  role	  of	  reduced	  adult	  progenitor	  cell	  number	  in	  disease,	  strategies	  
to	   boost	   adult	   progenitor	   cell	   populations	   have	   been	   developed.	   Indeed,	   there	   are	   now	  
reports	   that	   the	   beneficial	   effects	   of	   some	   key	   cardiovascular	   therapies	   that	   are	   already	  
available,	   such	  as	   statins	   can	  be	  attributed	   to	  boosting	  of	   EPC	  number	   (Vasa	  et	   al.,	   2001;	  
Walter	  et	  al.,	  2002).	  	  
	  
1.4.3	  	   Induced	  pluripotent	  stem	  cells	  
HESC	  have	  been	   limited	  by	  ethical	   concerns,	   their	  potential	   to	   cause	   immunogenicity	   and	  
teratoma	   formation	   (Knoepfler,	   2009).	   A	   research	   goal	   in	   the	   field	   of	   stem	   cell	   biology	  
therefore	  has	  been	   to	  overcome	   this.	   Indeed,	   autologous	   adult	   progenitor	   cells	   provide	   a	  
way	   around	   immunogenicity,	   as	   the	   patient’s	   own	   cells	   can	   be	   isolated	   and	   used.	   Adult	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progenitor	   stem	  cells	   however	   are	   less	  well	   characterised,	   particularly	   in	  disease	   settings,	  
and	  are	  not	  fully	  pluripotent.	  	  
	  
In	  2007	  a	  group	  in	  Japan,	  led	  by	  Prof.	  Shinya	  Yamanaka	  hypothesised	  that	  genes	  known	  to	  
maintain	  embryonic	  stem	  cell	  phenotypes	  could	  theoretically	  be	  used	  to	  reprogram	  somatic	  
cells	  from	  adults	   in	  to	  pluripotent	  phenotypes	  (Takahashi	  et	  al.,	  2007).	  The	  idea	  of	  cellular	  
reprogramming	  was	  not	  new	  as	   this	  was	  based	  on	   retro-­‐viral	   transcription,	  and	  had	  been	  
demonstrated	  previously	  by	  nuclear	  transfer.	  This	  nuclear	  transfer	  involved	  the	  isolation	  of	  
a	   host	   embryo	   and	   transfer	   of	   a	   somatic	   cell	   nucleus	   in	   to	   the	   cells	   were	   it	   assumes	   an	  
embryonic	  like	  state	  (McLaren,	  2000;	  Wilmut	  et	  al.,	  1997).	  This	  strategy	  formed	  the	  basis	  for	  
the	   cloning	   of	  Dolly	   the	   Sheep	   (BBC	  News,	   22	   February	   1997).	   For	   applications	   in	   human	  
tissue	  engineering	  however,	  a	  more	  controlled	  and	  embryo	  free	  approach	  was	  required.	  The	  
idea	  of	  reprograming	  cells	  with	  the	  intention	  to	  gain	  control	  of	  their	  phenotype	  in	  vitro	  was	  
revolutionary.	  It	  was	  known	  in	  2006	  that	  several	  genes	  are	  required	  for	  mouse	  and	  human	  
embryonic	  stem	  cells	  to	  maintain	  the	  pluripotency.	  These	  include	  the	  transcription	  factors,	  
Nanog,	  Oct3/4	  and	  Sox2.	  Other	  genes	  known	  to	  regulate	  stem	  cell	  proliferation	  were	  also	  
known	  and	  included	  Stat3,	  E-­‐Ras,	  Klf4	  and	  c-­‐myc.	   In	  2007,	  Yamanaka	  et	  al.	  constructed	  an	  
assay	  in	  which	  pluripotency	  could	  be	  detected	  as	  resistance	  to	  the	  drug	  G148	  (Takahashi	  et	  
al.,	  2007).	  This	  was	  achieved	  by	  transfecting	  cells	  with	  the	  G148	  resistance	  gene	  (βgeo)	  into	  
the	  promoter	  region	  of	  gene	  Fbx15,	  which	  is	  expressed	  by	  mouse	  embryonic	  stem	  cells	  but	  
not	  required	  for	  pluripotency.	  	  
	  
Using	  this	  assay,	  Takahashi	  et	  al.	  demonstrated	  that	  introduction	  of	  four	  factors;	  Oct4,	  Sox2,	  
klf4	  and	  c-­‐myc	   into	  mouse	  or	  adult	   fibroblasts	  gave	  rise	  to	  a	  cell	  population	  with	   identical	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properties	  to	  embryonic	  stem	  cells.	  These	  cells	  were	  termed	  induced	  pluripotent	  stem	  cells	  
(iPSCs)	   and	   have	   subsequently	   been	   shown	   to	   be	   differentiable	   in	   to	   endothelial	   cells	  
(Homma	  et	  al.,	  2010;	  Taura	  et	  al.,	  2009),	  vascular	  smooth	  muscle	  cells,	  T-­‐lymphocytes,	  and	  
cardiac	   myocytes.	   Other	   somatic	   cells	   have	   also	   been	   used	   a	   starting	  material	   for	   iPSCs.	  
These	   include	   neuronal	   cells	   and	   another	   putative	   progenitor	   cell	   derived	   cell,	   blood	  
outgrowth	  endothelial	  cells	   (BOEC).	  BOEC	  are	  thought	  to	  belong	  to	  the	  family	  of	  EPCs	  and	  
are	   discussed	   in	   detail	   later.	   In	   this	   study	   BOEC	   were	   reprogrammed	   to	   form	   induced	  
pluripotent	   stem	   cells	   and	   then	  differentiated	   in	   to	   induced	  pluripotent	   stem	   cell-­‐derived	  
endothelial	  cells.	  The	  rationale	  for	  this	  was	  that	  this	  kind	  of	  approach	  would	  overcome	  the	  
limitations	  of	  low	  cell	  number	  of	  adult	  progenitors,	  but	  will	  still	  allow	  individual	  progenitor	  
cell	  biology	  to	  be	  captured	  by	  the	   induced	  pluripotent	  stem	  cells	  which	  might	  go	  on	  to	  be	  
used	  as	  therapy.	  Like	  adult	  progenitors	  therefore,	  iPSC-­‐derived	  cells	  can	  be	  used	  to	  engineer	  
tissues	  or	  organs	  for	  individual	  donors.	  	  
	  
Induced	  pluripotent	  stem	  cell	  technology	  is	  not	  without	  its	  problems.	  Whilst	  these	  cells	  are	  
theoretically	   superior	   to	   other	   stem	   cells,	   the	   fact	   these	   cells	   have	   undergone	   genetic	  
manipulation	   represents	   a	   potential	   problem.	   As	   these	   cells	   have	   been	   transfected	   with	  
genes	  from	  a	  retrovirus	  they	  may	  not	  be	  safe	  for	  use	  in	  humans.	  The	  retroviral	  and	  lentiviral	  
based	   reprogramming	   used,	   whilst	   efficacious,	   means	   that	   viral	   genes	   are	   permanently	  
integrated	  into	  the	  human	  genome	  which	  poses	  a	  risk	  of	  mutagenesis	  and	  re-­‐activation	  of	  
re-­‐programming	  factors.	  In	  short,	  these	  cell	  therapy	  approaches,	  like	  embryonic	  stem	  cells,	  
could	  conceivably	  result	  in	  tumours.	  	  
Approaches	   to	  over	   come	   this	  have	  been	   investigated.	   It	   has	  been	   shown	  when	  neuronal	  
cells	   are	   used	   as	   starting	  material	   for	   example,	   that	   they	   require	   fewer	   transgenes	   to	   be	  
61	  
	  
incorporated	  to	  achieve	  an	  embryonic	   like	  state	   (Kim	  et	  al.,	  2008).	  This	   is	   thought	   to	  be	  a	  
result	   of	   higher	   endogenous	   levels	   of	   c-­‐myc	   and	   klf4	   in	   neuronal	   cells.	   It	   is	   noteworthy	  
however,	  that	  neuronal	  cells	  are	  relatively	  inaccessible	  compared	  to	  fibroblasts,	  and	  so	  this	  
approach	   rather	   replaces	   one	   limitation	   with	   another.	   Another	   focus	   in	   this	   area	   is	   to	  
develop	  transgene	  free	  approaches	  to	  incorporating	  pluripotency	  factors	  in	  to	  somatic	  cells.	  
Transgene	  free	  approaches	  to	  gene	  therapy	  are	  being	  developed	  for	  a	  range	  of	  gene	  therapy	  
applications.	  These	  include	  use	  of	  transposons	  such	  as	  PiggyBac.	  Transposon	  transgenesis	  is	  
a	  new	  technology	  which	  involves	  introduction	  of	  naked	  DNA	  using	  common	  plasmids,	  which	  
can	  then	  be	  excised,	  and	  so	  provide	  a	  safer	  alternative	  to	  using	  viral	  transfection	  protocols.	  
In	  the	  case	  of	   induced	  pluripotent	  stem	  cell	  protocols,	   the	  circular	  DNA	  transposon	  vector	  
PiggyBac	  can	  be	  loaded	  with	  the	  transcription	  factors	  c-­‐myc,	  Klf4,	  Oct4	  and	  Sox2	  under	  the	  
control	  of	  a	  doxycycline	   inducible	  promoter.	  This	  vector	  (PiggyBac-­‐TET-­‐MKOS)	  can	  then	  be	  
chemically	   transfected	   in	   to	  somatic	  cells,	   resulting	   in	  reprogramming	  and	  acquisition	  of	  a	  
pluripotent	   stem	   cell	   phenotype	   and	   the	   remaining	   PiggyBac-­‐TET	   elements	   removed	   by	  
addition	   of	   PiggyBac-­‐transposons.	   This	   results	   in	   a	   population	   of	   transgene	   free	   induced	  
pluripotent	   stem	   cells.	   Assessment	   of	   safety	   of	   stem	   cell	   therapies,	   especially	   those	   that	  
have	  undergone	  manipulation,	  will	  be	  critical	  to	  success.	  
	  
The	  applications	  of	  different	  stem	  cells,	  but	  requirement	  for	  functional	  characterisation,	  are	  






Figure	   1.5	   Applications	   of	   different	   stem	   cells	   and	   stem	   cell	   derived	   cells	   in	   research	   and	  
therapy.	   Prior	   to	   use	   however	   these	   cells	  must	   be	   characterised	   for	   key	   hallmarks	   of	   cell	  
phenotype.	  Differences	  in	  phenotype	  may	  be	  relevant	  to	  disease	  modelling	  and/or	  safety	  of	  




















1.4.4	  	   Building	  organs	  and	  modeling	  disease	  in	  a	  dish	  
The	  concept	  of	  building	  human	  organs	  for	  transplant	  has	  been	  around	  since	  the	  mid-­‐1930s.	  
In	   a	   book	   entitled	   ‘The	   Culture	   of	   Organs’	   by	   Alexis	   Carrel	   (Figure	   1.6)	   and	   famed	   pilot,	  
Charles	  Linbergh	  reported	  a	  device	   that	  allowed	  organs	   to	  exist	  outside	  the	  body	  and	   laid	  
the	  foundations	  for	  the	  engineering	  of	  living	  organs	  and	  tissues	  in	  the	  laboratory.	  With	  the	  
advent	   of	   stem	   cell	   technology,	   the	   idea	   of	   building	   organs	   and	   tissues	   in	   the	   lab	   has	  
become	  a	  reality.	  	  
	  
What	  do	  you	  need	  to	  build	  an	  organ?	  
1. A	  scaffold	  or	  platform	  on	  which	  to	  build	  complex	  3-­‐dimensional	  structures	  
2. A	  source	  of	  cells	  specific	  for	  the	  organ	  (cardiomyocytes,	  renal	  cells	  etc.)	  
3. A	  means	   to	   vascularise	   the	   tissue	   (stem	  cell	   derived	  vascular	   endothelial	   cells	   or	  
endothelial	  cells	  from	  vessels	  harvested	  and	  grown	  in	  culture)	  
	  
Thus,	   and	   as	   alluded	   to,	   healthy	   endothelial	   cells	   will	   be	   critical	   for	   any	   and	   all	   organ	  
regeneration	  programs.	  The	  need	  for	  greater	  therapeutic	  options	  in	  cardiovascular	  disease	  
is	  clear.	  The	  British	  Heart	  Foundation	  reports	  that	  three	  people	  die	  every	  day	   in	  UK	  whilst	  
waiting	  for	  an	  organ	  transplant	  and	  even	  of	  those	  receiving	  donor	  organs;	  these	  are	  limited	  
by	  post-­‐surgery	  complications.	  The	  ability	  to	  engineer	  organs	  and	  tissues	  as	  well	  as	  develop	  
therapies	  to	  regenerate	  tissues	  in	  the	  body	  thus	  has	  profound	  implications.	  This	  ability	  has	  

























Figure	  1.	  6.	  Origins	  of	  tissue	  and	  organ	  engineering	  from	  articles	  published	  in	  1930-­‐38.	  Book	  
cover	  redrawn	  from	  original:	  www.charleslindbergh.com.	  
	  
	  
Stem	  cells	  can	  also	  be	  used	  to	  model	  diseases	  ‘in	  a	  dish’.	  With	  the	  development	  of	  protocols	  
to	   differentiate	   iPSC	   and	   adult	   progenitor	   cells	   in	   the	   lab,	   we	   can	   now	   derive	   cells	   from	  
individual	   patients.	   This	   is	   particularly	   important	   when	   terminally	   differentiated	   cells	   like	  
neurones	  or	  cardiac	  myocytes	  are	  needed.	  One	  key	  example	  of	  the	  power	  of	  this	  approach	  
to	  research	  is	  in	  motor	  neuron	  disease.	  In	  a	  series	  of	  studies	  in	  2008	  and	  2009	  (Dimos	  et	  al.,	  
2008;	  Karumbayaram	  et	  al.,	  2009)	  induced	  pluripotent	  stem	  cells	  were	  derived	  from	  an	  82-­‐
year	  patient	  with	  motor	  neuron	  disease,	  differentiated	   in	  to	  motor	  neurons	  and	  shown	  to	  
recapitulate	   the	  disease	  versus	  healthy	   cells.	   This	  paved	   the	  way	   for	   further	   studies	  using	  
motor	  neurons	  derived	  from	  patient	  stem	  cells	  and	  led	  to	  the	  discovery	  of	  a	  novel	  pathway	  
(increased	   transactivase	   response	   DNA-­‐binding	   protein-­‐43	   (TDP-­‐43))	   involved	   in	   motor	  
neuron	   disease	   (Serio	   et	   al.,	   2013).	   Extensive	   examples	   of	   this	   exist	   in	   the	   literature.	   	   In	  

















right	  ventricular	  dysplasia	  and	  demonstrated	  for	  the	  first	  time	  that	  handling	  of	  metabolism	  
by	  these	  cells	  differed	  from	  healthy	  cells,	  and	  so	  proposed	  a	  novel	  targetable	  pathway.	  It	  is	  
important	  to	  note	  with	  this	  information,	  caution	  should	  be	  taken	  when	  considering	  these	  as	  
‘autologous’	  therapies.	  Autologous	  therapy	  might	  be	  advantageous	  in	  terms	  of	  overcoming	  
immunogenicity,	  but	  knowing	  that	  these	  cells	  recapitulate	  disease	  states	  means	  these	  cells	  
might	  not	  represent	  optimal	  stem	  cell	  therapies	  for	  patients.	  	  
	  
Adult	  stem	  cell-­‐derived	  cells	  have	  also	  been	  employed	  in	  disease	  modelling.	  As	  this	  is	  a	  key	  
feature	  of	  my	  PhD,	  this	  is	  discussed	  later	  in	  the	  context	  of	  applications	  of	  stem	  cell	  derived	  
endothelial	  cells.	  The	  current	  knowledge	  on	  stem	  cell-­‐derived	  endothelial	  cells,	  examples	  of	  
their	  use	   in	   therapy	  and	  engineering,	  and	   in	  vitro	   research	  will	  now	  be	  discussed.	   Indeed,	  
the	  goal	  of	  my	  PhD	  has	  been	  to	  build	  on	  this	  in	  terms	  of	  characterisation	  of	  these	  cells	  and	  











1.5	  STEM	  CELL	  DERIVED	  ENDOTHELIAL	  CELLS	  	  
Endothelial	  cells	  can	  be	  derived	  from,	  human	  embryonic	  stem	  cells	  (Levenberg	  et	  al.,	  2002),	  
adult	   progenitors	   (Ingram	   et	   al.,	   2004)	   and	   induced	   pluripotent	   stem	   cells	   (Taura	   et	   al.,	  
2009).	   As	   alluded	   to,	   these	   cells	   have	   potentially	   powerful	   applications	   for	   the	   study	   of	  
endothelial	   cell	  biology;	  offer	  new	  avenues	   for	  endothelial	   cell	  based	   therapy;	  and	  will	  be	  
essential	  for	  organ	  regeneration	  programmes.	  
	  
1.5.1	  	   Human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC)	  
hESC-­‐EC	   were	   first	   grown	   from	   undifferentiated	   hESC	   by	   Robert	   Langer’s	   lab	   in	   2002	  
(Levenberg	   et	   al.,	   2002).	   This	   protocol	   relied	   on	   allowing	   hESC	   to	   differentiate	  
spontaneously,	  which	  can	  be	  achieved	  by	  growing	  hESC	  on	  ultra-­‐low	  attachment	  cell	  culture	  
plates.	  This	  spontaneous	  differentiation	  results	   in	  the	  formation	  of	  complex	  3-­‐dimensional	  
structures	   known	  as	   embryoid	  bodies.	  Human	  embryoid	  bodies	   grown	   in	   the	  presence	  of	  
vascular	  growth	  hormones,	  including	  VEGF,	  express	  a	  network	  of	  vascular-­‐like	  channels	  that	  
express	   CD31	   and	   VE-­‐cadherin	   (Levenberg	   et	   al.,	   2002).	   As	   the	   differentiation	   proceeds,	  
pluripotency	  genes	  such	  as	  Oct4	  subsequently	  decrease,	  and	  this	   is	   favourable	   in	  terms	  of	  
reducing	   risk	   of	   tumourgenecity	   in	   stem	   cell	   therapies.	   A	   purer	   population	   of	   endothelial	  
cells	   was	   then	   isolated	   from	   embryoid	   bodies	   by	   isolating	   and	   expanding	   a	   CD31+	  
population	   by	   fluorescence	   activated	   cell	   sorting	   (FACS).	   Once	   isolated,	   hESC-­‐EC	   express	  
endothelial	  cell	  markers	  such	  as	  CD31	  and	  VE-­‐cadherin	  (Nourse	  et	  al.,	  2010).	  In	  early	  studies,	  
this	  kind	  of	  characterisation	  has	  typically	  been	  the	  extent	  of	  the	  in	  vitro	  characterisation	  of	  
these	   cells	   as	   authentic	   ‘endothelial	   cells’	   versus	   endothelial	   cells	   from	   vessels	   (normally	  
human	  umbilical	  veins;	  HUVEC).	  A	  number	  of	  papers	  have	  demonstrated	  that	  hESC-­‐EC	  form	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vascular	  networks	  in	  mice	  with	  severe	  combined	  immunodeficiency	  disease	  (SCID)	  (Ferreira	  
et	   al.,	   2007)	   when	   seeded	   on	   to	   biodegradable	   scaffolds	   or	   when	   injected	   directly	   to	  
ischemic	   tissue	   including	   infarcted	  myocardium	   (Kraehenbuehl	   et	   al.,	   2011).	   Others	   have	  
also	   shown	   that	  hESC-­‐EC	  align	   to	   shear	   stress	   (Metallo	  et	  al.,	  2008)	  but	   this	  has	  not	  been	  
tested	  routinely,	  nor	  has	  the	  ability	  of	  hESC-­‐EC	  to	  release	  vasoactive	  hormones	  been	  studied	  
systematically.	   Thus,	   whilst	   hESC-­‐EC	   have	   potential	   applications	   in	   therapy	   and	   tissue	  
engineering,	   there	   is	   arguably	   a	   relative	   lack	   of	   knowledge	   on	   critical	   endothelial	   cell	  
pathways	   in	   these	   cells.	   Indeed,	   protocols	   have	  been	  developed	   to	  produce	  hESC-­‐EC	   that	  
are	  suitable	   for	  clinical	  evaluation	   (Kaupisch	  et	  al.,	  2012),	  which	  could	  be	  used	  to	  prepare	  
cell	  therapies	  for	  large	  populations	  of	  patients,	  and	  thorough	  assessment	  of	  endothelial	  cell	  
phenotype	  will	  be	  critical.	  
	  
hESC-­‐EC	   have	   also	   been	   used	   to	   study	   the	   development	   of	   the	   cardiovascular	   system.	  
Indeed,	  elucidation	  of	  the	  differentiation	  pathway	  of	  endothelial	  cells	  from	  progenitors	  will	  
be	  essential	   for	   success	  of	   stem	  cell	   endothelial	   cell	   based	   therapies	   in	   the	   future.	   This	   is	  
true	   for	   all	   stem	   cell-­‐derived	   endothelial	   cells	   (embryonic,	   adult	   and	   induced	   pluripotent	  
derived)	  and	  so	   it	  may	  be	  argued	  that	  studies	  on	  all	  different	  stem	  cell	   sources	   in	  parallel	  
will	  be	  needed	  for	  success	  in	  this	  area.	  	  
	  
As	  discussed,	  characterisation	  of	  stem	  cell	  derived	  cells	  will	  be	  essential	  to	  success;	  and	  of	  
relevance	  to	  my	  PhD,	  characterisation	  of	  stem	  cell	  derived	  endothelial	  cells.	  In	  our	  group	  we	  
have	  previously	  shown	  that	  hESC-­‐EC,	  unlike	  endothelial	  cells	  from	  vessels;	  do	  not	  respond	  to	  
the	   TLR4	   agonist,	   LPS	   (Földes	   et	   al.,	   2010).	   This	   suggested	   that	   hESC-­‐EC	   might	   have	   an	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immature	  innate	  immune	  phenotype,	  and	  has	  been	  further	  explored	  and	  expanded	  upon	  in	  
detail	  in	  the	  first	  two	  chapters	  of	  my	  PhD.	  
	  
1.5.2	  	   EPC	  and	  blood	  outgrowth	  endothelial	  cells	  (BOEC)	  
As	  discussed,	  in	  1997,	  it	  was	  suggested	  by	  Asahara	  et	  al.	  that	  a	  population	  of	  cells	  exists	  that	  
are	  derived	  from	  the	  bone	  marrow	  and	  are	  capable	  of	  differentiating	  in	  to	  endothelial	  cells	  
and	  forming	  new	  vessels	  at	  sites	  of	  ischemia	  (Asahara	  et	  al.,	  1997).	  However,	  there	  has	  been	  
controversy	  over	  the	  definition	  of	  these	  cells	  and	  their	  role	  in	  vascular	  biology.	  As	  a	  result,	  
no	  unifying	  definition	  of	  these	  cells	  exists	  and	  the	  term	  EPC	  in	  fact	  encompasses	  a	  number	  
of	   cell	   types	   with	   putative	   roles	   in	   vascular	   homeostasis	   and	   disease.	   There	   is	   some	  
agreement	   on	   the	   nature	   of	   ‘early’	   versus	   ‘late’	   outgrowth	   EPCs	   that	   can	   be	   enriched	   in	  
cultures	   using	   specific	   isolation	   protocols.	   To	   date,	   it	   appears	   that	   endothelial	   progenitor	  
cells	  can	  be	  divided	  in	  to	  two	  categories.	  
	  
1. ‘Triple	  positive	  circulating	  EPCs’	  which	  are	  endothelial	  cell-­‐like	  in	  vitro	  expressing	  the	  
three	   specific	  markers,	   (i)	   CD133	   and	   (ii)	   CD34,	   expressed	   on	   hematopoietic	   stem	  
cells	   and	   vascular	   cells	   and	   (iii)	   VEGFR2,	   expressed	   on	   endothelial	   cells;	   but	   also	  
express	  hematopoietic	  	  associated	  markers	  CD45	  and	  CD14.	  
2. Blood	   outgrowth	   endothelial	   cells	   (BOEC),	   which	   express	   the	   endothelial	   markers	  
CD31	   and	   VEGFR2	   but	   are	   negative	   for	   hematopoietic	   markers	   and	   the	   stem	   cell	  
marker	  CD133	  and	  behave	  as	  mature	  endothelial	  cells	  in	  vitro.	  
	  
The	   relationship	   between	   these	   cells	   is	   unclear	   and	   has	   been	   discussed	   widely	   in	   the	  
literature	   (Hirschi	   et	   al.,	   2008;	   Ingram	   et	   al.,	   2004;	   Timmermans	   et	   al.,	   2009).	   Circulating	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EPCs	   have	   been	   shown	   to	   arise	   from	   a	   CD45+	   hematopoietic	   stem	   cell	   population	   in	   the	  
peripheral	  blood	  and	  bone	  marrow	  mononuclear	  cells,	  but	  that	  these	  cells	  do	  not	  contribute	  
to	   endothelial	   cell	   formation	   in	   vitro	   (Case	   et	   al.,	   2007).	   In	   order	   to	   study	   the	   role	   of	  
circulating	  EPCs	   in	  vascular	  homeostasis	   in	  vivo	  a	  number	  of	  approaches	  have	  been	  taken.	  
Using	  Id-­‐1	  (which	  is	  selectively	  expressed	  in	  some	  circulating	  EPCs)	  knockdown	  in	  a	  mouse	  
model	   of	   tumor	   angiogenesis	   it	   was	   suggested	   that	   circulating	   EPCs	   are	   involved	   in	  
angiogenesis	   (Ciarrocchi	   et	   al.,	   2007).	   However,	   as	   many	   of	   the	   markers	   used	   in	   these	  
approaches	   are	   also	   expressed	   by	   mature	   endothelial	   cells	   on	   vessels	   and/or	   in	   other	  
hematopoietic	   cells	   it	   remains	   unclear	   whether	   the	   new	   vessels	   formed	   in	   these	   in	   vivo	  
models	  are	  derived	  from	  mature	  endothelial	  cells	  that	  grow	  in	  from	  adjacent	  blood	  vessels	  
or	  bone	  marrow	  derived	  cells.	  Despite	  this,	  it	  remains	  an	  accepted	  possibility	  that	  these	  cells	  
contribute	  to	  vessel	  formation	  in	  vivo	  in	  an	  indirect	  manner	  (Rehman	  et	  al.,	  2003;	  Takakura	  
et	  al.,	  2000),	  and	  that	  they	  are	  useful	  biomarkers	  of	  cardiovascular	  function	  (Hill	  et	  al.,	  2003;	  
Timmermans	   et	   al.,	   2009).	   At	   this	   stage	   however,	   circulating	   EPCs	   do	   not	   appear	   to	  
represent	  a	  useful	  resource	  for	  the	  study	  of	  endothelial	  cell	  biology	  in	  vitro,	  namely	  because	  
they	  display	  specific	  differences	   in	  morphology	  and	  function	  compared	  to	  endothelial	  cells	  
from	  mature	  vessels	  (Bompais	  et	  al.,	  2004;	  Timmermans	  et	  al.,	  2009)	  
	  
BOEC,	   which	   are	   not	   necessarily	   circulating	   EPCs	   according	   to	   the	   original	   definition,	   but	  
differentiated	  from	  another	  putative	  endothelial	  progenitor,	  were	  first	  defined	  by	  Ingram	  et	  
al.	  in	  2004	  (Ingram	  et	  al.,	  2004)	  and	  can	  be	  expanded	  to	  endothelial	  cells	  using	  well	  defined	  
protocols	  (Martin-­‐Ramirez	  et	  al.,	  2012).	  BOEC,	  like	  circulating	  EPCs,	  express	  CD34,	  CD31,	  and	  
VEGFR2,	   but	   unlike	   circulating	   EPC,	   do	   not	   express	   the	   hematopoietic	   markers,	   CD133,	  
CD14,	   and	   CD45	   (Timmermans	   et	   al.,	   2009).	   When	   expanded	   in	   vitro,	   BOEC	   have	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cobblestone	  morphology	  and	   importantly	   form	  vessels	   in	  vitro	   (Timmermans	  et	  al.,	  2007).	  
The	   precursor-­‐product	   relationship	   between	   circulating	   EPC	   and	   BOEC	   has	   been	   studied	  
extensively,	  even	  in	  the	  relatively	  short	  period	  of	  time	  since	  the	  first	  description	  of	  these	  cell	  
populations.	  In	  2000,	  Lin	  et	  al.	  (Lin	  et	  al.,	  2000)	  showed	  that	  endothelial	  cells	  expanded	  from	  
bone	   marrow	   derived	   from	   patients	   that	   had	   received	   sex	   mismatched	   bone	   marrow	  
transplants,	   were	   donor	   derived.	   From	   this,	   the	   authors	   inferred	   that	   these	   cells	   were	  
derived	  from	  circulating	  EPC	  from	  the	  bone	  marrow.	  It	  has	  since	  been	  shown	  however,	  using	  
a	   comprehensive	   in	   vitro	   approach	   and	   fluorescence	   activated	   cell	   sorting	   (FACS)	   analysis	  
that	  BOEC	  might	  be	  derived	  from	  a	  CD45-­‐	  CD34+	  population	  that	  is	  distinct	  from	  circulating	  
EPC	   (Timmermans	   et	   al.,	   2007)	   and	   this	   population	   also	   likely	   originates	   from	   the	   bone	  
marrow.	  On	  the	  other	  hand,	  BOEC	  from	  patients	  with	  chronic	  myelogenous	  leukemia	  do	  not	  
harbor	  the	  mutation	  found	  in	  hematopoietic	  cells	  in	  these	  patients	  (BCR/ABL1)	  (Otten	  et	  al.,	  
2008),	  and	  this	  suggests	  that	  BOEC	  arise	  from	  a	  clonally	  distinct	  progenitor	  or	  a	  source	  other	  
than	   the	   bone	   marrow.	   Indeed,	   others	   have	   shown	   that	   a	   CD34-­‐	   multipotent	   adult	  
progenitor	  population	   is	   the	  BOEC-­‐precursor	   (Reyes	  et	  al.,	  2002)	  but	   the	  protocol	  used	   to	  
isolate,	   and	   for	   the	   definition	   of,	   BOEC	   across	   these	   papers	   is	   varied.	   As	   a	   result,	   and	  
because	   of	   current	   technical	   limitations	   in	   protocols	   to	   discriminate	   progenitor	   cell	  
populations,	   the	   exact	   identity	   of	   the	   BOEC-­‐precursor	   remains	   uncertain	   and	   part	   of	   an	  
ongoing	  research	  question.	  Nonetheless,	  BOEC,	  unlike	  circulating	  EPC,	  have	  great	  potential	  
applications	   in	  the	  study	  of	  endothelial	  cell	  and	  vessel	  biology.	  The	  current	  dogma	  for	  the	  
origin	  of	  EPC	  and	  BOEC	  from	  CD34+	  cells	  is	  shown	  in	  Figure	  1.7	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Figure	  1.7	  Origins	  and	  functions	  of	  endothelial	  progenitors	  cells	  and	  outgrowth	  endothelial	  
(OEC)-­‐precursors.	  Blood	  vessel	  image	  from	  pixabay.com.	  
	  
1.5.3	  	   iPSC-­‐EC	  
As	   discussed	   above,	   human	   induced	   pluripotent	   stem	   cells	   (iPSC),	   first	   engineered	   by	  
Yamanaka	   in	   2007	   (Takahashi	   et	   al.,	   2007),	   are	   adult	   human	   cells	   that	   have	   been	   re-­‐
programmed	   into	   a	   pluripotent	   phenotype.	   It	   was	   later	   shown	   (Taura	   et	   al.,	   2009)	   that	  
human	  iPSC	  can	  also	  be	  differentiated	  into	  endothelial	  cells.	  Human	  iPSC-­‐EC	  have	  now	  been	  
studied	   in	   pre-­‐clinical	   models	   of	   ischemia	   and	   found	   to	   be	   capable	   of	   forming	   vascular	  
networks	   and	   increasing	   blood	   perfusion	   of	   the	   hind	   limbs	   of	   SCID	  mice	   (Rufaihah	   et	   al.,	  
2011).	   iPSC-­‐EC,	   like	   circulating	   EPC	   and	   BOEC,	   also	   hold	   the	   potential	   for	   autologous	  
therapy,	  and	  in	  the	  phenotyping	  of	  individual	  patient	  endothelial	  cells.	  BOEC	  and	  iPSC-­‐EC,	  as	  






















of	  vascular	  disease,	  and	  be	  used	  for	  personalised	  medicine	  assays.	  This	  critical	  point	  forms	  a	  
basis	  for	  my	  PhD,	  in	  that	  both	  iPSC	  and	  BOEC	  can	  potentially	  be	  used	  to	  phenotype	  patient	  
vessel	  biology.	  
	  
1.5.4	  	   Stem	  cell	  derived	  endothelial	  cells	  in	  therapy	  
To	  date,	  and	  in	  terms	  of	  stem	  cell	  derived	  endothelial	  cells,	  only	  BOEC	  and	  circulating	  EPC,	  
either	  as	  mixed	  cell	  or	  purified	  populations,	  have	  been	  applied	  as	  therapies	  for	  humans.	  The	  
potential	  for	  the	  other	  types	  of	  stem	  cell	  derived	  endothelial	  cells	  as	  therapies	  has	  however	  
been	  considered	  in	  vitro	  and	  in	  vivo.	  
	  
As	  a	  result	  of	  the	  putative	  role	  of	  EPCs	  in	  vascular	  health	  and	  vessel	  formation	  following	  the	  
injection	  of	  these	  cells	  as	  therapeutic	  cells	  has	  been	  tested	  in	  clinical	  trials.	  To	  date,	  a	  search	  
for	  ‘endothelial	  progenitor	  cells’	  on	  the	  clinical	  trials	  data	  base	  (clinicaltrials.gov)	  yields	  232	  
results	  and	  illustrates	  that	  therapeutic	  angiogenesis,	  using	  endothelial	  progenitor	  cells,	  is	  an	  
actively	  studied	  potential	  approach	  to	  cardiovascular	  disease	  treatment.	  Equally,	  endothelial	  
cells	  from	  hESC	  and	  iPSC	  also	  have	  applications	  as	  cell	  therapies	  for	  cardiovascular	  disease,	  
but	  these	  have	  not	  yet	  been	  tested	  fully	  in	  humans.	  
	  	  
In	   humans,	   use	   of	   bone	   marrow	   derived	   mononuclear	   cells	   (BMD-­‐MNCs)	   has	   been	  
successful	  in	  clinical	  trials	  of	  patients	  with	  limb	  ischemia	  (Tateishi-­‐Yuyama	  et	  al.,	  2002);	  the	  
benefits	  of	  which	  have	  been	  attributed	  to	  the	  presence	  of	  endothelial	  progenitor	  cells	  and	  
pro-­‐angiogenic	  cytokine	  secreting	  haematopoetic	  cells	  (Asahara	  et	  al.,	  1997;	  Rafii	  and	  Lyden,	  
2003;	  Tateishi-­‐Yuyama	  et	  al.,	  2002).	  The	  TOPCARE-­‐AMI	  trial	  which	  begun	  in	  2002	  has	  shown	  
that	   direct	   intramyocardial	   injection	   of	   autologous	   bone	   marrow	   derived	   EPC	   enhances	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myocardial	   regeneration	   after	   acute	  myocardial	   infarction	   (Assmus	   et	   al.,	   2002),	   and	   the	  
benefits	   persist	   across	   a	   5	   year	   follow	   up	   (Leistner	   et	   al.,	   2011).	   Furthermore,	   a	   2014	  
Cochane	   review	  based	  on	  23	   randomised	   control	   trials	   also	   reported	  moderate	  benefit	   in	  
chronic	   ischemic	   heart	   disease	   (Fisher	   et	   al.,	   2014).	   Indeed,	   whether	   BMD-­‐MNCs	   or	   the	  
peripheral	  blood	  mononuclear	  fraction	  is	  the	  optimal	  source	  of	  cytokine	  releasing	  cells	  and	  
EPCs	   is	  unclear	   (Minamino	  et	  al.,	  2002;	  Moriya	  et	  al.,	  2009;	  Tateishi-­‐Yuyama	  et	  al.,	  2002).	  
Finding	   the	   optimum	   formulation	   of	   stem	   cells	   for	   therapeutic	   benefit	   therefore	   will	   be	  
important	  to	  deterime	  in	  the	  future.	  One	  possible	  limitation	  in	  using	  mixed	  peripheral	  blood	  
leukocytes	   as	   a	   source	   of	   cells	   is	   the	   low	   levels	   of	   cells	   in	   blood	   of	   patients	   with	  
cardiovascular	   disease.	   As	   discussed	   below,	   this	   stimulated	   interest	   in	   pharmacological	  
mobilisation	   of	   cells	   to	   ensure	   sufficient	   EPC	   presence	   in	   the	   peripheral	   blood.	   EPC	  
mobilisation	   from	   the	   bone	   marrow	   and	   recruitment	   to	   sites	   of	   damage	   is	   regulated	   by	  
cytokines	  such	  as	  VEGF,	  CXCL12,	  G-­‐CSF	  and	  s-­‐KitL.	   In	  2006,	  Boyle	  et	  al.	   took	  advantage	  of	  
knowledge	   of	   this	   axis	   and	   used	   G-­‐CSF	   to	   increase	   the	   yield	   of	   CD34+	   EPCs	   in	   blood	   for	  
isolation	   and	   subsequent	   re-­‐injection	   into	   5	   patients	  with	   chronic	   ischemic	   heart	   disease.	  
Symptoms	  were	  improved	  within	  the	  12	  months	  follow-­‐up	  period,	  however	  this	  trial	  lacked	  
a	   clear	   control	   arm.	   Other	   trials,	   using	   similar	   mobilisation	   and	   isolation	   strategies	   have	  
been	  carried	  out	  and	  report	  improved	  left	  ventricular	  ejection	  fraction	  in	  a	  6-­‐month	  follow	  
up	  of	  patients	  with	  acute-­‐myocardial	  infarction	  (Li	  et	  al.,	  2007).	  
	  
As	  adult	  progenitor	  derived	  cells	  already	  exist	  within	  the	  body,	  pharmacological	  mobilisation	  
of	  EPCs	  and/or	  BOEC-­‐precursors	  to	  the	  site	  of	  injury	  using	  pharmacological	  agents	  is	  now	  an	  
active	  area	  of	  research.	  In	  fact,	  outside	  the	  field	  of	  endothelial	  cell	  biology,	  mobilisation	  of	  
stem	  cells	  from	  the	  bone	  marrow	  of	  cancer	  patients	  using	  drugs	  such	  as	  GM-­‐CSF	  is	  part	  of	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standard	  chemotherapy	  (Keating,	  2011),	  and	  as	  discussed	  has	  provided	  a	  cornerstone	  in	  our	  
understanding	   of	   adult	   progenitor	   cell	   biology.	   Stem	   cell	   trafficking	   and	   mobilisation	   is	  
regulated	  by	  a	  cytokine	  axis	  involving	  CXCL12	  and	  CXCR4	  (Ceradini	  et	  al.,	  2004;	  Sugiyama	  et	  
al.,	   2006).	   Interference	   of	   this	   with	   the	   CXCR4	   antagonist	   AMD	   3100	   (Plexifor),	   which	   is	  
approved	  for	  use	  in	  patients	  with	  multiple	  myeloma,	  results	  in	  increased	  circulating	  levels	  of	  
hematopoetic	  stem	  cells	  (Dugan	  et	  al.,	  2010;	  Keating,	  2011).	  
	  
As	  alluded	  to	  in	  an	  earlier	  section,	  early	  evidence	  suggests	  that	  some	  common	  drugs	  used	  to	  
treat	  cardiovascular	  disease	  may	  act	  in	  part	  by	  cardiovascular-­‐stem	  cell	  mobilisation.	  Vesa	  et	  
al.	  in	  2001	  found	  that	  patients	  with	  coronary	  artery	  disease,	  without	  myocardial	  infarction,	  
when	  given	  atorvastatin	  had	   increased	   circulating	  CD34+VEGFR2+	  EPC	   (Vasa	  et	   al.,	   2001).	  
Similarly,	  in	  a	  later	  study,	  Fadini	  et	  al.	  in	  2010	  (Fadini	  et	  al.,	  2010)	  found	  that	  the	  dipeptidyl	  
peptidase-­‐4	  (DDP4)	  inhibitor,	  sitagliptin	  increased	  circulating	  levels	  of	  EPC	  in	  line	  with	  levels	  
of	  CXCL12,	  which	  is	  normally	  degraded	  by	  DDP4.	  The	  potential	  of	  	  cardiovascular	  stem	  cell	  
mobilisation	   was	   further	   demonstrated	   in	   mice	   by	   Smart	   et	   al.	   (Smart	   et	   al.,	   2007)	  who	  
showed	  that	  treatment	  of	  mouse	  epicardial	  explants	  with	  thymosin-­‐β4	  resulted	  in	  activation	  
of	  adult	  epicardial	  stem	  cells	  and	  differentiation	  into	  vascular	  cells	  (Smart	  et	  al.,	  2007)	  that	  
could	  restore	  cardiac	  function	  in	  a	  mouse	  model	  of	  cardiac	  injury	  (Smart	  et	  al.,	  2011).	  Clearly	  
there	   is	   a	   real	   opportunity	   for	   pharmacological	   innovation	   in	   the	   field	   of	   stem	   cell	  
mobilisation	  to	  repair	  the	  vasculature	  and	  in	  organ	  regeneration	  programs.	  	  
	  
Selected	  populations	  of	  EPC	  have	  also	  been	  considered	  in	  clinical	  trials	  for	  the	  treatment	  of	  
pulmonary	   arterial	   hypertension.	   Endothelial	   cell	   dysfunction	   is	   key	   feature	   of	   pulmonary	  
arterial	   hypertension	   pathophysiology	   and	   the	   concept	   of	   using	   stem	   cell	   derived	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endothelial	   cells	   to	   restore	   this	   function	   has	   proved	   attractive.	   In	   2007,	   a	   randomised	  
placebo	   control	   trial	   in	   patients	   with	   pulmonary	   arterial	   hypertension	   indicated	   that	  
injection	  of	  autologous	   triple	  positive	  EPCs	   (CD34+,	  CD133+,	  VEGFR2+)	   improved	  standard	  
clinical	  parameters	  (6-­‐min	  walk	  test,	  mean	  pulmonary	  artery	  pressure,	  pulmonary	  vascular	  
resistance,	  and	  cardiac	  output)	   (Wang	  et	  al.,	  2007).	  The	  role	  of	  EPCs	   in	  pulmonary	  arterial	  
hypertension	  has	   also	  been	  widely	   studied.	   In	   experimental	  models	   of	   pulmonary	   arterial	  
hypertension,	   which	   typically	   involves	   administration	   of	   monocrotaline	   to	   rats,	  
administration	   of	   autologous	   EPCs	   resulted	   in	   prevention	   and	   reversal	   of	   monocrotaline	  
induced	  PAH	  (Zhao	  et	  al.,	  2005).	  As	   this	  study	  used	  fluorescently	   labeled	  EPC,	   the	  authors	  
showed	  that	   lung	  sections	  of	  mice	  given	   injections	  of	  EPC	  contained	  vessel	  structures	  that	  
stained	  positive	  for	  the	  fluorescent	  label	  (green	  flouresecne	  protein;	  GFP).	  This	  suggests	  that	  
these	  cells	  hone	  to	   the	   lung,	  but	   it	   remains	  unclear	   if	   these	  cells	   form	  mature	  endothelial	  
cells	  on	  vessels.	  	  
	  
The	   potential	   for	   hESC-­‐EC	   and	   human	   iPCS-­‐EC	   in	   human	   cell	   therapy	   remains	   to	   be	  
investigated.	  However,	  these	  cell	  types	  deserve	  consideration	  particularly	  for	  patients	  were	  
EPC	  function	  is	  impaired	  (Tepper	  et	  al.,	  2002)	  and	  autologous	  therapy	  and	  bone	  marrow	  or	  
peripheral	  blood	   injections	  are	  not	  suitable,	  and	  since	  EPC/BOEC	  yield	   is	   low	  compared	  to	  
more	  pluripotent	  stem	  cell	  sources	  such	  as	  hESC.	  For	  the	  progression	  of	  iPSC-­‐EC	  towards	  the	  
clinic,	  these	  cells	  require	  additional	  questions	  to	  be	  answered	  before	  clinical	  application.	  As	  
discussed	  these	  may	  include	  identification	  of	  transgene	  free	  approaches	  to	  reprogramming	  
as	  well	  as	  more	  knowledge	  on	  the	  cellular	  reprogramming	  pathways.	  The	  need	  for	  greater	  
understanding	   of	   these	   pathways	   was	   illustrated	   by	   Kane	   et	   al.	   (Kane	   et	   al.,	   2010)	   who	  
demonstrated	   that	  use	  of	   reprogramming	  vectors	  alone,	  without	   transgenes,	  can	  result	   in	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somatic	  cell	  reprogramming.	  Understanding	  these	  pathways	  will	  allow	  prediction	  of	  the	  fait	  
of	   these	   stem	   cells	   when	   injected	   in	   humans	   which	   will	   be	   critical	   to	   develop	   safe	   cell	  
therapies.	  
	  
A	  Cochrane	   review	   (2012)	   (Clifford	  et	   al.,	   2012)	   in	   the	  area	  of	   adult	   stem	  cell	   therapy	   for	  
acute	  myocardial	   infarction	   concluded,	   on	   the	   basis	   of	   33	   randomised	   control	   trials,	   that	  
whilst	  stem	  cell	  therapy	  appears	  beneficial	  there	  is	  significant	  heterogeneity	  in	  trial	  design.	  
A	  more	  functional	  approach	  to	  assessing	  the	  function	  of	  stem	  cell	  derived	  endothelial	  cells	  
for	   therapy	  may	   therefore	   be	   important	   for	   success.	   Indeed,	   this	  may	   include	   the	   use	   of	  
assays	   to	   assess	   vascular	   phenotype	   and	   function,	   which	   may	   need	   to	   be	   demonstrated	  
routinely	  in	  endothelial	  –	  stem	  cell	  therapies.	  
	  
1.5.5	  	   Stem	  cell	  derived	  endothelial	  cells	  and	  organ	  engineering	  
A	  key	  challenge	   in	  organ	  and	  tissue	  engineering	   is	   to	  provide	  organs	  with	  blood	   flow.	  The	  
formation	   of	   viable	   and	  healthy	   vascular	   bed	   to	   allow	   transplanted	  organs	   to	   integrate	   is	  
clearly	  critical	  to	  success	  in	  tissue	  engineering.	  A	  number	  of	  approaches	  have	  been	  taken	  to	  
achieve	   this.	   In	  one	  approach,	  endothelial	   cells	   can	  be	   injected	  directly	  on	   to	  organs.	  This	  
was	   illustrated	   in	  SCID	  mice	  using	  HUVEC,	  which	  when	   injected	   into	   the	  abdomen	  wall	   as	  
part	   of	   mix	   of	   collagen	   and	   fibrin	   formed	   vessels	   (Schechner	   et	   al.,	   2000).	   The	   ability	   of	  
HUVEC	   to	   form	  mature	  vessels	  was	  enhanced	  when	   these	  cells	  were	   transfected	  with	   the	  
survival	  gene	  Bcl-­‐2.	  This	  approach	  however,	  appears	   limited	  by	  the	  need	  to	  transfect	  cells	  
with	  a	  survival	  gene	  which	  could	  conceivably	  result	  in	  tumourgenesis.	  This	  kind	  of	  approach	  
has	   also	   not	   been	   shown	   to	   provide	   vascularisation	   of	   transplanted	   tissues.	   In	   another	  
approach,	  grafts	  or	  tissues	  can	  be	  added	  without	  vascular	  cells	  but	  with	  the	  ability	  to	  release	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endothelial	  cell	  growth	  hormones,	  VEGF	  and	  PDGF	  in	  order	  to	  recruit	  progenitors	  from	  the	  
circulation	  (Nillesen	  et	  al.,	  2006).	  Indeed,	  whilst	  this	  approach	  improved	  vascularisation,	  the	  
time	  for	  vascular	  cell	  growth	  to	  occur	  within	  the	  graft	  may,	  in	  reality,	  be	  a	  limitation.	  A	  final	  
approach,	  is	  to	  pre-­‐vascularise	  the	  tissue	  in	  vitro	  prior	  to	  transplant	  (Chen	  et	  al.,	  2009).	  This	  
approach	  would	  allow	  transplanted	   tissues	   to	   immediately	  perform	  as	  organs	  and	  contain	  
healthy	  cells	  which	  have	  been	  tested	  in	  the	  lab.	  
	  
Taking	   tissue	   engineered	   vessel	   grafts	   as	   an	   example,	   a	   2011	   paper	   suggests	   that	   EPCs	  
represent	  a	  more	  suitable	  source	  of	  endothelium	  than	  vascular	  sources	  since	  in	  pigs,	  vessels	  
re-­‐vascularised	  with	  EPCs	  were	  more	  patent	  than	  non-­‐endothelialised	  grafts	  or	  grafts	  coated	  
with	  mature	  endothelial	  cells	  (Quint	  et	  al.,	  2011).	  In	  this	  study,	  EPCs	  remained	  in	  the	  vessel	  
post-­‐implant	  and	  integrated	  with	  the	  host	  vasculature	  (Quint	  et	  al.,	  2011).	  Stem	  cell	  derived	  
endothelial	   cells	   therefore	   have	   clear	   importance	   in	   organ	   and	   vessel	   engineering.	   The	  
essential	   features	   of	   stem	   cell	   derived	   endothelial	   cells	   and	   their	   applications	   are	  





Figure	   1.8.	   Applications	   and	   essential	   features	   of	   stem	   cell	   derived	   endothelial	   cells	   in	   1.	  
Organ	   engineering	   and	   2.	   In	   in	   vitro	   bioassays	   to	   study	   endothelial	   cell	   biology	   and	  
pharmacology.	   Prostacyclin	   (PGI2),	   nitric	   oxide	   (NO),	   endothelin	   (ET-­‐1),	   Toll-­‐like	   receptor	  
(TLR),	   nucleotide	   oligomerisation	   domain	   containing	   receptor	   (NOD).	   Heart	   image	   from	  



































1.6	  APPLICATIONS	  OF	  STEM	  CELL	  DERIVED	  ENDOTHELIAL	  CELLS	  IN	  VITRO	  
Stem	   cell	   derived	   endothelial	   cells,	   like	   other	   stem	   cells,	   can	   also	   be	   used	   to	   study	  
endothelial	  cell	  biology	  and	  pharmacology	   in	  vitro.	   In	  particular,	  BOEC	  and	   iPSC-­‐EC	  can	  be	  
used	   to	   phenotype	   individual	   patient	   endothelial	   cells	   and	   be	   used	   as	   ‘window	   to	   the	  
vasculature’.	  This	  is	  especially	  true	  for	  BOEC	  as	  these	  cells	  are	  less	  manipulated	  in	  vitro.	  
	  
In	  line	  with	  this,	  work	  by	  Ward	  et	  al	  (Ward	  et	  al.,	  2011)	  showed	  that	  EPCs	  from	  patients	  with	  
coronary	   artery	   disease	   have	   decreased	   eNOS	   function	   and	   lacked	   angiogenic	   ability	  
compared	  to	  EPCs	  from	  healthy	  donors.	  Further	  to	  this,	  Toshner	  et	  al	  (Toshner	  et	  al.,	  2009)	  
showed	  evidence	  of	  the	  role	  of	  dysfunctional	  EPCs	  in	  PAH.	  In	  our	  group	  we	  have	  also	  shown	  
that	  BOEC	  from	  patients	  with	  PAH	  have	  an	  increased	  pro-­‐inflammatory	  phenotype	  which	  is	  
relevant	   to	  PAH	  pathophysiology	  and	  vascular	   inflammation	   (George	  et	  al.,	  2013).	  Thus,	   it	  
has	   become	   clear	   that	   EPCs	   or	   BOEC	   from	   patients	   with	   disease	   retain	   phenotypic	  
differences	  in	  function	  that	  might	  impact	  therapeutic	  success	  and	  provide	  insights	  in	  disease	  
pathophysiology.	  	  
	  
The	   idea	   of	   using	   BOEC	   as	   an	   in	   vitro	   tool	   to	   study	   endothelial	   cells	   in	   disease	   is	   now	  
established.	   Indeed,	   we	   have	   recently	   shown	   that	   BOEC	   from	   patients	   with	   pulmonary	  
arterial	   hypertension	   have	   an	   increased	   inflammatory	   response	   to	   interferons	   (George	   et	  
al.,	  2013).	  Others	  have	  shown	  that	  disease	  phenotype	  is	  retained	  in	  BOEC	  from	  patients	  with	  
COPD	  (Paschalaki	  et	  al.,	  2013).	  Other	  groups	  have	  also	  combined	  iPSC	  technology	  with	  this	  
field	  whereby	  BOEC	  are	  used	  as	  a	  substrate	  for	   iPSC	  which	  could	  subsequently	  be	  used	  as	  
translational	  models	  of	  a	  range	  of	  cell	  types	  in	  disease	  (Geti	  et	  al.,	  2012).	  Clearly,	  it	  will	  be	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important	   to	   characterise	   these	   cells	   for	   hallmarks	   of	   cell	   phenotype,	   and	  whether	   these	  
cells	  retain	  a	  disease	  phenotype	  in	  vitro.	  
	  
Another	  important	  potential	  area	  for	  innovation	  in	  using	  stem	  cell	  derived	  endothelial	  cells	  
is	   in	   bioassays	   of	   drug	   efficacy	  or	   and/or	   toxicity.	   In	  my	   thesis	   I	   have	   applied	   this	   for	   the	  
specific	  use	  in	  assays	  to	  detect	  cytokine	  storm	  reactions	  to	  biological	  drugs	  (biologics).	  The	  
background	  to	  this	  area	  is	  discussed	  below.	  
	  
1.6.1	  	   Biologics	  	  
Biological	   therapies	   or	   biologics,	   which	   include	   antibodies	   and	   stem	   cells,	   are	   considered	  
increasingly	   important	   for	   the	   treatment	   of	   human	   disease,	   and	   are	   set	   to	   dominate	  
research	  efforts	  of	  the	  pharmaceutical	   industry.	   It	   is	  estimated	  that,	  by	  2016,	  seven	  of	  the	  
ten	  top	  selling	  drugs	  will	  be	  biological	  therapies	  (Malik,	  2012).	  In	  line	  with	  this,	  the	  idea	  of	  
tailoring	  therapies	  on	  a	  patient-­‐by-­‐patient	  basis	  in	  order	  to	  provide	  personalised	  medicine	  is	  
now	  a	  key	  consideration	  in	  drug	  development.	  	  
	  
The	  concept	  of	  biologics	  has	  been	  made	  possible	  following	  pioneering	  work	  by	  Kohler	  and	  
Milstein,	   which	   provided	   technology	   for	   the	   production	   of	  mouse	  monoclonal	   antibodies	  
against	  human	  targets	  (Köhler	  and	  Milstein,	  1975).	  Significant	  advances	  since	  this	  landmark	  
paper	  means	   that	   it	   is	   now	  possible	   to	   engineer	   humanized	   and	   fully	   human	  monoclonal	  
antibodies	   to	   any	   target	   (Lonberg,	   2005).	   This,	   for	   the	   first	   time,	   allowed	   for	   the	  
development	   of	   monoclonal	   antibodies	   as	   therapies	   that	   target	   proteins	   in	   disease.	   An	  
example	  of	   this	   is	   the	  use	  of	  anti-­‐TNF	  antibodies	   in	   the	   treatment	  of	   rheumatoid	  arthritis	  
(Feldman	  et	  al.,	  1998).	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Importantly,	  because	   these	  medicines	  are	  human	  specific,	  biological	   therapies	   require	   the	  
use	  of	  human	  tissue-­‐based	  bioassays	  for	  measures	  of	  efficacy	  and	  safety.	  The	  case	  for	  the	  
requirement	   of	   improved	   human	   tissue	   bioassays	   was	   emphasised	   by	   the	   unexpected	  
profound	  cytokine	  release	  caused	  by	  the	  CD28	  super	  agonist,	  TGN1412	  (Suntharalingam	  et	  
al.,	  2006).	  	  
	  
1.6.2	  	   TGN1412	  and	  the	  Northwick	  Park	  Hospital	  drug	  trial	  disaster	  	  
TGN1412	   was	   developed	   as	   an	   anti-­‐CD28	   superagonist	   to	   treat	   leukaemia	   and	   immune	  
suppression.	   CD28	   is	   a	   receptor	   expressed	   by	   Thelper	   cells	   and	   provides	   essential	   co-­‐
stimulation	   signals	   for	   lymphocyte	   activation	   and	   proliferation.	   Under	   physiological	  
conditions,	  CD28	  activation	  alone	  is	  not	  sufficient	  for	  cell	  activation	  which	  is	  dependent	  on	  
simultaneous	   activation	   of	   CD28	   and	   T-­‐cell	   receptor/CD3	   complexes	   by	   major	  
histocompatibility	  complexes	  (MHC)	  on	  antigen	  presenting	  cells.	  
	  
In	   the	   body,	   the	   ligands	   for	   CD28	   include	   CD80	   and	   CD86,	   and	   activation	   of	   downstream	  
signalling	  requires	  co-­‐stimulation	  by	  CD3/TCR	  complexes.	  A	  superagonist	  of	  CD28	  is	  defined	  
as	  any	  agonist	  that	  does	  not	  require	  these	  additional	  signals	  or	  CD3	  to	  activate	  T-­‐cells.	  It	  is	  
noteworthy	  however	  that,	  the	  downstream	  pathway	  activated	  by	  anti-­‐CD28	  superagonists,	  
is	   different	   to	   that	   of	   standard	   anti-­‐CD28	   antibodies	   in	   the	   presence	   of	   co-­‐stimulation	  
(Waibler	   et	   al.,	   2008).	   Nonetheless,	   the	   idea	   that	   T-­‐cell	   activation	   could	   be	   manipulated	  
through	  CD28	  was	  the	  premise	  for	  the	  development	  of	  anti-­‐CD28	  superagonist	  therapy.	  The	  
first	   of	   these	   drugs	  was	   developed	   by	   TeGerno	   and	   designated,	   TGN1412.	   This	   drug	  was	  
developed	  for	  the	  treatment	  of	  rheumatoid	  arthritis	  and	  acute	  lymphoid	  leukaemia,	  where	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activation	  of	  T-­‐cell	  and	   IL-­‐2	   release	  where	  hypothesized	   to	  underlie	   therapeutic	  benefit	   in	  
immunosuppressed	  patients.	  
	  
The	   area	   of	   biologic	   therapy,	   and	   especially	   anti-­‐CD28	   targeted	   therapy	   was	   severely	  
impacted	   in	   2006.	   In	   the	   phase	   I	   clinical	   trial	   for	   TGN1412	   six	   healthy	   volunteers	  
experienced	  a	  profound	  and	  a	  violent	  systemic	  response	  referred	  to	  as	  a	   ‘cytokine	  storm’.	  
This	   occurred	   despite	   TGN1412	   passing	   the	   required	   preclinical	   safety	   tests.	   Importantly,	  
these	  tests	  not	  only	  included	  the	  use	  of	  standard	  laboratory	  animals	  and	  primates	  but	  also	  
human	  T-­‐cells	   in	   vitro	   (Stebbings	  et	   al.,	   2007)	  which	  were	   the	   target	   cell	   for	   this	   therapy.	  
Whether	  this	  could	  have	  been	  predicted,	  based	  on	  what	  was	  known	  about	  CD28	  and	  CD3	  
signalling	  at	  the	  time	  has	  been	  widely	  debated	  (Horvath	  et	  al.,	  2012;	  Hünig,	  2012).	  	  
	  
Cytokine	  storm	  describes	  a	  cascade	  of	  exaggerated	  inflammatory	  responses	  resulting	  in	  the	  
release	   of	  more	   than	   150	   different	   cytokines	   and	   chemokines.	   The	   pathways	   involved	   in	  
such	   a	   reaction	   are	   clearly	   complex	   and	   are	   the	   product	   of	   countless	   cell	   interactions,	  
signaling	  cascades	  and	  dynamic	   interactions	  between	  a	  drug	  and	  the	   immune	  system.	   It	   is	  
thought	  that	  T-­‐cells,	  B-­‐cells	  and	  monocytes	  are	  the	  central	  orchestrators	  of	  cytokine	  release	  
syndrome.	   Cytokine	   release	   syndrome	   is	   characterized	   by	   rapid	   increases	   in	   the	   pro-­‐
inflammatory	  cytokines	  TNFα,	   IFNγ,	   IL-­‐6,	   IL-­‐10	  and	   IL-­‐2	  which	   results	   in	  clinical	  phenotype	  
akin	   to	   that	   of	   complement	   cascade	   activation	   or	   sepsis,	   including	   fatigue,	   headache,	  
urticaria,	   throat	  swelling,	   fever,	  vomiting,	  hypotension	  and	  tachycardia.	  Whether	  different	  
inducers	  of	  cytokine	  storm	  can	  induce	  different	  patterns	  and	  levels	  of	  cytokine	  release	  that	  
correlates	  with	   severity	   however	   is	   unknown.	   A	   number	   of	   biologics	   are	   known	   to	   cause	  
cytokine	   release	   syndrome.	   In	   fact,	   the	   first	   biologic	   licensed	   for	   use	   in	   humans;	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muromonab-­‐CD3	   (or	   OKT3)	   causes	   mild	   to	   severe	   cytokine	   release	   syndrome	   in	   some	  
patients.	   This	   reaction	   manifests	   as	   flu-­‐like	   symptoms	   and	   appears	   associated	   with	  
increased	  serum	  levels	  of	  TNFα,	  IL-­‐2,	  IL-­‐6	  and	  IFNγ	  (Bugelski	  et	  al.,	  2009).	  The	  propensity	  for	  
patients	   to	   experience	   cytokine	   release	   syndrome	   also	   varies	   from	   patient	   to	   patient	  
(Bugelski	   et	   al.,	   2009)	   and	   the	   basis	   for	   this	   is	   also	   under	   investigated.	   For	   example,	   in	  
patients	   receiving	   the	  mild	   cytokine	   storm	  causing	  drug,	  Rituximab,	   serum	  cytokine	   levels	  
and	  severity	  of	   symptoms	  are	  greater	   in	   those	  with	  higher	   lymphocyte	  counts	   (Winkler	  et	  
al.,	   1999).	   Clearly	   cytokine	   release	   syndrome	  and	   assays	   to	   study	   this	   adverse	   reaction	   in	  
patient	  groups	  or	  subgroups	  will	  be	  critical	  to	  future	  success.	  	  
	  
After	  the	  TGN1412	  drug	  trial	  disaster	  however,	  we	  now	  know	  that	  using	  simply	  the	  target	  
cells	   is	   not	   sufficient	   to	   detect	   cytokine	   storm	   responses	   to	   biologics.	   In	   this	   regard,	   the	  
TGN1412	  disaster	  defined	  an	  urgent	  unmet	  need	  for	  improved	  bioassays	  to	  detect	  cytokine	  
storm	  and	  understand	  CD28	  signalling	  in	  vivo.	  
	  
A	  number	  of	  key	  things	  are	  critical	  to	  point	  out:	  
• As	   these	   drugs	   are	   highly	   human	   specific,	   animal	   models	   of	   efficacy	   and	   toxicity	  
might	  be	  unsuitable.	  
• Studying	   responses	   in	   pure	   target	   cells	   does	   not	   capture	   the	   cell	   interactions	  
involved	   in	   response	   to	   biologics,	   especially	   those	   affecting	   immune	   or	   vascular	  
pathways,	  and	  are	  therefore	  not	  always	  adequate.	  
• As	  far	  as	  possible,	  assays	  must	  reflect	  the	  in	  vivo	  situation	  and,	  importantly,	  capture	  
the	  cells	  that	  are	  involved	  in	  cytokine	  storm	  responses	  (vascular	  and	  immune).	  This	  
may	  involve	  a	  combination	  of	  cells	  in	  co-­‐culture	  assays.	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• Clearly	  there	  is	  an	  opportunity	  for	  innovation	  in	  this	  area	  using	  stem	  cell	  derived	  cells	  
in	  assays	  to	  study	  cells	  and	  human	  tissues.	  
	  
1.6.3	  	   Current	  assays	  that	  detect	  cytokine	  storm	  reactions	  to	  drugs	  
A	  number	  of	  assays	   to	  detect	  cytokine	  storm	  responses	   to	  biologics	  have	  been	  developed	  
and	   these	   are	   described	   below.	   To	   date,	   there	   is	   no	   consensus	   on	   the	   optimum	  assay	   to	  
detect	  cytokine	  storm	  responses.	  	  
	  
Antibodies	  immobilised	  to	  plastic	  
We	  now	  know	  that	  TGN1412	  does	  not	  activate	  peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  
to	   release	   cytokines	   when	   antibodies	   are	   added	   in	   aqueous	   phase,	   unless	   there	   is	   an	  
endothelial	   cell	   interface	   present	   (Findlay	   et	   al.,	   2011b)	   (discussed	   in	   detail	   below).	  
However,	  when	  TGN1412	   is	   immobilised	  by	  non-­‐specific	  binding	  to	  a	  solid	  phase	  platform	  
such	  as	  plastic	  it	  does	  active	  PBMCs	  to	  release	  cytokines	  (Findlay	  et	  al.,	  2010;	  Findlay	  et	  al.,	  
2011b).	  Whilst,	   immobilising	   biologics	   to	   plastic	   provides	   a	   simple	   solution	   in	   the	   case	   of	  
TGN1412,	   it	   might	   be	   argued	   this	   approach	   is	   not	   representative	   of	   the	   physiological	  
environment	   nor	   necessarily	   capture	   the	   cells	   types	   that	   orchestrate	   cytokine	   storm	  
responses.	  	  
	  
Immobilised	  antibody	  assays,	  are	  indeed	  very	  sensitive	  to	  detect	  TGN1412,	  but	  also	  detect	  
variable	  cytokine	  responses	  (IL-­‐8	  (or	  CXCL8),	  IL-­‐6	  and	  TNFα)	  to	  non-­‐cytokine	  storm-­‐inducing	  
antibodies	   such	   as	   Tysabri	   (natalizumab),	   Avastin	   (bevacizumab)	   and	   Herceptin	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(trastuzumab)	   (Findlay	   et	   al.,	   2011a).	   It	   is	   also	   likely	   that	   the	   immobilising	   protocol	   that	  
works	  for	  TGN1412	  may	  not	  do	  the	  same	  for	  a	  different	  cytokine-­‐storm	  inducing	  antibody.	  	  
	  
Whole	  blood	  
As	  our	  group	  (Bailey	  et	  al.,	  2012)	  and	  others	  (Wolf	  et	  al.,	  2012)	  have	  recently	  described,	  an	  
alternative	   approach	   is	   to	   test	   therapeutic	   antibodies	   for	   cytokine	   storm	   responses	   using	  
undiluted	   human	   whole	   blood.	   Human	   whole	   blood	   responds	   readily	   to	   TGN1412-­‐like	  
antibodies	   in	   a	   way	   that	   does	   not	   require,	   and	   is	   not	   enhanced	   by,	   co-­‐culture	   with	  
endothelial	   cells	   (Bailey	   et	   al.,	   2012).	   However,	   whole	   blood	   assays	   have	   recently	   been	  
criticised	  (Thorpe	  et	  al.,	  2013a)	  are	  less	  sensitive	  (Bailey	  et	  al.,	  2012;	  Thorpe	  et	  al.,	  2013a),	  
do	  not	  discriminate	  between	  mild	  and	  severe	  cytokine	  storm	  inducing	  therapeutics	  (Bailey	  




Whilst	  TGN1412	  does	  not	  activate	  PBMCs	  alone,	  it	  does	  activate	  PBMCs	  in	  co-­‐cultures	  with	  
endothelial	  cells.	  The	  idea	  of	  using	  endothelial	  cells	  and	  PBMCs	  in	  co-­‐culture	  is	  not	  new,	  and	  
is	  known	  to	  be	  important	  to	  capture	  the	  vascular-­‐immune	  cell	  interactions	  that	  take	  place	  in	  
vivo	   (Ashida	   et	   al.,	   1981;	   Hughes	   et	   al.,	   1990;	   Ward	   et	   al.,	   2009).	   The	   advantage	   of	  
endothelial	   cell:PBMC	   co-­‐culture	   assays	   for	   cytokine	   storm	   testing	   over	   other	   assays	   is	  
accepted,	   as	   these	   assays	   recapitulate	   the	   cell	   interactions	   occurring	   in	   the	   vasculature	  
(Findlay	   et	   al.,	   2011b).	   However,	   to	   date,	   endothelial	   cell:	   PBMC	   co-­‐culture	   assays	   have	  
relied	  on	  using	  endothelial	  cells	  and	  PBMCs	  from	  different	  donors,	  typically	  HUVEC	  or	  HAEC	  
from	  one	  donor	  and	  PBMCs	  from	  another.	  These	  heterologous	  cell	  combinations	  therefore	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represent	  an	  inflammatory	  situation	  akin	  to	  a	  graft	  versus	  host	  disease	  phenotype	  (Huang	  et	  
al.,	  1994)	  which	  conceivably	  interferes	  with	  responses	  to	  biologics.	  	  
	  
Clearly,	   the	   best	   type	   of	   endothelial	   cell:	   PBMC	   bioassay,	   where	   mixed	   donor	   immune	  
response	  could	  be	  avoided,	  would	  be	  one	  that	  uses	  cells	  from	  the	  same	  donor.	  PBMCs	  are	  
easy	   to	   obtain	   from	   blood	   donated	   by	   volunteers,	   but	   adult	   endothelial	   cells	   on	   blood	  
vessels	   are	   inaccessible	  and	  can	  only	  be	  obtained	   from	   tissue	   removed	   in	   surgery	  or	  post	  
mortem.	   In	  my	   thesis	   I	   applied	   stem	   cell	   approaches	   to	   devise	   a	   bioassay	   that	   allows	   for	  
endothelial	  cells	  and	  PBMCs	  from	  the	  same	  donor	  to	  be	  used	  as	  cytokine	  storm	  detecting	  
bioassays.	  
	  











1.6.4	  Future	  directions	  in	  cytokine	  storm	  assays	  and	  endothelial:PBMC	  interactions	  
As	  discussed	  in	  detail,	  stem	  cell	  biology	  and	  research	  is	  offering	  significant	  advances	  in	  how	  
we	   treat	   and	   study	   disease.	   These	   stem	   cell	   technologies	   can	   also	   be	   used	   to	   develop	  
complex	  multi-­‐cell	   in	   vitro	  assays	   to	   study	  disease	  and	   test	   therapies	   for	  patients	   (Chapin	  
and	  Stedman,	  2009;	  Ferreira	  and	  Mostajo-­‐Radji,	  2013).	  In	  the	  final	  stages	  of	  my	  PhD,	  I	  went	  
on	   to	   consider	   therefore	   how	   stem	   cell	   derived	   endothelial	   cells	   could	   be	   applied	   in	   a	  

































































Endothelial	  cells	  are	  critical	  to	  cardiovascular	  health.	  Endothelial	  cells	  support	  the	  health	  of	  
cardiovascular	   system	   through	   the	   release	   of	   cardioprotective	   hormones	   such	   as	  
prostacyclin	   and	   NO,	   which	   rely	   on	   the	   concerted	   actions	   of	   enzymes	   expressed	   by	  
endothelial	   cells.	  Many	  of	   these	  pathways	  are	   regulated	  by	  shear	   stress	  as	  a	   result	  of	   the	  
flow	  of	  blood	  through	  the	  vessel.	  Endothelial	  cells	  are	  also	  critical	   in	   innate	   immunity	  and	  
respond	  to	  pathogens	  to	  release	  cytokines	  and	  recruit	  professional	  immune	  cells,	  ultimately	  
resulting	   in	   infection	   resolution.	   	  Pathogen	  sensing	   is	  conferred	   through	   the	  expression	  of	  
pattern	  recognition	  receptors	  including	  TLR4	  and	  NOD1.	  
	  
Endothelial	   cell	   dysfunction	   results	   in	   disease	   and	   can	  be	  driven	  by	   aberrant	   signaling,	   or	  
loss	   of	   function	   in	   any	   one	   of	   these	   pathways.	   As	   such,	   endothelial	   cell	   dysfunction	   is	   a	  
target	  for	  pharmacological	  therapy	  with	  most	  therapies	  act	  either	  to	  mimic	  cardioprotective	  
pathways	  (prostacyclin	  or	  NO)	  or	  block	  cardiotoxic	  pathways	  (ET-­‐1).	  
	  
Stem	  cells	  have	  the	  capacity	  to	  change	  how	  we	  think	  about	  and	  treat	  disease.	  Endothelial	  
cells	   can	   now	   be	   derived	   from	   stem	   cells.	   Using	   stem	   cell	   derived	   endothelial	   cells,	   a	  
patients	   own	   cells	   can	   be	   used	   to	   engineer	   autologous	   organs	   as	   well	   as	   be	   used	   to	  
recapitulate	  cardiovascular	  ‘disease	  in	  a	  dish’.	  Stem	  cell	  derived	  endothelial	  cells	  therefore	  
have	   applications	   spanning	   a	   number	   of	   biomedical	   and	   clinical	   research	   areas.	   The	  
characterisation	  of	   these	   cells	   in	   vitro	   for	   their	   ability	   to	   align	  under	   shear	   stress,	   release	  
vasoactive	  hormones	  and	   response	   to	  pathogens	  will	  be	  essential	   for	   their	  optimal	  use	   in	  




This	   forms	   the	   premise	   of	  my	   PhD	   that;	   characterization	   of	   stem	   cell	   derived	   endothelial	  
cells	  will	  be	  essential	  for	  their	  optimal	  use	  in	  therapy	  and	  in	  vitro	  assays.	  In	  the	  later	  stages	  
of	   my	   PhD,	   I	   went	   on	   to	   apply	   stem	   cell	   derived	   endothelial	   cells	   in	   a	   pharmacological	  
bioassay	   to	  detect	  cytokine	  storm	  reactions	   to	  biologics.	   I	  also	  used	  BOEC	  to	  phenotype	  a	  
patient	   with	   a	   homozygous	   mutation	   in	   the	   cPLA2	   gene	   (PLA2G4A),	   which	   results	   in	  
complete	  loss	  of	  function.	  
	  
General	  hypothesis:	  
Endothelial	  cells	  derived	  from	  stem	  cells	  function	  as	  endothelial	  cells	  from	  vessels	  and	  can	  
be	  used	  to	  make	  bioassays	  and	  to	  study	  vascular	  phenotype	  in	  patients	  with	  disease.	  
	  
Aims:	  
1. To	  characterise	  endothelial	  cells	  derived	  from	  different	  stem	  cells	  for	  their	  ability	  to	  
align	   under	   shear	   stress,	   respond	   to	   PAMPs	   and	   release	   vasoactive	   hormones	  
(prostacyclin	  and	  NO)	  similarly	  to	  endothelial	  cells	  from	  vessels.	  
2. To	  further	  study	  TLR4	  and	  NOD1	  pharmacology	  in	  hESC-­‐EC,	  and	  their	  response	  to	  live	  
Gram-­‐negative	  bacteria.	  
3. After	  selection	  of	  an	  appropriate	  stem	  cell	  derived	  endothelial	  cell,	  to	  employ	  these	  
cells	  in	  a	  bioassay	  to	  detect	  cytokine	  storm	  responses	  to	  biologics	  





























2.1	  MEDIA	  AND	  SOLUTIONS	  
The	  cell	  culture	  media	  used	  in	  my	  PhD	  was	  of	  particular	  importance.	  In	  order	  to	  select	  for,	  
expand	  and	  maintain	  stem	  cell	  derived	  endothelial	  cells,	  endothelial	  cell	  media	  was	  carefully	  
selected	  from	  suppliers	  and	  where	  modifications	  were	  made	  these	  have	  been	  explained	  in	  
detail.	  
	  
2.1.1	  	   Mouse	  embryonic	  fibroblast	  conditioned	  media	  
Human	   embryonic	   stem	   cells	   were	   maintained	   in	   their	   undifferentiated	   state	   in	   mouse	  
embryonic	  fibroblast	  (MEF)	  conditioned	  medium.	  The	  principle	  of	  this	  approach	  in	  provided	  
in	  section	  2.2	  Cells.	  
	  
MEF	  conditioned	  media	  is	  commercially	  available	  or	  can	  be	  prepared	  in-­‐house	  according	  to	  
published	   protocols	   (http://www.geron.com/PDF/scprotocols.pdf).	   For	   my	   PhD,	   MEF	  
conditioned	  media	  was	   prepared	   by	  members	   of	  Heart	   Science,	   Imperial	   College	   London.	  
MEF	  conditioned	  media	  was	  prepared	  as	  described	  in	  Brito-­‐Martins	  et	  al.	  (Brito-­‐Martins	  et	  
al.,	  2008)	  as	  below:	  
	  
“After	   isolation	   and	   expansion	   in	   culture,	  MEFs	  were	  mitotically	   inactivated	   at	   passage	   3.	  
After	   overnight	   attachment	   of	   12	   million	   inactive	   mouse	   embryonic	   fibroblasts	   onto	   pre-­‐
gelatinized	   T225	   flasks	   in	   10%	   fetal	   calf	   serum,	   medium	   was	   replaced	   with	   ‘human	  
embryonic	   stem	   cell	   medium’	   containing	   20%	   knockout	   serum	   replacement,	   (Life	  
Technologies,	  UK;	  Cat	  no.	  10828-­‐028)	  1	  mM	  L-­‐glutamine,	  10mM	  non-­‐essential	  amino	  acids	  
(1%	   of	   stock),	   0.1mM	   β-­‐mercaptoethanol,	   antibiotics	   (50U/ml	   penicillin	   50μg/ml	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streptomycin)	   and	   4ng/ml	   basic	   human	   fibroblast	   growth	   factor.	   Collections	   of	   150	  ml	   of	  
mouse	   embryonic	   fibroblast-­‐conditioned	   medium	   were	   made	   daily	   for	   a	   week.	  
Undifferentiated	  H7	  cells	  were	   fed	  each	  day	  with	   filtered	  MEF-­‐conditioned	  medium,	  which	  
was	   further	   supplemented	   with	   8	   ng	   ml−1	   basic	   human	   fibroblast	   growth	   factor.	   Before	  
subculturing	  or	  induction	  of	  differentiation,	  the	  latter	  usually	  1	  week	  following	  subculturing,	  
spontaneously	  differentiated	   fibroblast-­‐like	   cells	  among	   the	  ESC	  colonies	  were	   removed	  by	  
treatment	  with	  collagenase	  for	  10	  min	  at	  37	  °C.”	  
Text	  reproduced	  under	  licence	  from	  the	  Copyright	  Clearance	  Center.	  
	  
2.2.2	  	   Lonza-­‐EGM2	  medium	  
Lonza-­‐EGM2	   is	   supplied	   in	   multiple	   components.	   Lonza-­‐EBM2	   basal	   medium	   (Lonza,	  
Belgium;	   Cat	   no.	   CC-­‐3156)	   and	   a	   EGM2	   SingleOuat®	   Growth	   Factors	   and	   Supplements	  
(Lonza,	   Belgium;	   Cat	   no.	   CC-­‐4176).	   When	   combined	   this	   provides	   Lonza-­‐EGM2.	   The	  
supplements	  are	  selected	  growth	  factors	  and	  hormones	  to	  support	  endothelial	  cell	  growth.	  












Table	  2.1	   List	  of	   supplements	  and	  growth	   factors	   in	   Lonza-­‐EGM2	  SingleQuot	   supplements	  




For	  isolation	  of	  blood	  outgrowth	  endothelial	  cells	  (BOEC),	  the	  detailed	  method	  for	  which	  is	  
described	  below,	  media	  was	  further	  supplemented	  with	  10%	  Hyclone	  foetal	  bovine	  serum	  
(FBS)	  (Fisher	  Scientific,	  Dublin,	  Ireland;	  Cat	  no.	  HYC-­‐001-­‐330Y	  and	  10703464).	  Hyclone	  FBS	  is	  
an	   advanced	   preparation	   of	   FBS	   and	   supplier	   information	   states	   the	   following	   advanced	  
handling	  steps:	  
“Defined	  FBS	   is	   filtered	  through	  serial	  40nm	  (0.04μm)	  pore	  size	  rated	  filters,	  which	  are	  the	  
most	  retentive	  filters	  used	  in	  commercial	  FBS	  production.	  Defined	  FBS	  is	  the	  highest	  quality	  
FBS	   available	   and	   is	   widely	   used	   by	   those	   cell	   culturists	   who	   have	   a	   concern	   for	   viral	  
contaminants	   and	   require	   an	   extensive	   biochemical	   profile.	   This	   type	   of	   filtration	   is	   a	  













will	  remove	  as	  many	  as	  eight	  logs	  of	  viral	  challenge.	  This	  is	  a	  dramatic	  improvement	  over	  the	  
current	   industry	   standard	   of	   using	   filters	   with	   mean	   pore	   sizes	   of	   100nm.	   Studies	  
demonstrate	  that	  this	  filtration	  regime	  has	  no	  adverse	  effect	  on	  cell	  growth.	  Product	  is	  of	  U.S	  
origin”	  	  
*Information	   from	   product	   information	   page	   at	   http://www.webshop.fishersci.com.	  
Accessed	  February	  2014.	  
	  
Most	   other	   standard	   serum	   preparations	   are	   filtered	   in-­‐house	   using	   0.2μM	   filters.	   Upon	  
arrival	   the	   Hyclone	   FBS	   was	   heat	   inactivated	   to	   deactivate	   and	   destroy	   any	   remnants	   of	  
serum	   complement	   proteins	   that	   would	   cause	   inflammatory	   activation	   of	   cells.	   As	   per	  
manufactures	   instructions	  500ml	  bottles	  of	  Hyclone	  FBS,	  were	   thawed	  out	  overnight,	   and	  
heated	  to	  56oC	  and	  maintained	  at	  56oC	  for	  30	  minutes.	  Serum	  was	  then	  allowed	  to	  cool	  to	  
room	  temperature	  with	  inversion	  and	  mixing	  of	  the	  serum	  at	  10	  min	  intervals.	  	  
	  
All	  experiments	  on	  endothelial	  cells	  and	  stem	  cell	  derived-­‐endothelial	  cells,	  unless	  otherwise	  
stated	   in	   figure	   legends,	   were	   carried	   out	   in	   Lonza-­‐EGM2	  with	   10%	   Hyclone	   FBS.	  Where	  
possible	  protocols	   comparing	   responses	  of	  different	   cell	   types	   to	  agonists,	   cells	  were	  also	  
run	  head-­‐to-­‐head	  in	  protocols	  in	  identical	  media.	  
	  
2.2.3	  	   Vasculife®	  endothelial	  cell	  medium	  
Induced	  pluripotent	  stem	  cell	  (iPSC)	  derived	  endothelial	  cells	  (iPSC-­‐EC)	  were	  purchased	  from	  
Cellular	  Dynamics	  International	  (iCell®	  Endothelial	  Cells;	  Cat	  no.	  ECC-­‐100-­‐010-­‐001;	  discussed	  
in	  a	  later	  section)	  and	  maintained	  in	  a	  specially	  formulated	  ‘Maintenance	  Medium’.	  This	  was	  
prepared	   by	   addition	   of	   a	   proprietary	   iCell®	   Endothelial	   Media	   Supplement	   (Cellular	  
95	  
	  
Dynamics,	   California,	  USA;	   Cat	   no.	   ECM	  100-­‐031-­‐001)	   and	   all	   components	   of	   a	   Vasculife®	  
VEGF	  Medium	  Complete	  Kit	  (Lifeline	  Cell	  Technology,	  Maryland,	  USA;	  Cat	  no.	  LL-­‐0003),	  with	  
the	  exception	  of	  FBS	  as	  per	  instructions	  from	  Cellular	  Dynamics,	  to	  500ml	  of	  Vasculife®	  Basal	  
Medium	  (Lifeline	  Cell	  Technology,	  Maryland,	  USA;	  Cat	  no.	  LL-­‐0002).	  Media	  was	  stored	  at	  2-­‐
8oC	  for	  not	  longer	  than	  one	  month.	  The	  contents	  of	  the	  Vasculife®	  Medium	  Complete	  kit	  (LL-­‐
0003)	  is	  given	  in	  Table	  2.2.	  
	  
Table	   2.2	   List	   of	   supplements	   and	   growth	   factors	   in	   Vasculife®	  Medium	   Complete	   kit	   LL-­‐
0003.	   Table	   drawn	   from	   information	   in	   the	   product	   information	   sheet	   at	  
cellulardynamics.com.	  
	  
To	  ensure	  consistency	   in	  protocols	  however,	   iPSC-­‐EC	  used	   in	  experiments	   in	  my	  PhD	  were	  
plated	  in	  Lonza-­‐EGM2	  with	  10%	  Hyclone	  FBS	  as	  described	  above.	  
	  
2.2.4	  	   Dulbecco’s	  Modifed	  Eagle	  Medium	   (DMEM)	  and	  Roswell	  Park	  Memorial	   Institute	  
(RPMI)	  medium	  
DMEM	  (Cat	  no.	  D5546)	  and	  RPMI	  (Cat	  no.	  R0883)	  were	  purchased	  from	  Sigma	  UK.	  To	  both	  
formulations	   the	   following	   standard	   supplements	  were	   added:	   Non-­‐essential	   amino	   acids	  
(Life	  technologies,	  UK;	  Cat	  no.	  11140-­‐050),	  L-­‐glutamine	  (25mM),	  Penicillin-­‐Streptomycin	  and	  













2.2.5	  	   Matrix	  proteins	  and	  plate	  coating	  
Since	   in	  vessels	  endothelial	   cells	  adhere	   to	  extracellular	  matrix	  proteins,	   it	   is	   important	   to	  
mimic	  this	  when	  growing	  endothelial	  cells	  in	  culture.	  To	  achieve	  this,	  cell	  culture	  plates	  can	  
be	   coated	  with	  matrix	   proteins	   including	   gelatin,	   fibronectin	   and	   collagen.	   To	   coat	   plates	  
with	  gelatin,	  gelatin	  solution	  (Sigma,	  UK;	  Cat	  no.	  G-­‐1393)	  was	  added	  to	  cell	  culture	  plates	  at	  
a	  concentration	  of	  100µg/cm2	  (1%	  solution	  in	  PBS)	  and	  plates	   incubated	  for	  10	  minutes	  at	  
37oC,	  5%	  CO2,	   followed	  by	  aspiration.	  To	  coat	  plates	  with	  collagen,	  type-­‐1	  rat	  tail	  collagen	  
solution	   (BD	   Biosciences,	   USA;	   Cat	   no.	   35423)	   was	   prepared	   in	   0.02N	   glacial	   acetic	   acid,	  
according	   to	  manufacturer’s	   instructions,	   at	   a	   concentration	  of	   50µg/ml	   and	  used	   to	  pre-­‐
coat	   surfaces	   used	   for	   BOEC	   isolation	   and	  maintenance.	   Coating	  was	   achieved	   by	   adding	  
5.2µg/cm2	   (1ml)	   collagen	   solution	   and	   incubating	   at	   37oC,	   5%	   CO2	   for	   1	   hour	   prior	   to	  
washing	   three	   times	   with	   1	   x	   phosphate	   buffered	   saline	   (PBS)	   without	   MgCl2	   or	   CaCl2	  
(Sigma,	   UK;	   Cat	   no.	   59321C).	   Fibronectin	   coating	  was	   achieved	   by	   addition	   of	   fibronectin	  
solution	  (Invitrogen,	  UK;	  Cat	  no.	  33016-­‐015)	  at	  a	  concentration	  of	  3µg/cm2.	  Details	  of	  which	  








2.2	  REAGENTS	  AND	  DRUGS	  
2.2.1	  	   TLR	  and	  NOD	  agonists	  
As	   discussed,	   Toll-­‐like	   receptors	   (TLR)	   and	   nucleotide	   oligomerisation	   domain	   (NOD)	  
receptors,	  respond	  to	  pathogen	  associated	  molecular	  patterns	  (PAMPs).	  Different	  TLRs	  and	  
NODs	  respond	  to	  specific	  PAMPs	  to	  result	  in	  activation	  of	  downstream	  signalling	  pathways,	  
which	   activate	   innate	   immune	   responses.	   These	   PAMPs,	   or	   mimics	   thereof,	   are	  
commercially	   available	   and	   can	  be	  used	   to	   activate	   specific	   TLRs	   and	  NOD	   receptors.	   The	  
function	  of	  particular	  receptors	  on	  cells	  in	  culture	  can	  therefore	  be	  assessed.	  The	  agonists	  of	  








Table	   2.3	   Agonists	   and	   pathogen	   associated	   molecular	   patterns	   (PAMPs)	   and	   their	  
associated	  receptors.	  ‘PAMPs	  used	  in	  vitro’	  were	  used	  to	  activate	  their	  specific	  receptors	  in	  
cell	  treatment	  protocols.	  
	  
	  
TLR1-­‐9	  agonists	  were	  purchased	  as	  a	  kit	  of	  agonists	  (Invivogen,	  UK;	  Cat	  no.	  tlrl-­‐kit1hw).	  All	  
agonists	   were	   prepared	   from	   lyophilized	   powders	   according	   manufacturer’s	   instructions.	  
Preparation	  instructions	  are	  shown	  below	  in	  Table	  2.4	  


























TLR3' RNA'Viruses' dsRNA' Poly(I:C)' +'
TLR7' RNA'Viruses' ssRNA' Imiquimod' C'
TLR8' RNA'Viruses' ssRNA' ssRNA40' C'












Table	   2.4	   Table	   from	   Invivogen	   TLR1-­‐9	   agonist	   kit	   product	   information	   leaflet	   showing	  
instructions	   for	  preparation	  of	   stock	   concentrations.	   Table	  drawn	   from	   information	   in	   the	  
product	  information	  sheet	  at	  invivogen.com.	  
	  
The	  NOD1	  agonist	  γ-­‐D-­‐glutamyl-­‐meso-­‐diamopimelyl-­‐D-­‐alanine	  (iE-­‐DAP)	  (Invivogen,	  USA;	  Cat	  
no.	  tlrl-­‐dap)	  is	  a	  commonly	  used	  NOD1	  agonist	  and	  represents	  the	  minimal	  motif	  recognised	  
by	  NOD1.	  In	  most	  experiments	  in	  my	  PhD	  however	  I	  have	  used	  a	  form	  of	  iE-­‐DAP	  that	  has	  a	  
lipophilic	   lauroyl	   group	   added	   to	   its	   structure	   (C12-­‐iE-­‐DAP)	   (Invivogen,	   USA;	   Cat	   no.	   tlrl-­‐
c12dap).	   This	   increases	   membrane	   permeability,	   and	   potency	   of	   the	   iE-­‐DAP	   moiety	   on	  
NOD1.	   The	   rationale	   for	   the	   use	   of	   this	   more	   potent	   agonist	   in	   my	   PhD	   was	   to	   enable	  
comparisons	  to	  be	  made	  between	  TLR4	  and	  NOD1,	  which	  are	  expressed	  by	  endothelial	  cells,	  







Pam3CSK4) 0.1)–)1μg/ml) 100μg/ml) 100μl)H20)
HKLM) 108)cells/ml) 1010)cell/ml) 100μl)H20)
Poly)(I:C)) 10ng)–)10μg/ml) 1mg/ml) 500μl)H20)
Poly)(I:C))LMW) 30ng)–)10μg/ml)) 1mg/ml) 500μl)H20)
LPS) 10ng)–)10μg/ml) 100μg/ml) 1ml)H20)
)
Flagellin) 10ng)–)10μg/ml) 100μg/ml) 100μl)H20)
FSLE1) 1ng)E)1μg/ml) 100μg/ml) 100μl)H20)
Imiquimod) 0.25)–)10μg/ml) 100μg/ml) 250μl)H20)
ssRNA40) 0.25)–)10μg/ml) 100μg/ml) 250μl)H20)




2.2.2	  	   Pharmacological	  antagonists	  
To	   study	   the	   NOD1	   signalling	   in	   stem	   cell	   derived-­‐endothelial	   cells	   in	   more	   detail,	   the	  
rationale	  for	  which	  is	  given	  in	  Chapter	  3	  and	  4,	  antagonists	  of	  key	  proteins	  were	  used.	  	  
	  
Inhibitors	  used	  were:	  the	  dual	  p38	  MAPK	  and	  RIP2	   inhibitor	  (SB203580;	  Merck,	  Germany),	  
the	   IKK	   inhibitor	   (SC-­‐514;	   Tocris	   Bioscience,	   UK),	   and	   the	   p38	   MAPK	   selective	   inhibitor	  
(BIRB0796;	   Axonmedchem,	   Netherlands).	   Novel	   inhibitors	   of	   NOD1	   (GSK’214)	   and	   is	  
associated	  the	  adapter	  protein,	  RIP2	  (GSK’214)	  were	  a	  gift	  from	  Dr	  John	  Bertin	  and	  Dr	  Peter	  
Gough,	  GSK,	  Philadelphia,	  USA.	  Precise	  structural	  details	  of	  these	  drugs	  are	  not	  available	  but	  
we	   have	   previously	   validated	   these	   drugs	   as	   inhibitors	   of	  NOD1	   agonist	   induced	   cytokine	  
release	  in	  endothelial	  cells	  (Gatheral	  et	  al.,	  2012).	  
	  
To	   study	   cytosolic	   phospholipase	  A2	   (cPLA2)	   in	   endothelial	   cells,	   the	   rationale	   for	  which	   is	  
given	   in	   Chapter	   6,	   the	   cPLA2	   inhibitor	   pyrophenone	   (PYR;	   Biomol,	   Germany;	   Cat	   no.	  
Cay13294-­‐5)	  was	  used.	  	  
	  
2.2.3	   	  NOD1	  Small	  interfering	  (si)RNA	  
Targeting	   NOD1	   siRNA	   (Qiagen,	   UK;	   Cat	   no.	   SI02655450)	   was	   used	   according	   to	  
manufacturer’s	  instructions.	  The	  NOD1	  siRNA	  was	  supplied	  as	  premix,	  which	  contains	  siRNA	  
molecules	  and	  proprietary	  stabilisers.	  This	  solution	  can	  be	  added	  directly	  to	  wells	  of	  a	  cell	  
culture	  plate	  to	  give	  a	  final	  concentration	  of	  25nM.	  The	  ability	  of	  the	  NOD1	  siRNA	  molecule	  
selected	  to	  knockdown	  NOD1	  expression	  was	  assessed	  at	  the	  gene	  level	  (mRNA	  expression)	  
and	  functional	  level	  (CXCL8	  release	  in	  response	  to	  NOD1	  agonist).	  Protocols	  using	  siRNA	  and	  




AllStars	  Negative	  control	  siRNA	  which	  does	  not	  target	  any	  known	  mammalian	  gene	  was	  also	  
purchased	   from	   Qiagen,	   UK	   (Cat	   no.	   SI03650318).	   This	   was	   also	   used	   according	   to	  
manufacturer’s	  instructions.	  	  
	  
2.2.4	  	   Haemophilus	  influenzae	  
Haemophilus	  influenzae:	  strain	  code	  49247,	  was	  purchased	  from	  the	  American	  Type	  Culture	  
Collection	   (ATCC)	  and	  provided	   for	  my	  PhD	  under	  collaboration	  with	  Dr	  Aurica	  Telcain,	  Dr	  
Mike	  Edwards	  and	  Prof.	  Sebastian	  Johnston	   in	  the	  Dept.	  of	  Respiratory	  Medicine,	   Imperial	  
College	   London.	   Haemophilus	   influenzae	   was	   provided	   in	   ATCC®	   Medium	   814:	   GC	  
Agar/Broth	   at	   unknown	   concentration.	  Haemophilus	   influenzae	   from	   this	   broth	  was	   then	  
seeded	   on	   to	   Columbia	   Agar/Chocolate	  Horse	   Blood	   plates	   (Oxoid,	   UK;	   Cat	   no.	   PB0124A)	  
and	   incubated	  overnight	  at	  37oC	  5%	  CO2.	  A	  single	  colony	  was	  then	   isolated	  and	  multiplied	  
further	   in	   fresh	   Columbia	   Agar/Chocolate	   Horse	   Blood	   plates.	   From	   these	   multiplied	  
cultures,	  Haemophilus	  influenzae	  was	  scraped	  off	  and	  suspended	  in	  2ml	  Brain	  Heart	  Infusion	  
Broth	   (Oxoid,	   UK;	   Cat	   no.	   CM1135B)	   and	   added	   to	   18ml	   DMEM	   with	   10%	   glycerol.	   This	  
solution	  was	   then	   aliquoted	   in	   to	   1ml	   vials	   and	   frozen	   immediately	   at	   -­‐80oC.	   Samples	   of	  
these	   vials	  were	   expanded	  on	   Columbia	  Agar/Chocolate	  Horse	   Blood	   plates	   to	   determine	  
colony	  forming	  units	  (CFU)/ml.	  	  
	  
Further	   dilutions	   for	   experiments	   were	   made	   in	   Lonza-­‐EGM2	   medium	   for	   use	   in	   assays,	  




Appropriate	  safety	  procedures	  should	  always	  be	  used	  with	  this	  material.	  Laboratory	  safety	  is	  
discussed	   in	   the	   current	   publication	   of	   the	   Biosafety	   in	   Microbiological	   and	   Biomedical	  
Laboratories	   from	   the	  U.S.	  Department	  of	  Health	  and	  Human	  Services	  Centers	   for	  Disease	  
Control	  and	  Prevention	  and	  National	  Institutes	  for	  Health.	  	  
From:	  https://www.lgcstandards-­‐atcc.org/~/ps/49247.ashx.	  Accessed	  February	  2014.	  
	  
With	  this	   information,	  Haemophilus	   influenzae	  when	  used	  in	  the	  laboratory	  can	  be	  carried	  
out	  using	  category	  II	  biological	  safety	  cabinets,	  but	  these	  cabinets	  must	  be	  dedicated	  for	  the	  
handling	  of	  pathogenic	  material	  and	  experiments	  must	  be	  carried	  out	  in	  isolation	  from	  other	  
non-­‐pathogen	   related	   cell	   culture	   work.	   As	   a	   result,	   for	   experiments	   using	   Haemophilus	  
influenzae	  in	  my	  PhD,	  these	  were	  carried	  out	  in	  the	  Dept.	  of	  Respiratory	  Medicine,	  Imperial	  
College	   London	   under	   collaboration	   with	   Prof.	   Sebastian	   Johnston.	   Experiments	   were	  
carried	   out	  with	   the	   help	   and	   support	   of	  Dr.	  Mike	   Edwards	   and	  Dr.	   Aurica	   Telcian	   in	   this	  
department.	  	  
	  
Haemophilus	   influenzae,	   is	   a	   Gram-­‐negative	   bacteria	   which	   expresses	   LPS	   and	   Gram-­‐
negative	  bacterial	  peptidoglycan	  and	  is	  reportedly	  sensed	  by	  TLR4	  (Hirano	  et	  al.,	  2009)	  and	  
NOD1	   (Ratner	   et	   al.,	   2007)	   respectively.	   In	   infection	   protocols,	   discussed	   fully	   below,	  
Haemophilus	   influenzae	   was	   used	   at	   colony	   forming	   unit	   concentrations	   of	   108-­‐105	   for	  
24hours.	  In	  these	  experiments	  a	  ‘filter	  control’	  was	  also	  included.	  This	  control	  represents	  a	  
bacteria	   free	  eluent	  of	  conditioned	  media	  produced	  by	   filtering	  cultures	  through	  a	  30-­‐kDa	  
membrane	   (Ultrafree-­‐0.5	   PBTK	   Centrifugal	   Filter	   Unit	   30kDa	   Millipore	   UFV5BTK00)	  
(Millipore,	  Gloucestershire,	  UK).	  When	  107	  CFU/ml	  of	  Haemophilus	  influenza	  was	  filtered	  in	  
this	  way	   and	   added	   to	   cells,	   CXCL8	   release	  was	   reduced	   to	   below	  basal	   (Figure	   2.1).	   This	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illustrates	  cell	  activation	  by	  the	  107	  CFU/ml	  Haemophilus	  influenzae	  stock	  was	  a	  function	  of	  
the	  bacteria	  and	  not	  a	  broth	  consistent.	  	  
	  
Figure	   2.1	   Representative	   data	   (n=3)	   of	   effect	   of	   Haemophilus	   influenzae	   (HIN)	   broth	  
constriuents	  on	  CXCL8	  release	  from	  human	  umbilical	  vein	  endothelial	  cells	  (HUVEC).	  
	  
2.2.5	  	   Therapeutic	  antibodies	  
Therapeutic	  antibodies	  were	  selected	   for	   testing	   in	  cytokine	  storm	  assays	   to	   include	  gold-­‐
standard	   cytokine	   storm	   inducing	  drugs	  as	  well	   as	   clinically	  used	  and	  mild	   cytokine	   storm	  
inducing	   drugs,	   as	   well	   as	   negative	   control	   antibodies	   that	   are	   used	   clinically	   but	   do	   not	  
cause	  cytokine	  storm.	  	  
	  
The	   biologics/therapeutic	   antibodies,	   their	   clinical	   use	   and	   cytokine	   storm	   profile	   in	  





Table	  2.5	  Summary	  of	  characteristic	  of	  biologics	  studies	  in	  Chapter	  5.	  
	  
As	   shown	   in	   Table	   2.5,	   antibodies	   can	   be	   chimeric,	   humanized	   or	   fully	   human.	   Chimeric	  
antibodies	   are	   antibodies	   that	   have	   had	   the	   animal	   Fc	   region	   replaced	   with	   a	   human	   Fc	  
region,	   examples	   of	  which	   include	   that	   anti-­‐TNFα	  drug	   Etanercept.	  Humanised	   antibodies	  
are	   distinct	   from	   chimeric	   antibodies	   as	   they	   have	   gone	   through	   additional	   processing	   to	  


































































































determining	   regions	   which	   bind	   the	   target	   protein	   often	   remain	   of	   animal	   origin.	   Many	  
antibodies	   approved	   for	   use	   in	   therapy	   are	   humanized	   and	   examples	   include	   Campath,	  
Herceptin	   and	  Avastin.	   Technology	  also	  exists	   that	  enables	   the	  production	  of	   fully	  human	  
therapeutic	   antibodies.	   Such	   approaches	   typically	   involve	   using	   a	   ‘phage	   display	   system’.	  
This	   protocol	   involves	   use	   of	   gene	   libraries	   of	   specific	   antibody	   sequences	   which	   when	  
transfected	  into	  phage	  bacteria	  are	  transcribed	  and	  produced	  in	  high	  quantities.	  It	  should	  be	  
noted	   that	   this	   approach	   yields	   only	   the	   Fab	   fragment	   of	   the	   antibody	   and	   so	   requires	  

















2.3.1	  	   Human	  embryonic	  stem	  cells	  (hESC)	  and	  hESC-­‐derived	  endothelial	  cells	  (hESC-­‐EC)	  
hESC-­‐EC	  were	  derived	  from	  the	  H7	  cell	   line	  of	  hESC	  according	  to	  a	  protocol	   that	  has	  been	  
published	  and	  developed	  in	  the	  literature	  (Levenberg	  et	  al.,	  2002;	  Li	  et	  al.,	  2009).	  The	  H7	  cell	  
is	  one	  of	  many	  available	  hESC	  lines.	  Some	  of	  these	  cell	  lines	  have	  normal	  XY	  karyotype	  (H1,	  
H13	  and	  H14	  for	  example)	  and	  some	  have	  normal	  XX	  karyotype	  (H7	  and	  H9	  for	  example).	  
The	  genotype	  and	  phenotype	  of	  these	  cells	  in	  terms	  of	  most	  pluripotency	  marker	  expression	  
and	   telomerase	  expression	  does	  not	  differ	  between	   the	  cell	   lines.	  H7	  hESC	  express	   stage-­‐
specific	   embryonic	   antigen	   (SSEA)-­‐3,	   SSEA-­‐4,	   TRA-­‐1-­‐60	   and	   TRA-­‐1-­‐80.	   Only	   SSEA-­‐3	  
expression	  varies	  between	  hESC	  lines	  but	  this	  is	  thought	  to	  be	  due	  to	  restricted	  access	  of	  the	  
SSEA-­‐3	  antibody	  to	  the	  epitope	  (Thomson	  et	  al.,	  1998).	  The	  H7	  line	  of	  hESC	  were	  derived	  by	  
James	   Thomson’s	   lab	   (Thomson	   et	   al.,	   1998)	   from	   the	   pre-­‐implantation	   blastocyst	   of	  
fertilized	  embryos	  surplus	  to	  in	  vitro	  fertilisation	  (IVF)	  procedures.	  Cells	  were	  cultured	  to	  the	  
blastocyst	   stage	   and	   the	   inner	   cell	  mass	   isolated.	   hESC,	   like	   human	  embryonal	   carcinoma	  
cells	   and	  mouse	   embryonic	   stem	   cells,	   form	   all	   three	   germ	   layers	   when	   injected	   in	   SCID	  
mice.	  These	  are	  endoderm	  (epithelial	  cells),	  mesoderm	  (endothelial	  cells,	  cardiac	  myocytes,	  
cartilage,	   bone,	   smooth	   muscle)	   and	   ectoderm	   (neuronal	   epithelium	   and	   stratified	  
squamous	  epithelium).	  
	  
Experiments	   using	   hESC	   in	  my	   PhD	  were	   approved	   by	   the	   UK	   Stem	   Cell	   bank	   and	   under	  
collaboration	   agreements	   with	   the	   Geron	   Corporation	   (Menlo	   Park,	   CA,	   USA).	   As	   hESC	  
undergo	  spontaneous	  differentiation	  in	  culture,	  hESC	  were	  maintained	  in	  MEF	  conditioned	  
media	  which	  suppresses	  differentiation	  without	  affecting	  proliferation.	  This	  occurs	  as	  mouse	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embryonic	   fibroblasts	   secrete	   as	   many	   as	   136	   proteins	   that	   are	   involved	   in	   growth	   and	  
differentiation	   (Lim	   and	   Bodnar,	   2002).	   The	   precise	   proteins	   involved	   in	   maintaining	  
pluripotency	  remains	  under	  investigation.	  
	  
Undifferentiated	  cells	  were	  maintained	   in	   the	  MEF	  conditioned	  media	  as	  described	  above	  
on	  Matrigel	  (BD	  Biosciences	  UK;	  Cat	  no.	  356234)-­‐coated	  6-­‐well	  plates	  (Nunc,	  Denmark;	  Cat	  
no	  140675).	  For	  differentiation	  of	  hESC	  to	  hESC-­‐EC	  well	  developed	  published	  protocols	  were	  
followed.	   hESC	   were	   dissociated	   into	   clumps	   and	   plated	   on	   ultra-­‐low	   attachment	   plates	  
(Nunc,	  Denmark;	  Cat	  no:	  145383)	  and	  incubated	  in	  Lonza-­‐EGM2	  complete	  media	  (see	  Table	  
2.1)	  to	  allow	  formation	  of	  embryoid	  bodies.	  Embryoid	  bodies	  are	  3D	  structures	  that	  contain	  
endoderm,	   mesoderm	   and	   ectoderm	   cells,	   which	   arise	   from	   hESC.	   After	   4	   days	   of	  
spontaneous	  differentiation	  and	  growth,	  embryoid	  bodies	  were	  re-­‐plated	  on	  gelatin-­‐coated	  
6-­‐well	   plates	   (Sigma-­‐Aldrich,	   St	   Louis,	   USA;	   Cat	   no.	   G1393)	   in	   Lonza-­‐EGM2.	   After	   13	   days	  
cells	  were	  stained	  for	  the	  endothelial	  cell	  marker	  CD31	  using	  an	  AlexaFluor	  488	  fluorescence	  
dye	  labelled	  anti-­‐CD31	  antibody	  (BD	  Biosciences,	  Oxford,	  UK)	  (see	  staining	  protocols	  below).	  
Cells	  were	  sorted	  using	  a	  FACS	  Aria	  II	  cell	  sorter	  (BD	  Biosciences,	  Oxford,	  UK)	  and	  expanded	  
in	   gelatin	   coated-­‐96-­‐well	   plates	   (Nunc,	  Denmark)	   in	   Lonza-­‐EGM2	  medium	   for	   further	  use.	  
Cells	   were	   maintained	   in	   Lonza-­‐EGM2	   media	   and	   grown	   on	   gelatin	   coated	   75cm2	   flasks	  
(Nunc,	  Denmark;	  Cat	  no.	  178905).	  Cells	  were	  used	  between	  passages	  2-­‐8.	  
	  











2.3.2	   	  Blood	  outgrowth	  endothelial	  cells	  (BOEC)	  
BOEC	  were	  isolated	  according	  to	  published	  protocols	  (Ingram	  et	  al.,	  2004;	  Martin-­‐Ramirez	  et	  
al.,	  2012;	  Reed	  et	  al.,	  2011;	  Starke	  et	  al.,	  2010)	  with	  minor	  modifications.	  This	  protocol	   is	  
discussed	  in	  detail	  under	  appropriate	  subheadings	  below.	  
	  
Principle	  of	  density	  gradient	  separation	  of	  human	  blood	  
BOEC	  are	   thought	   to	  arise	   from	  a	  CD34+	  population	  of	  cells	  and	  can	  be	   isolated	   from	  the	  
peripheral	  blood	  mononuclear	  cell	   (PBMC)	  fraction	  using	  a	  density	  gradient	  approach.	  The	  
concept	  of	  density	  gradient	  separation	  of	  cells	   in	   the	  blood	  has	  been	  around	   for	  decades.	  
Today,	   density	   gradient	   separations	   are	   typically	   carried	   out	   using	   Histopaque®	   or	   Ficoll®	  































and	  dextrans	  that	  separate	  to	  give	  a	  solution	  of	  different	  densities	  when	  a	  centrifugal	  force	  
is	   applied.	  When	   a	  mixed	   cell	   population	   leukocytes,	   as	   in	   the	   blood	   is	   added	   these	   cells	  
localise	   in	  the	  different	  areas	  of	  the	  Histopaque®	  or	  Ficoll®	  gradient	  to	  match	  the	  solution	  
density,	   and	   so	   can	   be	   separated	   from	   blood	   and	   studied	   in	   vitro.	   Different	   types	   of	  
Histopaque®	  are	  available	  which	  are	  optimised	   for	   the	   separation	  and	   isolation	  of	   certain	  
cells.	   Histopaque®	   1077	   for	   example	   is	   used	   for	   separation	   of	   PBMCs	   from	   blood.	   For	  
isolation	   of	   BOEC,	   achieving	   high	   yield	   of	   PBMCs	   is	   important	   so	   for	   these	   protocols,	  
commercially	  available	  Ficoll®	  gradient	  tubes	  that	  are	  further	  enhanced	  for	  PBMC	  isolations	  
were	  used.	  	  
	  
	  
Figure	  2.3	   Illustration	  of	  the	  layering	  of	  PBMCs	  and	  other	  cell	  fractions	  in	  BD®	  CPTTM	  Ficoll	  



















Isolation	  and	  culture	  of	  BOEC	  
Blood	  (48ml;	  6	  x	  8ml	  tubes/patient)	  was	  collected	   into	  tubes	  with	  Ficoll	   (Thill	  et	  al.,	  2008)	  
(Figure	  2.3),	  from	  healthy	  volunteers	  aged	  24-­‐45	  and	  inverted	  8	  times	  as	  per	  manufacturer’s	  
instructions.	  	  Tubes	  were	  then	  centrifuged	  at	  1600	  RCF	  for	  30	  minutes	  at	  room	  temperature	  
with	  maximum	  acceleration	  and	  braking	  rates	  to	  obtain	  PBMCs.	  Tubes	  were	  then	  inverted	  a	  
further	  8	  times	  to	  allow	  mixing	  of	  the	  buffy	  coat	  (which	  contains	  PBMCs	  and	  platelets)	  and	  
plasma	  fraction.	  The	  fractions	  of	  blood	  are	  shown	  in	  Figure	  2.3.	  	  The	  contents	  of	  8	  tubes	  was	  
then	  carefully	  pooled	  into	  a	  50ml	  falcon	  tube	  and	  10%	  FBS/PBS	  added	  to	  give	  a	  final	  volume	  
of	  50ml.	  Cells	  were	  then	  centrifuged	  at	  520	  RCF	  for	  10	  minutes	  with	  maximal	  acceleration	  
and	  intermediate	  braking.	  The	  supernatant	  was	  discarded	  and	  pellets	  resuspended	  in	  10ml	  
of	  10%	  FBS/PBS	  solution.	  This	  process	  was	  repeated	  a	  further	  two	  times	  giving	  three	  washes	  
in	   total.	   After	   the	   final	   centrifugation,	   the	   pellet	   was	   resuspended	   in	   10ml	   Lonza-­‐EGM2	  
supplemented	   with	   10%	   FBS	   (ThermoFischer,	   UK;	   Hyclone).	   A	   sample	   (10µl)	   of	   the	  
suspension	   was	   then	   diluted	   in	   media	   (90µl)	   and	   10µl	   added	   to	   a	   haemocytometer	   for	  
counting.	  The	  counting	  procedure	  and	  the	  calculation	  for	  plating	  of	  cells	  at	  the	  appropriate	  






Figure	  2.4	  (A)	  Protocol	  for	  counting	  cells	  on	  haemocytometer	  and	  (B)	  Calculation	  of	  dilution	  
of	   cells	   to	   required	   seeding	   density.	   Image	   of	   haemocytometer	   modified	   from	  
en.wikipedia.com.	  Attribution:	  Zephyris	  at	  the	  English	  Language	  Wikipedia.	  
	  
PBMCs	  were	  then	  resuspended	  in	  an	  appropriate	  amount	  of	  Lonza-­‐EGM2	  with	  10%	  FBS	  and	  
distributed	  across	  5.2µg/cm2	  collagen	  coated	  6-­‐well	  plates	  (Nunc,	  Denmark)	  at	  a	  density	  of	  3	  
x	  107	  cells/well.	  Plates	  were	  incubated	  at	  37oC,	  5%	  CO2.	  After	  24	  hours	  media	  was	  carefully	  
removed.	  As	   the	  BOEC-­‐precursor	   is	   a	   rare	   cell	   and	  as	  adherence	  of	   this	   cell	   to	   the	  well	   is	  
required,	  media	  changes	  were	  carried	  out	  using	  a	  P1000	  pipette	  with	  extreme	  care	  and	  with	  
plates	  kept	  flat	  at	  all	  times.	  Cells	  were	  then	  washed	  with	  1ml	  Lonza-­‐EGM2	  with	  10%FBS	  and	  
plates	  tipped	  back	  and	  forth	  once	  only.	  This	  media	  was	  then	  removed,	  again	  with	  extreme	  
care	  and	  4	  ml	  of	  fresh	  Lonza-­‐EGM2	  10%	  FBS	  added	  to	  each	  well.	  Cells	  were	  kept	  under	  close	  


















next	  72	  hour	  and	  at	  24	  hour	  intervals,	  this	  process	  was	  repeated	  a	  further	  two	  times.	  After	  4	  
days	   media	   was	   replaced	   every	   48-­‐56	   hours	   without	   washing	   until	   cobblestone	   colonies	  
appeared.	  Colonies	  of	  endothelial	  cells	  typically	  emerged	  between	  days	  5-­‐21.	  	  
	  
A	  summary	  of	  donor	  characteristics	  of	  BOEC	  isolated	  in	  my	  PhD	  is	  shown	  in	  Table	  2.6.	  	  
	  
	  
Table	   2.6	   List	   of	   donor	   characteristics	  with	   successful	   isolations	   of	   BOEC	   and	   used	   in	  my	  
PhD.	  –	  indicates	  a	  missing	  record	  on	  this	  particular	  isolation.	  
	  
Once	  colonies	  emerged	  they	  were	  allowed	  to	  expand	  for	  not	  more	  than	  3-­‐5	  days.	  Colonies	  
were	  removed	  by	  trypsin	  (Invitrogen,	  UK;	  TrypLE®	  1x)	  digest	  using	  2ml	  trypsin/well.	  Trypsin	  
was	  neutralised	  with	  4ml	  Lonza-­‐EGM2	  10%	  FBS	  and	  the	  6ml	  cell/trypsin	  mix	  collected	   in	  a	  
DONOR%ID% AGE% SEX% TIME%TO%COLONY%
APPEARANCE%(days)%
EPCA% 25% M% 20%
EPCB% 28% F% 16%and%21%
EPCC% 41% M% 8%and%12%
EPCF% 24% F% 18%
EPCM% 3% F% 11%
EPCQ% 26% F% 5%
EPCS% 26% F% 19%
EPCZ% 35% M% 16%
EPCAG% 26% F% 13%
EPCAK% 28% F% 7%
113	  
	  
50ml	   falcon	   tube	   and	   centrifuged	   at	   190RCF	   for	   5	   minutes	   at	   room	   temperature	   with	  
maximal	   acceleration	   and	   intermediate	   brake	   settings.	   Cells	   were	   then	   plated	   on	   and	  
expanded	  and	  maintained	  on	  5.2µg/cm2	   collagen	   coated	  25cm2	  and/or	  75cm2	   cell	   culture	  
flasks	   (Nunc,	  Denmark)	   as	   for	   all	   other	  endothelial	   cells.	   Cells	  were	   tested	   for	   endothelial	  
cell	  phenotype	  by	  morphology	  using	  a	  light	  microscope	  and	  expression	  of	  CD31	  and/or	  VE-­‐
cadherin	  expression.	  
	  












Figure	  2.5	  Summary	  of	  method	  for	  the	  isolation	  of	  blood	  outgrowth	  endothelial	  cells	  (BOEC)	  
from	   peripheral	   blood	  mononuclear	   cells	   (PBMCs)	   for	   use	   in	   experiments.	   Abbreviations:	  
room	  temperature	  (RT),	  foetal	  bovine	  serum	  (FBS).	  	  
	  
	  
Ethics	  for	  isolation	  of	  BOEC	  
For	  the	  collection	  of	  human	  blood,	  and	  the	  protocol	  for	  isolation	  of	  BOEC,	  ethical	  approval	  
was	   granted	   by	   the	   Royal	   Brompton	   and	   Harefield	   Ethics	   Committee	   (ethics	   code:	  
08/H0708/69).	   Informed	   written	   consent	   was	   given	   by	   all	   participants.	   The	   consent	  
procedure,	  and	  associated	  patient	  information	  sheets	  and	  consent	  forms,	  were	  approved	  by	  
the	  Royal	  Brompton	  and	  Harefield	  Ethics	  Committee.	  Consent	  records	  were	  maintained	  as	  
























2.3.3	  	   Induced	  pluripotent	  stem	  cell	  derived-­‐endothelial	  cells	  (iPSC-­‐EC)	  
IPSC-­‐ECs	   are	   commercially	   available	   and	   were	   purchased	   from	   Cellular	   Dynamics	  
international	  (Colorado	  USA;	  Cat	  no.	  ECC-­‐100-­‐010-­‐001).	  Cells	  were	  supplied	  as	  a	  cryovial	  and	  
recovered	   under	   manufacturer’s	   instructions.	   Thus,	   iPSC-­‐EC	   were	   cultured	   on	   fibronectin	  
(Invitrogen,	  UK;	  Cat	  no.	  33016-­‐015)	   (3µg/cm2)	  coated	  75cm2	  cell	   culture	   flasks.	  Cells	  were	  
maintained	  in	  Vasculife®	  VEGF	  Medium	  Complete	  Kit	  as	  indicated	  in	  the	  media	  and	  solutions	  
section	  above.	  
	  
Method	  for	  the	  production	  of	  iPSC-­‐EC	  
As	  discussed	  in	  Chapter	  1,	   iPSC	  are	  derived	  from	  somatic	  cells	  (fibroblasts)	  that	  have	  been	  
reprogrammed	   to	   a	   ‘pluripotent’	   state	   using	   retroviral	   or	   lentiviral	   packaged	  pluripotency	  
genes	  (Takahashi	  et	  al.,	  2007).	  The	  method	  for	  differentiating	   iPSC	  into	  a	   iPSC-­‐EC	  is	   in	  fact	  
identical	   to	   that	   of	   the	  method	   for	   isolation	  of	   hESC-­‐EC	   from	  hESC.	   The	   ability	   of	   iPSC	   to	  
form	   iPSC-­‐EC	   in	   vitro	   was	   first	   demonstrated	   by	   the	   same	   group	   to	   develop	   to	  
reprogramming	   technology	   in	   2009	   (Taura	   et	   al.,	   2009).	   As	   the	   iPSC-­‐EC	   used	   in	   my	   PhD	  
(iCell®	  endothelial	  cells)	  were	  purchased	  from	  company,	  some	  data	  on	  the	  characterisation	  
was	   available	   from	   the	   company	   and	   is	   show	   in	   Figure	   2.6.	   Information	   supplied	   by	   the	  
company	   states	   that	   these	   cells	   are	   derived	   from	   human	   foetal	   lung	   fibroblasts.	   Due	   to	  
restrictions	   applied	  by	   the	   company	   I	  was	  not	   able	   to	  obtain	   the	  precise	   starting	   cell	   line	  
used	  to	  generate	  these	  cells	  and	  so,	  for	  control	  experiments,	  I	  used	  human	  lung	  fibroblasts	  
(HLFs)	  grown	  from	  tissue	  supplied	  surplus	  to	  clinical	  requirement	  from	  surgeries	  at	  the	  Royal	  





Figure	  2.6	  Representative	  of	  images	  of	  induced	  pluripotent	  stem	  cell	  derived	  endothelial	  cell	  
(iPSC-­‐EC)	   characterisation.	   (A)	   Cobblestone	   morphology	   and	   (B)	   von-­‐willebrand	   factor	  
expression	   of	   iCell	   endothelial	   cells	   purchased	   from	  Cellular	  Dyanamics	   (Cat	   no.	   ECC-­‐100-­‐
010-­‐001).	  	  
Image	  is	  from	  iCell®	  endothelial	  cell	  product	  information	  sheet:	  	  
http://www.cellulardynamics.com/.	  	  With	  permission.	   	  
2.3.4	  	   Isolation	  and	  culture	  HLFs	  
As	   a	   control	   for	   the	   iPSC-­‐EC	   HLFs	   were	   used.	   HLFs	   isolated	   from	   human	   lung	   tissue	   as	  
described	   previously	   (Maher	   et	   al.,	   2010)	   from	  histologically	   normal	   peripheral	   lung	   from	  
lung	  cancer	  resection	  surgieries	  carried	  out	  at	  the	  Royal	  Brompton	  Hospital	  under	  a	  blanket	  
ethics	   agreement.	   Cells	   were	   grown	   in	   supplemented	   DMEM	   with	   10%	   FBS,	   and	   were	  
passaged	  every	  3–4	  days.	  All	  experiments	  were	  performed	  from	  passage	  3–10	  
	  
2.3.5	  	   Endothelial	  cells	  from	  vessels	  
Human	  umbilical	  vein	  endothelial	  cells	   (HUVEC)	  used	  throughout	  my	  PhD	  were	  a	  gift	   from	  
Caroline	  Wheeler-­‐Jones	  (Royal	  Veterinary	  College,	  London)	  and	  were	  maintained	   in	  Lonza-­‐
EGM2	  medium.	  Cells	  isolated	  from	  fresh	  umbilical	  veins	  and	  used	  at	  passage	  2	  on	  arrival	  and	  




Human	   lung	  microvascular	   endothelial	   cells	   (HMVEC),	   and	   human	   aortic	   endothelial	   cells	  
(HAEC)	  were	  purchased	   from	  Lonza	  or	  Promocell	  as	  cryopreserved	  cells.	  Cells	  were	  grown	  
out	  and	  maintained	  in	  Lonza-­‐EGM2	  media	  and	  grown	  on	  1%	  gelatinised	  (Sigma,	  USA)	  75cm2	  





















2.4	  SHEAR	  STRESS	  MODELLING	  IN	  VITRO	  
Why	  model	  shear	  stress	  in	  vitro?	  
As	  discussed	   in	  Chapter	  1,	   endothelial	   cells	  on	   vessels	   are	  exposed	   to	  physical	   forces	  and	  
respond	   by	   aligning	   in	   the	   direction	   of	   flow.	   Shear	   stress	   in	   the	   vessel	   can	   be	  
multidirectional/oscillatory	   or	   unidirectional/laminar	   and	   defines	   endothelial	   cell	  
morphology	  (Meyer	  et	  al.,	  2009;	  Potter	  et	  al.,	  2011).	  In	  areas	  of	  unidirectional/laminar	  shear	  
stress	  endothelial	   cells	   appear	  elongated	  and	  aligned	  whereas	   in	  areas	  of	  multidirectional	  
flow	  they	  typically	  have	  a	  cobblestone	  appearance	  (Potter	  et	  al.,	  2011).	  Endothelial	  cells	  are	  
very	  sensitive	  to	  their	  biomechanical	  environment	  and	  shear	  stress	  is	  known	  to	  affect	  gene	  
expression	  and	  the	  development	  of	  atherosclerosis	  (Suo	  et	  al.,	  2007;	  Warboys	  et	  al.,	  2010).	  
As	  such,	  the	  study	  of	  these	  pathways	  is	  important	  and	  was	  the	  focus	  of	  the	  PhD	  project	  of	  
my	  colleague	  Dr.	  Claire	  Potter.	  To	  test	  the	  ability	  of	  endothelial	  cells	  to	  assume	  an	  aligned	  
and	  elongated	  phenotype	  I	  employed	  this	  model	  and	  this	  is	  described	  below.	  	  
	  
Modelling	  shear	  stress	  on	  the	  orbital	  shaker	  
Endothelial	   cells	   (hESC-­‐EC,	  BOEC	  or	  HAEC)	  were	  plated	  on	  gelatin-­‐coated	  6-­‐well	  plates	   (as	  
described	  above)	  at	  a	  density	  of	  100,000	  cells/well	  and	  grown	  to	  confluence.	  Time	  to	  reach	  
confluence	  in	  these	  conditions	  was	  typically	  4	  days	  in	  2ml	  of	  Lonza-­‐EGM2	  with	  10%	  FBS	  with	  
a	  media	   change	   on	   the	   second	   day.	   Once	   confluent,	  media	  was	   replaced	   (2ml)	   and	   cells	  
were	   either	   placed	   on	   a	   PS-­‐300	   orbital	   shaker	   (Grant	   Instruments,	   UK)	   or	   grown	   under	  
normal	   static	   conditions,	   both	   at	   37oC,	   5%	   CO2.	   	   The	   shaker	   was	   set	   to	   150	   RPM.	   The	  
movement	  of	  the	  shaker	  results	  in	  a	  wave	  of	  media	  that	  travels	  around	  the	  well	  resulting	  in	  
a	   complex	   pattern	   of	   shear	   applied	  with	   uni-­‐directional/laminar	   shear	   stress	   towards	   the	  
edge	   of	   the	   well,	   and	   non-­‐directional/oscillatory	   shear	   at	   the	   centre.	   In	   this	   model	  
119	  
	  
therefore,	  cells	  at	  the	  centre	  and	  edge	  of	  the	  well	  are	  analogous	  to	  those	  in	  the	  lesser	  and	  
greater	  curvature	  of	  the	  aortic	  arch	  respectively.	  After	  application	  of	  shear	  stress	  for	  4	  days,	  
cells	  were	  washed	  and	  fixed	  in	  4%	  paraformaldehyde	  for	  staining	  and	  imaging.	  Alignment	  of	  
cells	   was	   visualised	   by	   light	   microscopy	   using	   a	   Nikon	   microscope	   (Nikon,	   Japan;	   Eclipse	  
TS100	  with	  a	  Nikon	  VR	  ISO3200	  camera	  attachment).	  In	  some	  experiments,	  cells	  were	  also	  
stained	   for	   endothelial	   cell	   markers	   CD31	   and/or	   VE-­‐cadherin.	   Methods	   for	   staining	   and	  
imaging	  are	  given	  in	  a	  later	  section.	  Figure	  2.7	  summarises	  the	  pattern	  of	  shear	  stress	  in	  a	  6-­‐





Figure	  2.7	  Features	  of	  shear	  stress	  forces	  at	  different	  locations	  in	  the	  well	  of	  a	  6-­‐well	  plate	  




















2.5	  CELL	  TREATMENTS	  AND	  PHARMACOLOGICAL	  ASSAYS	  
2.5.1	  	   Plating	  cells	  for	  experiments	  
For	  all	  experiments,	  unless	  otherwise	  stated	  in	  figure	  legends,	  stem	  cell	  derived	  endothelial	  
cells	   or	   endothelial	   cells	   from	   vessels	   were	   plated	   on	   gelatin-­‐coated	   plates	   (as	   described	  
above)	   at	   a	   density	   of	   7,000	   cells/well	   in	   96-­‐well	   plates.	   Cell	   counts	  were	   determined	   as	  
shown	  in	  Figure	  2.4.	  Plating	  at	  this	  density	  ensures	  that	  the	  cells	  are	  added	  at	  sub-­‐confluent	  
levels,	  allowed	  to	  adhere	  and	  proliferate	  to	  form	  endothelial	  cell	  monolayers.	  As	  endothelial	  
cells	  on	  vessels	  are	  constantly	  exposed	   to	  serum	  proteins	  and	  proliferation	   is	   inhibited	  by	  
contact,	  serum	  starvation	  was	  not	  carried	  out	  for	  any	  protocols.	  	  
	  
2.5.2	  	   Activation	  of	  TLR	  and	  NOD	  receptors	  on	  endothelial	  cells	  
Treatment	  protocol	  
Cells	  were	  plated	  as	  described	  above.	  TLR1-­‐9	  agonists	  were	  prepared	  from	  stock	  solutions	  
as	   described	   above.	   Supernatants	   from	   confluent	   cells	   on	   a	   96-­‐well	   plate	  were	   discarded	  
and	  180ul	  of	  fresh	  Lonza-­‐EGM2	  added	  followed	  by	  20ul	  of	  drugs	  at	  10x	  concentrated	  stocks	  
to	  provide	  the	  desired	  final	  concentration	  in	  the	  well.	  Concentrations	  were	  selected	  based	  
on	   supplier	   information	   or	   from	   extensive	   data	   on	   the	   potency	   and	   efficacy	   of	   these	  
agonists	   from	   our	   group.	   Final	   concentrations	   of	   agonists	   were:	   heat	   killed	   Listeria	  
monocytogenes	   (HKLM)	   (TLR2	   agonist;	   107	   cells/ml),	   Pam3CSK4	   (TLR1/2	   agonist;	   1μg/ml),	  
FSL-­‐1	  (TLR2/6	  agonist;	  1μg/ml),	  PolyIC	  (TLR3	  agonist;	  10μg/ml),	  LPS	  (TLR4	  agonist;	  1μg/ml),	  
ST-­‐FLA	  (Staphylococcus	  aureus	  derived	  flagellin)	  (TLR5	  agonist;	  100ng/ml),	   IMI	  (imiquimod)	  
(TLR7	  agonist;	  1μg/ml),	   ssRNA40	   (TLR8	  agonist;	  1µg/ml,	  ODN2006	   (TLR9	  agonist;	  5µM).	   In	  
most	   protocols	   IL-­‐1β	   (1ng/ml)	   was	   also	   added	   to	   activate	   MyD88	   and	   NF-­‐κB	   signalling	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independently	  of	  TLRs.	  In	  later	  protocols	  where	  cells	  were	  treated	  with	  the	  NOD1	  agonists	  
(iE-­‐DAP;	  1μg/ml	  or	  C12-­‐iE-­‐DAP;	  10μg/ml),	  or	  Haemophilus	  influenzae	  (105-­‐108	  CFU/ml),	  LPS	  
and	  IL-­‐1β	  were	  again	  included	  to	  ensure	  cell	  responses	  were	  consistent	  across	  protocols	  and	  
isolations	  of	  cells.	  All	  dilutions	  of	  drugs	  were	  carried	  out	  in	  media	  in	  Lonza-­‐EGM2	  medium.	  
After	   24	   hours	   supernatants	   were	   collected	   and	   stored	   at	   -­‐20oC	   for	   analysis.	   In	   some	  
experiments,	   cells	   were	   treated	   for	   1	   hour,	   supernatants	   collected,	   and	   cells	   fixed	   for	  
imaging	  and	  measurement	  of	  NF-­‐κB	  nuclear	  translocation.	  Details	  of	   the	  protocols	   for	  this	  
analysis	  are	  discussed	  below.	  	  
	  
Principle	  of	  the	  assay	  
As	  TLRs	  activate	  innate	  immune	  pathways	  that	  culminate	  on	  defined	  transcription	  factors	  to	  
cause	   non-­‐specific	   inflammation,	   the	   function	   of	   TLRs	   and	   NODs	   can	   be	   assessed	   via	  
measurement	   of	   ubiquitous	   markers	   in	   vitro.	   CXCL8	   is	   released	   in	   response	   to	   NF-­‐κB	  
activation	  and	   is	   a	  ubiquitous	  marker	  of	   inflammatory	  activation.	  CXCL8	  has	  been	  used	   in	  
immunological	  and	  pharmacological	  assays	  in	  vitro	  for	  decades	  (Paul-­‐Clark	  et	  al.,	  2012),	  and	  
is	  easy	  to	  measure	  by	  simple	  immunoassay	  (discussed	  later).	  CXCL8	  is	  also	  a	  critical	  mediator	  
of	   innate	   immune	   responses	  and	  disease,	  and	   is	   increased	   following	   infection,	   sepsis,	  and	  
chronic	   inflammatory	  disease.	  On	   the	  other	  hand,	   activation	  of	   TRIF	   and	   IRF	   transcription	  
factors	   results	   in	   release	   of	   interferon-­‐related	   protein-­‐10	   (IP10),	   which	   can	   be	   used	   as	  
marker	  of	  TRIF	  activation	  in	  response	  to	  agonists.	  	  
	  
Including	   IL-­‐1β	   in	   these	  protocols	   indexes	   the	   function	  of	  MyD88	   signalling	   in	   these	   cells.	  
That	  is	  to	  say,	  a	  lack	  of	  response	  to	  any	  particular	  TLR	  agonist	  which	  signals	  through	  MyD88	  
but	  in	  cells	  that	  respond	  to	  IL-­‐1β,	  suggests	  that	  the	  ‘lacking	  component’	  is	  at	  the	  level	  of	  the	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receptor.	  Knowing	  this	  is	  also	  useful	  as	  whether	  the	  effects	  of	  pathway	  inhibition	  of	  specific	  
proteins	  and/or	  TLRs	  or	  NODs	  are	  specific	  can	  be	  determined	  by	  comparing	  responses	  to	  IL-­‐
1β.	  This	   is	  discussed	  later	   in	  sections	  on	  the	  principles	  of	  assays	  for	  NOD1	  knockdown	  and	  
inhibition.	  	  
	  
2.5.3	  	   Infection	  assay	  
Treatment	  protocol	  
Cells	   were	   plated	   as	   described	   above.	  Haemophilus	   influenzae	   was	   prepared	   from	   a	   109	  
CFU/ml	   stock	   and	   diluted	   in	   Lonza-­‐EGM2	  medium	   to	   give	   final	   concentrations	   of	   108-­‐105	  
CFU/ml.	  Once	  suspended	  in	  media	  at	  10x	  concentrated	  stocks,	  bacteria	  were	  added	  in	  20ul	  
aliquots	   to	  180ul	  of	  media	   in	   the	  96-­‐well	  plate.	  Cells	  were	  also	  treated	  with	  LPS	   (1µg/ml),	  
C12-­‐iE-­‐DAP	  (10µg/ml)	  and	  IL-­‐1β	  (0.01-­‐0.1ng/ml).	  After	  24	  hours	  supernatants	  were	  collected	  
and	  stored	  at	  -­‐20oC	  for	  analysis.	  
	  
Principle	  of	  the	  assay	  
As	  discussed,	  Gram-­‐negative	  bacteria	  are	  sensed	  by	  two	  key	  PRR	  pathways:	  TLR4,	  which	  is	  
the	  receptor	  for	  LPS,	  and	  NOD1,	  which	  is	  the	  receptor	  for	  peptidoglycan	  moieties.	  In	  order	  
to	   test	   the	   potential	   of	   endothelial	   cells	   (hESC-­‐EC	   and	   HUVEC	   for	   these	   protocols)	   to	  
respond	  to	  whole	  Gram-­‐negative	  bacteria,	  cells	  were	  infected	  with	  Haempohilus	  influenzae.	  
As	  with	  other	  types	  of	  Gram-­‐negative	  bacteria,	  Haempohilus	  influenzae	  is	  reportedly	  sensed	  
by	  cells	  via	  TLR4	  and/or	  NOD1	  PRR	  pathways	  (Hirano	  et	  al.,	  2009;	  Ratner	  et	  al.,	  2007).	  The	  
relative	  contribution	  of	  TLR4	  and	  NOD1	  was	  then	  assessed	  using	  HUVEC,	  hESC-­‐EC	  (which	  are	  
TLR4-­‐deficient),	  NOD1	  targeting	  siRNA,	  and	  pharmacological	  inhibitors	  of	  NOD1	  and	  RIP2.	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2.5.4	  	   siRNA	  knockdown	  of	  NOD1	  
Treatment	  Protocol	  
To	  achieve	  knockdown	  of	  NOD1	  at	  the	  gene	  level,	  an	  siRNA	  knockdown	  approach	  was	  taken.	  
Cells	  were	  plated	  as	  described	  above.	  Supernatants	  were	  removed	  and	  188µl	  of	  fresh	  Lonza-­‐
EGM2	   was	   added.	   Importantly,	   the	   antibiotic	   (gentamicin-­‐amphotericin-­‐B)	   was	   excluded	  
from	  this	  media	  as	  this;	  according	  to	  the	  siRNA	  manufacturer’s	  (Qiagen,	  UK)	  instructions	  will	  
interfere	  with	   the	   interaction	   of	   the	   siRNA	  with	   the	   cell	   DNA.	   Accordingly,	   12ul	   of	   NOD1	  
siRNA	   premix	   or	   negative	   control	   were	   added	   to	   the	   plates	   according	   to	   manufacturer’s	  
instructions.	  After	  24	  hours	  or	  48	  hours	  supernatants	  were	  discarded.	  Cells	  were	  then	  either	  
treated	  with	  Tri-­‐reagent	  to	  lyse	  cells	  for	  isolation	  of	  RNA,	  or	  fresh	  media	  added	  and	  C12-­‐iE-­‐
DAP,	  IL-­‐1β	  or	  Haempohilus	  influenzae	  as	  described	  above.	  
	  
Principle	  of	  the	  assay	  
siRNAs	  are	  double	  stranded,	  small	  interfering	  RNA	  molecules	  of	  20-­‐25	  base	  pairs	  in	  length,	  
and	  were	  first	  developed	  as	  biomedical	  research	  tools	  in	  2001	  (Elbashir	  et	  al.,	  2001).	  Prior	  to	  
this,	   it	   was	   known	   that	   small	   double-­‐stranded	   RNAs	   (dsRNA)	   could	   induce	   mRNA	  
degradation	   in	   Drosophilia	   cells.	   These	   dsRNA	   molecules	   bind	   specific	   homologous	  
sequences	   of	   DNA	   and	   result	   in	   the	   activation	   of	   a	   cascade	   events	   that	   results	   in	  
degradation	  of	  the	  target	  mRNA.	  This	  allows	  the	  transcription	  of	  specific	  genes	  in	  cells	  to	  be	  
‘knocked	   -­‐down’	   and	   the	   effects	   studied	   at	   the	   gene	   level	   and	   functional	   level.	   As	   this	  
regulation	   involves	   an	   evolutionarily	   conserved	   pathway,	   accordingly,	   this	   pathway	  
represents	  a	  physiological	  post-­‐transcriptional	  gene	  silencing	   function	   in	  human	  cells.	  This	  
pathway	  involves	  two	  key	  proteins,	  RISC	  and	  DICER.	  Once	  activated,	  these	  proteins	  remove	  
double	  stranded	  RNA	  and	  so	  ‘knockdown’	  expression	  of	  the	  target	  gene.	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Validation	  of	  the	  assay	  
In	   any	   assay	   using	   siRNA	   to	   knockdown	   a	   receptor,	   in	   this	   case	   NOD1,	   it	   is	   important	   to	  
validate	  the	  assay	  in	  a	  number	  of	  ways:	  
1. That	  expression	  of	  the	  target	  gene	  is	  reduced	  versus	  a	  housekeeping	  gene.	  This	  can	  
be	   measured	   post-­‐transfection	   with	   the	   siRNA	   using	   real	   time-­‐PCR	   (see	  
measurements	  section	  below).	  In	  this	  case	  NOD1	  mRNA	  expression.	  
2. 	  That	   response	   to	   a	   known	   specific	   agonist	   is	   reduced.	   In	   this	   case,	   NOD1	   agonist	  
induced	  CXCL8	  release.	  
3. That	   response	   to	   an	   agonist,	   known	   to	   cause	   similar	   responses	   in	   vitro,	   but	   via	   a	  
different	  receptor	  or	  pathway	  is	  unaffected.	  In	  this	  case,	  IL-­‐1β	  which	  induces	  NF-­‐κB	  
and	  CXCL8	  release	  independently	  of	  NOD1.	  
4. And	  the	  response	  is	  not	  a	  result	  of	  loss	  of	  cell	  viability,	  which	  can	  be	  assessed	  using	  
commercially	   available	   assays,	   and	   in	   my	   PhD,	   this	   was	   the	   Alamarblue®	   assay	  
(discussed	  in	  the	  measurements	  section	  below)	  
	  
Indeed,	  all	  of	  the	  measurements	  must	  be	  measured	  against	  a	  non-­‐targeting	  siRNA	  molecule	  
in	  order	  to	  account	  for	  non-­‐specific	  effects	   induced	  by	  the	  addition	  of	  RNA	  in	  to	  cells.	  The	  
protocol	   for,	   and	   pathways	   involved	   in	   siRNA-­‐mediated	   knockdown	   of	   NOD1	   are	  
summarised	  in	  Figure	  2.8	  
	  
2.5.5	  	   Pharmacological	   inhibition	   protocols	   for	   NOD1	   and	   downstream	   signalling	  
pathways	  for	  NOD1	  and	  TLR4	  
Pharmacological	  antagonists	  of	  NOD1	  and	  associated	  signalling	  pathways	  are	  available	  and	  
are	   highlighted	   in	   the	   drugs	   and	   reagents	   section	   above.	   	   Cells	  were	   plated	   as	   described.	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Supernatants	  were	  then	  removed	  and	  160μl	  of	  fresh	  media	  was	  added.	  As	  these	  inhibitors	  
were	  prepared	   in	  DMSO,	  with	   a	   final	   concentration	  of	   0.1%	  DMSO,	   cells	   in	   controls	  wells	  
were	  treated	  with	  media	  containing	  0.1%	  DMSO	  as	  vehicle.	  Inhibitors	  used	  for	  protocols	  to	  
determine	   the	   contribution	   of	   NOD1	   to	   C12-­‐iE-­‐DAP	   and	  Haemophilus	   inlfuenzae	   induced	  
responses	  were	   added	   as	   	   pre-­‐treatments	   for	   30	  minutes	   (NOD1	   inhibitor;	   GSK1219217A	  
(GSK’217);	  300nM;	  RIP2	   inhibitor;	  GSK2576214A	  (GSK’214);	  300nM).	   In	  some	  experiments,	  
inhibitors	   of	   IKK	   (SC-­‐514;	   0.01-­‐1μM),	   RIP2/p38	   MAPK	   (SB203580;	   0.01-­‐1μM)	   and	   the	  
selective	  p38	  MAPK	  (BIRB0976;	  0.1-­‐10μM)	  were	  added	  in	  identical	  protocols.	  As	  with	  other	  
treatment	  protocols,	  drugs	  were	  added	  from	  10x	  concentrated	  stocks	  to	  give	  a	  final	  volume	  
of	   200μl	   in	   the	   well	   of	   the	   96-­‐well	   plate.	   Plates	   were	   then	   incubated	   for	   30	   minutes,	  
followed	   by	   the	   addition	   of	   C12-­‐iE-­‐DAP	   (10μg/ml),	  Heamophilus	   influenzae	   (107	   CFU/ml),	  
LPS	  (1μg/ml)	  or	  IL-­‐1β	  (0.01-­‐1ng/ml)	  for	  24	  hours.	  
	  
Protocols	  for	  inhibition	  of	  NOD1	  pathways	  using	  siRNA	  and	  the	  pharmacological	  approaches	  











Figure	   2.8	   Summary	   of	   pathways	   activated	   and	   inhibited	   by	   protocols	   employing	   (A)	  
pharmacological	  inhibitors	  and	  (B)	  NOD1	  targeting	  siRNA	  to	  study	  NOD1	  signalling	  in	  human	  





















































Pharmacological	  inhibition	  protocols	  to	  study	  cPLA2	  in	  endothelial	  cells	  
In	  protocols	  to	  determine	  the	  contribution	  of	  cPLA2	  versus	  iPLA2	  to	  prostacyclin	  release	  by	  
endothelial	  cells,	  a	  cPLA2	  inhibitor	  (pyrrophenone)	  was	  used.	  For	  these	  protocols,	  cells	  were	  
plated	   on	   96-­‐well	   plates	   as	   described,	   and	   in	   addition	   on	   48	   well	   plates	   at	   a	   density	   of	  
20,000	  cells/well.	  Supernatants	  were	  collected	  and	  fresh	  media	  added	  with	  or	  without	  IL-­‐1β	  
(1ng/ml)	  to	  activate	  cyclooxygenase	  (COX).	  After	  24	  hours,	  supernatants	  were	  collected	  and	  
stored	   at	   -­‐20oC	   for	   analysis.	   For	   96-­‐well	   plates	   only,	   an	   inhibitor	   of	   cPLA2	   (Pyrophenone;	  
PYR;	  0.001-­‐0.1μM)	  or	  vehicle	   (0.1%	  DMSO)	  was	  added.	   IL-­‐1β	  or	  vehicle	   (Lonza-­‐EGM2)	  was	  
replaced	  in	  the	  required	  wells.	  After	  30	  minutes	  supernatants	  were	  collected	  and	  stored	  for	  
analysis.	  The	  cPLA2	  inhibitor,	  with	  and	  without	  IL-­‐1	  β	  was	  then	  replaced	  followed	  by	  addition	  
of	   three	   prostacyclin	   release	   inducing	   agents	   of	   the	   Ca2+	   ionophore	   (A23187;	   50nM),	  
arachidonic	   acid	   (AA;	   30nM)	  or	   thrombin	   (1unit/ml).	   Cells	  were	   incubated	   for	   30	  minutes	  
and	   supernatants	   collected	   and	   stored	   at	   -­‐20oC	   for	   analysis.	   For	   the	   48-­‐well	   protocols,	  
inducers	  of	  prostacyclin	  release	  were	  added	  as	  described	  above,	  cells	  were	  incubated	  for	  30	  
minutes	   and	   supernatants	   collected	   and	   stored	   at	   -­‐80oC	   for	   lipidomics	   analysis	   (discussed	  
below).	   Cell	   monolayers	   on	   48-­‐well	   plates	   were	   also	   lysed	   and	   collected	   for	   DNA/RNA	  
extraction.	  	  
	  
In	   further	   experiments	   to	   assess	   the	   contribution	   of	   cPLA2	   versus	   iPLA2	   to	   prostacyclin	  
production	  by	  endothelial	  cells	  from	  vessels,	  mouse	  aortic	  rings	  were	  employed.	  Isolation	  of	  
aortic	  rings	  was	  carried	  out	  by	  my	  colleague	  Dr.	  Nick	  Kirkby.	  Aortic	  rings	  were	  isolated	  from	  
CO2-­‐euthanised	   mice	   (male,	   BALB/c,	   10	   weeks;	   n=6),	   and	   incubated	   for	   1	   hour	   at	   37oC.	  
Mouse	   aortic	   rings	   were	   then	   incubated	   for	   30	   minutes	   with	   the	   cPLA2	   inhibitor,	  
pyrrophenone	  (PYR;	  0.1-­‐10µM),	  or	  the	  iPLA2	  inhibitor	  bromoenol	  lactone	  (BEL;	  0.1-­‐10µM)	  or	  
128	  
	  
vehicle	  (0.1%	  DMSO)	  as	  above.	  Mouse	  aortic	  rings	  do	  not	  respond	  robustly	  to	  thrombin,	  so	  
for	   these	   experiments,	   prostacyclin	   release	   was	   stimulated	   for	   30	   minutes	   with	  
acetylcholine	  (ACh;	  1µM;	  saline),	  which	  also	  acts	  via	  a	  Gq-­‐protein	  coupled	  receptor	  signalling	  
pathway	   to	   activate	   PLA2	   pathways	   in	   a	   similar	   fashion	   to	   thrombin.	   Supernatants	   were	  
collected	  and	  stored	  at	  -­‐80oC	  for	  analysis.	  
	  
cPLA2-­‐deficient	  patient	  
To	  further	  study	  the	  contribution	  of	  cPLA2	  to	  prostacyclin	  production	  from	  endothelial	  cells	  I	  
was	   able	   to	   take	   advantage	   of	   a	   rare	   mutation	   in	   a	   pair	   of	   siblings	   with	   a	   frameshift	  
mutation	  in	  the	  cPLA2α	  gene	  (PLA2G4A).	  This	  mutation	  results	  in	  a	  decrease	  in	  prostaglandin	  
production	  and	  circulating	  levels	  of	  prostacyclin	  (Brooke	  et	  al.,	  2012).	  As	  BOEC	  are	  derived	  
from	  adult	  stem	  cells,	  I	  have	  employed	  these	  cells	  to	  phenotype	  the	  endothelial	  cells	  of	  this	  
patient	   in	   chapter	   6.	   This	   accords	  with	   the	   idea	   that	   adult	   stem	   cells	   represent	   powerful	  
translational	   research	   tools	  and	  can	  be	  used	   to	   study	   ‘disease	   in	  a	  dish’.	  Blood	  was	   taken	  
from	  the	  patient	  at	  Barts	  and	  the	  London	  Hospital	  and	  BOEC	   isolated	  as	  descried	   in	  detail	  
above.	  These	  cells	  were	  then	  treated	  with	  and	  without	  IL-­‐1β	  for	  24	  hours,	  media	  removed	  
and	   replaced	   with	   media	   for	   30	   min	   containing	   	   agents	   to	   activate	   PLA2	   (A23187	   or	  
thrombin)	   or	   supply	   substrate	   	   (arachidonic	   acid)	   directly.	   Using	   these	   cells	   and	   the	   Ca2+	  
ionophore	  A23187	   and	   the	  Gq	   agonist	   thrombin	   allowed	  me	   to	   determine	  whether	   these	  
pathways	   act	   through	   cPLA2,	   treating	   the	   patient	   BOEC	   as	   ‘knockout’	   human	   cells.	  
Arachidonic	  acid	  was	  included,	  as	  in	  other	  protocols,	  to	  bypass	  the	  requirement	  for	  PLA2	  and	  
ensure	   that	   cells	   were	   able	   to	   produce	   prostacyclin	   via	   COX.	   This	   serves	   to	   support	   any	  
findings	  as	  being	  a	  result	  of	  inhibition	  or	  loss	  of	  cPLA2	  rather	  the	  inhibition	  or	  loss	  of	  other	  
downstream	   proteins	   required	   for	   prostacyclin	   release.	   For	   experiments	   using	   cPLA2-­‐
129	  
	  
deficient	  BOEC,	  supernatants	  were	  collected	  and	  frozen	  at	  -­‐80oC	  for	  analysis	  of	  prostacyclin	  
release	   (using	   6-­‐ketoPGF1α	   by	   ELISA,	   see	   below)	   and	   by	   mass	   spectrometry	   for	   a	   full	  
lipidomics	  analysis	  (discussed	  in	  measurement	  section	  below).	  
	  
The	   pathways	   activated	   and	   inhibited	   to	   assess	   the	   contribution	   of	   cPLA2	   to	   prostacyclin	  









Figure	  2.9	  (A)	  Summary	  of	  pathways	  activated	  and	  inhibited	  in	  protocols	  to	  determine	  the	  
contribution	   of	   cPLA2	   to	   prostacyclin	   release	   from	   endothelial	   cells.	   (B)	   Blood	   outgrowth	  
endothelial	  cells	  (BOEC)	  were	  also	  grown	  from	  a	  patient	  with	  a	  homozygous	  mutation	  in	  the	  
PLA2G4A	   gene	  which	   results	   in	   loss	   of	   cPLA2	   function.	   The	   impact	   on	   endothelial	   cells	   is	  
unknown	   and	   was	   studied.	   Agonists	   added	   in	   the	   protocol	   are	   circled	   in	   green.	  
Abbreviations:	  G-­‐protein	  coupled	  receptor	   (GPCR),	  phospholipase	  A2	   (PLA2),	  phospholipase	  
Cγ	   (PLCγ),	   phosphatidylinositol	   4,5-­‐bisphosphate	   (PIP2),	   inositol	   1,4,5-­‐trisphosphate	   (IP3),	  
cycloxgenase	   (COX),	   arachidonic	   acid	   (AA),	   prostacyclin	   synthase	   (PGIS),	   prostaglandin	   H2	  





























































2.5.6	  	   Autologous	  BOEC:PBMC	  co-­‐culture	  protocols	  
To	  allow	  co-­‐culture	  of	  endothelial	  cells	  and	  PBMCs	  from	  the	  same	  donor,	  BOEC	  were	  grown	  
from	  blood	  as	  described	  and	  plated	  on	  gelatin	  coated	  96-­‐well	  plates.	  Once	  confluent,	  PBMCs	  
from	   the	   same	   donors	   from	   which	   the	   BOEC	   were	   isolated	   were	   recalled	   and	   PBMCs	  
isolated	  using	  a	  Histopaque®	  gradient	  approach.	  PBMCs	  were	  resuspended	  in	  a	  50:50	  mix	  of	  
Lonza-­‐EGM2	   (BOEC	   medium)	   and	   RPMI	   (PBMC	  medium)	   with	   10%	   FBS.	   PBMCs	   or	   50:50	  
media	  alone	  was	  then	  added	  to	  wells	  with	  and	  without	  BOEC	  from	  the	  same	  donor.	  Media	  
was	   also	   added	   to	   BOEC	   alone	   giving	   rise	   to	   three	   conditions:	   BOEC	  monoculture,	   PBMC	  
monoculture,	  BOEC:PBMC	  co-­‐culture.	   Indeed,	  endothelial	   cell:PBMC	  co-­‐culture	   is	  not	  new	  
(Ashida	   et	   al.,	   1981;	   Bailey	   et	   al.,	   2012;	   Stebbings	   et	   al.,	   2007;	  Ward	   et	   al.,	   2009)	   and	   is	  
valuable	  since	  they	  represent	  some	  of	  the	  key	  cell	  interactions	  in	  the	  vessel	  that	  modulate	  
inflammatory	   responses.	   However,	   this	   approach	   using	   BOEC,	   allows	   for	   the	   first	   time,	  
endothelial	  cells	  and	  PBMCs	  from	  the	  same	  donor	  to	  be	  grown	  in	  co-­‐culture.	  This	  assay	  was	  
filed	  for	  a	  patent	  in	  March	  2013	  on	  which	  I	  am	  a	  ‘contributor	  to	  the	  work	  of	  the	  invention’.	  
	  
BOEC:PBMC	  co-­‐cultures	  and	  monocultures	  of	  each	  cell	   type	  alone	  were	   then	   treated	  with	  
biologics/therapeutic	   antibodies:	   anti-­‐CD28-­‐superagonist	   ANC28	   (10μg/ml),	   the	   anti-­‐CD52	  
drug	   Campath	   (10μg/ml),	   the	   anti-­‐HER2	   drug	   Herceptin	   (10μg/ml),	   the	   anti-­‐VEGF	   drug	  
Avastin	  (10μg/ml)	  or	  Arzerra	  (10μg/ml).	  These	  concentrations	  were	  selected	  based	  on	  those	  
run	  in	  key	  assays	  in	  the	  literature	  and	  are	  relevant	  therapeutic	  doses.	  Cells	  were	  also	  treated	  
with	   PAMPS	   and	   cytokines:	   the	   TLR4	   agonist	   LPS	   (1μg/ml),	   the	   TLR2	   agonist	   Pam3CSK4	  
(1μg/ml),	  the	  NOD1	  agonist	  C12-­‐iE-­‐DAP	  (10μg/ml),	  and	  the	  cytokines	  TNFα	  (10ng/ml)	  or	  IL-­‐




The	  protocol	  for	  this	  assay	  is	  summarised	  in	  Figure	  2.10.	  As	  the	  development,	  validation	  and	  
application	   of	   this	   assay	   formed	   a	   key	   aspect	   of	   my	   PhD,	   this	   is	   discussed	   in	   detail	   in	  




Figure	  2.10	  Schematic	  of	  protocol	  for	  set	  up	  of	  same	  donor	  blood	  outgrowth	  endothelial	  cell	  
(BOEC):	   Peripheral	   blood	  mononuclear	   cell	   (PBMC)	   co-­‐culture	   assays.	   This	   assay	  has	  been	  








2.6	  STAINING	  AND	  IMAGING	  
Antibodies	  for	  immunofluorescence	  staining	  of	  endothelial	  cells	  are	  summarised	  in	  Table	  2.7	  
For	   all	   staining	   protocols,	   cell	   monolayers	   were	   washed	   three	   times	   with	   PBS	   and	   fixed	  
immediately	   in	   4%	   para-­‐formaldehyde	   (PFA)	   for	   10	  minutes	   at	   room	   temperature.	   Plates	  
were	   then	  washed	   three	   times	  with	  PBS	  at	  5	  minute	   intervals.	   Plates	  were	  permeabilized	  





	  Table	   2.7	   List	   of	   antibodies,	   dilutions	   and	   secondary	   antibodies	   used	   to	   stain	   endothelial	  
cell	  monolayers.	  NB.	  All	  secondary	  antibodies	  were	  diluted	  1:400	  in	  3%	  BSA/PBS	  
	  


























































Primary	  antibodies	  were	  added	   in	  3%	  bovine	  serum	  albumin	  (BSA)	   in	  PBS	  and	  plates	  were	  
incubated	   for	   1	   hour	   at	   room	   temperature.	   Except	   for	   CD31	  which	   is	   tagged	  with	   a	   488-­‐
Alexa	  Fluor	  molecule,	  an	  appropriate	  secondary	  antibody-­‐Alexa	  Fluor	  probe	  (Table	  2.7)	  was	  
added	   in	   3%	   BSA/PBS	   for	   45	   min	   at	   room	   temperature.	   For	   this	   incubation,	   and	   for	   all	  
further	  stages,	  plates	  were	  protected	  from	  light.	  	  Cell	  nuclei	  were	  stained	  with	  the	  nuclear	  
dye,	  4',6-­‐diamidino-­‐2-­‐phenylindole	  (DAPI)	  (10μg/ml).	  Plates	  were	  then	  stored	  in	  PBS	  at	  -­‐4oC	  
prior	  to	  imaging.	  
	  
Images	   were	   acquired	   using	   a	   Cellomics®	   VTi	   HCS	   Arrayscan	   (camera	   make/model:	  
Arrayscan	  12bit	  dynamic	  range	  high	  resolution	  thermo-­‐cooled	  with	  a	  Zeiss	  Plan	  Neurofluour	  
10	  x	  objective	  lens)	  (Thermo	  Fisher,	  Pittsburgh,	  USA).	  The	  Cellomics®	  Arrayscan	  is	  a	  platform	  
that	  uniquely	  allows	  the	  spatial	  and	  temporal	  distribution	  of	  fluorescence	  to	  be	  quantified	  in	  
96-­‐well	   plates.	   This	   includes	   nucleus	   and	   cytosolic	   levels	   of	   fluorescence,	   which	   allows	  













2.7.1	  	   ELISAs	  
Protocol	  	  
CXCL8	  and	  ET-­‐1	  were	  measured	  using	  a	  simple	  enzyme	  linked	  immunosorbent	  assay	  (ELISA).	  
Specific	  ELISAs	  were	  purchased	  from	  R	  and	  D	  Systems	  (CXCL8;	  Cat	  no.	  DY208;	  ET-­‐1;	  Cat	  no.	  
SET100).	   ELISAs	  were	   carried	  out	   according	   to	  manufacturers	   instructions.	  Briefly,	   specific	  
‘capture’	   antibodies	   specific	   to	   CXLC8	   were	   added	   to	   96-­‐well	   high	   binding	   half	   plates	  
(Greiner	   bio-­‐one,	   UK;	   Cat	   no.	   675061)	   and	   incubated	   at	   room	   temperature	   overnight	  
(CXCL8).	  For	  ET-­‐1	  ELISAs,	  plates	  are	  supplied	  pre-­‐coated	  with	  ET-­‐1	  primary	  antibodies	  from	  
the	  company.	  After	  all	   incubations	  plates	  were	  washed	   three	   times	   in	  0.5%	  Tween/trizma	  
buffered	  saline	  (TBS).	  	  Supernatants	  of	  cells	  treated	  in	  the	  protocols	  described	  above	  were	  
thawed	  from	  frozen	  stocks	  at	  room	  temperature.	  Supernatants	  were	  diluted	  in	  assay	  buffer	  
(reagent	   diluent)	   for	   the	   specific	   assays	   (CXCL8	   reagent	   diluent;	   0.1%	   BSA	   in	   0.5%	  
Tween/TBS	  at	  pH	  7.2).	  ET-­‐1	  reagent	  diluent	  was	  supplied	  prepared	  by	  the	  manufacturer	  as	  
an	   18ml	   solution	   of	   buffered	   protein	   in	   a	   mix	   of	   proprietary	   stabilisers.	   Dilutions	   were	  
determined	   using	   in-­‐house	   knowledge	   of	   expected	   basal	   levels,	   and/or	   dilutions	   were	  
adjusted	  and	  assays	  repeated	  as	  required.	  For	  CXCL8	  ELISA,	  plates	  were	  incubated	  at	  room	  
temperature	   for	   1	   hour	   in	   1%	   BSA/PBS	   to	   block	   non-­‐specific	   binding	   prior	   to	   addition	   of	  
standards	  or	  samples.	  Standard	  concentrations	  of	  CXCL8	  and	  ET-­‐1	  were	  prepared	  according	  
to	   manufacturer’s	   instructions.	   Example	   standard	   curves	   for	   CXCL8	   and	   ET-­‐1	   ELISAs	   are	  





Figure	  2.11	  Examples	  of	  standard	  curves	  for	  (A)	  CXCL8	  and	  (B)	  ET-­‐1	  ELISAs	  
	  
Samples	   or	   standards	   were	   then	   added	   to	   the	   plate,	   covered	   with	   adhesive	   strip	   and	  
incubated	   at	   room	   temperature	   (2	   hours	   for	   CXCL8	   and	   1	   hour	   for	   ET-­‐1).	   Samples	   or	  
standards	  were	   then	   aspirated	   from	  wells	   and	   plates	  washed	   three	   times	   in	  wash	   buffer	  
(0.5%	  Tween/PBS).	  Plates	  were	  inverted	  and	  blotted	  on	  paper	  towels	  to	  ensure	  wells	  were	  
dry.	  Specific	  secondary	  ‘detection’	  antibodies	  attached	  to	  a	  conjugate	  (biotin	  for	  CXCL8	  and	  
proprietary	  conjugate	  for	  ET-­‐1)	  were	  then	  added	  to	  all	  wells	  and	  plates	  incubated	  at	  room	  
temperature	   (2	   hours	   for	   CXCL8	   and	  3	  hours	   for	   ET-­‐1).	  Wells	  were	   aspirated	   and	  washed	  
three	  times	  in	  wash	  buffer	  as	  above.	  	  Horseradish	  peroxidase	  (HRP)-­‐streptavidin	  (50μl)	  was	  
then	   added	   and	   plates	   incubated	   at	   room	   temperature	   for	   20	  minutes.	  Wells	   were	   then	  
aspirated	  and	  washed	  as	  above.	  A	  substrate	  solution	  was	  then	  prepared	  by	  adding	  substrate	  
A	   to	   substrate	   B	   in	   a	   1:1	   ratio	   and	   added	   (50μl)	   to	   the	   plate.	   Plates	  were	   incubated	   and	  
protected	  from	  light	  for	  20	  minutes.	  To	  stop	  the	  reaction	  25μl	  of	  2N	  H2SO4	  was	  added	  and	  
optical	  density	  was	  determined	  using	  a	  microplate	  reader	  (Dyne,	  Madellan	  Biosciences)	  with	  
absorbance	  readings	  at	  450-­‐570nm.	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Principle	  of	  the	  assay	  	  
ELISA	  technology	  was	  first	  developed	  in	  1977	  as	  an	  immunoassay	  to	  quantify	  the	  amount	  of	  
unknown	  compound	  or	   ‘anylate’	   in	  a	  sample.	  Such	  measurement	  could	  be	  made	   in	  blood,	  
serum	  and	  cell	  culture	  supernatants.	  ELISAs	  work	  on	  the	  principle	  of	  capture	  and	  detection	  
of	  the	  anylate.	  Anylate	  can	  be	  captured	  using	  primary	  antibodies	  bound	  to	  the	  surface	  of	  96-­‐
well	  plates,	  which	  bind	  and	   ‘capture’	  a	   target	  anylate.	  This	  can	  be	  then	  be	  detected	  using	  
secondary	  antibodies,	  also	  targeted	  at	  the	  anylate	  but	  conjugated	  to	  a	  binding	  protein	  such	  
as	  biotin.	  An	  enzyme	  attached	  to	  strepavidin,	  typically	  HRP	  is	  then	  added	  which	  binds	  to	  the	  
biotin.	   In	   fact,	  up	   to	   four	  molecules	  of	   streptavidin	  can	   tag	  biotinylated	  antibodies	  and	  so	  
this	  step	  also	  serves	  to	  amplify	  to	  signal.	  At	  this	  stage	  therefore,	  the	  amount	  of	  enzyme	  is	  
proportional	   to	   the	   amount	   of	   anylate.	   An	   appropriate	   substrate	   solution	   is	   then	   added,	  
typically,	   3,3’,5,5’-­‐tetramethylbenzidine	   (TMB)	   which	   is	   a	   chromogenic	   substrate	   that	  
donates	   protons	   for	   the	   reduction	   of	   hydrogen	   peroxide	   to	   water	   by	   HRP.	   This	   causes	   a	  
colour	  change	  from	  colourless	  to	  blue,	  were	  the	  intensity	  of	  the	  signal	  is	  proportional	  to	  HRP	  
activity.	  Finally,	  an	  acid	  solution,	  typically	  H2SO4	  is	  added	  to	  stop	  the	  reaction	  and	  results	  in	  
blue-­‐to-­‐yellow	  colour	  change,	  which	  can	  be	  read	  on	  a	  spectrophotometer.	  In	  order	  to	  relate	  
the	  colour	  intensity	  to	  a	  concentration	  of	  anylate,	  standard	  curves	  of	  known	  concentration	  
of	   anylate	   are	   prepared	   for	   each	   assay.	   This	   allows	   the	   absorbance	   readings	   of	   unknown	  







2.7.2	  	   Measurement	  of	  cytokines	  and	  chemokines	  by	  MSD	  
Protocol	  
Human	  pro-­‐inflammatory	  9-­‐Plex	  MULTISPOT	  96-­‐well	   -­‐10	  spot	  MSD	  plates	   (N05007A-­‐1	  and	  
9-­‐plex	   MULTISPOT	   96-­‐well	   -­‐10	   spot	   MSD	   plates	   (K15001C-­‐2)	   were	   purchased	   from	   MSD	  
(Gaithersburg,	   Maryland,	   USA).	   Assays	   were	   carried	   out	   according	   to	   manufacturer’s	  
instructions.	  
	  
Briefly,	   an	   8-­‐point	   standard	   curve	   (2500-­‐0.61pg/ml;	   4	   fold	   dilutions)	   was	   prepared	   using	  
supplier	  ‘calibrator	  blend’,	  which	  contains	  known	  concentrations	  of	  9	  anylates	  (9	  cytokines	  
or	  9	  chemokines).	  Samples	  were	  diluted	  1:10	  in	  Lonza-­‐EGM2	  medium.	  Following	  30	  minutes	  
incubation	  of	  plates	  at	  room	  temperature	  with	  ‘diluent	  2’,	  samples	  or	  standards	  (25μl)	  were	  
added	  to	  each	  well.	  Plates	  were	  incubated	  for	  2	  hours	  at	  room	  temperature	  with	  vigorous	  
shaking	  (500	  RPM).	   	  Plates	  were	  then	  washed	  3	  times	   in	  ELISA	  wash	  buffer	  and	  blotted	  to	  
ensure	  plates	  were	  dry.	  Detection	  antibody	  solution	  (25μl)	  was	  then	  added	  to	  each	  well	  and	  
plates	   incubated	   for	   a	   further	   2	   hours	  with	   vigorous	   shaking	   (500RPM).	   Plates	  were	   then	  
washed	  three	  times	  as	  above	  and	  150μl	  of	  2	  X	  read	  buffer	  (supplier	  provided)	  was	  added	  to	  
each	   well.	   Plates	   were	   read	   using	   an	   MSC	   Sector	   Imager	   2400	   and	   analysed	   using	   MSD	  
Discovery®	  Workbench	  software.	  Cytokines	  analysed	  were	  IL-­‐2,	  CXCL8,	  IL-­‐12p70,	  IL-­‐1β,	  GM-­‐
CSF,	  IFNγ,	  IL-­‐6,	  IL-­‐10.	  Chemokines	  analysed	  were	  eotaxin,	  MCP-­‐1,	  MIP-­‐1β,	  eotaxin-­‐3,	  MCP-­‐4,	  
TARC,	  IP-­‐10	  and	  MDC.	  
	  
Principle	  of	  the	  assay	  
MSD	  plates	  multispot	  plates	  uniquely	  allow	  for	  the	  measurement	  of	  multiple	  readouts	  in	  a	  
sample.	  They	  work	  on	  a	  similar	  principle	  to	  ELISA	  but	  rather	  than	  plates	  being	  coated	   in	  a	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single	  antibody,	  they	  are	  coated	  with	  spots	  containing	  immobilised	  capture	  antibodies	  to	  a	  
target	  anylate	  (in	  this	  case	  a	  cytokine	  or	  chemokine).	  These	  capture	  antibodies	  are	  attached	  
to	  a	  working	  electrode	  surface.	  Once	  samples	  or	  standards	  have	  been	  added	  and	  anylates	  
bound	   to	   capture	   antibodies	   an	   MSD-­‐SULFO-­‐TAG™	   detection	   antibody	   is	   added.	   These	  
SULFO-­‐TAG™	   antibodies	   are	   activated	   by	   voltage	   stimulate	   which	   is	   applied	   to	   the	   MSD	  
Sector	   Imager.	   The	   luminescence	   emitted	  by	   each	   spot,	  measured	   separately,	   affords	   the	  
measurement	  of	  the	  9-­‐anylates	  (in	  this	  case	  cytokines	  or	  chemokines).	  The	  principle	  of	  the	  
assay	  as	  depicted	   in	  the	  manufacturers	  handbook	   is	  shown	  in	  Figure	  2.12	  and	  an	  example	  




Figure	   2.12	   Principal	   of	   multi-­‐spot	   electro-­‐chemoluminescence.	   Figure	   drawn	   from	  






















Figure	  2.13	  Example	  standard	  curves	  for	  MSD	  multiplex	  9-­‐spot	  cytokine	  assay.	  
	  
	  
2.7.3	  	   Measurement	  of	  6-­‐keto	  PGF1a	  by	  inverse	  binding-­‐ELISA	  
Protocol	  
Prostacyclin	  release	  was	  measured	  as	  its	  breakdown	  product	  6-­‐keto	  PGF1α,	  which	  is	  formed	  
by	   spontaneous	   non-­‐enzymatic	   hydrolysis	   of	   prostacyclin	   (Figure	   2.9).	   For	   this	   a	   specific	  
inverse	   binding	   ELISA	   was	   used	   (Cayman	   Chemical,	   UK;	   Cat	   no.	   515211).	   Buffers	   were	  
prepared	  according	  to	  manufacturer’s	  instructions.	  Supplier	  10X	  EIA	  buffer	  was	  diluted	  to	  1X	  
supplier	  buffer	  using	  ultrapure	  water.	  6-­‐keto	  PGF1α	  acetycholineesterase	  (AChE)	  Tracer	  and	  
EIA	  Antiserum	  were	  reconstituted	  in	  EIA	  buffer	  according	  to	  manufacturer’s	  instructions.	  	  
	  
Wash	   buffer	   for	   these	   assays	  was	   prepared	   using	   supplier	   ‘wash	   buffer’	   concentrate	   and	  
made	  with	  0.05%	  supplier	  Polysorbate	  20.	  Samples	  were	  diluted	  1:2	  or	  1:5	  in	  Lonza-­‐EGM2	  
according	   to	   supplier	   recommendation	   for	   dilution	   of	   tissue	   culture	   samples.	   A	   standard	  
curve	   (1000-­‐1.6pg/ml)	   was	   prepared	   according	   to	   manufacturer’s	   instructions.	   Samples,	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standards	  (50µl)	  and	  assay	  controls	  were	  added	  to	  the	  plate,	  followed	  by	  addition	  of	  tracer	  
(50µl)	   and	   antiserum	   (50µl)	   according	   to	   manufacturer’s	   instructions.	   Plates	   were	   then	  
incubated	  at	  4oC	  for	  18	  hours.	  Plates	  were	  aspirated	  and	  washed	  five	  times	  with	  wash	  buffer	  
followed	  by	  addition	  of	   the	  Ellman’s	   reagent	  provided	   (details	  are	  given	  below).	  After	  2-­‐3	  
hours	  optical	  density	  was	  read	  at	  420nm.	  Data	  was	  recorded	  when	  B0	  wells	  which	  contains	  
supplier	  buffer,	  tracer	  and	  antiserum	  only,	  were	  	  in	  the	  range	  of	  	  0.3-­‐1.0	  absorbance	  units.	  
	  
Principle	  of	  the	  assay	  
Inverse	  binding	  assays	  are	  similar	   to	  ELISAs	  described	  above,	  but	   in	   these	  assays,	  anylates	  
must	   compete	   for	   the	   binding	   sites	   of	   antibodies	   with	   a	   specific	   fluorescent	   tagged	   or	  
‘tracer’	  ligand	  for	  the	  antibody.	  As	  a	  result,	  the	  more	  anylate	  there	  is	  in	  a	  sample,	  the	  lower	  
the	   signal	   (fluorescence	  or	   absorbance)	   as	  more	  of	   the	   labelled	   form	   is	   competed	  off	   the	  
binding	  site.	  
	  
In	  this	  inverse	  binding	  assay	  for	  6-­‐keto	  PGF1α,	  the	  plates	  are	  coated	  with	  a	  mouse	  anti-­‐rabbit	  
antibody	  which	  captures	  anti-­‐6-­‐keto	  PGF1α	  in	  the	  supplier	  antiserum.	  Once	  bound,	  these	  act	  
as	   a	   receptor	   for	   either	   free	  6-­‐keto	  PGF1α	   in	   the	   sample	  or	   standard,	  or	   can	  be	  bound	  by	  
‘tracer’,	  and	  tracer	  and	  6-­‐keto	  PGF1α	   in	  the	  sample	  must	  compete	  for	  the	  binding	  site.	  The	  
‘tracer’	   contains	   molecules	   of	   PGF1α	   covalently	   attached	   to	   AChE.	   AChE	   catalyses	   the	  
conversion	   of	   acetylthiocholine	   to	   thiolcholine,	   which	   in	   turn	   undergoes	   non-­‐enzymatic	  
hydrolysis	   to	   liberate	   5-­‐thio-­‐nitrobenzoic	   acid	  which	   absorbs	   light	   at	   412nm.	   An	   example	  





Figure	   2.14	   Example	   of	   standard	   curve	   for	   the	   Cayman	   Chemical	   inverse	   binding	  
immunoassay	  for	  6-­‐keto	  PGF1α.	  
	  
	  
2.7.4	  	   Measurement	  of	  NF-­‐κB	  nuclear	  translocation	  
Protocol	  
To	  quantify	  translocation	  of	  NF-­‐κB	  to	  the	  nucleus,	  and	  thereby	  activation	  of	  cell	  signalling,	  a	  
compartment	   analysis	   bio-­‐application	   (Thermo	   Scientific,	   USA)	   attached	   a	   Cellomics®	   VTi	  
HCS	  Arrayscan	  was	  used.	  Wells	  of	  96-­‐well	  plates	  treated	  with	  TLR,	  NOD	  agonists	  or	  IL-­‐1β	  for	  
1	  hour,	   and	   stained	  with	  primary	   antibodies	   for	  NF-­‐κB	  as	  described,	  were	   imaged	   in	  PBS.	  
The	   algorithm	  applied	   identifies	   objects	   (cells)	   based	  on	  DAPI	   staining	   and	   applies	   a	   2μM	  
border	   (ring)	   around	   the	  edge	  of	   the	  nucleus.	   This	   ring	   is	  used	   to	  quantify	   staining	   in	   the	  
cytosol	   of	   uniformly	   distributed	   cytosolic	   transcription	   factors	   and	   has	   been	   applied	   by	  
others	   (Ding	   et	   al.,	   1998).	   This	   allows	   for	   nuclear	   intensity/cell	   to	   be	   calculated	   as	   the	  
difference	  between	  nuclear	  intensity	  and	  cytosolic	  intensity	  for	  each	  cell.	  Data	  was	  acquired	  
from	  1000	  cells/well	  and	  treated	  wells	  were	  normalised	  to	  control	  (100%).	  The	  application	  
of	  the	  algorithm	  to	  a	  representative	  image	  of	  endothelial	  cells	  is	  shown	  in	  Figure	  2.15.	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Figure	  2.15	  Application	  of	  the	  ThermoFisher	  compartment	  analysis	  algorithm	  to	  determine	  
nuclear	  intensity	  of	  NF-­‐κB	  staining	  in	  individual	  cells.	  
	  
Principle	  of	  the	  assay	  
The	  release	  of	  cytokines	  such	  as	  CXCL8	  can	  be	  driven	  by	  activation	  of	  transcription	  factors	  
including	   NF-­‐κB.	   These	   transcription	   factors	   reside	   in	   the	   cytosol	   in	   an	   inactive	   form	   and	  
often	  sequestered	  by	  an	  inhibitor	  or	  retention	  protein.	  Once	  activated,	  these	  transcription	  
factors	   translocate	   to	   the	  nucleus	  and	  bind	   response	  elements	   that	  activate	  genes,	  which	  
ultimately	   result	   in	   a	   response	   (for	   example,	   cytokine	   release).	   Nuclear	   translocation	   is	  
therefore	   an	   early	   event	   in	   cellular	   responses	   and	   can	   be	   visualised	   and	  measured	   using	  
staining	  protocols	  as	  described.	  
	  
2.7.5	  	   Measurement	  of	  eicasonoids	  by	  LC-­‐MS/MS	  
Protocol	  
To	  consider	  a	  more	  complete	  profile	  of	  eicosanoids	  released	  by	  BOECs,	  supernatants	  were	  
also	   analysed	   using	   a	   liquid	   chromatography	   –	   tandem	   mass	   spectrometry	   (LC-­‐MS/MS)	  
‘lipidomics’	   approach.	   These	   protocols	   were	   carried	   out	   at	   the	   National	   Institute	   of	  
Environmental	  Health	  Sciences,	  USA,	  under	  collaboration	  with	  Matthew	  Edin,	  and	  with	  the	  










active	   lipid	   mediators	   within	   a	   small	   sample	   volume	   (Kirkby	   et	   al.,	   2013;	   Masoodi	   and	  
Nicolaou,	  2006).	  Prostanoids	  were	  extracted	  and	  analysed	  as	  previously	  described	  (Edin	  et	  
al.,	   2011;	  Newman	  et	  al.,	   2002).	   Indeed,	   this	   kind	  of	  omics	  approach	  will	  be	   important	   to	  
study	   broad	   ranges	   of	   cytokine	   release,	   lipid	   release,	   gene	   transcription	   changes	   in	  
personalised	  medicine	  assays.	  
	  	  
Briefly,	   samples	   were	   spiked	   with	   PGE2-­‐d4,	   10(11)-­‐epoxyheptadecanoic	   acid	   and	   10(11)-­‐	  
dihydroxynonadecanoic	  acid	   internal	  standards	  then	  mixed	  with	  0.1	  volumes	  for	  1%	  acetic	  
acid	   (v/v)	   in	   50%	   methanol.	   Samples	   were	   then	   pre-­‐extracted	   using	   Oasis	   HLB	   C18	   3ml	  
columns,	   and	   then	   further	   separated	   by	   high	   pressure	   liquid	   chromatography	   with	  
Phenomenex	  Luna	  C18(2)	  columns.	  Extracts	  were	  analysed	  using	  negative	   ion	  electrospray	  
ionization	  tandem	  mass	  spectrometry	  in	  triplicate	  using	  an	  MDS	  Sciex	  API	  3000	  instrument	  
with	  Applied	   Biosystems	   TurboIonSpray	   source.	   Lipid	  mediator	   abundance	  was	   quantified	  
from	  peak	  areas	  of	  characteristic	   fragments	  and	  normalised	  to	  the	  extraction	  efficiency	  of	  
internal	  standards.	  
	  
Principle	  of	  the	  assay	  
LC-­‐MS/MS	   allows	   for	   the	   quantitative	   analysis	   of	   large	   numbers	   of	   cell	   metabolites,	  
proteins,	  and	  in	  this	  case	  eicosanoids.	  These	  experiments	  can	  be	  performed	  using	  targeted	  
or	  untargeted	  analysis	  wherein	  structures	  of	   lipids	  being	  analysed	   in	  sample	  are	  known	  or	  
unknown	  respectively.	  MS	  works	  on	  the	  principle	  that	  when	  a	  complex	  structure	  is	  ionised	  
and	  accelerated	  through	  an	  electromagnet,	  unique	  patterns	  of	  deflection	  emerge	  as	  result	  
of	   the	   mass	   of	   the	   ionised	   species.	   These	   can	   be	   detected	   and	   the	   relative	   intensity	   of	  
different	  anylates	  based	  on	  mass-­‐to-­‐charge	  ratio	  can	  be	  plotted.	  In	  LC-­‐MS/MS	  this	  samples	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are	   first	   separated	   by	   mass	   using	   liquid	   chromatography	   before	   being	   fed	   in	   to	   an	   ion	  
source.	   Ionisation	   in	   most	   modern	   mass	   spectrometers	   is	   achieved	   by	   electrospray	  
ionisation	  which	  prevents	  fragmentation	  of	  the	  anylate	  prior	  to	  separation	  based	  on	  mass.	  
In	   LC-­‐MS/MS	   this	   process	   is	   coupled	  with	   a	   second	   round	  of	  mass	   spectrometry	   in	  which	  
fragmentation	   of	   the	   anylate	   occurs	   and	   these	   unique	   fragment	   patterns	   can	   be	   used	   to	  
determine	  precise	   chemical	   structures.	   In	   targeted	   LC-­‐MS/MS	   this	   is	   advantageous	   as	   the	  
fragmentation	  pattern	  of	  particular	  anylates	   is	  unique	  to	  the	  target	  anylate	  and	  so	  can	  be	  
used	   to	   quantify	   large	   numbers	   of	   molecules	   in	   complex	   fluids	   including	   cell	   culture	  
supernatants	  and	  serum.	  	  
	  
2.7.6	  	   Measurement	  cell	  viability	  
Cell	  viability	  following	   incubations	  was	  determined	  using	  either	  the	  commercially	  available	  
AlamarBlue®	   assay	   or	   based	   on	   cell	   counts.	   For	   cell	   counts,	   fixed	   cells	  were	   stained	  with	  
10µg/ml	  DAPI	  and	  imaged	  using	  the	  Cellomics®	  VTi	  HCS	  Arrayscanner.	  Data	  for	  cell	  counts	  
are	  expressed	  as	  average	  cells/field	  based	  on	  49	  fields.	  
	  
2.7.7	  	   Cell	  proliferation	  
In	   some	   protocols,	   run	   as	   part	   of	   a	   collaboration	  with	   the	  National	   Institute	   of	   Biological	  
Standards	  and	  Control	   (NIBSC),	  proliferation	  assays	  were	  carried	  out	  by	  NIBSC	  using	  an	   in-­‐






2.7.8	  	   Statistical	  analysis	  
Unless	   otherwise	   stated	   data	   is	   the	   mean	   ±	   SEM	   for	   n-­‐experiments	   where	   n	   represents	  
separate	  treatments.	  Unless	  otherwise	  stated	  all	  experiments	  were	  carried	  out	  on	  cells	  of	  at	  
least	  3	  separate	  donors	  or,	  as	  for	  cell	  lines,	  on	  at	  least	  3	  separate	  isolations	  with	  separately	  
prepared	  drugs.	  Data	  was	   analysed	  using	   appropriate	   tests	   and	  GraphPad	  Prism	   software	  
with	  specific	   tests	  defined	   in	   individual	   figure	   legends.	  Statistical	  significance	  was	  taken	  to	  
be	   achieved	   where	   p<0.05.	   In	   some	   experiments,	   data	   was	   analysed	   using	   a	   principle	  
component	  analysis,	  which	  is	  described	  in	  detail	  in	  Chapter	  5.	  
	  
In	   some	   experiments,	   where	   valuable	   drugs	   were	   being	   used,	   I	   chose	   to	   prioritise	  
experimental	   replicates	   over	   biological	   replicates,	   whereby	   some	   experiments	   were	   run	  
with	  single	  treatment	  wells	  but	  at	  least	  three	  times.	  This	  approach	  captures	  both	  biological	  
variation	  (due	  to	  drug	  preparations	  and	  pipetting	  errors)	  and	  experimental	  variation	  (due	  to	  
different	  donor	  cells	  and	  those	  at	  different	  passage).	  This	  is	  consistent	  with	  the	  directive	  of	  
Cumming	  et	  al	  (Cumming	  et	  al.,	  2007).	  
	  
Technical	   replicates,	   which	   are	   defined	   as	   repeat	   measurements	   from	   one	   cell	   isolation	  
(well)	   were	   not	   carried	   out	   during	   this	   thesis,	   except	   in	   the	   capacity	   of	   standard	   curves	  































3.1	  RATIONALE	  	  
Stem	   cell	   derived	   endothelial	   cells	   have	   a	   growing	   number	   of	   applications	   within	   clinical	  
medicine	  and	  biomedical	  research.	  Endothelial	  cells	  can	  now	  be	  derived	  from	  a	  number	  of	  
distinct	   stem	   cell	   populations	   giving	   rise	   to:	   human	   embryonic	   stem	   cell	   (hESC)	   derived	  
endothelial	   cells	   (hESC-­‐EC),	   blood	  outgrowth	  endothelial	   cells	   (BOEC)	   (derived	   from	  blood	  
progenitors)	  and	  induced	  pluripotent	  stem	  cell	  derived	  endothelial	  cells	  (iPSC-­‐EC).	   In	  order	  
for	   these	  stem	  cell	  derived	  endothelial	  cells	   to	  be	  used	  optimally	   it	   is	   important	   that	   they	  
are	   fully	   assessed	   for	   the	   cardinal	   hallmarks	   of	   endothelial	   cell	   biology	   and	   phenotype.	  
Previous	   characterisation	   of	   these	   cells	   has	   typically	   been	   restricted	   to	   endothelial	   cell	  
marker	  expression;	  however,	  a	  key	  limitation	  of	  this	  approach	  is	  that	  many	  of	  these	  markers	  
overlap	  across	  several	  cell	  phenotypes	  (Hirschi	  et	  al.,	  2008;	  Reed	  et	  al.,	  2012).	  	  
	  
Thus,	  the	  initial	  aim	  of	  my	  PhD	  was	  to	  derive	  and/or	  acquire	  these	  three	  key	  types	  of	  stem	  
cell	  derived	  endothelial	  cells	  and	  then	  use	  previously	  established	  protocols	  to	  characterise	  
them	  according	  to	  their	  ability	  to:	  
1. Express	   typical	   endothelial	   cell	   cobblestone	  morphology	   when	   grown	   under	   static	  
culture	   conditions	   (Potter	   et	   al.,	   2011;	   Potter	   et	   al.,	   2012)	   and	   to	   align	   under	  
directional	   (laminar)	   shear	   stress	  by	  assuming	   the	  associated	  elongated	  phenotype	  
found	  in	  endothelial	  cells	  on	  vessels	  (Potter	  et	  al.,	  2011).	  
2. 	  Given	  that	  endothelial	  cells	  on	  vessels	  are	  critical	  for	   innate	  immune	  responses;	  to	  
sense	  pathogen	  associated	  molecular	  patterns	  (PAMPs)	  by	  releasing	  cytokines.	  	  
3. To	   release	   two	   key	   endothelial	   cell	   hormones,	   endothelin	   (ET)-­‐1	   and	   prostacyclin	  




3.2	  SUMMARY	  OF	  METHODS	  	  
A	   full	   description	   of	   the	   methods	   used	   in	   this	   chapter	   is	   given	   in	   Chapter	   2	   and	   are	  
summarised	  below.	  
	  
3.2.1	  	   Isolation	  and	  culture	  of	  hESC-­‐EC	  
Differentiation	  of	  hESCs	  (H7	  cell	   line)	   into	  hESC-­‐EC	  was	  carried	  out	  as	  described	  previously	  
(Földes	   et	   al.,	   2010).	   Briefly,	   cells	   were	   dissociated	   into	   clumps	   and	   plated	   on	   ultra-­‐low	  
attachment	   plates	   (Nunc,	   Denmark)	   with	   Lonza-­‐EGM2	   to	   allow	   formation	   of	   embryoid	  
bodies.	  After	  4	  days	  embryoid	  bodies	  were	  re-­‐plated	  on	  1%	  gelatinised	  (Sigma,	  USA)	  6-­‐well	  
plates	   in	   Lonza-­‐EGM2.	   	   After	   13	   days	   clusters	   were	   dissociated	   and	   stained	   for	   the	  
endothelial	   cell	  marker	  CD31	  using	  an	  AlexaFluor	  488	   fluorescence	  dye	   labelled	  anti-­‐CD31	  
antibody	   (BD	   Biosciences,	   UK).	   Cells	   were	   sorted	   using	   a	   FACS	   Aria	   II	   cell	   sorter	   (BD	  
Biosciences,	   UK)	   and	   expanded	   in	   Lonza-­‐EGM-­‐2	   medium	   for	   further	   use.	   Cells	   were	  
maintained	  in	  Lonza-­‐EGM2	  media	  and	  grown	  on	  1%	  gelatinised	  (Sigma,	  USA)	  75cm2	  flasks.	  
Cells	  were	  used	  between	  passages	  2-­‐8.	  
	  
3.2.2	  	   Isolation	  and	  culture	  of	  BOEC	  
BOEC	  were	   isolated	  as	  described	   in	   chapter	  2.	  Briefly,	  peripheral	  blood	  mononuclear	   cells	  
(PBMCs)	  were	  isolated	  from	  blood	  and	  expanded	  on	  tissue	  culture	  plates	  for	  up	  to	  22	  days	  
in	   Lonza-­‐EGM2	   with	   10%	   fetal	   bovine	   serum	   (FBS)	   on	   5.2μg/cm2	   collagen	   coated	   plates.	  
Typically	   between	   5	   and	   21	   days	   in	   culture,	   endothelial	   cell	   colonies	   emerged	   and	   were	  
expanded	   for	   use	   in	   experiments.	   Cells	  were	  maintained	   in	   Lonza-­‐EGM2	  media	  with	   10%	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FBS.	   Cells	   were	  maintained	   in	   Lonza-­‐EGM2	  media	   and	   grown	   on	   collagen	   coated	   (Sigma,	  
USA)	  75cm2	  flasks.	  Cells	  were	  used	  between	  passages	  2-­‐8.	  
	  
3.2.3	  	   Acquisition	  and	  maintenance	  of	  iPSC-­‐EC	  
IPSC-­‐EC	   used	   in	   my	   PhD	   were	   purchased	   from	   Cellular	   Dynamic	   International	   (Madison,	  
USA).	   Cells	   were	   maintained	   in	   Lonza-­‐EGM2	   (see	   general	   methods)	   on	   fibronectin	  
(Invitrogen,	   California,	   USA)	   coated	   75cm2	   flasks	   (Nunc,	   Denmark)	   according	   to	  
manufacturer’s	  instructions.	  	  
	  
3.2.4	  	   Isolation	  and	  culture	  of	  human	  lung	  fibroblasts	  (HLF)	  
HLFs	   were	   isolated	   from	   human	   lung	   tissue	   as	   described	   previously	   (Maher	   et	   al.,	   2010)	  
from	  histologically	  normal	  peripheral	   lung	  from	  lung	  cancer	  resection.	  Cells	  were	  grown	  in	  
supplemented	  DMEM,	  and	  were	  passaged	  every	  3–4	  days.	  All	  experiments	  were	  performed	  
from	  passage	  3–10	  
	  
3.2.5	  	   Endothelial	  cells	  from	  vessels	  
Human	  umbilical	  vein	  endothelial	  cells	   (HUVEC)	  used	  throughout	  my	  PhD	  were	  a	  gift	   from	  
Caroline	  Wheeler-­‐Jones	  (Royal	  Veterinary	  College,	  London)	  and	  were	  maintained	   in	  Lonza-­‐
EGM2	   medium.	   Cells	   were	   at	   passage	   2	   on	   arrival	   and	   used	   for	   experiments	   between	  
passages	  2-­‐8.	  	  
	  
Human	   lung	  microvascular	   endothelial	   cells	   (HMVEC),	   and	   human	   aortic	   endothelial	   cells	  
(HAEC)	  were	  purchased	   from	  Lonza	  or	  Promocell	  as	  cryopreserved	  cells.	  Cells	  were	  grown	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out	  and	  maintained	  in	  Lonza-­‐EGM2	  media	  and	  grown	  on	  1%	  gelatinised	  (Sigma,	  USA)	  75cm2	  
flasks.	  Cells	  were	  used	  between	  passages	  2-­‐8.	  
	  
3.2.6	  	   Cell	  staining	  
All	  cells	  were	  stained	  for	  the	  endothelial	  cell	  markers	  CD31	  and/or	  VE-­‐cadherin.	  Cells	  were	  
also	  stained	  for	  COX-­‐1,	  which	  is	  expressed	  by	  endothelial	  cells.	  Undifferentiated	  hESC	  were	  
also	   stained	   for	   the	  pluripotency	  marker	  TRA-­‐1-­‐60	   (Wright	   and	  Andrews,	  2009).	   In	   all	   cell	  
staining	  protocols,	  cells	  were	  cultured	  for	  4	  days,	  unless	  stated	  otherwise	  in	  figure	  legends,	  
and	  media	  was	   discarded	   or	   collected	   for	   analysis	  where	   required.	   Cell	  monolayers	  were	  
then	  washed	   three	   times	   in	   PBS	   and	   fixed	   for	   10	  minutes	   in	   4%	  paraformaldehyde.	  After	  
fixing,	   cell	   membranes	   were	   permeated	   using	   0.2%	   Triton-­‐X100	   and	   blocked	   with	   4%	  
FBS/PBS.	  Cells	  were	  the	  stained	  with	  specific	  antibodies	  as	  required,	  followed	  by	  secondary	  
staining	  with	  Alexa	  Fluor®	   conjugated	   secondary	  antibodies.	  Cell	   nuclei	  were	   stained	  with	  
10µg/ml	  of	  4',6-­‐diamidino-­‐2-­‐phenylindole	  dihydrochloride	  (DAPI).	  Details	  of	  specific	  primary	  
and	  secondary	  antibodies	  combinations	  used	  are	  given	  in	  chapter	  2.	  Images	  were	  acquired	  
using	  either	  a	  Nikon	  inverted	  fluorescence	  microscope,	  a	  confocal	  laser	  scanning	  microscope	  
or	  a	  Cellomics®	  VTi	  HCS	  Arrayscanner.	  Acquisition	  settings	  for	  individual	  protocols	  are	  stated	  
in	  figure	  legends.	  Images	  were	  acquired	  at	  x10	  magnification	  at	  room	  temperature	  with	  PBS	  




3.2.7	  	   Assessment	  of	  the	  ability	  of	  stem	  cell	  derived	  endothelial	  cells	  to	  align	  under	  shear	  
stress	  
Endothelial	   cell	   alignment	   under	   shear	   stress	   was	   determined	   using	   a	   model	   previously	  
defined	   by	   our	   group	   and	   developed	   by	  my	   colleague	   Claire	   Potter	   (Potter	   et	   al.,	   2011).	  
Briefly,	   cells	  were	  cultured	  on	  standard	  1%	  gelatinised	  6-­‐well	  plates	   (Nunc,	  Denmark)	  and	  
placed	  on	  an	  orbital	   shaker.	  The	  movement	  of	   the	  shaker	   results	   in	  a	  wave	  of	  media	   that	  
oscillates	  around	   the	  well	   resulting	   in	  a	   complex	  pattern	  of	   shear	  applied	  with	  directional	  
(laminar)	  shear	   towards	   the	  edge	  of	   the	  well,	  and	  non-­‐directional	   (turbulent)	  shear	  at	   the	  
centre.	  Alignment	  of	  cells	  was	  visualised	  by	  light	  microscopy	  and	  by	  fluorescence	  imaging	  of	  
cells	  stained	  with	  appropriate	  markers	  as	  described	  above	  in	  3.2.6.	  
	  
3.2.8	  	   Treatment	  protocols	  and	  responses	  to	  PAMPs	  
Cells	   were	   plated	   on	   1%	   gelatinised	   96-­‐well	   plates	   (Nunc,	   Denmark)	   and	   grown	   to	  
confluence.	   All	   cells	   were	   plated	   and	   incubated	   throughout	   experiments	   in	   Lonza-­‐EGM2	  
media	   with	   10%	   FBS	   unless	   otherwise	   stated.	   Cells	   were	   seeded	   at	   a	   density	   of	   7,000	  
cells/well.	  For	  assessment	  of	   responses	   to	  PAMPs,	  cells	  were	   treated	  with	  agonists	  of	  Toll	  
like	   receptors	   (TLR)1-­‐9	  or	  nucleotide	  oligomerisation	  domain	   receptor-­‐1	  NOD1	   (see	   figure	  
legends	   and	   Table	   2.3	   in	   chapter	   2;	   all	   from	   Invitrogen,	   UK)	   for	   1	   or	   24	   hours.	   Where	  
possible	   responses	  of	   cells	  of	  different	  origins	  were	  compared	  directly	   in	   the	   same	  media	  
and	  treated	  under	  identical	  conditions.	  At	  24	  hours,	  supernatants	  were	  collected	  and	  stored	  
at	  -­‐20oC	  for	  analysis.	  Cells	  were	  also	  treated	  IL-­‐1β	  (R	  &	  D	  Systems,	  Abingdon,	  UK)	  for	  1	  or	  24	  




3.2.9	  	   Measurement	  of	  CXCL8,	  IP10,	  ET-­‐1	  and	  prostacyclin	  
CXCL8,	  IP10,	  ET-­‐1	  and	  prostacyclin	  (measured	  as	  its	  breakdown	  product	  6-­‐keto-­‐PGF1α)	  were	  
measured	  in	  supernatants	  by	  specific	  ELISA	  according	  to	  manufacturer’s	  instructions;	  details	  
are	  defined	  in	  Chapter	  2.	  Optical	  density	  was	  determined	  using	  a	  microplate	  reader	  (Dyne,	  
Madellan	   Biosciences)	   with	   absorbance	   readings	   at	   wavelengths	   according	   to	  
manufacturer’s	  instructions	  
	  
3.2.10	  	  Measurement	  of	  NF-­‐κB	  nuclear	  translocation	  
For	  measurement	  of	  translocation	  of	  NF-­‐κB,	  cells	  were	   incubated	  with	  NF-­‐κB-­‐p65	  (human)	  
primary	   antibodies	   raised	   in	   rabbit	   (Santa	   Cruz	   Biotechnology,	   UK)	   for	   1	   hour	   at	   room	  
temperature	   followed	   by	   secondary	   staining	   with	   AlexaFluor®	   546	   anti-­‐rabbit	   antibodies	  
raised	   in	   goat	   (Invitrogen,	   UK)	   for	   45	   minutes	   at	   room	   temperature.	   Cells	   were	   washed	  
three	   times	  between	   incubations	  with	  PBS	   at	   5	  minute	   intervals.	   Cell	   nuclei	  were	   stained	  
with	   10µg/ml	   DAPI.	   Plates	   were	   imaged	   using	   a	   Cellomics®	   VTi	   HCS	   Arrayscanner.	   Some	  
wells	   were	   treated	   with	   secondary	   antibody	   only.	   Images	   were	   acquired	   at	   x10	  
magnification	  at	  room	  temperature	  with	  PBS	  as	  imaging	  medium.	  	  
	  
3.2.11	   	  Measurement	  of	  cell	  viability	  
Cell	  viability	  following	   incubations	  was	  determined	  using	  either	  the	  commercially	  available	  
AlamarBlue®	  assay	  or	  based	  on	  cell	  counts.	  For	  cell	  counts,	  cells	  were	  stained	  with	  10µg/ml	  
4',6-­‐diamidino-­‐2-­‐phenylindole	   (DAPI)	   or	   Hoescht	   nuclear	   stains	   (both	   Invitrogen,	   UK)	   and	  
imaged	  using	  the	  Cellomics®	  VTi	  HCS	  Arrayscanner.	  Data	  are	  expressed	  as	  average	  cells/field	  




3.3.1	  	   Basic	  morphology	  and	  endothelial	   cell	  markers	  associated	  with	   stem	  cell	  derived	  
endothelial	  cells	  
hESC-­‐EC	  
hESCs	   had	   a	   colony	   morphology	   typical	   of	   undifferentiated	   stem	   cells	   (Figure	   3.1A)	   and	  
expressed	  the	  pluripotency	  marker	  TRA-­‐1-­‐60	  (Figure	  3.1B).	  When	  cells	  were	  grown	  in	  Lonza-­‐
EGM2	   on	   ultra-­‐low	   attachment	   plates	   and	   allowed	   to	   spontaneously	   differentiate	  
approximately	   0.1%	   of	   the	   total	   population	   expressed	   the	   endothelial	   cell	  marker,	   CD31,	  
indicating	   a	   small	   population	   of	   endothelial	   cells	   were	   present;	   these	   were	   isolated	   and	  
sorted	  from	  the	  mixed	  cell	  population	  by	  FACS	  (Figure	  3.2A).	  These	  cells,	  now	  assumed	  to	  be	  
endothelial	  cells	  were	  defined	  as	  hESC-­‐EC.	  HESC-­‐EC	  were	  plated	  and	  expanded	  using	  Lonza-­‐
EGM2	  and	  continued	  to	  express	  CD31	   in	  culture	  (Figure	  3.2B).	  hESC-­‐EC	  also	  expressed	  the	  
endothelial	   cell	   enzyme,	   COX-­‐1	   (Figure	   3.2B).	   Notably	   however,	   hESC-­‐EC	   did	   not	   have	  
cobblestone	   morphology	   typical	   of	   endothelial	   cells	   (Jaffe	   et	   al.,	   1973b)	   and	   appeared	  
elongated	  (Figure	  3.2B).	  	  
	  
BOEC	  
BOEC	   were	   grown	   from	   PBMC	   fraction	   of	   human	   blood	   as	   previously	   described	   (Martin-­‐
Ramirez	  et	  al.,	  2012;	  Starke	  et	  al.,	  2010;	  Starke	  et	  al.,	  2013).	  When	  PBMCs	  were	  plated	  on	  
collagen	  coated	  6-­‐well	  plates,	  colonies	  of	  endothelial	  cells	  typically	  emerged	  between	  days	  5	  
and	  22	  (Figure	  3.3;	  day	  11	  colony	  shown).	  Once	  the	  colony	  had	  appeared	  to	  stop	  expanding,	  
typically	  4	  days	  after	  emergence,	   cells	  were	  expanded	   to	  confluence	   in	  25cm2	  cell	   culture	  
flasks	  and,	  unlike	  hESC-­‐EC	  but	  like	  endothelial	  cells	  from	  vessels,	  had	  typical	  endothelial	  cell	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cobblestone	  morphology	  when	  grown	  under	  static	  culture	  conditions	   (Figure	  3.3	  and	  3.4).	  
The	   same	   was	   true	   for	   BOEC	   expanded	   in	   75cm2	   (Figure	   3.3)	   cell	   culture	   flasks	   and	   this	  
morphology	  was	  maintained	  throughout	  use	  in	  experiments	  up	  to	  at	  least	  passage	  8.	  BOEC	  




iPSC-­‐EC	  were	  purchased	  from	  Cellular	  Dynamics	  International	  (Colorado,	  USA).	  Cells	  arrived	  
as	  a	  cryovial	  and	  when	  expanded	  these	  cells	  were	  characterised	  as	  having	  endothelial	  cell	  
morphology	   and	   expressed	   CD31,	   VE-­‐cadherin	   and	   COX-­‐1	   (Figure	   3.5A).	   These	   cells	   were	  
originally	  derived	  from	  human	  foetal	  lung	  fibroblasts	  using	  a	  reprogrammed	  strategy	  similar	  
to	  that	  in	  the	  original	  seminal	  work	  on	  these	  cells	  (Takahashi	  et	  al.,	  2007;	  Taura	  et	  al.,	  2009;	  
Yu	   et	   al.,	   2007).	   Thus,	   in	   order	   to	   validate	   these	   cells,	   head	   to	   head	   protocols	   between	  
human	   lung	   fibroblasts	   (as	   controls)	   and	   iPSC-­‐EC	   were	   run	   for	   CD31	   expression.	   As	  
mentioned,	   iPSC-­‐EC	   expressed	   CD31	   but	   human	   lung	   fibroblasts	   did	   not	   (Figure	   3.5B),	  
indicating	   that	   iPSC-­‐EC	   had	   ‘acquired’	   an	   endothelial	   cell	   phenotype	   through	   the	  
reprogramming	   protocol	   (Takahashi	   et	   al.,	   2007;	   Yu	   et	   al.,	   2007).	   Both	   iPSC-­‐EC	   and	   HLF	  
expressed	  COX-­‐1	  (Figure	  3.5)	  
	  
3.3.2	  	   Response	  of	  stem	  cell	  derived	  and	  vessel	  endothelial	  cells	  to	  shear	  stress	  
As	  with	   endothelial	   cells	   grown	   from	   the	   vasculature	   (in	   this	   case	  HAEC)	   endothelial	   cells	  
from	  blood	  progenitors	   (BOEC)	  were	  cobblestone	   in	  appearance	  when	  grown	  under	   static	  
culture	  conditions	  (Figure	  3.6A)	  or	  when	  exposed	  to	  non-­‐directional/turbulent	  shear	  stress	  
(Figure	   3.6B;	   center).	   	   As	   with	   HAEC,	   BOEC	   aligned	   under	   conditions	   of	   directional	   shear	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stress	   (Figure	   3.6B;	   edge).	   By	   contrast,	   as	   mentioned	   above,	   endothelial	   cells	   from	  
embryonic	   stem	   cells	   (hESC-­‐EC)	   had	   a	   different	   morphology	   and	   were	   elongated	   (rather	  
than	  cobblestone)	  when	  cultured	  under	  static	  conditions	  (Figure	  3.6)	  or	  under	  conditions	  of	  
non-­‐directional	  shear	  stress	  (Figure	  3.6B;	  center),	  and	  as	  a	  consequence,	  any	  ‘alignment’	  in	  
response	   to	   directional	   shear	   stress	   was	   not	   detectable	   (Figure	   3.6B;	   edge).	   Due	   to	  
limitations	   in	   cells	   I	   was	   not	   able	   to	   study	   the	   effects	   of	   shear	   stress	   on	   iPSC-­‐EC.	   This	   is	  
discussed	  in	  the	  limitations	  section	  of	  this	  chapter.	  	  
	  
3.3.3	  	   Responses	   of	   stem	   cell	   derived	   endothelial	   cells	   to	   inflammatory	   stimuli:	   PAMPs	  
and	  cytokines	  
Endothelial	   cells	   are	   critical	   sensors	   of	   bacteria	   and	   viruses	   and	   signal	   to	   professional	  
immune	   cells	   to	   orchestrate	   inflammatory	   reactions	   (Mitchell	   et	   al.,	   2007;	   Opitz	   et	   al.,	  
2009).	   As	   discussed	   in	   chapter	   1,	   endothelial	   cells	   on	   vessels	   fulfil	   their	   role	   in	   innate	  
immunity	   through	   expression	   of	   pattern	   recognition	   receptors	   (PRRs)	   including	   TLRs	   and	  
NOD	   receptors,	   which	   respond	   to	   PAMPS	   (Gatheral	   et	   al.,	   2012;	   Opitz	   et	   al.,	   2005).	  
Endothelial	  cells	  also	  respond	  to	  IL-­‐1β,	  which	  activates	  cells	  independently	  of	  PRRs,	  but	  via	  
the	  shared	  adapter	  protein	  MyD88.	  In	  protocols	  to	  determine	  the	  ability	  of	  stem	  cell	  derived	  
endothelial	  cells	  to	  respond	  to	  PAMPs,	  comparisons	  were	  again	  made	  with	  endothelial	  cells	  
from	   the	   vasculature	   (either	   HMVEC	   or	   HUVEC).	   In	   this	   chapter	   the	   well-­‐studied	   pro-­‐
inflammatory	   cytokine/chemokine	   CXCL8	   was	   measured	   as	   a	   generic	   readout	   of	   cell	  
activation.	  In	  some	  experiments	  cell	  activation	  was	  additionally	  confirmed	  at	  the	  level	  of	  NF-­‐
κB	  nuclear	  translocation.	  The	  release	  of	  a	  larger	  range	  of	  pro-­‐inflammatory	  cytokines	  from	  




All	   the	   cell	   types	   tested	   responded	   to	   IL-­‐1β	   to	   release	   increased	   CXCL8	   (Figure	   3.7)	   and	  
translocation	   of	   NF-­‐κB	   (Figure	   3.8).	   All	   endothelial	   cells	   tested,	   except	   for	   hESC-­‐EC	  
responded	   to	   LPS	   (Figure	   3.7).	   Notably,	   whilst	   HUVEC	   released	   CXCL8	   at	   levels	   similar	   to	  
BOEC,	  HUVEC	  tended	  to	  show	  weaker	  signals	  for	  NF-­‐κB	  translocation	  at	  this	  time	  point.	  This	  
is	  discussed	  in	  more	  detail	   in	  the	  general	  discussion.	  Importantly,	  hESC-­‐EC	  did	  not	  respond	  
to	   any	   of	   the	   PAMPs	   tested	   (Table	   3.1).	   By	   contrast,	   BOEC,	   iPSC-­‐EC,	   HMVEC	   or	   HUVEC	  
responded	   to	   PAMPs	   against	   TLR2	   and	   TLR3	   (Table	   3.1).	   All	   endothelial	   cells	   tested,	  
including	  hESC-­‐EC,	   responded	   to	   the	  NOD1	  agonist	  C12-­‐iE-­‐DAP	  or	   to	   IL-­‐1β,	  with	   increased	  
CXCL8	  (Figure	  3.7)	  and	  nuclear	  translocation	  of	  NFκB	  (Figure	  3.8).	  The	  relative	  consequence	  
of	  lack	  of	  TLR4,	  but	  replete	  NOD1,	  responses	  in	  the	  immune	  function	  to	  live	  Gram-­‐negative	  
bacteria	  in	  hESC-­‐EC	  is	  addressed	  in	  detail	  in	  the	  subsequent	  chapter	  (Chapter	  4).	  	  
	  
Cell	  viability	  was	  not	  affected	  by	  any	  treatments	  in	  these	  protocols	  (Table	  3.2	  and	  3.3).	  
	  
3.3.4	  	   Release	  of	  vasoactive	  	  hormones	  by	  stem	  cell	  derived	  endothelial	  cells	  
As	  discussed,	  endothelial	  cells	  on	  vessels	  release	  prostacyclin,	  which	  is	  cardioprotective,	  and	  
ET-­‐1,	  which	   is	  associated	  with	  cardiovascular	  disease	  (Mitchell	  et	  al.,	  2008;	  Mombouli	  and	  
Vanhoutte,	   1999).	   In	   culture,	   endothelial	   cells	   can	   be	   activated	   to	   release	   prostacyclin,	  
which	   is	   measured	   as	   its	   breakdown	   product,	   6-­‐keto-­‐PGF1α.	   Under	   basal	   conditions	   in	  
culture,	   endothelial	   cells	   also	   release	   high	   levels	   of	   ET-­‐1	   (Stewart	   et	   al.,	   1990).	   These	   are	  
specific	  features	  of	  endothelial	  cells	  and	  were	  therefore	  used	  to	  test	  further	  the	  phenotype	  






BOEC	   and	   iPSC-­‐EC	   released	   comparable	   levels	   of	   ET-­‐1	   to	   endothelial	   cells	   from	   vessels	  
including	  HMVEC,	  HUVEC	  and	  HAEC	   (Figure	  3.9).	  hESC-­‐EC	  and	  HLFs	   released	  undetectable	  
levels	  of	  ET-­‐1	  under	  basal	  conditions	  (Figure	  3.9).	  	  
	  
Prostacyclin	  
Under	   control	   culture	   conditions,	   or	   after	   stimulation	  with	   IL-­‐1β,	   prostacyclin	   release	  was	  
detected	   from	   each	   cell	   type	   tested	   with	   the	   following	   rank	   order	   magnitude	  







It	  this	  chapter	  I	  have	  shown	  that:	  
• Where	  tested,	  BOEC	  and	  iPSC-­‐EC	  where	  more	  morphologically	  similar	  than	  hESC-­‐EC	  
to	  endothelial	  cells	  from	  vessels.	  
• hESC-­‐EC,	   unlike	   BOEC	   and	   endothelial	   cell	   from	   vessels	   do	   not	   align	   under	   shear	  
stress,	  and	  have	  an	  elongated	  phenotype	  under	  static	  conditions	  
• hESC-­‐EC,	   unlike	   BOEC,	   HUVEC,	   HMVEC	   and	   iPSC-­‐EC,	   did	   not	   respond	   to	   the	   TLR4	  
ligand,	  LPS,	  to	  release	  CXCL8.	  
• hESC-­‐EC,	  BOEC,	   iPSC-­‐EC	  and	  endothelial	  cells	  from	  vessels	  do	  respond	  to	  the	  NOD1	  
agonist,	  C12-­‐iE-­‐DAP	  to	  release	  CXCL8.	  
• hESC-­‐EC	  released	  lower	  levels	  of	  both	  ET-­‐1	  and	  prostacyclin	  compared	  to	  BOEC,	  iPSC-­‐
EC	  and	  endothelial	  cells	  from	  vessels.	  
	  
The	  premise	  of	  this	  chapter	  was	  that	  the	  assessment	  of	  stem	  cell	  derived	  endothelial	  cells	  in	  
terms	  of	  morphology,	   response	   to	   shear	   stress,	   innate	   immunity	  and	  vasoactive	  hormone	  
release	  is	  important	  for	  their	  full	  characterisation	  as	  relevant	  to	  ‘authentic’	  endothelial	  cells	  
from	  blood	  vessels.	  
	  
During	   the	   course	   of	   my	   PhD,	   some	   studies	   have	   demonstrated	   the	   ability	   of	   BOEC	   to	  
respond	  to	  shear	  stress	  and	  function	  as	  autologous	  vascular	  grafts	  (Ensley	  et	  al.,	  2012),	  and	  
the	   importance	   of	   studying	   shear	   stress	   pathways	   in	  more	   detail	   in	   these	   cells	   has	   been	  




Unlike	  hESC-­‐EC,	  both	  BOEC	  and	  iPSC-­‐EC	  aligned	  under	  shear	  stress,	  responded	  to	  TLR	  ligands	  
and	  released	  high	  levels	  of	  ET-­‐1	  and	  prostacyclin.	  	  These	  findings	  made	  both	  of	  these	  stem	  
cell	  derived	  endothelial	  cells	  suitable	  for	  further	  study	  in	  bioassays.	  In	  my	  thesis	  I	  opted	  to	  
take	  forward	  BOEC,	  which	  I	  went	  on	  to	  apply	  in	  in	  vitro	  assays	  described	  in	  chapter	  5	  and	  6.	  
This	  was	  principally	  because	  BOEC	  are	  more	  accessible	  and	  less	  manipulated	  than	  iPSC-­‐EC.	  
	  
As	   hESC-­‐EC	   did	   respond	   to	   agonists	   of	   NOD1,	   in	   the	   next	   chapter	   I	   have	   specifically	  




Summary	  Figure	  1.	  Summary	  of	  endothelial	   cell	   functions	   in	   stem	  cell	  derived	  endothelial	  
cells	   determined	   in	   Chapter	   3.	   +++	   and	   +	   etc.	   indicates	   rank	   order	   for	   cells	   releasing	  
prostacyclin.	   Release	   data	   is	   24h	   release	   under	   basal	   conditions	   for	   ET-­‐1	   and	   following	  






















+* +* +* +* ++*
hESC0EC* 0**
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Summary	  Figure	  2.	  Endothelial	  cells	  being	  used	  in	  therapy	  or	  as	  research	  tools	  will	  require	  
the	   key	   functions	   and	   pathways	   shown.	   1.	   Innate	   immunity	   through	   pattern	   recognition	  
receptors	   (TLR4	   and	  NOD1).	   2.	   Response	   to	   shear	   stress	   to	   form	  an	   aligned	  phenotype.	   3	  
Release	   of	   vasoactive	   hormones	   (endothelin-­‐1	   and	   prostacyclin)	  which	   are	   synthesised	   by	  
key	   enzymes	   in	   endothelial	   cells	   (ECE;	   endothelin	   converting	   enzyme	   and	   COX;	  
cyclooxgenase).	  Nitric	  oxide	  release	  is	  also	  important	  feature	  of	  endothelial	  cells	  but	  is	  more	  
difficult	   to	   study	   in	   human	   cells	   and	   has	   not	   been	   addressed	   in	   protocols	   of	   Chapter	   3.	  
Abbreviations:	   Toll-­‐like	   receptor	   (TLR),	   nucleotide	   oligomerisation	   domain	   containing	  





















































The	  data	  presented	  in	  this	  chapter	  are	  limited	  in	  a	  number	  of	  ways,	  which	  are	  outlined	  and	  
discussed	  below:	  
	  
A	  notable	  limitation	  of	  this	  chapter	  is	  that	  I	  was	  not	  able	  to	  demonstrate	  directly	  that	  the	  h7	  
hESC	  line	  used	  to	  generate	  hESC-­‐EC	  used	  in	  my	  PhD	  expressed	  a	  larger	  panel	  of	  pluripotency	  
markers,	   including	   SSEA3,	   Oct4,	   c-­‐myc.	   These	   markers	   are	   used	   widely	   to	   confirm	   a	  
pluripotent	   phenotype	   and	   have	   been	   shown	   in	   this	   cell	   type	   by	   others	   (Thomson	   et	   al.,	  
1998).	  My	   colleague	   Dr.	   Gabor	   Foldes	   also	   demonstrated	   in	   pilot	   work	   that	   this	   cell	   line	  
expresses	  SSEA4	  and	  high	  levels	  of	  Oct4	  mRNA.	  Information	  on	  the	  characterisation	  of	  the	  
pluripotent	  phenotype	  of	  these	  cells	  is	  also	  available	  via	  the	  University	  of	  Wisconsin	  Biobank	  
where	  these	  cells	  were	  first	  isolated	  and	  are	  commercially	  available	  for	  use	  in	  research.	  
	  
It	   is	   also	   noteworthy	   that	   the	   yield	   of	   hESC-­‐EC	   (0.1%)	   generated	   from	   the	   differentiation	  
protocol	   was	   low.	   Whilst	   this	   was	   sufficient	   to	   allow	   cells	   to	   be	   expanded	   for	   use	   in	  
experiments	   this	   will	   be	   important	   to	   address	   when	   scaling	   up	   these	   cells	   for	   wider	  
application.	  Developing	  this	  protocol	  further	  however	  was	  outside	  the	  scope	  of	  my	  PhD.	  
	  
Whilst	   every	   effort	   was	   made	   to	   run	   all	   protocols	   to	   characterise	   the	   stem	   cell-­‐derived	  
endothelial	   in	  direct	  parallel,	   this	  was	  not	  always	  possible.	  As	  a	   result,	  whilst	  all	  protocols	  
were	  suitably	  and	  carefully	  controlled	  some	  protocols	  were	  run	  with	  small	  differences.	  This	  
limitation	  occurred	  as	  a	  result	  of	  cells	  being	  available	  at	  different	  times	  and	  protocols	  being	  
developed	   and	  modified	   during	   the	   course	   of	   this	   project.	   However,	   I	   believe	   that	   these	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relatively	  small	  differences	  did	  not	  have	  a	  major	  impact	  on	  the	  conclusions/summary	  points	  
shown	  above.	  
	  
It	  should	  also	  be	  noted	  that	  in	  experiments	  where	  staining	  was	  carried	  out	  using	  antibodies	  
that	   I	  was	  not	   able	   to	   test	   the	   effect	   of	   isotype	   controls	   for	   these	   antibodies.	   This	  would	  
have	   added	   to	   the	   certainty	   as	   to	   the	   specificity	   of	   the	   staining	   on	   endothelial	   cells.	   An	  
additional	   approach	   to	   testing	   for	   specificity	   would	   include	   the	   addition	   of	   a	   blocking	  
peptide	  that	  represents	  the	  original	  peptide	  sequence	  to	  which	  the	  antibody	  was	  raised.	  To	  
compensate	  for	  this	  limitation	  however,	  I	  was	  able	  to	  show	  that	  the	  antibody	  used	  to	  stain	  
for	  CD31,	  which	  is	  expressed	  by	  endothelial	  cells,	  did	  not	  result	  in	  positive	  staining	  in	  human	  
lung	  fibroblasts,	  which	  do	  not	  express	  CD31	  (Figure	  3.5).	  Taken	  together,	  this	  suggests	  that	  
the	  CD31	  staining	  by	  endothelial	  cells	  in	  my	  PhD	  was	  specific	  to	  endothelial	  cells.	  
	  
Another	   limitation	   is	   that	   I	   was	   not	   always	   able	   to	   perform	   sufficient	   numbers	   of	  
experiments	   to	  use	   statistically	   testing	   and	  extra	  n-­‐values	   for	   some	  protocols	  would	  have	  
increased	   the	   robustness	  of	   the	  data.	  However,	   this	  being	  said,	  data	  presented	  was	  clear,	  
consistent	  and,	  as	  in	  all	  protocols,	  included	  appropriate	  controls	  where	  necessary.	  	  
	  
A	  key	  finding	  of	  this	  chapter	  was	  that	  hESC-­‐EC	  do	  not	  have	  TLR4	  function.	  I	  have	  exclusively	  
used	   cells	   derived	   from	   the	   H7	   cell	   line	   to	   demonstrate	   this.	   This	   is	   clearly	   an	   important	  
limitation	   and	   it	   would	   therefore	   be	   interesting	   to	   look	   if	   this	   ‘no	   TLR4’	   phenotype	   is	  
preserved	   across	   other	   hESC-­‐line	   derived	   endothelial	   cells.	   Going	   forward,	   it	   might	   be	  
equally	   important	   to	   consider	   the	   phenotype	   of	   hESC-­‐EC	   derived	   using	   subtly	   different	  
protocols,	   including	   those	   that	   have	   been	   developed	   for	   large	   scale	   production	   of	   cell	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therapies.	  Notably,	   others	   in	   the	   group	   showed	   that	   undifferentiated	   hESCs	   derived	   from	  
two	  separate	  lines	  are	  devoid	  of	  TLR4	  function	  (Földes	  et	  al.,	  2010)	  and	  this	  may	  add	  weight	  
to	  the	  findings	  in	  this	  particular	  hESC-­‐EC	  line.	  
	  
Finally,	   in	   order	   to	   establish	   the	   parallels	   of	   endothelial	   cells	   from	   stem	   cell	   origins	   with	  
those	  from	  vessels	  it	  is	  important	  to	  test	  their	  functionality	  in	  vascular	  response	  models;	  the	  
key	  ones	  being	   thrombosis	  and	  vasomotor	  control.	  This	   is	  a	   limitation	  of	   this	   chapter	  and	  


























































Figure	  3.1	   Images	  of	  undifferentiated	  human	  embryonic	  stem	  cells	  (hESC).	  (A)	  Morphology	  
(Foldes	  et	  al.,	  2010:	  CC-­‐BY	  licence)	  and	  (B)	  pluripotency	  (TRA-­‐1-­‐60;	  green)	  marker	  expression	  
in	  hESC.	  For	  panel	  A	  images	  were	  acquired	  using	  a	  light	  microscope	  at	  10x	  magnification	  and	  
for	  panel	  B	  using	  an	  inverted	  fluorescence	  microscope	  at	  10x	  magnification.	  Cell	  nuclei	  were	  







Figure	  3.2	  Isolation	  and	  characterisation	  of	  human	  embryonic	  stem	  cell	  derived	  endothelial	  
cells	  (hESC-­‐EC)	  from	  embryoid	  bodies.	  (A)	  Contour	  plots	  for	  separation	  of	  CD31+	  cells	  from	  
embryoid	  bodies;	  (i)	  forward	  scatter	  (FSC)	  and	  side	  scatter	  (SSC)	  of	  total	  sample	  (P1;	  red),	  (ii)	  
FSC	  and	  SSC	  of	  population	  (P)-­‐1	  showing	  doublet	  exclusion,	  (iii)	  CD31	  expression	  of	  P2	  (blue)	  
to	  give	  P3	  (green)	  (CD31-­‐)	  and	  P4	  (pink)	  (CD31+).	  P4	  which	  was	  selected	  and	  plated	  on	  1%	  
gelatinized	  coated	  plates	  for	  expansion.	  	  (B)	  Morphology	  of	  15	  day	  expanded	  hESC-­‐EC,	  CD31	  
(green;	  Foldes	  et	  al.,	  2010:	  CC-­‐BY	  licence)	  and	  COX-­‐1	  (red)	  expression	  in	  cells	  (left	  to	  right).	  
Cell	   nuclei	   are	   stained	   with	   10µg/ml	   DAPI	   (blue).	   Images	   for	   morphology	   were	   acquired	  
using	  a	  light	  microscope,	  for	  CD31	  using	  an	  inverted	  fluorescence	  microscope,	  and	  for	  COX-­‐1	  







Figure	   3.3	   Isolation	   of	   blood	   outgrowth	   endothelial	   cells	   (BOEC)	   from	   peripheral	   blood	  
mononuclear	  cells	  (PBMCs).	  At	  day	  1,	  PBMCs	  were	  plated	  at	  3	  x	  107	  cells/well	  in	  4ml	  Lonza-­‐
EGM2	  media	  with	  10%	  FBS.	  Colonies	  emerged	  between	  day	  7	  and	  20	  (day	  11	  in	  the	  example	  
above).	  Cells	  were	  then	  expanded	  to	  25cm2	  and	  then	  75cm2	  flasks	  for	  use	  in	  experiments	  at	  
passage	  3	  or	  cryopreservation.	  Images	  were	  captured	  using	  a	  light	  microscope	  with	  a	  Nikon	  

































Figure	   3.4	   Characterisation	   of	   blood	   outgrowth	   endothelial	   cells	   (BOECs)	   in	   culture.	  
Morphology	   of	   BOEC	   imaged	   by	   light	   microscope	   with	   a	   Nikon	   VR	   ISO3200	   camera	  
attachment	  and	  CD31	  (green),	  VE-­‐cadherin	  (red)	  and	  COX-­‐1	  (red)	  expression	  in	  BOECs	  (left	  to	  
right).	  Cell	  nuclei	   are	   stained	  with	  10µg/ml	  DAPI	   (blue).	   Images	   for	  CD31	  and	  VE-­‐cadherin	  
were	   acquired	   using	   a	   Cellomics	   HCS	   VTi	   arrayscanner	   and	   for	   COX-­‐1	   using	   a	   confocal	  
microscope.	  All	  images	  are	  at	  10x	  magnification	  with	  scale	  bar	  indicated	  for	  the	  COX-­‐1	  image	  


















Figure	  3.5	  Characterisation	  of	  induced	  pluripotent	  stem	  cell	  derived	  endothelial	  cells	  (iPSC-­‐
ECs)	  versus	  human	  lung	  fibroblasts	  (HLF).	  (A)	  Morphology	  of,	  and	  CD31	  (green),	  VE-­‐cadherin	  
(red)	   and	   COX-­‐1	   (red)	   expression	   in	   iPSC-­‐ECs.	   Cell	   nuclei	  were	   stained	  with	   10µg/ml	  DAPI	  
(blue).	  (B)	  Morphology	  of,	  and	  CD31	  (green)	  and	  COX-­‐1	  (red)	  expression	  in,	  HLF.	  Images	  for	  
morphology	   were	   acquired	   using	   a	   light	   microscope	   with	   a	   Nikon	   VR	   ISO3200	   camera	  
attachment,	   for	  CD31,	  VE-­‐cadherin	  and	  COX-­‐1	  using	  a	  confocal	  microscope.	  All	   images	  are	  
cropped	   equally	   from	   images	   at	   10x	   magnification.	   All	   images	   were	   captured	   at	   10x	  
















Figure	  3.6	  Responses	  of	  different	  stem	  cell	  derived-­‐endothelial	  cells	  to	  shear	  stress.	  Human	  
embryonic	  stem	  cell	  derived	  endothelial	   cells	   (hESC-­‐EC),	  blood	  outgrowth	  endothelial	   cells	  
(BOEC),	  and	  human	  aortic	  endothelial	  cells	  (HAEC)	  (left	  to	  right)	  under	  (A)	  static	  conditions	  
and	  (B)	  after	  4	  days	  of	  shear	  stress.	  Images	  were	  taken	  at	  the	  edge	  of	  the	  well,	  where	  shear	  
stress	  is	  unidirectional	  and	  cells	  align,	  and	  at	  the	  center	  of	  the	  well	  where	  shear	  stress	  had	  
no	   preferred	   direction.	   Images	   shown	   are	   at	   10x	  magnification	  with	   scale	   bars	   shown	   on	  
hESC-­‐EC	  centre	  images	  and	  are	  true	  for	  all	  images.	  	  Black	  arrows	  on	  shear	  plate	  edge	  images	  





























Figure	  3.7	  CXCL8	  release	  from	  different	  stem	  cell	  derived	  endothelial	  cells	  in	  response	  to	  (A)	  
TLR4	   and	   NOD1	   agonists	   and	   (B)	   IL-­‐1β	   stimulation.	   Human	   embryonic	   stem	   cell	   derived	  
endothelial	   cells	   (hESC-­‐EC)	   (n=8),	   blood	   outgrowth	   endothelial	   cells	   (BOEC)	   (n=8),	   human	  
lung	   induced	   pluripotent	   stem	   cell	   derived	   endothelial	   cells	   (iPSC-­‐EC)	   (n=2	   from	  one	   pilot	  
experiment),	   human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   (n=8)	   and	   human	  
microvascular	  endothelial	  cells	  (HMVEC)	  (n=6)	  were	  treated	  for	  24h	  with	  LPS	  (TLR4	  agonist;	  
1µg/ml)	   or	   C12-­‐iE-­‐DAP	   (NOD1	   agonist;	   10μg/ml)	   or	   IL-­‐1β	   (1ng/ml).	   For	   iPSC-­‐EC,	   n=2	   from	  
one	  pilot	  experiment.	   Statistical	   significance	  was	  determined	  by	  one-­‐way	  ANOVA	   followed	  
by	   Dunnett’s	   multiple	   comparison	   test	   for	   each	   cell	   type	   (*p<0.05).	   Analysis	   was	   not	  
performed	  on	  data	  from	  iPSC-­‐EC.	  	  
	  
















































Figure	  3.8	  Response	  of	  stem	  cell	  derived	  endothelial	  cells	  to	  pathogen	  associated	  molecular	  
patterns	   (PAMPs)	   in	   terms	   of	   NF-­‐κB	   nuclear	   translocation.	   (A)	   Representative	  
immunocytochemistry	   images	   of	   human	   embryonic	   stem	   cell	   derived	   endothelial	   cells	  
(hESC-­‐EC),	  blood	  outgrowth	  endothelial	  cells	  (BOEC),	  human	  umbilical	  vein	  endothelial	  cells	  
(HUVEC)	   and	   human	   lung	   microvascular	   endothelial	   cells	   (HMVEC)	   stained	   for	   NF-­‐κB	  












1μg/ml)	  or	   IL-­‐1β	   (1ng/ml).	  Nuclei	  were	   stained	  with	  10μg/ml	  DAPI.	   Images	  were	  acquired	  
using	  a	  Cellomics	  VTi	  HCS	  Arrayscanner	  with	  a	  Carl	  Zeiss	  microscope.	  Images	  were	  acquired	  
at	   10	   x	   magnifications	   with	   scale	   bars	   indicated.	   (B)	   Quantification	   of	   NF-­‐κB	   nuclear	  
translocation	   in	  hESC-­‐EC	   (n=6),	  BOEC	  (n=1	  from	  one	  pilot	  experiment)	  and	  HUVEC	  (n=6)	   in	  
response	  to	  the	  above	  treatments.	  Data	  are	  normalised	  to	  1000	  cells/well	  and	  normalised	  to	  
control	  (100%).	  Data	  are	  mean	  (%control)	  ±	  SEM.	  Statistical	  significance	  was	  determined	  by	  
one-­‐sample	   t-­‐test	   (*p<0.05).	   Statistical	   testing	   was	   not	   carried	   out	   BOEC.	   Statistical	  





























Figure	   3.9	   Endothelin-­‐1	   (ET-­‐1)	   release	   from	   different	   stem	   cell	   derived	   endothelial	   cells	  
versus	   endothelial	   cells	   from	   vessels	   and	   human	   lung	   fibroblasts	   (HLF).	   ET-­‐1	   release	   from	  
human	  embryonic	  stem	  cell	  derived	  cells	  (hESC-­‐EC;	  n=8),	  blood	  outgrowth	  endothelial	  cells	  
(BOEC;),	  induced	  pluripotent	  stem	  cell	  derived	  endothelial	  cells	  (iPSC-­‐EC;	  n=2	  from	  one	  pilot	  
experiment),	   human	   lung	  microvascular	   endothelial	   cells	   (HMVEC;	   n=4),	   human	   umbilical	  
vein	   endothelial	   cells	   (HUVEC;	   n=6),	   human	   aortic	   endothelial	   cells	   (HAEC;	   n=3	   from	   1	  
experiment)	   or	   HLF	   (n=2).	   Cells	   were	   grown	   in	   similar	   conditions	   and	   basal	   ET-­‐1	   release	  























































Figure	   3.10	   Prostacyclin	   release	   from	   different	   stem	   cell	   derived	   endothelial	   cells	   versus	  
human	   lung	  microvascular	  endothelial	   cells	   (HMVEC).	  Human	  embryonic	   stem	  cell	  derived	  
cells	   (hESC-­‐EC;	   n=5),	   blood	   outgrowth	   endothelial	   cells	   (BOEC;	   n=9),	   induced	   pluripotent	  
stem	   cell	   derived	   endothelial	   cells	   (iPSC-­‐EC;	   n=2	   from	   one	   pilot	   experiment),	   human	   lung	  
microvascular	  endothelial	  cells	  (HMVEC;	  n=5).	  Prostacyclin	  release	  was	  measured	  as	  6-­‐keto	  
PGF1α	   following	   24h	   incubation	   +/-­‐	   IL-­‐1β	   (1ng/ml).	   Data	   are	   mean	   ±	   SEM.	   Statistical	  





























































Table	  3.1	  Effect	  of	  TLR	  agonists	  and	  IL-­‐1β	  on	  CXCL8	  release	  from	  different	  stem	  cell	  derived	  
endothelial	   cells	   and	   human	   lung	   microvascular	   endothelial	   cells	   (HMVEC).	   Human	  
embryonic	  stem	  cell	  derived	  endothelial	  cells	   (hESC-­‐EC),	  blood	  outgrowth	  endothelial	  cells	  
(BOEC),	   human	   lung	   induced	   pluripotent	   stem	   cell	   derived	   endothelial	   cells	   (iPSC-­‐EC)	   and	  
human	  microvascular	  endothelial	   cells	   (HMVEC)	  were	   treated	   for	  24h	  with/without	  HKLM	  
(TLR2	   agonist;	   107	   cells/ml),	   Pam3CSK4	   (TLR1/2	   agonist;	   1μg/ml),	   FSL-­‐1	   (TLR2/6	   agonist;	  
1μg/ml),	  PolyIC	  (TLR3	  agonist;	  10μg/ml),	  LPS	  (TLR4	  agonist;	  1μg/ml),	  ST-­‐FLA	  (Staphylococcus	  
aureus	  derived	  flagellin)	  (TLR5	  agonist;	  100ng/ml),	  IMI	  (imiquimod)	  (TLR7	  agonist;	  1μg/ml),	  
ssRNA40	  (TLR8	  agonist;	  1µg/ml,	  ODN2006	  (TLR9	  agonist;	  5µM)	  or	   IL-­‐1β	  (1ng/ml).	  Data	  are	  
mean	  ±	  SEM	  (hESC-­‐EC	  n=	  8-­‐10;	  BOEC	  n=	  14;	  iPSC-­‐EC	  n=2	  from	  one	  pilot	  study;	  HMVEC	  n=4).	  
Statistical	   signifance	  was	   determined	   by	   one-­‐way	   ANOVA	   followed	   by	   Dunnett’s	  multiple	  
comparison	  test	  (*p<0.05).	  Analysis	  was	  not	  carried	  out	  on	  iPSC-­‐EC.	  
	  
	  





























































































Table	   3.2	   Effect	   of	   TLR	   agonists	   and	   IL-­‐1β	   on	   cell	   viability	   of	   different	   stem	   cell	   derived	  
endothelial	   cells	   and	   human	   lung	   microvascular	   endothelial	   cells	   (HMVEC).	   Human	  
embryonic	  stem	  cell	  derived	  endothelial	  cells	   (hESC-­‐EC),	  blood	  outgrowth	  endothelial	  cells	  
(BOEC),	   human	   lung	   induced	   pluripotent	   stem	   cell	   derived	   endothelial	   cells	   (iPSC-­‐EC)	   and	  
human	  microvascular	  endothelial	   cells	   (HMVEC)	  were	   treated	   for	  24h	  with/without	  HKLM	  
(TLR2	   agonist;	   107	   cells/ml),	   Pam3CSK4	   (TLR1/2	   agonist;	   1μg/ml),	   FSL-­‐1	   (TLR2/6	   agonist;	  
1μg/ml),	  PolyIC	  (TLR3	  agonist;	  10μg/ml),	  LPS	  (TLR4	  agonist;	  1μg/ml),	  ST-­‐FLA	  (Staphylococcus	  
aureus	  derived	  flagellin)	  (TLR5	  agonist;	  100ng/ml),	  IMI	  (imiquimod)	  (TLR7	  agonist;	  1μg/ml),	  
ssRNA40	  (TLR8	  agonist;	  1µg/ml,	  ODN2006	  (TLR9	  agonist;	  5µM)	  or	   IL-­‐1β	  (1ng/ml).	  Data	  are	  
mean	  ±	  SEM	  (hESC-­‐EC	  n=	  6;	  BOEC	  n=	  6;	  iPSC-­‐EC	  n=2	  from	  one	  pilot	  study;	  HMVEC	  n=2).	  All	  
data	   are	   from	   experiments	   on	   cells	   with	   representative	   CXCL8	   profiles	   in	   response	   to	  
treatments.	  
	  




























































































Table	  3.3	  Effect	  of	  TLR4	  and	  NOD1	  agonists	  on	   cell	   viability	  of	  different	   stem	  cell	  derived	  
endothelial	  cells.	  Cells	  were	  treated	  for	  24h	  with	  LPS	  (TLR4	  agonist;	  1µg/ml)	  or	  C12-­‐iE-­‐DAP	  
(NOD1	  agonist;	   10μg/ml).	   Cell	   viability	   of	   human	  embryonic	   stem	   cell	   derived	   endothelial	  
cells	  (hESC-­‐EC)	  and	  human	  umbilical	  vein	  endothelial	  cells	  (HUVEC)	  was	  determined	  using	  a	  
Cellomics	  VTi	  HCS	  Arrayscanner	  and	   results	   are	  expressed	  as	   the	  average	  number	  of	   cells	  
per	   field	   of	   view.	   Cell	   viability	   of	   blood	   outgrowth	   endothelial	   cells	   (BOEC),	   and	   human	  
induced	   pluripotent	   stem	   cell	   derived	   endothelial	   cells	   (iPSC-­‐EC)	   was	   determined	   using	  
alamarBlue	   and	   results	   are	   expressed	   as	   absorbance	   at	   570nm-­‐630nm.	   Data	   are	  mean	   ±	  














CHAPTER	   4:	   RESPONSES	   OF	   HESC-­‐EC	   TO	   HAEMOPHILUS	  






















4.1	  RATIONALE	  	  
In	   the	  previous	   chapter	   I	   showed	   that	  unlike	  endothelial	   cells	   from	  other	   sources,	  human	  
embryonic	   stem	   cell	   derived	   endothelial	   cells	   (hESC-­‐EC)	   shared	   some	   characteristics	   of	  
endothelial	  cells,	  in	  that	  they	  express	  markers,	  but	  do	  not	  respond	  to	  the	  Toll-­‐like	  receptor	  4	  
(TLR4)	   agonist	   LPS.	   	   These	   findings	   have	   important	   implications,	   which	   could	   mean	   that	  
hESC-­‐EC	   are	   either	   (i)	   superior	   to	   other	   endothelial	   cells	   as	   therapies	   because	   TLR4	   is	  
involved	  in	  atherosclerosis	  or	  (ii)	  carry	  increased	  side	  effects	  because	  without	  TLR4	  the	  cells	  
would	   be	   immuno-­‐deficient.	   Thus,	   in	   this	   chapter	   I	   have	   followed	   up	   specifically	   on	   the	  
implications	  of	  TLR4	  deficiency	  in	  hESC-­‐EC.	  
	  
In	   Chapter	   3	   I	   used	  CXCL8	   as	   a	   generic	  marker	   of	   cell	   activation.	  However,	   LPS	   induces	   a	  
range	  of	  pro-­‐inflammatory	  cytokines.	   In	  order	   to	  be	  sure	   that	   the	  effects	   seen	   in	  hESC-­‐EC	  
were	   not	   due	   to	   a	   specific	   dysfunction	   in	   TLR4/CXCL8	   signalling,	   here	   I	   have	   repeated	  
experiments	   and	  measured	   a	   full	   range	   of	   9	   separate	   pro-­‐inflammatory	   cytokines	   in	   cells	  
stimulated	  with	  LPS.	  	  
	  
In	   Chapter	   3	   I	   also	   found	   that	   hESC-­‐EC	   respond	   to	   nucleotide	   oligomerisation	   domain	  
receptor	   (NOD1)	  agonists.	   TLR4	  and	  NOD1	  are	   the	  principal	  pattern	   recognition	   receptors	  
(PRR)	   expressed	   by	   endothelial	   cells	   that	   sense	   Gram-­‐negative	   bacteria	   (Gatheral	   et	   al.,	  
2012;	  Opitz	  et	  al.,	   2009).	   In	   this	   chapter	   I	  have	   investigated	   the	   impact	  of	   the	  absence	  of	  
TLR4	  in	  hESC-­‐EC	  on	  the	  ability	  of	  the	  cells	  to	  respond	  to	  live	  Gram-­‐negative	  bacteria.	  This	  is	  
further	  explored	  by	  addressing	  the	  role	  of	  NOD1	  in	  these	  responses	  and	  whether	  NOD1	  can	  




The	  specific	  questions	  addressed	  in	  this	  chapter	  are:	  
1. Is	  the	  inability	  of	  hESC-­‐EC	  to	  release	  CXCL8	  in	  response	  to	  LPS	  recapitulated	  when	  a	  
full	  range	  of	  pro-­‐inflammatory	  cytokines	  is	  measured?	  
2. How	   do	   hESC-­‐EC	   respond	   to	   the	   live	   Gram-­‐negative	   bacteria	   compared	   to	  
endothelial	  cells	  from	  vessels	  (HUVEC;	  which	  have	  both	  TLR4	  and	  NOD	  functions)?	  




















4.2	  SUMMARY	  OF	  METHODS	  	  
A	   full	   description	   of	   the	   methods	   used	   in	   this	   chapter	   is	   given	   in	   Chapter	   2	   and	   are	  
summarised	  below.	  
4.2.1	  	   Cell	  culture	  and	  treatments	  
hESC-­‐EC	  and	  human	  umbilical	  vein	  endothelial	  cells	  (HUVEC)	  were	  cultured	  as	  described	  in	  
Chapter	   2	   and	   3,	   and	   plated	   on	   96-­‐well	   plates	   	   (Nunc,	   Denmark)	   at	   a	   seeding	   density	   of	  
7,000	   cells/well	   in	   Lonza-­‐EGM2	  media.	   Once	   confluent,	   cells	   were	   treated	  with	   reagents,	  
drugs	  or	  live	  Gram	  negative	  Haemophilus	  influenzae	  bacteria	  for	  either	  1	  or	  24	  hours	  before	  
media	  was	  collected	  and	  cells	  fixed	  for	  imaging,	  lysed	  for	  extraction	  of	  RNA	  or	  treated	  with	  
Alamarblue	  for	  measurement	  of	  cell	  viability.	  Drugs	  used	  included	  LPS	  (TLR4	  agonist),	  iE-­‐DAP	  
(NOD1	  agonist),	   C12-­‐iE-­‐DAP	   (NOD1	  agonist),	  GSK2576214A	   (GSK’214;	  RIP2	   inhibitor;	   a	   gift	  
from	  GSK),	  GSK1219217A	  (GSK’217;	  NOD1	  inhibitor;	  a	  gift	  from	  GSK),	  SC-­‐514	  (IKK	  inhibitor),	  
SB203580	   (RIP2/p38	   inhibitor),	   BIRB0796	   (p38	   inhibitor).	   In	   these	   experiments,	   cells	  were	  
incubated	  with	  inhibitors	  for	  30	  minutes	  prior	  to	  addition	  of	  agonists	  and/or	  bacteria.	  
	  
For	  experiments	  with	  bacteria,	  cells	  were	  incubated	  with	  live	  Haemophilus	  influenzae	  (ATTC	  
strain	   49247)	   at	   colony	   forming	   units	   (CFU)	   of	   108-­‐105	   per	  ml	   for	   24	   hours.	  Haemophilus	  
influenzae	   comes	   from	   the	   supplier	   in	   bacteria	   support	   media.	   In	   some	   experiments	  
bacteria-­‐free	   samples	   of	   this	   media	   were	   prepared	   by	   filtering	   the	   broth	   and	   used	   as	  
experimental	   ‘vehicle’	   controls	   (see	  Figure	  2.1;	   chapter	  2).	   In	   later	  experiments	  cells	  were	  
pre-­‐incubated	  with	   and	  without	   NOD1	   targeting	   siRNA	   or	   NOD1	   and	   RIP2	   antagonists	   as	  




4.2.2	  	   Quantitative	  real	  time	  PCR	  (qRT-­‐PCR)	  for	  TLR4	  and	  NOD1	  expression	  
TLR4	   expression	  was	  measured	   using	   a	   commercially	   available	   focused	   array	   (Gene	  Array	  
PAHS-­‐058,	   SABiosciences,	   UK)	   and	   NOD1	   was	   measured	   using	   specific	   primers	   (TaqMan	  
Chemistry,	  Applied	  Biosystems,	  UK)	   for	   qRT-­‐PCR.	  All	   assays	  were	   carried	  out	   according	   to	  
manufactures	  instructions.	  For	  TLR4,	  data	  were	  normalised	  to	  the	  mean	  of	  5	  housekeeping	  
genes	   included	   in	   the	   array	   (B2M,	   HPRT1,	   RPL13A,	   GAPDH,	   ACTB)	   and	   for	   NOD1	   to	   the	  
house	  keeping	  gene,	  GAPDH.	  	  The	  PCR	  was	  performed	  with	  ABI	  5700	  (Applied	  Biosystems,	  
USA)	   and	   Rotor-­‐Gene	   3000	   (Corbett	   Research,	   UK)	   RT-­‐PCR	   instruments.	   Relative	   gene	  
expression	  was	  determined	  by	  the	  ΔΔCt	  method	  were	  fold	  changes	  is	  calculated	  as	  =	  2−ΔΔCt.	  	  
	  
4.2.3	  	   Measurement	  of	  pro-­‐inflammatory	  cytokines	  using	  a	  Meso	  Scale	  discovery	  (MSD)	  
platform	  
Levels	  of	  9	  pro	   inflammatory	  cytokines	  were	  measured	  using	   ‘human	  pro-­‐inflammatory	  9-­‐
Plex	   MULTISPOT	   96-­‐well	   -­‐10	   spot’	   purchased	   from	   MSD	   (Gaithersburg,	   Maryland,	   USA).	  
Samples	   were	   diluted	   1:10	   in	   assay	   buffer	   and	   assays	   carried	   out	   according	   to	  
manufacturer’s	   instructions.	  MSD	  plates	  were	   read	  using	  an	  MSC	  Sector	   Imager	  2400	  and	  
analysed	  using	  MSD	  Discovery®	  Workbench	  software.	  Cytokines	  analysed	  were	  TNFα,	   IL-­‐2,	  
CXCL8,	  IL-­‐12q70,	  IL-­‐1β,	  GM-­‐CSF,	  IFNγ,	  IL-­‐6,	  IL-­‐10.	  	  
	  
4.2.4	  	   Small	  interfering-­‐RNA	  (siRNA)	  mediated	  knockdown	  of	  NOD1	  
For	   NOD1	   siRNA	   knockdown	   protocols,	   targeting	   NOD1	   siRNA	   (Qiagen,	   UK)	   was	   used	  
according	   to	  manufacturer’s	   instructions.	   Cells	   were	   plated	   24	   hours	   before	   transfection.	  
Scrambled	   non-­‐targeting	   siRNA	   (Qiagen,	   UK)	   was	   used	   as	   negative	   control.	   Following	   48	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hours	  of	  transfection	  cells	  were	  either	  lysed	  for	  extraction	  of	  RNA	  or	  fresh	  media	  added	  with	  
treatments	  as	  above.	  After	  24	  hours	  supernatants	  were	  collected	  for	  analysis.	  	  
	  
4.2.5	  	   Measurement	  of	  CXCL8	  
CXCL8	  was	  measured	  by	  ELISA	  (R	  and	  D	  Systems)	  according	  to	  manufacturer’s	  instructions.	  
Optical	   density	   was	   determined	   using	   a	   microplate	   reader	   (Dyne,	   Madellan	   Biosciences)	  
with	  absorbance	  readings	  at	  450-­‐570nm.	  
	  
4.2.6	   Measurement	  of	  cell	  viability	  
Cell	  viability	  following	   incubations	  was	  determined	  using	  either	  the	  commercially	  available	  
AlamarBlue®	   assay	   (Invitrogen,	   UK)	   or	   based	   on	   cell	   counts.	   For	   cell	   counts,	   cells	   were	  
stained	  with	  10µg/ml	  4',6-­‐diamidino-­‐2-­‐phenylindole	  (DAPI)	  and	  imaged	  using	  the	  Cellomics	  
VTi	  HCS	  Arrayscan	  (Thermofisher,	  USA).	  Data	  are	  expressed	  as	  average	  cells/field	  based	  on	  












4.3.1	  	   Effect	   of	   the	   TLR4	   agonist	   LPS	   versus	   NOD1	   agonists	   on	   release	   of	   a	   range	   of	  
cytokines	  from	  hESC-­‐EC	  
As	  seen	  in	  chapter	  3,	  the	  NOD1	  agonist	  C12-­‐iE-­‐DAP,	  as	  well	  as	  iE-­‐DAP,	  induced	  CXCL8	  release	  
from	  either	  HUVEC	  or	  hESC-­‐EC	  whilst	  the	  TLR4	  agonist	  LPS	  released	  CXCL8	  from	  HUVEC	  only	  
(Figure	  4.1).	   In	  order	   to	  be	  sure	   this	   response	  was	  not	   limited	   to	  CXCL8	  8	  other	  cytokines	  
were	  measured	  in	  conditioned	  media	  from	  these	  cells.	  As	  with	  CXCL8,	  hESC-­‐EC	  and	  HUVEC	  
responded	  to	  the	  NOD1	  agonist	  C12-­‐iE-­‐DAP	  to	  release	  GM-­‐CSF,	  IL-­‐12p70,	  IL-­‐2,	  IL-­‐6,	  IL1β	  and	  
TNFα.	  HUVEC,	  but	  not	  hESC-­‐EC,	  also	  tended	  to	  release	  GM-­‐CSF,	  IFNγ,	  IL-­‐12p70,	  IL-­‐2,	  IL-­‐6	  and	  
TNFα	  in	  response	  to	  treatment	  with	  LPS	  (Figure	  4.2	  to	  4.9).	  
	  
4.3.2	  	   Relative	  expression	  of	  TLR4	  and	  NOD1	  in	  hESC-­‐EC	  versus	  HUVEC	  
In	  line	  with	  what	  was	  seen	  for	  cytokine	  release,	  hESC-­‐EC	  expressed	  lower	  levels	  of	  TLR4	  than	  
HUVEC	  whereas	  levels	  of	  NOD1	  gene	  were	  comparable	  between	  the	  two	  cell	  types	  (Figure	  
4.10).	  
	  
4.3.3	  	   Responses	  of	  hESC-­‐EC	  to	  Haemophilus	  influenzae	  
The	   experiments	   above	   confirm	   that	   hESC-­‐EC	   have	   no	   TLR4	   function,	   and	   that	   this	   is	  
explained	  by	  reduced	  receptor	  expression.	  As	  discussed,	  Gram-­‐negative	  bacteria	  are	  sensed	  
by	   two	   key	   pattern	   recognition	   receptor	   (PRR)	   pathways;	   TLR4	   and	  NOD1.	   As	  with	   other	  
types	  of	  Gram-­‐negative	  bacteria,	  Haemophilus	   influenzae	   is	   reportedly	   sensed	  by	   cells	   via	  
TLR4	  and/or	  NOD1	  pathways	  (Hirano	  et	  al.,	  2009;	  Ratner	  et	  al.,	  2007).	  I	  therefore	  performed	  
experiments	   where	   cells	   were	   infected	   with	   live	   bacteria	   to	   establish	   the	   impact	   of	   a	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dysfunctional	   TLR4	   pathway	   on	   the	   sensing	   of	   Gram-­‐negative	   bacteria.	   As	   with	   other	  
protocols,	   hESC-­‐EC	   did	   not	   respond	   to	   LPS,	   but	   did	   respond	   to	   C12-­‐iEDAP,	   whilst	   HUVEC	  
responded	  to	  both	  (Figure	  4.11A).	  hESC-­‐EC	  and	  HUVEC	  both	  responded	  to	  infection	  with	  the	  
Gram-­‐negative	   bacteria	   Haemophilus	   influenzae	   by	   releasing	   CXCL8	   (Figure	   4.11B).	   The	  
potency	  of	  Haemophilus	   influenza	  was	  similar	   in	  both	  cell	   types.	  Haemophilus	   influenza	   in	  
control	  media	  incubated	  for	  24	  hours	  without	  cells	  did	  not	  interfere	  with	  the	  CXCL8	  ELISA.	  
	  
4.3.4	  	   Role	  of	  NOD1	  in	  responses	  of	  hESC-­‐EC	  to	  HIN	  to	  release	  CXCL8	  
In	  order	  to	  establish	  the	  role	  of	  NOD1	  receptors	  in	  the	  activation	  of	  hESC-­‐EC	  by	  Haemophilus	  
influenzae,	   both	   a	   molecular	   approach-­‐using	   gene	   knock	   down,	   and	   a	   pharmacological	  
approach	  using	  selective	  inhibitors	  of	  NOD1	  and	  RIP2	  was	  employed.	  	  
	  
NOD1	   receptors	   can	   be	   knocked	   down	   using	   conventional	   targeting	   siRNA	   (see	   general	  
methods	  and	  above).	  As	  expected,	   incubation	  of	  hESC-­‐EC	  with	  NOD	  targeting	  siRNA	  for	  48	  
hour	  resulted	  in	  knockdown	  of	  NOD1	  gene	  expression	  (Figure	  4.12A).	  Knockdown	  of	  NOD1	  
receptors	  at	  the	  gene	  level	  also	  reduced	  responses	  of	  hESC-­‐EC	  to	  the	  NOD1	  agonist	  C12-­‐iE-­‐
DAP	  and,	  importantly,	  also	  to	  Haemophilus	  influenzae	  infection	  (Figure	  4.12B).	  Responses	  to	  
IL-­‐1β	   were	   not	   affected	   by	   NOD1	   siRNA	   targeted	   knockdown	   indicating	   that	   the	   loss	   of	  
response	  to	  Haemophilus	  influenzae	  by	  hESC-­‐EC	  was	  specific	  to	  NOD1	  (Figure	  4.13).	  	  
	  
To	   further	   examine	   the	   role	   of	   NOD1	   and	   corroborate	   these	   findings,	   pharmacological	  
assays	  were	  employed.	  In	  early	  experiments	  characterising	  the	  signalling	  pathways	  involved	  
in	  NOD1	  agonist	   induced	  CXCL8	   release	  by	  hESC-­‐EC,	   I	   found	  selective	   inhibition	  of	  C12-­‐iE-­‐
DAP	  responses	  with	  SB203580	  which	  inhibits	  RIP2	  and	  p38,	  with	  only	  mild	  inhibitory	  effects	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with	  BIRB0796,	  which	  inhibits	  p38	  (Table	  4.2).	  Responses	  to	  both	  C12-­‐iE-­‐DAP	  and	  IL-­‐1β	  were	  
inhibited	  by	  SC-­‐514	  which	  inhibits	  NF-­‐κB	  mediated	  responses.	  These	  observations	  suggested	  
that	  NOD1	  responses	   in	  hESC-­‐EC,	  as	   in	  other	  cell	   types,	  are	  mediated	  by	  RIP2.	   In	  order	   to	  
test	   this	   further,	   I	   used	   novel	   inhibitors	   of	  NOD1	   and	   its	   associated	   adapter	   protein	   RIP2	  
developed	  by	  GSK,	  which	  have	  previously	  been	  used	  and	  validated	  by	  our	  group	  (Gatheral	  et	  
al.,	   2012).	  We	   have	   previously	   shown	   using	   endothelial	   cells	   from	   vessels	   that	   the	  NOD1	  
antagonist	  GSK’217	   or	   the	   RIP2	   inhibitor	  GSK’214	   inhibit	   CXCL8	   release	   induced	  by	  NOD1	  
agonists,	  without	  affecting	  TLR4	  responses	  (Gatheral	  et	  al.,	  2012).	  In	  line	  with	  this,	  GSK’217	  
or	  GSK’214	   reduced	  CXCL8	   release	   (Figure	   4.14)	   as	  well	   as	  NF-­‐κB	   nuclear	   translocation	   in	  
hESC-­‐EC	   stimulated	   with	   C12-­‐iE-­‐DAP	   (Table	   4.3).	   Importantly,	   CXCL8	   release	   from	  
Haemophilus	   influenzae	   infected	   hESC-­‐EC	   was	   also	   reduced	   by	   NOD1	   and	   RIP2	   inhibition	  
(Figure	   4.14).	   CXCL8	   levels	   from	   IL-­‐1β	   treated	   hESC-­‐EC	   were	   not	   affected	   by	   the	   NOD1	  














In	  the	  previous	  chapter	  is	  was	  determined	  that	  hESC-­‐EC,	  unlike	  endothelial	  cells	  from	  adult	  
progenitors	   (BOEC)	   or	   induced	   pluripotent	   stem	   cells	   (iPSC-­‐EC),	   or	   endothelial	   cells	   from	  
vessels	   do	   not	   respond	   to	   the	   TLR4	   agonist,	   LPS.	   hESC-­‐EC	   do	   however	   respond	   to	   NOD1	  
agonist	  to	  release	  CXCL8.	  
	  
	  In	  this	  Chapter	  I	  have	  shown	  that:	  
• In	  addition	  to	  CXCL8,	  hESC-­‐EC	  do	  not	  respond	  to	  the	  TLR4	  agonist	  LPS	  to	  release	  a	  
release	   a	   range	   of	   additional	   pro-­‐inflammatory	   cytokines,	   and	   this	   is	   explained	  
through	  lower	  TLR4	  expression	  compared	  to	  HUVEC.	  	  
• However,	   despite	  no	   TLR4	   function,	   hESC-­‐EC	   are	   able	   to	   sense	   the	  Gram-­‐negative	  
bacteria	  Haemophilus	  influenzae.	  	  
• Using	  a	  molecular	  and	  pharmacological	  approach,	  NOD1	  and	  its	  associated	  adapter	  
protein	   RIP2	   accommodate	   and	   drive	   responses	   in	   hESC-­‐EC	   to	   C12-­‐iE-­‐DAP	   and	  
Gram-­‐negative	  bacteria.	  	  
	  
As	   TLR4	   is	   now	   implicated	   in	   atherosclerosis	   (Edfeldt	   et	   al.,	   2002)	   these	   observations	  
enabled	   me	   to	   speculate	   that	   the	   lack	   of	   TLR4	   on	   hESC-­‐EC	   might	   afford	   these	   cells	   an	  
advantage	  over	  other	  stem	  cell	  derived	  endothelial	  cells	  when	  used	  in	  engineered	  organs	  or	  
as	  cell	  therapies.	  This	  is	  discussed	  in	  more	  detail	  in	  Chapter	  7	  and	  in	  the	  context	  of	  potential	  
benefits	  and	  limitations	  of	  hESC-­‐EC.	  The	  full	  implications	  of	  observations	  in	  this	  chapter	  and	  
















Summary	  Figure	  3.	  Human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	   (hESC-­‐EC)	  do	  not	  
express	   TLR4	   or	   respond	   to	   TLR4	   agonists	   (LPS)	   to	   release	   any	   cytokines	   associated	   with	  
inflammation.	  hESC-­‐EC	  do	  express	  NOD1,	  and	  utilise	   this	   receptor	   to	   sense	  Gram	  negative	  
bacteria	  such	  as	  Haemophilus	  influenzae	  (HIN)	  which	  results	  in	  cytokine	  release	  essential	  for	  
innate	   immunity	   and	   organ	   survival.	   As	  many	   cytokines	   associated	   with	   the	   activation	   of	  
TLR4	  in	  disease	  drive	  vascular	  inflammation,	  these	  cells	  might	  be	  protected	  for	  disease	  risk	  















































The	  data	  presented	  in	  this	  chapter	  are	  limited	  in	  a	  number	  of	  ways,	  which	  are	  outlined	  and	  
discussed	  below:	  
	  
Whilst	  the	  Haemophilus	   influenzae	  was	  a	  good	  representative	  Gram-­‐negative	  bacteria,	  the	  
inclusion	  of	  other	  Gram-­‐negative	  bacteria	  might	  have	  been	  useful	  and	  provided	  support	  to	  
the	   conclusions	   drawn	   in	   this	   chapter.	   Examples	   of	   other,	   perhaps	   more	   relevant	   (to	  
cardiovascular	  disease)	  would	  be	  Chlamydia	  and	  Listeria	  species	  which	  have	  been	  implicated	  
in	   cardiovascular	   disease.	   Bacteria	   that	   have	   been	   associated	  with	   cardiovascular	   disease	  
and	  reviewed	  by	  Libby	  et	  al.	  (Libby	  et	  al.,	  1997)	  and	  discussed	  in	  more	  detail	  in	  Chapter	  7.	  
	  
Given	  that	  hESC-­‐EC	  did	  not	  have	  TLR4	  function	  I	  chose	  to	  investigate	  these	  cells	  in	  particular	  
over	  other	  stem	  cell	  derived	  endothelial	  cells.	  However,	  it	  may	  also	  have	  been	  of	  interest	  to	  
look	  at	  responses	  of	  other	  stem	  cell	  derived	  endothelial	  cells,	  as	  well	  as	  other	  hESC-­‐EC	  lines,	  
to	  live	  bacteria	  but	  this	  was	  beyond	  the	  premise	  of	  this	  chapter.	  	  
	  
Other	   methods	   to	   assess	   the	   signalling	   pathway	   involved	   in	   responses	   of	   hESC-­‐EC	   to	  
Haemophilus	  influenzae	  are	  also	  available.	  These	  include	  short	  hairpin-­‐RNAs	  and	  additional	  
siRNAs	   to	   all	   the	   various	   proteins	   involved	   in	   innate	   immune	   signalling,	   as	   well	   as	   omics	  
approaches	  to	  look	  at	  genes,	  proteins	  and	  lipids.	  Whilst	  this	  would	  have	  been	  of	  interest	  and	  
added	  some	  support	  to	  the	  conclusions	  drawn,	  this	  was	  beyond	  the	  scope	  and	  purpose	  of	  




Furthermore,	   whilst	   I	   was	   able	   to	   show	   that	   incubation	   of	   hESC-­‐EC	   with	   NOD1	   targeting	  
siRNA	  resulted	  in	  (i)	  a	  decrease	  in	  NOD1	  mRNA	  expression	  and	  (ii)	  a	  decrease	  in	  the	  ability	  of	  
the	   cells	   to	   release	   cytokines	   in	   response	   to	   a	  NOD1	   selective	   agonist;	   I	   did	   not	  measure	  
directly	   transfection	   efficiency	   and	   this	   is	   a	   limitation	   of	   this	   experiment.	   This	   limitation	  
would	   be	   addressed	   by	   co-­‐transfecting	   with	   a	   fluorescently	   labelled	   siRNA	   (for	   example,	  
with	  green	  fluorescent	  protein;	  GFP)	  which	  can	  be	  visualised	  by	  microscopy	  and	  this	  can	  be	  
used	  to	  calculate	  transfection	  efficiency	  as	  a	  function	  of	  fluorescent	  cells	  versus	  total	  cells.	  
Whilst	  this	  would	  have	  been	  important	  to	  do,	   in	  this	  chapter	  I	  have	  combined	  a	  molecular	  
approach	   with	   a	   pharmacological	   approach	   to	   conclude	   that	   NOD1	   receptors	   drive	  
responses	  to	  bacteria	  and	  NOD1	  agonist	  in	  hESC-­‐EC.	  Whilst	  I	  was	  able	  to	  show	  effects	  of	  the	  
NOD1	  targeting	  siRNA	  versus	  non-­‐targeting	  siRNA	  using	  the	  same	  transfection	  reagents,	   it	  
would	  have	  been	  useful	   to	  determine	   the	  effect	  of	   the	   transfection	   reagent	  alone	  on	   the	  
cells	  to	  provide	  a	  mock	  transfection	  control.	  
	  
Expression	  of	  TLR4	  in	  hESC-­‐EC	  and	  HUVEC	  was	  based	  on	  data	  from	  a	  multi-­‐gene	  array	  which	  
could	  have	  been	  confirmed	  using	  specific	  primers	  for	  TLR4	  and	  a	  semi-­‐quantitative-­‐RT-­‐PCR	  
approach.	   Conclusions	   based	   on	   this	   data	   however	   were	   based	   on	   head	   to	   head	  
experiments	   for	   hESC-­‐EC	   versus	   HUVEC	   and	   so	   the	   effect	   of	   this	   limitation	   is	   somewhat	  
reduced	   by	   this	   design.	   In	   this	   Chapter	   I	   have	   also	   speculated	   that	   through	   significantly	  
lower	  expression	  of	  TLR4	  mRNA,	  and	  lack	  of	  function,	  that	  hESC-­‐EC	  might	  be	  protected	  from	  
atherosclerosis.	   To	   assess	   this	   fully,	   an	   animal	  model	   of	   post-­‐transplant	   atherosclerosis	   in	  
which	  stem	  cell	  derived	  organs	  have	  been	  transplanted,	  and	  where	  the	  atherosclerosis	  has	  
been	   shown	   to	  be	  a	   result	   of	   TLR4	  activation,	  would	  be	  needed,	   and	   this	   is	   currently	  not	  































Figure	  4.1	  CXCL8	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	   (hESC-­‐
EC)	  (left)	  and	  human	  umbilical	  vein	  endothelial	  cells	  (HUVEC)	  (right)	  in	  response	  to	  TLR4	  and	  
NOD1	  agonist.	  Cells	  were	  treated	  +/-­‐	  iE-­‐DAP	  (1µg/ml),	  C12-­‐iE-­‐DAP	  (10µg/ml)	  or	  LPS	  (1µg/ml)	  
for	   24h.	   Data	   are	  mean	   ±	   SEM	   (n=3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  






































































Figure	  4.2	  GM-­‐CSF	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐
EC)	  (left)	  and	  human	  umbilical	  vein	  endothelial	  cells	  (HUVEC)	  (right)	  in	  response	  to	  TLR4	  and	  
NOD1	  agonist.	  Cells	  were	  treated	  +/-­‐	  iE-­‐DAP	  (1µg/ml),	  C12-­‐iE-­‐DAP	  (10µg/ml)	  or	  LPS	  (1µg/ml)	  
for	   24h.	   Data	   are	  mean	   ±	   SEM	   (n=3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  





































































Figure	  4.3	  IFNγ	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC)	  
(left)	   and	   human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   (right)	   in	   response	   to	   TLR4	   and	  
NOD1	  agonist.	  Cells	  were	  treated	  +/-­‐	  iE-­‐DAP	  (1µg/ml),	  C12-­‐iE-­‐DAP	  (10µg/ml)	  or	  LPS	  (1µg/ml)	  
for	   24h.	   Data	   are	  mean	   ±	   SEM	   (n=3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  































































Figure	  4.4	  IL-­‐10	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC)	  
(left)	   and	   human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   (right)	   in	   response	   to	   TLR4	   and	  
NOD1	  agonist.	  Cells	  were	  treated	  +/-­‐	  iE-­‐DAP	  (1µg/ml),	  C12-­‐iE-­‐DAP	  (10µg/ml)	  or	  LPS	  (1µg/ml)	  
for	   24h.	   Data	   are	  mean	   ±	   SEM	   (n=3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  


































































Figure	  4.5	  IL-­‐12p70	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐
EC)	  (left)	  and	  human	  umbilical	  vein	  endothelial	  cells	  (HUVEC)	  (right)	  in	  response	  to	  TLR4	  and	  
NOD1	  agonist.	  Cells	  were	  treated	  +/-­‐	  iE-­‐DAP	  (1µg/ml),	  C12-­‐iE-­‐DAP	  (10µg/ml)	  or	  LPS	  (1µg/ml)	  
for	   24h.	   Data	   are	  mean	   ±	   SEM	   (n=3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  





































































Figure	  4.6	  IL-­‐1β	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC)	  
(left)	   and	   human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   (right)	   in	   response	   to	   TLR4	   and	  
NOD1	  agonist.	  Cells	  were	  treated	  +/-­‐	  iE-­‐DAP	  (1µg/ml),	  C12-­‐iE-­‐DAP	  (10µg/ml)	  or	  LPS	  (1µg/ml)	  
for	   24h.	   Data	   are	  mean	   ±	   SEM	   (n=3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  



































































Figure	  4.7	  IL-­‐2	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC)	  
(left)	   and	   human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   (right)	   in	   response	   to	   TLR4	   and	  
NOD1	  agonist.	  Cells	  were	  treated	  +/-­‐	  iE-­‐DAP	  (1µg/ml),	  C12-­‐iE-­‐DAP	  (10µg/ml)	  or	  LPS	  (1µg/ml)	  
for	   24h.	   Data	   are	  mean	   ±	   SEM	   (n=3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  





































































Figure	  4.8	  IL-­‐6	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC)	  
(left)	   and	   human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   (right)	   in	   response	   to	   TLR4	   and	  
NOD1	  agonist.	  Cells	  were	  treated	  +/-­‐	  iE-­‐DAP	  (1µg/ml),	  C12-­‐iE-­‐DAP	  (10µg/ml)	  or	  LPS	  (1µg/ml)	  
for	   24h.	   Data	   are	  mean	   ±	   SEM	   (n=3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  

































































Figure	  4.9	  TNFα	  release	  from	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC)	  
(left)	   and	   human	   umbilical	   vein	   endothelial	   cells	   (HUVEC)	   (right)	   in	   response	   to	   TLR4	   and	  
NOD1	  agonist.	  Cells	  were	  treated	  +/-­‐	  iE-­‐DAP	  (1µg/ml),	  C12-­‐iE-­‐DAP	  (10µg/ml)	  or	  LPS	  (1µg/ml)	  
for	   24h.	   Data	   are	  mean	   ±	   SEM	   (n=3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  
ANOVA	  followed	  Dunnett’s	  multiple	  comparison	  test	  (*p<0.05).	  




























































Figure	  4.10	  TLR4	  and	  NOD1	  expression	   in	  human	  embryonic	  stem	  cell	  derived	  endothelial	  
cells	  (hESC-­‐EC).	  TLR4	  and	  NOD1	  expression	  was	  determined	  relative	  to	  expression	  in	  HUVEC	  
in	   vitro.	   Data	   are	  mean	   ±	   SEM	   (n=3-­‐4)	   and	   are	   normalised	   to	   GAPDH	   for	   each	   cell	   type.	  







































Figure	   4.11	  Responses	   of	   human	   embryonic	   stem	   cell	   derived	   endothelial	   cells	   (hESC-­‐EC)	  
and	  human	  umbilical	   vein	   endothelial	   cells	   (HUVEC)	   to	  Gram	  negative	  bacteria.	   (A)	  CXCL8	  
release	   from	   cells	   (open	  bars,	   hESC-­‐EC;	   filled	  bars,	  HUVEC)	  were	   treated	   for	   24h	  with	   LPS	  
(1μg/ml)	  or	  C12-­‐iE-­‐DAP	  (10μg/ml).	  (B)	  CXCL8	  release	  from	  cells	  (hESC-­‐EC,	  solid	  line;	  HUVEC,	  
dashed	   line)	   treated	   for	   24h	   with	   H.influenzae	   (HIN)	   (105-­‐108
	  
CFU/ml).	   Experiments	   were	  
also	  run	  with	  HIN	  in	  the	  absence	  of	  cells	  (no	  cells;	  filled	  diamonds).	  	  Data	  are	  mean	  ±	  SEM;	  
n=3	  representative	  of	  6	  hESC-­‐EC	  isolations.	  Statistical	  significance	  for	  responses	  to	  drugs	  or	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Figure	  4.12	  Effect	  of	  NOD1	  siRNA	  knockdown	  on	  responses	  of	  human	  embryonic	  stem	  cell	  
derived	   endothelial	   cells	   (hESC-­‐EC)	   to	   HIN	   and	   C12-­‐iE-­‐DAP.	   (A)	   Relative	   expression	   (vs.	  
GAPDH)	   of	  NOD1	   following	   48h	   incubation	  with	  NOD1	   siRNA	  normalized	   to	   non-­‐targeting	  
siRNA	   (n=6).	   (B)	   CXCL8	   release	   from	   hESC-­‐EC	   following	   48h	   pre-­‐incubation	   with	   non-­‐
targeting	  siRNA	  (open	  bars)	  or	  NOD1-­‐siRNA	  (filled	  bars)	  and	  24h	  treatment	  +/-­‐	  C12-­‐iE-­‐DAP	  




	  CFU/ml)	  (n=7-­‐8).	  For	  panel	  A,	  statistical	  
significance	  was	  determined	  by	  one-­‐sample	  t-­‐test.	  For	  panel	  B,	  statistical	  significance	  within	  
siRNA	   groups	   was	   determined	   by	   one-­‐way	   ANOVA	   followed	   by	   Dunnett’s	   multiple	  
comparison	   test	   (*p<0.05),	   and	   between	   groups	   by	   two-­‐way	   ANOVA	   followed	   by	  















































































Figure	   4.13	  Effects	   of	  NOD1	   siRNA	   targeting	   on	   IL-­‐1β	   induced	   CXCL8	   release	   from	  human	  
embryonic	   stem	   cell	   derived	   endothelial	   cells	   (hESC-­‐EC).	   CXCL8	   release	   from	   hESC-­‐EC	  
following	   48h	   pre-­‐incubation	   with	   non-­‐targeting	   siRNA	   (open	   bars)	   or	   NOD1-­‐siRNA	   (filled	  
bars)	  and	  24h	  treatment	  with/without	  IL-­‐1β	  (0.01-­‐0.1ng/ml).	  Data	  are	  mean	  ±	  SEM	  (n=6-­‐8).	  
Statistical	   testing	   was	   carried	   out	   by	   one-­‐way	   ANOVA	   followed	   by	   Dunnett’s	   multiple	  
comparison	   test	   for	   the	   effect	   of	   IL-­‐β	   (*p<0.05)	   and	   by	   two-­‐way	   ANOVA	   followed	   by	  


































Figure	  4.14	  Effect	  of	   inhibition	  of	  NOD1	  and	  RIP2	  on	  responses	  of	  human	  embryonic	  stem	  
cell	  derived	  endothelial	  cells	  (hESC-­‐EC)	  to	  NOD1	  agonist	  and	  Haemphilus	  influenzae	  (HIN;	  107	  
CFU/ml).	   CXCL8	   release	   from	   hESC-­‐EC	   pre-­‐treated	   for	   30min	   with	  GSK’214	   (300nM;	   RIP2	  
inhibitor)	   or	   GSK’217	   (300nM;	   NOD1	   inhibitor)	   or	   vehicle	   (0.1%	   DMSO),	   followed	   by	   24h	  
treatment	  with	  HIN	  (108CFU/ml)	  or	  C12-­‐iE-­‐DAP	  (10μg/ml)	  (n=4).	  It	  should	  be	  noted	  that	  GSK	  
drugs	   increased	  CXCL8	   release	  under	  basal,	   for	  each	  experiment	   this	  was	   subtracted	   from	  
the	  C12-­‐iE-­‐DAP	  and	  HIN	  treatment	  groups.	  Statistical	  significance	  for	  the	  effects	  of	  inhibitor	  
of	   C12-­‐iE-­‐DAP	   or	   HIN	   induced	   CXCL8	   was	   determined	   by	   one-­‐way	   ANOVA	   followed	   by	  














































Effect of the RIP2 inhibitor (GSK-214) and the NOD1 antagonist (GSK-217) on activaition of HESC-ECs by the NOD1 
agonist C12...and infection with live Gram negative HIN bacteria. Data represents the mean +/- SEM for n=4 from 2 
separate cell isolation. GSK drugs increased CXCL8 release under basal condtions; for each experiment this was 














Figure	  4.15	  	  Effects	  of	  NOD1	  and	  RIP2	  inhibition	  on	  IL-­‐1β	  induced	  CXCL8	  release	  from	  human	  
embryonic	   stem	   cell	   derived	   endothelial	   cells	   (hESC-­‐EC).	   CXCL8	   release	   from	   hESC-­‐EC	  
following	  30	  minute	  pre-­‐treatment	  with	  GSK’214	  (RIP2	  inhibitor;	  300nM)	  or	  GSK’217	  (NOD1	  
inhibitor;	  300nM)	  followed	  by	  24h	  treatment	  with/without	  IL-­‐1β	  (0.1ng/ml).	  Data	  are	  mean	  
±	  SEM	  (n=4).	  Data	  were	  handled	  and	  corrected	  for	  inhibitor	  drug	  induced	  CXCL8	  background	  
as	  in	  Figure	  4.14.	  Statistical	  testing	  for	  the	  effects	  of	  inhibitor	  on	  IL-­‐1β	  induced	  CXCL8	  release	  
































Effect of the RIP2 inhibitor (GSK-214) and the NOD1 antagonist (GSK-217) on activaition of HESC-ECs by the NOD1
agonist C12...and infection with live Gram negative HIN bacteria. Data represents the mean +/- SEM for n=4 from 2
separate cell isolation. GSK drugs increased CXCL8 release under basal condtions; for each experiment this was











Table	   4.1	   Effect	   of	   NOD1	   siRNA	   and	   Haemophilus	   influenzae	   on	   cell	   viability	   of	   human	  
embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC).	  AlamarBlue	  assay	  for	  hESC-­‐EC	  pre-­‐
treated	  for	  48h	  with	  NOD1	  siRNA	  followed	  by	  24h	  treatment	  with	  C12-­‐iE-­‐DAP	  (10µg/ml),	  IL-­‐

















control' 0.308'±'0.007' 0.313'±'0.009' 0.311'±''0.007'
C122iE2DAP' 0.306'±''0.001' 0.304'±''0.005' 0.306'±''0.005'
HIN' 0.331'±''0.008' 0.326'±''0.015' 0.345'±''0.016'




Table	   4.2	   Effect	   of	   inhibition	   of	   RIP2,	   p38	   and	   IKK	   on	   NOD1	   agonist	   and	   IL-­‐1β	   induced	  
responses	  in	  human	  embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC).	  hESC-­‐EC	  were	  
pre-­‐treated	  for	  30	  minutes	  with	  SB203580	   	   (RIP2	  and	  p38	   inhibitor;	  0.01-­‐10μM)	  or	  SC-­‐514	  
(IKK	   inhibitor;	  0.1-­‐30μM)	  or	  BIRB0796	   (p38	  selective	   inhibitor;	  0.1-­‐30μM)	   followed	  by	  24h	  
treatment	  with	  C12-­‐iE-­‐DAP	  (10μg/ml)	  or	  IL-­‐1β	  (1ng/ml).	  Data	  are	  –logIC50	  ±	  SEM	  and	  Emax	  
is	  expressed	  as	  %	  inhibition	  of	  agonist	  induced	  CXCL8	  release	  (n=3-­‐4).	  Statistical	  significance	  



































	   	  
	  
Table	   4.3	   and	   Figure	   4.16	   Effect	   of	   inhibition	   of	   NOD1	   and	   RIP2	   on	   responses	   of	   human	  
embryonic	  stem	  cell	  derived	  endothelial	  cells	  (hESC-­‐EC)	  to	  NOD1	  in	  terms	  of	  NF-­‐κB	  nuclear	  
translocation.	   (A)	  Change	   in	   nuclear	   NF-­‐kB/cell	   (average	   of	   100	   cells	   for	   nucleus-­‐cytosolic	  
intensity	  difference)	  for	  hESC-­‐EC	  pre-­‐treated	  for	  30min	  with	  RIP2	  inhibitor	  (GSK’214;	  300nM)	  
or	   NOD1	   inhibitor	   (GSK’217;	   300nM)	   or	   vehicle	   (0.1%	   DMSO)	   followed	   by	   24h	   treatment	  
C12-­‐iE-­‐DAP	   (10µg/ml)	   for	   1h.	   Statistical	   significance	   was	   determined	   by	   one-­‐way	   ANOVA	  
followed	  by	  Dunnett’s	  multiple	  comparison	  test	  (p>0.05).	  (B)	  Representative	   images	  of	  NF-­‐




























CHAPTER	   5:	   USE	   OF	   BLOOD	   OUTGROWTH	   ENDOTHELIAL	  
CELLS	   (BOEC)	   IN	   A	   PHARMACOLOGICAL	   BIOASSAY	   TO	  




















5.1	  RATIONALE	  	  
The	  overall	  aim	  of	  my	  thesis	  is	  to	  study	  endothelial	  cells	  derived	  from	  stem	  cell	  populations	  
in	  order	  to	  better	  understand	  how	  they	  can	  be	  utilised	  as	  therapeutically.	  One	  way	  in	  which	  
stem	  cells	  are	  currently	  being	  used	  is	  in	  the	  screening	  of	  drug	  toxicity.	  	  In	  this	  chapter	  I	  have	  
specifically	  addressed	  the	  idea	  of	  using	  endothelial	  cells	  derived	  from	  stem	  cells	  to	  develop	  
and	  validate	  a	  novel	  assay	  using	  autologous	  cells	  in	  co-­‐culture.	  
	  
In	  2006	  a	  clinical	  study	  held	  at	  Northwick	  Park	  to	  test	  the	  anti-­‐CD28	  superagonist,	  TGN1412,	  
resulted	  in	  all	  6	  healthy	  male	  volunteers	  suffering	  a	  profound	  cytokine	  storm	  response.	  This	  
was	  despite	  the	  drug	  passing	  all	  preclinical	  safety	  testing,	  including	  tests	  of	  human	  isolated	  
T-­‐lymphocytes	  (Stebbings	  et	  al.,	  2007).	  In	  this	  way,	  TGN1412	  defined	  an	  urgent	  unmet	  need	  
for	  improved	  bioassays	  to	  detect	  cytokine	  storm	  inducing	  drugs	  (Hünig,	  2012;	  Stebbings	  et	  
al.,	  2012).	  We	  now	  know	  that	  TGN1412	  does	  not	  activate	  T-­‐lymphocytes	  or	  peripheral	  blood	  
mononuclear	   cells	   (PBMCs)	   to	   release	   cytokines	   when	   antibodies	   are	   added	   in	   aqueous	  
phase,	  unless	  there	  is	  an	  endothelial	  cell	  interface	  present	  (Findlay	  et	  al.,	  2011b;	  Stebbings	  
et	  al.,	  2007).	  This	  can	  be	  mimicked	  when	  TGN1412	  is	  immobilised	  by	  non-­‐specific	  binding	  to	  
a	   solid	  phase	  platform	   such	  as	  plastic	   (Findlay	  et	   al.,	   2010;	   Findlay	  et	   al.,	   2011b).	  Current	  
endothelial	   cell:PBMC	   co-­‐culture	   assays	   have	   employed	   endothelial	   cells	   derived	   from	  
human	  umbilical	  vein	  or	  cell	   lines	  (Findlay	  et	  al.,	  2011b).	  However,	  this	  type	  of	  assay	  relies	  
on	  cells	  from	  two	  separate	  donors,	  which	  inevitably	  results	   in	  tissue	  mis-­‐match	  responses,	  
including	   those	  driven	  by	  heterologous	  major	  histocompatibility	   complex	   (MHC)	   reactions	  
(Huang	  et	  al.,	  1994).	  Clearly,	   the	  best	   type	  of	  assay	  would	  be	  one	  where	  endothelial	   cells	  




Up	  until	  now,	  same	  donor	  endothelial	  cell:	  PBMC	  co-­‐culture	  has	  not	  been	  possible	  due	  to	  
difficulties	   in	   isolating	  and	  growing	  endothelial	  cells	   from	  vessels	  of	   living	  donors.	  As	  stem	  
cells	  offer	   the	  opportunity	   to	  grow	  cells	   from	   living	  donors,	   I	   considered	  blood	  outgrowth	  
endothelial	   cells	   (BOEC)	   as	   a	   viable	   source	   of	   cells	   from	  which	   PBMCs	   could	   be	   obtained	  
from	   the	   same	   donor	   for	   future	   co-­‐culture	   bioassay	   protocols.	   In	   this	   chapter	   I	   have	  
therefore	  shown	  how	  autologous	  BOEC	  and	  PBMCs	  can	  be	  cultured	  together	  and	  how	  they	  
respond,	  compared	  to	  HUVEC:PBMC	  co-­‐cultures	  to	   inflammatory	  agents.	  Specifically	  these	  
have	   included	   pathogen	   associated	   molecular	   patterns	   (PAMPs),	   cytokines	   and	   ‘proof	   of	  
concept’	  biologic	  antibodies,	  including	  a	  TGN1412-­‐like	  anti-­‐CD28	  superagonist	  (ANC28).	  
	  
The	  specific	  questions	  addressed	  in	  this	  chapter	  are:	  
1. How	  do	   co-­‐cultures	  of	  BOEC	  and	  PBMCs	  derived	   from	   the	   same	  donor	   respond	   to	  
PAMPs	  and	  cytokines	  compared	  to	  HUVEC	  and	  PBMCs	  in	  co-­‐culture?	  
2. How	  do	   co-­‐cultures	  of	  BOEC	  and	  PBMCs	  derived	   from	   the	   same	  donor	   respond	   to	  
therapeutic	   antibodies	   used	   clinically	   compared	   to	   a	   TGN1412-­‐like	   anti-­‐CD28	  
superagonist	   (ANC28)	   to	   release	   CXCL8,	   as	   well	   as	   range	   of	   pro-­‐inflammatory	  
cytokines	  and	  chemokines?	  
3. How	   well	   do	   BOEC:PBMC	   co-­‐culture	   assays	   distinguish	   cytokine	   storm	   causing	  
biologics	   from	   control	   antibodies	   when	   run	   through	   an	   unbiased	   principal	  
components	  analysis?	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5.2	  SUMMARY	  OF	  METHODS	  	  
A	   full	   description	   of	   the	   methods	   used	   in	   this	   chapter	   is	   given	   in	   Chapter	   2	   and	   are	  
summarised	  below.	  
	  
5.2.1	  	   BOEC	  culture	  
BOEC	  were	  isolated	  as	  described	  in	  chapter	  2.	  Briefly,	  PBMCs	  were	  isolated	  from	  blood	  and	  
expanded	  on	  tissue	  culture	  plates	  for	  up	  to	  22	  days	  in	  Lonza-­‐EGM2	  with	  10%	  foetal	  bovine	  
serum	   (FBS)	   on	   5.2μg/cm2	   collagen	   coated	   plates.	   Typically	   between	   5	   and	   22	   days	   in	  
culture,	  endothelial	  cell	  colonies	  emerged	  and	  were	  expanded	  for	  use	  in	  experiments.	  Cells	  
were	  maintained	  in	  Lonza-­‐EGM2	  media	  with	  10%	  FBS.	  
	  
5.2.2	  	   Autologous	  BOEC:PBMC	  cytokine	  storm	  assay	  
For	   autologous	   co-­‐culture,	   BOEC	   were	   plated	   on	   1%	   gelatinised	   96-­‐well	   plates	   (Nunc,	  
Denmark)	   and	   allowed	   to	   adhere	  overnight.	   The	   same	  donor	   from	  whom	   the	  BOEC	  were	  
derived	  was	   then	   recalled	  and	  PBMCs	   isolated	  using	  a	  Histopaque	  gradient	   separation,	  as	  
detailed	   in	   the	   general	  methods.	   Same	  donor	   PBMCs	  were	   then	   added	   to	  wells	  with	   and	  
without	  BOECs.	  Cells	  were	  added	  at	  the	  following	  seeding	  densities:	  BOEC;	  7000	  cells/well,	  
PBMC	  at	  100000	  cells/well	   in	  96-­‐well	  plates.	  For	  assessment	  of	   responses	   to	  PAMPs,	  cells	  
were	   treated	   with	   agonists	   of	   Toll	   like	   receptors	   (TLR)1-­‐9	   or	   nucleotide	   oligomerisation	  
domain	   receptor-­‐1	   (NOD1)	   (see	   figure	   legends	   and	   Table	   2.3	   in	   general	   methods)	   for	   24	  
hours.	  Cells	  were	  also	  treated	  IL-­‐1β	  (0.1-­‐1ng/ml)	  (R	  &	  D	  Systems,	  UK)	  for	  24	  hours.	  Cytokine	  
storm	   inducing	   drugs:	   the	   TGN1412-­‐like	   anti-­‐CD28	   superagonists	   (ANC28.	   1.5D10)	  
(10µg/ml),	   which	   models	   TGN1412	   (Waibler	   et	   al.,	   2008),	   and	   Campath	   (anti-­‐CD52:	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alemtuzumab)	   (10µg/ml)	  were	   then	   added.	   Avastin	   (anti-­‐VEGFR2:	   basaliximab)	   (10µg/ml),	  
Herceptin	   (anti-­‐EGFR2:	   traztuzumab)	   and	   Arzerra	   (anti-­‐CD20:	   ofatumumab)	   (10µg/ml),	  
which	  are	  therapeutic	  antibodies	  that	  do	  not	  cause	  cytokine	  storm	  reactions,	  were	  included	  
as	  negative	  controls.	  Drugs	  were	  a	  gift	  from	  Huntingdon	  Life	  Sciences	  (Cambridgeshire,	  UK).	  
Plates	  were	  then	  incubated	  for	  24	  hours.	  Supernatants	  were	  collected	  and	  stored	  at	  -­‐20oC	  
for	  further	  analysis	  for	  CXCL8	  by	  ELISA	  and	  at	  -­‐80oC	  for	  analysis	  of	  multiple	  cytokines	  using	  
MSD	  technology.	  Some	  experiments	  were	  carried	  out	  at	  the	  National	  Institute	  of	  Biological	  
Standards	   and	  Control	   (NIBSC).	  Unless	  otherwise	   stated	   in	   figure	   legends,	   all	   experiments	  
were	  carried	  out	  in	  media	  containing	  10%	  FBS.	  	  
	  
5.2.3	   	  Measurement	  of	  CXCL8	  
CXCL8	  was	  measured	  by	  ELISA	  (R	  and	  D	  Systems)	  according	  to	  manufacturer’s	  instructions.	  
Optical	   density	   was	   determined	   using	   a	   microplate	   reader	   (Dyne,	   Madellan	   Biosciences)	  
with	  absorbance	  readings	  at	  450-­‐570nm.	  
	  
5.2.4	  	   Measurement	  of	  pro-­‐inflammatory	  cytokines	  using	  a	  Meso	  Scale	  discovery	  (MSD)	  
platform	  
Levels	   of	   9	   pro-­‐inflammatory	   cytokines	   and	   9	   chemokines	  were	  measured	   using	   separate	  
‘human	  pro-­‐inflammatory	  9-­‐Plex	  MULTISPOT	  96-­‐well	   -­‐10	  spot’	  plates	  purchased	  from	  MSD	  
(Gaithersburg,	  Maryland).	  Samples	  were	  diluted	  1:10	  in	  assay	  buffer	  and	  assays	  carried	  out	  
according	  to	  manufacturer’s	  instructions.	  MSD	  plates	  were	  read	  using	  an	  MSC	  Sector	  Imager	  
2400	   and	   analysed	   using	  MSD	   Discovery®	  Workbench	   software.	   Cytokines	   analysed	  were	  
TNFα,	   IL-­‐2,	   CXCL8,	   IL-­‐12q70,	   IL-­‐1β,	   GM-­‐CSF,	   IFNγ,	   IL-­‐6,	   IL-­‐10.	   Chemokines	   analysed	   were	  
eotaxin,	  MCP-­‐1,	  MIP-­‐1β,	  eotaxin-­‐3,	  MCP-­‐4,	  TARC,	  IP-­‐10	  and	  MDC.	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5.2.5	  	   Measurement	  of	  cell	  viability	  
Cell	   viability	  was	   determined	   using	   commercially	   available	   AlamarBlue®	   assay	   (Invitrogen,	  
UK).	   Unless	   otherwise	   stated	   none	   of	   the	   treatments	   greatly	   affected	   cell	   viability	   (Table	  
5.1).	  
	  
5.2.6	  	   Assessment	  of	  cell	  proliferation	  
Cell	   proliferation	   in	   response	   to	   TGN1412-­‐like	   anti-­‐CD28	   superagonist	   (ANC28)	   was	  
determined	   using	   a	   3H-­‐thymidine	   incorporation	   assay.	   Proliferation	   experiments	   were	  
carried	  out	  at	  the	  National	  Institute	  of	  Biological	  Standards	  of	  Control	  (NIBSC),	  using	  an	  in-­‐
house	  assay	  (Stebbings	  et	  al.,	  2007).	  
	  
5.2.7	  	   Principal	  component	  analysis	  
Principal	  component	  analysis	  based	  on	  co-­‐variances	  between	  17	  cytokines	  and	  chemokines	  









5.3.1	  	   Characterization	  of	  classical	  inflammatory	  responses	  in	  same-­‐donor	  BOEC:PBMC	  or	  
blood	  bioassays	  
As	  discussed	   in	   the	   foregoing	  chapters,	  endothelial	  cells	   respond	  to	  PAMPs	  and	  cytokines.	  
Others	  have	  shown	  that	  endothelial	  cells	   interact	  with	  PBMCs	  to	  enhance	  these	  responses	  
in	  some	  in	  vitro	  assays	  (Ward	  et	  al.,	  2009).	  At	  the	  level	  of	  TLR4	  for	  example,	  it	  is	  known	  that	  
endothelial	   cells	   from	   HUVEC	   interact	   with	   PBMCs	   in	   vitro	   to	   increase	   CXCL8	   release	   in	  
response	   to	   LPS	   (Ward	   et	   al.,	   2009).	   It	   was	   important	   therefore	   to	   consider	   how	   BOEC	  
responded	  to	  PAMPs	  in	  the	  absence	  and	  presence	  of	  same	  donor	  PBMCs.	  
	  
Same	  donor	  BOEC:PBMC	   co-­‐cultures,	   and	  mono-­‐cultures	   of	   either	   cell	   type,	  were	   treated	  
with	   LPS	   (TLR4	   agonist),	   Pam3CSK4	   (TLR2	   agonist),	   C12-­‐iE-­‐DAP	   (NOD1	   agonist),	   and	   the	  
cytokines,	   IL-­‐1β	   and	   TNFα.	   PBMCs	   and	   BOEC	  monocultures	   released	   low	   levels	   of	   CXCL8	  
under	  control	  culture	  conditions	  (Figure	  5.1A).	  Co-­‐culture	  of	  same	  donor	  BOEC	  and	  PBMCs	  
had	  no	  discernible	  effect	  above	  additive	  on	  levels	  of	  CXCL8	  release	  when	  compared	  to	  levels	  
released	  by	  either	  cell	  type	  alone	  under	  control	  conditions.	  All	  inflammatory	  agonists	  tested	  
tended	  to	  increase	  CXCL8	  release	  by	  BOEC,	  with	  statistically	  significant	  responses	  seen	  with	  
LPS	  and	   IL-­‐1β	   (Figure	  5.1A).	  On	   the	  whole	  CXCL8	   release	  stimulated	   from	  PBMCs	  was	   less	  
than	  seen	  for	  BOEC	  (Figure	  5.1A).	  When	  cells	  were	  stimulated	   in	  co-­‐culture	  CXCL8	  release	  
was	  essentially	  equivalent	  to	  the	  release	  from	  BOEC	  alone	  or	  an	  additive	  amount	  from	  BOEC	  
and	   PBMC	   cultures,	   except	   for	   experiments	   with	   LPS	   where	   there	   was	   a	   tendency	   for	   a	  
greater	  than	  additive	  effect	  (Figure	  5.1A).	  With	  the	  exception	  of	  LPS,	  broadly	  similar	  results	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were	  seen	  when	  HUVEC:PBMC	  co-­‐cultures	  were	  treated	  with	  the	  same	  panel	  of	  PAMPs	  and	  
cytokines	  (Figure	  5.1B).	  
	  
5.3.2	  	   Responses	  of	  the	  autologous/same-­‐donor	  BOEC:	  PBMC	  bioassay	  to	  cytokine	  storm	  
inducing	  biologics:	  CXCL8	  and	  proliferation	  
For	   same	   donor	   endothelial	   cell:	   PBMC	   bioassays	   to	   be	   useful	   it	   should	   show	   cytokine	  
release	  to	  therapeutic	  antibodies	  known	  to	  cause	  cytokine	  storm	  in	  man,	  but	  not	  to	  those	  
used	  in	  man	  with	  no	  discernible	  cytokine	  storm	  associated	  side	  effects.	  	  I	  therefore	  tested	  a	  
small	  panel	  of	  therapeutic	  antibodies	  with	  different	  cytokine	  storm	  inducing	  characteristics	  
(see	  Table	  2.5).	  Notably,	  this	  included	  two	  positive	  control	  antibodies,	  a	  TGN1412-­‐like	  anti-­‐
CD28	   superagonist	   known	   to	   bind	   a	   region	   of	   CD28	   on	   PBMCs	   that	   activates	   an	   identical	  
signaling	   pathway	   to	   TGN1412	   (Waibler	   et	   al.,	   2008)	   and	   	   a	   CD52	   antibody	   alemtuzumab	  
(Campath).	   Three	   negative	   control	   antibodies	   (Herceptin,	   Avastin	   and	   Arzerra),	  which	   are	  
used	   therapeutically,	  but	  don’t	  cause	  cytokine	  storm	  responses	  were	  also	   included.	  When	  
CXCL8	   was	   measured	   as	   a	   read	   out,	   PBMC	   or	   BOEC	   cultures	   alone	   did	   not	   respond	  
appreciably	  to	  any	  of	  the	  antibodies	  tested	  (Figure	  5.2A).	  Similarly	  co-­‐cultures	  of	  PBMCs	  and	  
BOEC	  incubated	  with	  Herceptin,	  Avastin	  or	  Arzerra	  did	  not	  release	  increased	  levels	  of	  CXCL8.	  
Co-­‐cultures	   of	   same	   donor	   PBMCs	   and	   BOEC	   released	   increased	   levels	   of	   CXCL8	   when	  
stimulated	  with	  the	  TGN1412–like	  anti-­‐CD28	  superagonist	  (ANC28)	  or	  with	  Campath	  where	  
ANC28>Campath.	   This	   correlates	   with	   the	   expected	   severity	   of	   cytokine	   storm	   for	   these	  
agents	  (Eastwood	  et	  al.,	  2010;	  Suntharalingam	  et	  al.,	  2006).	  The	  effects	  of	  the	  TGN1412-­‐like	  
anti-­‐CD28	  superagonist,	  ANC28,	  were	  concentration	  dependent	  with	  maximal	  effects	  seen	  
at	  10μg/ml	  (Figure	  5.2B).	  Furthermore,	  and	  in	  line	  with	  what	  is	  expected	  for	  TGN1412	  in	  in	  
vitro	   assays,	   the	   TGN1412-­‐like	   anti-­‐CD28	   superagonist,	   ANC28	   resulted	   in	   a	   proliferation	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response	   in	  same	  donor	  BOEC:PBMC	  co-­‐cultures	  (Figure	  5.3).	  Unlike	  TGN1412	  however,	   in	  
these	  assays	  ANC28	  resulted	  in	  proliferation	  of	  PBMC	  monocultures,	  and	  this	  is	  in	  line	  with	  
what	   is	   known	   for	   ANC28	   versus	   TGN1412	   activity	   (Figure	   5.3).	   Notably,	   when	   the	  
Alamarblue	  assay	  was	  used	  to	  determine	  cell	  number/proliferation,	  no	  response	  to	  ANC28	  
was	  detected	  (Table	  5.1).	  Whilst	  not	  conclusive,	  one	  possible	  explanation	  for	  this	  is	  based	  in	  
differences	  between	  the	  assays	  to	  measure	  ‘proliferation’.	  As	  3H-­‐thymidine	  must	  enter	  the	  
cell	  where	   it	   is	   incorporated	   into	  DNA	  and	  RNA	  of	  active	   cells,	   this	   can	  occur	  prior	   to	   cell	  
division,	  which	  may	  not	  have	  occurred	  at	  24	  hours.	  The	  Alamarblue	  assay	  on	  the	  other	  hand	  
relies	  on	  cell	  respiration	  to	  oxidise	  components	  of	  the	  reagent	  which	  typically	  corresponds	  
with	  cell	  number.	  Thus,	  these	  cells	  may	  have	  been	  activated	  to	  proliferate	  as	  suggested	  by	  
the	  3H-­‐thymidine	  incorpotation	  but	  not	  yet	  undergone	  cell	  division	  at	  24	  hours	  as	  suggested	  
by	   the	  Alamarblue	  data.	   In	  published	   literature	   showing	  proliferative	   responses	  of	  human	  
lymphocytes	   to	   TGN1412	   (Stebbings	   et	   al.,	   2007)	   these	   have	   typically	   been	   carried	   out	  
following	  3	  day	  incubations	  with	  drugs.	  	  
	  
5.3.3	  	   Responses	  of	  the	  autologous/same-­‐donor	  BOEC:	  PBMC	  bioassay	  to	  cytokine	  storm	  
inducing	  biologics:	  full	  range	  of	  ‘cytokine	  storm’	  cytokines	  
Although	  CXCL8	   is	  key	  cytokine	  associated	  with	  cytokine	  storm	  responses	  (Suntharalingam	  
et	   al.,	   2006),	   vascular	   inflammation	   and	   sepsis	   (Gatheral	   et	   al.,	   2012);	   cytokine	   storm	  
responses	  are	  defined	  by	  the	  concerted	  release	  of	  a	  broad	  range	  of	  cytokines	  (Findlay	  et	  al.,	  
2011a;	  Harrison,	  2010;	  Suntharalingam	  et	  al.,	  2006).	  Specifically,	  TGN1412	   in	  vivo	   induced	  
increases	  in	  CXCL8,	  IL-­‐2,	  IL-­‐6,	  IFNγ	  and	  TNFα	  (Suntharalingam	  et	  al.,	  2006).	  Therefore,	  it	  was	  
important	  to	  analyse	  this	  autologous	  assay	  further,	  and	  measure	  a	  full	  range	  of	  cytokines.	  In	  
addition	   to	   CXCL8;	   GM-­‐CSF,	   IL-­‐6,	   IL-­‐10,	   IFNγ	   and	   IL-­‐2	   were	   significantly	   increased	   whilst	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TNFα	  and	  IL-­‐12p70	  tended	  to	  increase	  in	  response	  to	  the	  TGN1412-­‐like	  superagonist,	  ANC28	  
in	  BOEC:PBMC	  co-­‐cultures	   (Figure	  5.4	   to	  5.9).	   The	  pro-­‐inflammatory	   chemokines:	   eotaxin,	  
MCP-­‐1	   and	   TARC	   were	   also	   increased	   by	   the	   TGN1412-­‐like	   superagonist,	   ANC28,	   in	  
BOEC:PBMC	   co-­‐cultures	   but	   not	   monocultures	   of	   either	   cell	   type	   (Figure	   5.7	   to	   5.9).	  
Importantly	   and	   in	   line	   with	   data	   in	   Figure	   5.2A,	   with	   the	   exception	   of	   eotaxin,	   less	  
cytokine/chemokine	   release	  was	   detected	   in	   response	   to	   Campath	   than	  ANC28.	   The	   only	  
cytokine/chemokine	   measured	   that	   was	   released	   by	   monocultures	   of	   PBMCs	   stimulated	  
with	  ANC28	  was	  MIP-­‐1β	  (Figure	  5.7)	  Interesting,	  unlike	  other	  cytokines	  measured	  Campath	  
induced	  more	  MIP-­‐1β	  than	  ANC28	  (Figure	  5.7)	  
	  
5.3.4	  	   Principal	   Components	  Analysis	   of	   responses	   of	   BOEC,	   PBMC	  and	  BOEC:PBMC	   co-­‐
culture	  cytokine/chemokine	  responses	  to	  biologics	  
Principal	  components	  analysis	  allows	  for	  complex	  data	  with	  multiple	  groups	  and	  variables	  to	  
be	  transformed	  in	  to	  a	  coordinate	  system	  that	  reveals	  patterns	  and	  sources	  of	  variation	  in	  
an	  unbiased	  way.	   I	   considered	   this	   to	  be	   important	   to	   carry	  out	  on	   this	  data	   to	   allow	   for	  
unsupervised	  analysis	  of	  the	  17	  cytokines/chemokines	  measured	   in	  response	  to	  treatment	  
of	   same	   donor	   BOEC:PBMC	   co-­‐cultures,	   and	   respective	   monocultures,	   to	   the	   biologics	  
tested.	   Taking	   this	   kind	   of	   approach	  when	   testing	   new	   drugs	   in	   individual	   patient	   groups	  
using	  autologous	  BOEC:PBMCs	  co-­‐culture	  assays	  could	  conceivably	   reveal	  new	  and	  unique	  
patterns	   of	   cytokine	   release	   that	   are	   associated	   with	   certain	   phenotypes	   and/or	   drugs	  
(particularly	   biological	   drugs	   such	   as	   therapeutic	   antibodies	   where	  multiple	   readouts	   are	  
required).	   Principal	   components	   analysis	   confirmed	   the	   TGN1412-­‐like	   anti-­‐CD28	  
superagonist,	   ANC28,	   treated	   	   BOEC:PBMC	   co-­‐culture	   group	   as	   a	   major	   contributor	   to	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variation	   (increases	  or	  decreases)	   in	   cytokine/chemokine	   levels	   (Figure	  5.10).	   There	  was	  a	  
clear	  dissociation	  of	  this	  condition	  from	  similarly	  treated	  mono-­‐cultures	  or	  co-­‐cultures	  with	  
any	   other	   antibody	   tested	   (Figure	   5.10).	   The	   loadings	   plot	   indicated	   positive	   correlations	  
between	  all	  cytokines	  and	  chemokines	  measured	  (Figure	  5.11).	  	  	  
	  
5.3.5	  	   Effect	  of	  therapeutic	  antibodies	  on	  heterologous	  BOEC:PBMC	  and	  HUVEC:PBMC	  co-­‐
culture	  assays	  
In	   separate	   experiments	   I	   also	   compared	   responses	   of	   non-­‐same	   (heterologous)	   donor	  
mixes	  of	  BOEC:PBMC	  to	  therapeutic	  antibodies.	  Heterologous	  donor	  BOEC:PBMC	  co-­‐culture	  
assays	  appeared	  to	  give	  more	  variable	  results	  but	  detected	  ANC28	  as	  well	  as	  other,	  albeit,	  
milder	  cytokine	  storm	  inducing	  drugs	  such	  as	  Campath	  (Figure	  5.12).	  For	  experiments	  where	  
BOEC	  were	  replaced	  by	  HUVEC	  (Figure	  5.13),	  results	  typical	  of	  HUVEC:PBMC	  assays	  (Bailey	  
et	   al.,	   2012;	   Findlay	   et	   al.,	   2011b)	  were	   seen	  were	   the	  TGN1412-­‐like	   superagonist	  ANC28	  












In	   the	  previous	   chapters	   I	   have	   shown	   that,	   like	   endothelial	   cell	   from	  vessels,	   BOEC	  have	  
cobblestone	   morphology,	   align	   under	   shear	   stress,	   respond	   to	   PAMPs	   and	   release	  
prostacyclin	   and	   endothelin-­‐1.	   As	   these	   cells	   are	   easily	   accessible	   and	   have	   undergone	  
minimal	   manipulation	   in	   vitro,	   this	   made	   them	   viable	   candidates	   for	   application	   in	   a	  
pharmacological	  bioassay.	  
	  
	  In	  this	  chapter	  I	  have	  shown	  that:	  
• Same	  donor	  BOEC:PBMC	  co-­‐cultures	  respond	  to	  PAMPs	  and	  cytokines	  and	  to	  release	  
CXCL8.	  	  
• Same	   donor	   BOEC:PBMC	   respond	   to	   ‘proof	   of	   concept’	   therapeutic	   antibodies	   to	  
release	   CXCL8	  with	   rank	   order	   TGN-­‐like	   anti-­‐CD28	   superagonist	   (ANC28)>Campath	  
and	  did	  not	  respond	  to	  negative	  control	  antibodies	  (Herceptin,	  Avastin	  and	  Arzerra).	  
• Same	   donor	   BOEC:PBMC	   co-­‐culture	   also	   results	   in	   proliferative	   responses	   and	  
released	  additional	  key	  cytokines	  and	  chemokines	  in	  response	  to	  ANC28.	  	  
• Principal	   components	   analysis	   indicated	   that	   for	   same	   donor	   BOEC:PBMC	   co-­‐
cultures,	   the	   TGN1412-­‐like	   anti-­‐CD28	   superagonist,	   ANC28,	   treated	   group	   was	  
separate	  from	  Campath	  treated	  cells	  and	  negative	  control	  antibodies.	  ANC28	  drove	  
positive	  correlations	  in	  17	  cytokines	  and	  chemokines.	  
• Mixed	  donor	  BOEC:PBMC	  co-­‐cultures,	  like	  HUVEC:PBMC	  co-­‐cultures	  also	  responded	  
to	   TGN1412-­‐like	   anti-­‐CD28	   superagonist	   but	  with	  more	   variable	   responses	   to	  non-­‐




Cytokine	  storm	  responses	  represent	  a	  significant	  clinical	  problem	  in	  the	  field	  of	  biologic	  drug	  
use	  and	  development.	  Any	  new	  assays	  that	  are	  developed	  to	  test	  for	  cytokine	  response	  side	  
effects	  must	  first	  be	  shown	  to	  perform	  ‘at	  least’	  as	  well	  as	  current	  gold	  standard	  assays.	  In	  
this	  chapter	  I	  have	  characterised	  responses	  of	  same	  donor	  BOEC:PBMC	  co-­‐cultures	  as	  being	  
able	   to	   respond	   to	   key	   cytokine	   storm	   causing	   drugs	   in	   a	   manner	   ‘at	   least’	   as	   well	   as	  
HUVEC:PBMC	  assays.	  The	  advantage	  of	  HUVEC:PBMC	  assay	  over	  other	  assays	  is	  accepted,	  as	  
these	   assays	   recapitulate	   the	   cell	   interactions	   occurring	   in	   the	   vasculature	   that	   drive	  
cytokine	   storm	   reactions	   (Findlay	  et	   al.,	   2011b).	   Same	  donor	  BOEC:PBMC	  assays	   take	   this	  
same	  advantage	  further,	  as	  they	  do	  not	  rely	  on	  endothelial	  cells	  and	  PBMCs	  from	  different	  
donors	  and	  so	  are	  not	  limited	  by	  mixed	  donor	  cell	  interactions.	  
	  
Clearly,	   using	   endothelial	   cells	   and	   PBMCs	   from	   the	   same	  donor	  would	   recapitulate	   even	  
further	   the	   true	   interactions	   between	  endothelial	   cells	   and	  PBMCs	   in	   the	   vasculature.	  Up	  
until	   now,	   same	   donor	   endothelial	   cell:PBMC	   co-­‐culture,	   has	   not	   been	   possible	   due	   to	  
difficulties	   and	   technical	   limitations	   in	   how	   endothelial	   cells	   are	   sourced	   from	   tissue,	  
typically	  removed	  	  during	  surgery	  or	  reliant	  on	  HUVEC	  which	  represent	  foetal	  cells.	  
	  
Autologous	   BOEC:PBMC	   assays	   have	   clear	   implications	   in	   personalised	   medicine	   and	   the	  
study	  of	  immune	  signalling	  in	  the	  vasculature,	  both	  as	  an	  assay	  to	  screen	  therapies	  and	  as	  a	  
tool	   to	  study	   immune	  signalling.	  As	   this	  assay	   is	   the	   first	   report	  of	  using	  stem	  cell	  derived	  
cells	  to	  create	  an	  autologous	  endothelial	  cell:PBMC	  co-­‐culture	  assay	  this	  invention	  was	  filed	  
for	  a	  patent	  on	  23rd	  March	  2013	  on	  which	  I	  am	  an	  author,	  and	  named	  as	  ‘contributor	  to	  the	  






















Summary	  Figure	  4.	  Summary	  for	  chapter	  5	  showing	  applications	  of	  same	  donor	  BOEC:	  PBMC	  
co-­‐culture	  assays	  in	  personalised	  medicine.	  BOEC:	  PBMC	  assays	  could	  also	  be	  used	  to	  screen	  
for	   ‘drugable’	   targets	   in	   patients	  with	   cancer	   and	   rare	  diseases.	   Shown	   on	   the	   left	   BOEC:	  
PBMC	  assays	  could	  also	  be	  used	  to	  screen	  for	  immune	  responses	  of	  patients	  to	  cell	  therapy	  
which	   will	   be	   important	   to	   avoid	   rejection	   of	   allogeneic	   therapy	   is	   patient	   cells	   are	  
unsuitable	  due	  to	  disease.	  Principal	  component	  analysis	  (PC)	  of	  patterns	  of	  cytokine	  release	  
























Summary	  Figure	  5.	  Summary	  for	  chapter	  5	  showing	  applications	  of	  same	  donor	  BOEC:	  PBMC	  
co-­‐culture	   assays	  as	   an	   off-­‐the-­‐shelf	   assay	   to	   determine	   cytokine	   storm	   risk	   for	   a	   drug	   or	  































The	  data	  presented	  in	  this	  chapter	  are	  limited	  in	  a	  number	  of	  ways,	  which	  are	  outlined	  and	  
discussed	  below:	  
	  
During	  the	  course	  of	  my	  PhD	  I	  did	  not	  have	  access	  to	  authentic	  TGN1412	  and	  relied	  on	  the	  
substitute	  ANC28,	  which	  has	  been	  used	   in	   this	  way	  by	  others	   (Waibler	  et	  al.,	  2008)	  and	   is	  
commercially	  available.	  However,	  ANC28	  is	  not	  identical	  to	  TGN1412	  in	  that	  it	  is	  thought	  to	  
bind	  a	  different	  region	  of	   the	  domain	  of	  CD28	  that	  confers	  superagonist	  activity	   (personal	  
communication	  with	  Richard	  Stebbings,	  NIBSC).	  It	  is	  important	  that	  the	  assay	  described	  here	  
be	  repeated	  with	  authentic	  TGN1412.	  To	  this	  end,	  I	  have	  formed	  collaborations	  with	  NIBSC	  
to	   pursue	   optimisation	   of	   the	   assay	   with	   TGN1412	   and	   a	   related	   in-­‐house	   anti-­‐CD28	  
superagonist.	  Subsequent	  to	  this,	  data	  has	  arisen	  from	  the	  collaboration	  which	  shows	  that	  
same	   donor	   BOEC:PBMC	   co-­‐cultures	   respond	   to	   original	   TGN1412	   recovered	   from	   the	  
Northwick	   Park	   clinical	   trial	   to	   release	   IL-­‐6,	   IL-­‐2,	   TNFα	   	   and	   CXCL8	   and	   that	   this	   assay	   is	  
superior	  to	  HUVEC:PBMC	  co-­‐cultures.	  
	  
Throughout	  this	  Chapter,	   I	  have	  suggested	  that	  same	  donor	  BOEC:PBMC	  co-­‐culture	  assays	  
represent	  a	  new	  standard	  assays	  that	  can	  be	  used	  to	  test	  therapies	  for	  individual	  patients.	  It	  
is	  noteworthy	  however,	  that	  the	  time	  to	  grow	  BOEC	  from	  a	  patient	  is	  currently	  up	  to	  20	  days	  
and	  patients	  are	  required	  to	  make	  a	  second	  visit	  for	  the	  isolation	  of	  PBMCs.	  This	  currently	  
limits	   the	   use	   of	   this	   assay	   in	   clinical	   practice	   and	   as	   an	   off-­‐the-­‐shelf	   assay.	   It	   would	   be	  
important	   in	   the	   future	   to	   investigate	   how	   to	   scale	   this	   assay	   up	   for	   industry	   use.	   For	  
example,	  it	  is	  important	  to	  know	  how	  BOEC	  and	  PBMCs	  respond	  after	  being	  frozen	  in	  stocks	  
and	   how	   they	   response	   after	   multiple	   passages.	   However,	   many	   treatment	   regimens	   for	  
228	  
	  
critically	   ill	   patients	   can	   take	   many	   weeks	   to	   develop	   and	   so	   this	   lag	   time	   might	   be	  
acceptable	  for	  patients	  with	  rare	  disease	  and	  requiring	  testing	  in	  a	  high-­‐end	  assay.	  
	  
However,	  in	  pilot	  studies,	  and	  as	  part	  of	  other	  projects	  in	  the	  group,	  I	  have	  shown	  that	  BOEC	  
can	  be	  cryo-­‐preserved	   in	   liquid	  nitrogen	  and	   recovered	  with	   their	  phenotype	  and	  viability	  
intact.	  In	  the	  future	  therefore,	  BOEC	  from	  different	  patient	  groups	  could	  be	  biobanked	  and	  
upon	   requesting	   of	   testing	   of	   a	   therapeutic	   agent,	   BOEC	  would	   be	   recovered	   from	   liquid	  
nitrogen	   and	  PBMCs	   added	  either	   freshly	   isolated	  or	   also	   from	   cryo-­‐storage.	   This	   in	   turn,	  
would	  make	  the	  assay	  a	  2-­‐3	  day	  process.	  The	  feasibility	  of	  this	  is	  under	  investigation.	  
	  
Finally,	  given	  the	  disparity	   in	  proliferation	  data	   from	  two	  different	  readouts	   (3H-­‐thymidine	  
incorporation	  and	  Alamarblue)	  the	  optimum	  condition	  to	  detect	  a	  proliferative	  response	  in	  
these	  assays	  will	  be	  important	  to	  establish	  in	  future	  studies.	  	  
	  
It	  is	  important	  to	  note	  that	  whilst	  BOEC	  are	  highly	  proliferative,	  yield	  of	  these	  cells	  for	  large	  
scale	  assays	  might	  be	  a	  limiting	  factor.	  Therefore,	  developing	  protocols	  to	  improve	  yield	  of	  
BOEC	  will	   be	   important	   going	   forward.	   In	  my	   PhD,	   and	   for	   purpose	   of	   this	   assay,	   I	   have	  
chosen	   to	   apply	   BOEC	   as	   a	   same	   donor	   endothelial	   cell	   interface.	  Other	   sources	   of	   same	  
donor	   endothelial	   cells	   also	   exist	   in	   the	   form	   of	   iPSC-­‐EC	  which	   could	   be	   applied	   to	   same	  
donor	  assays	  and	  stored	   in	   large	  numbers	  of	  use	   in	  assays.	  This	  however	  was	  beyond	   the	  
scope	  of	  my	  PhD	  where	   I	   have	  established	  protocols	  within	   the	   group	   to	   grow	  BOEC	  and	  
apply	  them	  to	  key	  assays.	  The	  extent	  to	  which	  both	  BOEC	  and	  iPSC-­‐EC	  from	  patients	  retain	  a	  
relevant	   phenotype	   in	   in	   vitro	   asssays	   will	   be	   a	   critical	   consideration	   in	   the	   personalised	  
















Figure	  5.1	  Effect	  of	  co-­‐culture	  of	  blood	  outgrowth	  endothelial	  cells	  (BOECs)	  with	  autologous	  
peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  on	  responses	  to	  pathogen	  associated	  molecular	  
patterns	   (PAMPs).	   (A)	   BOECs	   and	   (B)	  HUVEC	   with/without	   PBMCs	   were	   treated	   with	   LPS	  
(1µg/ml),	  which	   activates	   TLR4,	   Pam3CSK4	   (Pam3)	   (1µg/ml),	  which	   activates	   TLR2,	   C12-­‐iE-­‐
DAP	   (10µg/ml),	   which	   activates	   NOD1	   and	   TNFα	   (10ng/ml)	   and	   IL-­‐1β	   (1ng/ml)	   which	  
activate	   similar	   inflammatory	   pathways	   via	   cytokine	   receptors	   and	   independent	   of	   TLRs.	  
Data	  are	  mean	  ±	  SEM	  (panel	  A;	  n=5,	  panel	  B;	  n=3).	  Statistical	  significance	  was	  determined	  by	  
one-­‐way	   ANOVA	   followed	   by	   Dunnett’s	  multiple	   comparison	   test	   (*p<0.05).	  NB.	   Different	  




EPCA and F and C 24h antibodies








































































Figure	  5.2	  Response	  of	  same	  donor	  blood	  outgrowth	  endothelial	  cell	  (BOEC)	  and	  peripheral	  
blood	   mononuclear	   cell	   (PBMC)	   co-­‐culture	   assays	   to	   biologics.	   (A)	   Effect	   of	   therapeutic	  
antibodies	   on	   CXCL8	   release	   by	  mono	   cultures	   and	   co-­‐cultures	   of	   same	   donor	  BOEC	   and	  
PBMCs.	   Cells	   were	   treated	   with	   the	   TGN-­‐like	   anti-­‐CD28	   superagonist;	   ANC28	   (1/5D10;	  
10μg/ml),	  Campath	  (10μg/ml),	  Herceptin	  (10μg/ml)	  Avastin	  (10μg/ml)	  or	  Arzerra	  (10μg/ml)	  
for	   24h.	   Data	   are	  mean	   ±	   SEM	   (n=8).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	  
ANOVA	   (*p<0.05)	   followed	   by	   Bonferroni	   post-­‐test.	   	   (B)	  Concentration	   response	   curve	   for	  
BOEC	  and	  PBMC	  monocultures	  of	  co-­‐cultures	  treated	  with	  ANC28	  (0.001-­‐10μg/ml)	  for	  24h.	  
Data	  are	  mean	  ±	  SEM	  (n=3).	  Statistical	  testing	  was	  carried	  out	  by	  one-­‐way	  ANOVA	  followed	  









































Transform of EPCAG and S and AK TGN curve





























Figure	  5.3	  Proliferative	  response	  of	  same	  donor	  blood	  outgrowth	  endothelial	  cell	  (BOEC)	  and	  
peripheral	   blood	   mononuclear	   cell	   (PBMC)	   co-­‐culture	   assays	   to	   TGN1412-­‐like	   anti-­‐CD28	  
superagonist	  (ANC28).	  Cells	  were	  treated	  with	  the	  TGN-­‐like	  anti-­‐CD28	  superagonist;	  ANC28	  
(1/5D10;	  10μg/ml)	   or	   IgG4	   isotype	   control,	   for	   24h.	  Data	   are	  mean	  ±	   SEM	   (n=3	   from	  one	  























Figure	  5.4	  TNFα,	  CXCL8	  and	  IL-­‐2	  release	  from	  blood	  outgrowth	  endothelial	  cell	  (BOEC)	  and	  
peripheral	  blood	  mononuclear	  cell	  (PBMC)	  mono-­‐cultures	  and	  same	  donor	  BOEC:PBMC	  co-­‐
cultures.	  Data	  are	  as	  per	  Figure	  5.2A	  except	  measurements	  were	  carried	  out	  using	  an	  MSD	  
10-­‐spot	  9-­‐plex	  Pro-­‐Inflammatory	  Assay.	  Data	  are	  mean	  ±	  SEM	  (n=5).	  Statistical	   testing	  was	  



































































































































































































































































































































































Figure	   5.5	   IFNγ,	   IL-­‐6	   and	   IL-­‐1β	   release	   from	   blood	   outgrowth	   endothelial	   cell	   (BOEC)	   and	  
peripheral	  blood	  mononuclear	  cell	  (PBMC)	  mono-­‐cultures	  and	  same	  donor	  BOEC:PBMC	  co-­‐
cultures.	  Data	  are	  as	  per	  Figure	  5.2A	  except	  measurements	  were	  carried	  out	  using	  an	  MSD	  
10-­‐spot	  9-­‐plex	  Pro-­‐Inflammatory	  Assay.	  Data	  are	  mean	  ±	  SEM	  (n=5).	  Statistical	   testing	  was	  
carried	  out	  by	  one-­‐way	  ANOVA	   followed	  by	  Dunnett’s	  multiple	  comparison	   test	   (*p<0.05).	  


































































































































































































































































































































































Figure	  5.6	  IL-­‐10,	  GM-­‐CSF	  and	  IL-­‐12p70	  release	  from	  blood	  outgrowth	  endothelial	  cell	  (BOEC)	  
and	  peripheral	  blood	  mononuclear	  cell	  (PBMC)	  mono-­‐cultures	  and	  same	  donor	  BOEC:PBMC	  
co-­‐cultures.	   Data	   are	   as	   per	   Figure	   5.2A	   except	  measurements	  were	   carried	   out	   using	   an	  
MSD	  10-­‐spot	  9-­‐plex	  Pro-­‐Inflammatory	  Assay.	  Data	  are	  mean	  ±	  SEM	   (n=).	   Statistical	   testing	  
was	   carried	   out	   by	   one-­‐way	   ANOVA	   followed	   by	   Dunnett’s	   multiple	   comparison	   test	  
(*p<0.05).	  Where	  cytokines	  were	  not	  detected	  the	  minimum	  detectable	  level	  was	  added	  to	  






































































































































































































































































































































































Figure	  5.7	  Eotaxin,	  MCP-­‐1	  and	  MIP-­‐1β	  release	  from	  blood	  outgrowth	  endothelial	  cell	  (BOEC)	  
and	  peripheral	  blood	  mononuclear	  cell	  (PBMC)	  mono-­‐cultures	  and	  same	  donor	  BOEC:PBMC	  
co-­‐cultures.	   Data	   are	   as	   per	   Figure	   5.2A	   except	  measurements	  were	   carried	   out	   using	   an	  
MSD	  10-­‐spot	  9-­‐plex	  Pro-­‐Inflammatory	  Assay.	  Data	  are	  mean	  ±	  SEM	  (n=5).	  Statistical	  testing	  






















































































































































































































































































































































Figure	  5.8	  Eotaxin-­‐3,	  MCP4	  and	  TARC	  release	  from	  blood	  outgrowth	  endothelial	  cell	  (BOEC)	  
and	  peripheral	  blood	  mononuclear	  cell	  (PBMC)	  mono-­‐cultures	  and	  same	  donor	  BOEC:PBMC	  
co-­‐cultures.	   Data	   are	   as	   per	   Figure	   5.2A	   except	  measurements	  were	   carried	   out	   using	   an	  
MSD	  10-­‐spot	  9-­‐plex	  Pro-­‐Inflammatory	  Assay.	  Data	  are	  mean	  ±	  SEM	  (n=5).	  Statistical	  testing	  































































































































































































































































































































Figure	  5.9	  Eotaxin-­‐3,	  MCP4	  and	  TARC	  release	  from	  blood	  outgrowth	  endothelial	  cell	  (BOEC)	  
and	  peripheral	  blood	  mononuclear	  cell	  (PBMC)	  mono-­‐cultures	  and	  same	  donor	  BOEC:PBMC	  
co-­‐cultures.	   Data	   are	   as	   per	   Figure	   5.2A	   except	  measurements	  were	   carried	   out	   using	   an	  
MSD	  10-­‐spot	  9-­‐plex	  Pro-­‐Inflammatory	  Assay.	  Data	  are	  mean	  ±	  SEM	  (n=5).	  Statistical	  testing	  























































































































































































































































































































Figure	  5.10	  Scores	  plot	  for	  principal	  component	  analysis	  of	  blood	  outgrowth	  endothelial	  cell	  
(BOEC)	   and	   peripheral	   blood	   mononuclear	   cell	   (PBMC)	   monocultures	   and	   same	   donor	  
BOEC:PBMC	  co-­‐cultures	  treated	  with	  the	  TGN-­‐like	  anti-­‐CD28	  superagonist;	  ANC28	  (1/5D10;	  
10μg/ml),	  Herceptin	  (10μg/ml),	  Campath	  (10μg/ml),	  Herceptin	  (10μg/ml),	  Avastin	  (10μg/ml)	  
or	  Arzerra	   (10μg/ml)	   for	  24h	  and	   the	   following	  cytokines	  and	  chemokines	  were	  measured	  
and	   included	   in	   the	   analysis;	   GM-­‐CSF,	   IFNγ,	   IL-­‐2,	   IL-­‐6,	   CXCL8,	   TNFα,	   IL-­‐1β,	   IL-­‐10,	   IL-­‐12p70,	  
Eotaxin,	  Eotaxin	  3,	  IP10,	  MCP-­‐1,	  MCP-­‐4,	  MDC,	  MIP-­‐1β,	  TARC.	  Values	  were	  entered	  for	  each	  























































Figure	  5.11	  Loadings	  plot	   for	  principal	  component	  analysis	  of	  blood	  outgrowth	  endothelial	  
cell	   (BOEC)	  and	  peripheral	  blood	  mononuclear	   cell	   (PBMC)	  monocultures	  and	  same	  donor	  
BOEC:PBMC	  co-­‐cultures	  treated	  with	  the	  TGN-­‐like	  anti-­‐CD28	  superagonist;	  ANC28	  (1/5D10;	  
10μg/ml),	  Herceptin	  (10μg/ml),	  Campath	  (10μg/ml),	  Herceptin	  (10μg/ml),	  Avastin	  (10μg/ml)	  
or	  Arzerra	   (10μg/ml)	   for	  24h	  and	   the	   following	  cytokines	  and	  chemokines	  were	  measured	  
and	   included	   in	   the	   analysis;	   GM-­‐CSF,	   IFNγ,	   IL-­‐2,	   IL-­‐6,	   CXCL8,	   TNFα,	   IL-­‐1β,	   IL-­‐10,	   IL-­‐12p70,	  
Eotaxin,	  Eotaxin	  3,	  IP10,	  MCP-­‐1,	  MCP-­‐4,	  MDC,	  MIP-­‐1β,	  TARC.	  Values	  were	  entered	  for	  each	  








































Figure	   5.12	   Response	   of	   mixed	   donor	   blood	   outgrowth	   endothelial	   cell	   (BOEC)	   and	  
peripheral	  blood	  mononuclear	  cell	  (PBMC)	  co-­‐culture	  assays	  to	  biologics.	  Cells	  were	  treated	  
with	   the	  TGN-­‐like	  anti-­‐CD28	   superagonist;	  ANC28	   (1/5D10;	  10μg/ml),	  Campath	   (10μg/ml),	  
Herceptin	  (10μg/ml)	  Avastin	  (10μg/ml)	  or	  Arzerra	  (10μg/ml)	  for	  24h.	  Data	  are	  mean	  ±	  SEM	  
(n=3).	   Statistical	   significance	   was	   determined	   by	   one-­‐way	   ANOVA	   (*p<0.05)	   followed	   by	  














































Figure	  5.13	  Response	  of	  human	  umbilical	  vein	  endothelial	  cell	  (HUVEC)	  and	  peripheral	  blood	  
mononuclear	  cell	  (PBMC)	  co-­‐culture	  assays	  to	  biologics.	  Cells	  were	  treated	  with	  the	  TGN-­‐like	  
anti-­‐CD28	   superagonist;	   ANC28	   (1/5D10;	   10μg/ml),	   Campath	   (10μg/ml),	   Herceptin	  
(10μg/ml)	   Avastin	   (10μg/ml)	   or	   Arzerra	   (10μg/ml)	   for	   24h.	   Data	   are	   mean	   ±	   SEM	   (n=3).	  


































































Table	   5.1	   AlamarBlue®	   data	   for	   effect	   of	   therapeutic	   antibodies	   on	   cell	   activity	   of	   mono	  
cultures	   and	   co-­‐cultures	   of	   autologous	   blood	   outgrowth	   endothelial	   cells	   (BOEC)	   and	  
peripheral	  blood	  mononuclear	  cells	  (PBMCs).	  Cells	  were	  treated	  with	  the	  TGN-­‐like	  anti-­‐CD28	  
superagonist;	  ANC28	   (1/5D10;	  10μg/ml),	  Campath	   (10μg/ml),	  Herceptin	   (10μg/ml)	  Avastin	  
(10μg/ml)	   or	   Arzerra	   (10μg/ml)	   for	   24h.	   Data	   are	   mean	   ±	   SEM	   (n=6).	   alamar	   blue®	  	  
measurements	   were	   taken	   at	   wavelength	   of	   570-­‐620nm	   at	   6h	   post	   addition	   of	   10%	  













MEDIA& 0.434&±&0.069& 0.378&±&0.080& 0.420&±&&0.047&
ANC28& 0.433&±&0.066& 0.423&±&0.109& 0.402&±&0.036&
CAMPATH& 0.423&±&0.066& 0.352&±&0.067& 0.384&±&0.040&
HERCEPTIN& 0.420&±&0.063& 0.348&±&0.059& 0.385&±&0.040&
AVASTIN& 0.423&±&0.062& 0.342&±&0.054& 0.392&±&0.037&













Table	  5.2	  Effect	  of	  therapeutic	  antibodies	  on	  CXCL8	  release	  by	  same	  donor	  BOEC:PBMC	  co-­‐
cultures	   from	  8	  healthy	  donors.	   Cells	  were	   treated	  with	   the	  TGN-­‐like	   anti-­‐CD28	  antibody;	  
ANC28	   (1/5D10;	  10μg/ml),	  Herceptin	   (10μg/ml),	  Campath	   (10μg/ml),	  Herceptin	   (10μg/ml),	  


























2694.92 &4203.864 &5242.842 &3250.47 &6518.04 &23856.94 &10261.76 &&&&797.53&
&
&
37936.5 &12230.51 &35161.56 &108258.0 &15609.40 &38014.00 &52866.86&&&&&49218.52&
&
&
23703.28 &6588.711 &11634.86 &2342.246 &18190.27 &52583.4 &46919.76 &&&5132.27&
&
&
3800.45 &3432.637 &4490.92 &4528.572 &2562.80 &31786.66 &28641.6 &&&3847.91&
&
&
3712.35 &7333.211 &5677.08 &3320.974 &3164.62 &41707.1 &3288.744 &&&13888.85&
&
&
3168.66 &5521.58 &5504.42 &4774.344 &9247.12 &32982.08 &8008.88 &&&4334.41&
245	  
	  
CHAPTER	   6:	   APPLICATION	   OF	   BLOOD	   OUTGROWTH	  
ENDOTHELIAL	   CELLS	   (BOEC)	   TO	   (I)	   VALIDATE	   THE	  
PHENOTYPE	   OF	   A	   PATIENT	   WITH	   A	   GENETIC	   MUTATION	  
AND	   (II)	   FURTHER	  STUDY	  OF	  PHOSPHOLIPASE-­‐A2	   ISOFORM	  


















6.1	  RATIONALE	  	  
One	  of	  the	  important	  applications	  of	  blood	  outgrowth	  endothelial	  cells	  (BOEC)	  derived	  from	  
donor	  stem	  cells	  is	  the	  ability	  to	  use	  them	  to	  phenotype	  vascular	  function	  in	  patients.	  In	  this	  
chapter	   I	   have	   used	   BOEC	   to	   do	   this	   in	   a	   patient	  who	   has	   a	   frame	   shift	  mutation	   in	   the	  
PLA2G4A	  gene,	  which	  results	  in	  loss	  of	  function	  of	  cytosolic	  phospholipase-­‐A2α	  (cPLA2α).	  This	  
results	  in	  severe	  clinical	  symptoms	  including	  gastrointestinal	  inflammation	  and	  renal	  failure.	  
These	  clinical	  manifestations	  are	  consistent	  with	  a	  person	  taking	  long-­‐term	  high	  dose	  non-­‐
steroidal	   anti-­‐inflammatory	   drugs	   (NSAIDs).	   Indeed,	  my	   group	   has	   shown	   full	   clinical	   and	  
genetic	   characteristics	  of	   this	  patient	  and	   relatives	  and	   that	  platelets	   from	  this	  patient	  do	  
not	  release	  cyclooxygenase	  (COX)	  products	  when	  stimulated	  in	  vitro	  (Brooke	  et	  al.,	  2012).	  
	  
PLA2	  encompasses	  a	  family	  of	  enzymes	  that	  cleave	  the	  sn-­‐2	  ester	  bonds	  of	  phospholipids	  to	  
liberate	   free	   fatty	   acids	   (Funk,	   2001);	   including	   arachidonic	   acid.	   As	   discussed	   previously,	  
arachidonic	  acid	  serves	  as	  a	  substrate	  for	  COX.	  Numerous	  isoforms	  of	  PLA2	  exist	  and	  these	  
fit	  broadly	  in	  to	  three	  families.	  These	  are	  secreted	  PLA2	  (sPLA2),	  cytosolic	  PLA2	  (cPLA2),	  and	  
calcium-­‐independent	  PLA2	  (iPLA2).	  It	  is	  thought	  to	  be	  the	  Ca2+-­‐dependent	  cPLA2	  isoform	  that	  
is	  required	  for	  arachidonic	  acid	  release	  associated	  with	  prostaglandin	  synthesis	  (Adler	  et	  al.,	  
2008;	   Brooke	   et	   al.,	   2012).	   As	   loss	   of	   prostacyclin	   in	   the	   gastric	   and	   renal	   circulations	   is	  
associated	   with	   the	   type	   of	   symptoms	   experienced	   by	   the	   patient	   lacking	   cPLA2α,	   this	   is	  
consistent	  with	  the	  idea	  that	  cPLA2	  supports	  prostacyclin	  synthesis	  in	  vivo.	  	  However,	  others	  
have	   reported	   that	   in	   blood	   vessels	   iPLA2	   is	   linked	   to	   arachidonic	   acid	   release	   and	  
prostacyclin	   production	   by	   endothelial	   cells	   (Sharma	   et	   al.,	   2011)	   and	   vascular	   smooth	  




In	  this	  Chapter,	  I	  sought	  to	  grow	  BOEC	  from	  the	  patient	  with	  a	  mutation	  in	  the	  cPLA2α	  gene,	  
PLA2G4A	   and	   to	   phenotype	   these	   cells	   for	   ability	   to	   release	   prostacyclin	   as	  well	   as	   a	   full	  
range	  of	  eicosanoids.	  
	  
The	  specific	  questions	  addressed	  in	  this	  chapter	  are:	  
1. Can	  BOEC	  be	  successfully	  grown	  out	  of	  the	  blood	  from	  the	  patient	  with	  the	  PLA2G4A	  
mutation,	   and	   how	   do	   their	   differentiation	   kinetics	   compare	   to	   cells	   from	   healthy	  
controls?	  
2. How	  does	  the	  phenotype,	   in	  terms	  of	  morphology	  and	  response	  to	  shear	  stress,	  of	  
BOEC	   from	   the	   patient	  with	   the	   PLA2G4A	   polymorphism	   compare	  with	   cells	   from	  
healthy	  donors?	  
3. How	  does	  loss	  of	  cPLA2α	  affect	  the	  ability	  of	  BOEC	  to	  release	  prostacyclin	  and	  other	  
eicosanoids?	  
4. What	   is	  the	  relative	  role	  of	  cPLA2	  vs	   iPLA2	   in	  the	  release	  of	  prostacyclin	  from	  BOEC	  
from	  healthy	  donors?	  











6.2	  SUMMARY	  OF	  METHODS	  	  
A	   full	   description	   of	   the	   methods	   used	   in	   this	   chapter	   is	   given	   in	   Chapter	   2	   and	   are	  
summarised	  below.	  
	  
6.2.1	  Patient	  characteristics	  
Blood	  was	  collected	  from	  a	  patient	  defined	  by	  our	  group	  as	  having	  homozygous	  mutation	  in	  
the	   cPLA2α	   gene,	  PLA2G4A.	  The	   clinical	   characteristics	   and	  medical	  history	  of	   the	  affected	  
female	  used	  in	  my	  PhD	  are	  shown	  in	  Table	  6.1	  
	  
6.2.2	  	   BOEC	  culture	  from	  healthy	  donors	  and	  a	  patient	  with	  PLA2G4A	  mutation	  
BOEC	  were	  isolated	  from	  healthy	  volunteers	  and	  a	  patient	  with	  a	  homozygous	  mutation	  in	  
the	   cPLA2α	   encoding	   gene,	   PLA2G4A.	   This	   patient	   was	   identified	   previously	   by	   our	   group	  
(Brooke	  et	  al.,	  2012).	  Blood	  was	  collected,	  and	  cells	  were	  grown,	  at	  Barts	  and	  The	  London	  
Hospital.	  Cells	  derived	  from	  the	  patient,	  as	  with	  BOEC	  used	  previously,	  were	  characterised	  
for	  alignment	  under	  shear	  stress,	  and	  expression	  of	  CD31,	  and	  VE-­‐cadherin.	  
	  
6.2.3	  	   Assessment	  of	   the	  ability	  of	  BOEC	   from	  a	   cPLA2α-­‐deficient	  patient	   to	   align	  under	  
shear	  stress	  
Endothelial	   cell	   alignment	   under	   shear	   stress	   was	   determined	   using	   a	   model	   previously	  
defined	  by	  our	  group	  and	  developed	  by	  my	  colleague	  Claire	  Potter	  (Potter	  et	  al.,	  2011)	  and	  
in	  chapters	  2	  and	  3	  of	  this	  thesis.	  Briefly,	  cells	  were	  cultured	  on	  standard	  1%	  gelatinised	  6-­‐
well	  plates	  and	  placed	  on	  an	  orbital	  shaker.	  The	  movement	  of	  the	  shaker	  results	  in	  a	  wave	  
of	  media	  that	  oscillates	  around	  the	  well	  resulting	  in	  a	  complex	  pattern	  of	  shear	  applied	  with	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directional	   (laminar)	   shear	   towards	   the	   edge	   of	   the	  well,	   and	   non-­‐directional	   (oscillatory)	  
shear	   at	   the	   centre.	   Alignment	   of	   cells	   was	   visualised	   by	   light	   microscopy	   and	   by	  
fluorescence	  imaging	  of	  cells	  stained	  with	  appropriate	  markers	  as	  described	  above.	  
	  
6.2.4	  	   BOEC	  treatment	  protocols	  
BOEC	   from	   healthy	   volunteers	   or	   the	   cPLA2α-­‐deficient	   patient	   were	   incubated	   with	   or	  
without	   IL-­‐1β	   (1ng/ml)	   for	   24	   hours	   to	   activate	   COX.	   They	   were	   then	   stimulated	   with	  
thrombin	   (1U/ml;	   phosphate	   buffered	   saline	   (PBS))	   or	   Ca2+	   ionophore	   (A23187;	   30µM;	  
dimethyl	  sulphoxide	  (DMSO)	  0.1%	  final)	   to	  activate	  endogenous	   iPLA2	  and	  cPLA2	  enzymes,	  
respectively,	   or	   with	   arachidonic	   acid	   (50µM;	   ethanol	   0.05%	   final),	   which	   stimulates	  
prostacyclin	   formation	  without	   the	   requirement	   of	   PLA2	   and	   so	   bypasses	   this	   part	   of	   the	  
pathway	  to	  prostacyclin	  release.	  In	  some	  experiments,	  cells	  were	  pre-­‐treated	  for	  30	  minutes	  
with	  or	  without	  the	  cPLA2	  inhibitor	  pyrrophenone	  (0.1-­‐10µM)	  or	  vehicle	  (0.1%	  DMSO).	  
	  
6.2.5	  	   Mouse	  aortic	  ring	  experiments	  
Isolation	   of	   aortic	   rings	   in	   this	   chapter	   was	   carried	   out	   by	  my	   colleague	   Dr.	   Nick	   Kirkby.	  
Aortic	   rings	  were	   isolated	   from	   CO2-­‐euthanised	  mice	   (male,	   BALB/c,	   10	  weeks;	   n=6),	   and	  
incubated	  for	  1	  hour	  at	  37oC.	  Mouse	  aortic	  rings	  were	  then	  incubated	  for	  30	  minutes	  with	  
the	   cPLA2	   inhibitor,	   pyrrophenone	   (PYR;	   0.1-­‐10µM),	   or	   the	   iPLA2	   inhibitor	   bromoenol	  
lactone	   (BEL;	   0.1-­‐10µM)	   or	   vehicle	   (0.1%	   dimethyl	   sulphoxide	   (DMSO))	   as	   above.	  Mouse	  
aortic	   rings	   do	   not	   respond	   robustly	   to	   thrombin,	   so	   for	   these	   experiments,	   prostacyclin	  
release	  was	  stimulated	  for	  30	  minutes	  with	  acetylcholine	  (ACh;	  1µM;	  saline),	  which	  also	  acts	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via	  a	  Gq-­‐protein	  coupled	  receptor	  signalling	  pathway	  to	  activate	  PLA2	  pathways	  in	  a	  similar	  
fashion	  to	  thrombin.	  Supernatants	  were	  collected	  and	  stored	  at	  -­‐80oC	  for	  analysis.	  
	  
6.2.6	  	   Measurement	  of	  prostacyclin	  release	  
In	   all	   assays,	   prostacyclin	   release	  was	  measured	   in	   the	   supernatant	   after	   24	   hours	   or	   30	  
minutes	   as	   its	   breakdown	  product,	   6-­‐ketoPGF1α	  by	  ELISA.	  Optical	   density	  was	  determined	  
using	  a	  microplate	  reader	  (Dyne,	  Madellan	  Biosciences)	  with	  absorbance	  readings	  at	  450nm	  
	  
6.2.7	  	   Lipidomics	  by	  LC/MS/MS	  
To	  consider	  a	  more	  complete	  profile	  of	  eicosanoids	   released	  by	  BOEC,	   supernatants	  were	  
also	   analysed	   using	   a	   liquid	   chromatography	   –	   tandem	   mass	   spectrometry	   (LC/MS/MS)	  
‘lipidomics’	  approach.	  This	  allows	  for	  unbiased	  analysis	  of	  a	  wide	  range	  of	  biologically	  active	  
lipid	  mediators	  within	   a	   small	   sample	   volume	   (Kirkby	  et	   al.,	   2013;	  Masoodi	   and	  Nicolaou,	  
2006).	   For	   this,	   supernatants	   from	   A23187	   or	   vehicle	   treated	   BOEC	   were	   sent	   to	   the	  
National	  Institute	  of	  Environmental	  and	  Health	  Research,	  USA,	  under	  collaboration	  with	  Dr.	  
Matthew	  Edin	  and	  Prof.	  Daryl	  Zeldin.	  Prostanoids	  were	  extracted	  and	  analysed	  as	  previously	  
described	  (Edin	  et	  al.,	  2011;	  Newman	  et	  al.,	  2002).	  
	  
Briefly,	   samples	   were	   spiked	   with	   PGE2-­‐d4,	   10(11)-­‐epoxyheptadecanoic	   acid	   and	   10(11)-­‐	  
dihydroxynonadecanoic	  acid	   internal	  standards	  then	  mixed	  with	  0.1	  volumes	  for	  1%	  acetic	  
acid	  (volume/volume)	   in	  50%	  methanol.	  Samples	  were	  then	  pre-­‐extracted	  using	  Oasis	  HLB	  
C18	  3ml	  columns,	  and	  then	  further	  separated	  by	  high	  pressure	  liquid	  chromatography	  with	  
Phenomenex	  Luna	  C18(2)	  columns.	  Extracts	  were	  analysed	  using	  negative	   ion	  electrospray	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ionization	  tandem	  mass	  spectrometry	  in	  triplicate	  using	  an	  MDS	  Sciex	  API	  3000	  instrument	  
with	  Applied	   Biosystems	   TurboIonSpray	   source.	   Lipid	  mediator	   abundance	  was	   quantified	  






















6.3.1	  	   Characterisation	  of	  BOEC	  from	  a	  cPLA2α	  deficient	  patient	  
As	   in	   previous	   chapters,	   it	   was	   important	   to	   characterise	   BOEC	   grown	   from	   the	   cPLA2α-­‐
deficient	   patient.	   Colonies	   of	   BOEC	   grown	   from	   the	   cPLA2α-­‐deficient	   patient,	   like	   healthy	  
BOEC,	  had	  cobblestone	  morphology	  (Figure	  6.1A).	  However,	  BOEC	  from	  the	  cPLA2α-­‐deficient	  
patient	   emerged	   sooner	   and	   in	   greater	   number	   than	   for	   healthy	   donors	   (Figure	   6.1B).	  
Similarly	   to	   BOEC	   from	   healthy	   donors,	   cells	   grown	   from	   the	   patient	  with	   a	   homozygous	  
deletion	  of	  cPLA2α	  expressed	  CD31,	  and	  VE-­‐cadherin,	  and	  aligned	  under	  shear	  stress	  (Figure	  
6.2)	  
	  
6.3.2	  	   Prostacyclin	  release	  from	  cPLA2α	  deficient	  BOEC	  
As	   expected,	   BOEC	   from	   healthy	   patients	   released	   prostacyclin	   in	   response	   to	   thrombin,	  
A23187	  and	  arachidonic	  acid.	  CPLA2α-­‐deficient	  BOEC,	  whilst	  able	   to	   release	  prostacyclin	   in	  
response	   to	   arachidonic	   acid,	   released	   lower	   levels	  of	  prostacyclin	   in	   response	   to	  A23187	  
and	  thrombin	  (Figure	  6.3).	  
	  
6.3.3	  	   Lipidomics	   analysis	   of	   eicosanoid	   release	   from	   BOEC	   from	   a	   cPLA2α	   deficient	  
patient	  
To	   further	   explore	   the	   effect	   of	   cPLA2α	   deficiency	   on	   a	   range	   of	   eicosanoid	   pathways	   in	  
endothelial	   cells,	   in	   addition	   to	   prostacyclin,	   a	   lipidomics	   approach	   was	   employed.	   This	  
approach,	   which	   employs	   a	   combination	   of	   tandem	  mass	   spectrometry	   coupled	   to	   liquid	  
chromatography	   (LC-­‐MS/MS)	   (Edin	  et	   al.,	   2011;	  Newman	  et	   al.,	   2002)	   allowed	   for	   a	  more	  
complete	   analysis	   of	   the	   lipids	   that	  might	   be	   regulated	   by	   cPLA2α	   in	   BOEC.	   Across	   all	   the	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eicosanoids	  measured,	   in	   response	   to	   A23187,	   healthy	   BOEC	   released	   increased	   levels	   of	  
AA-­‐derived	  COX	  products	  (prostacyclin,	  PGF2α,	  PGE2,	  PGD2),	  AA-­‐derived	  P450/LOX	  products	  
(15-­‐HETE,	  12-­‐HETE,	  11-­‐HETE,	  8-­‐HETE	  and	  5-­‐HETE),	   LA-­‐derived	  P450	  products	   (13-­‐HODE,	  9-­‐
HODE,	  12,13-­‐DHOME	  and	  9,10,13-­‐THOME),	  and	  the	  DHA	  P450	  product,	  19,20-­‐EpDPE	  (Figure	  
6.4).	   Release	   of	   all	   these	   eicosanoids,	   except	   PGF2α	   and	   8-­‐HETE,	   were	   reduced	   in	   BOEC	  
lacking	  cPLA2α.	  
	  
6.3.4	  	   Effect	  of	  pharmacological	  inhibition	  of	  cPLA2	  in	  BOEC	  from	  healthy	  donors	  	  
As	  shown,	  thrombin,	  A23187,	  and	  AA	  induced	  robust	  prostacyclin	  release	  from	  BOEC	  from	  
healthy	  donors	   (Figure	  6.3).	   Furthermore,	  pre-­‐treatment	  of	  BOEC	  with	   the	  cPLA2	   selective	  
inhibitor,	   pyrrophenone,	   resulted	   in	   a	   concentration-­‐dependent	   inhibition	   of	   prostacyclin	  
release	   in	   response	   to	   both	   A23187	   (Figure	   6.6)	   and	   thrombin	   (Figure	   6.7).	   Inhibition	   of	  
cPLA2	  had	  no	  effect	  on	  arachidonic	  acid	  induced	  prostacyclin	  release	  (Figure	  6.8).	  
	  
6.3.5	  	   Prostacyclin	  release	  from	  mouse	  aortic	  ring	  preparations	  
In	  line	  with	  observations	  in	  BOEC,	  inhibition	  of	  cPLA2	  with	  pyrophenone,	  but	  not	  iPLA2	  with	  
bromoenol	  lactone,	  resulted	  in	  a	  concentration	  dependent	  decrease	  in	  prostacyclin	  release	  









In	  this	  chapter	  I	  have	  shown	  that:	  
• BOEC	   from	   a	   cPLA2α-­‐deficient	   patient,	   like	   BOEC	   from	   healthy	   donors,	   expressed	  
CD31	  and	  VE-­‐cadherin	  and	  aligned	  under	  shear	  stress.	  
• BOEC	   lacking	   cPLA2α	   released	   lower	   levels	   of	   prostacyclin,	   as	   well	   as	   other	  
eicosanoids,	  in	  response	  to	  Ca2+	  ionophore	  (A23187)	  and	  thrombin.	  
• Pharmacological	  inhibition	  of	  cPLA2	  reduced	  Ca2+	  ionophore	  (A23187)	  and	  thrombin	  
induced	  prostacyclin	  release	  from	  healthy	  BOEC.	  
• Pharmacological	   inhibition	  of	  cPLA2	  but	  not	  iPLA2	  reduced	  Ach	  induced	  prostacyclin	  
release	  from	  mouse	  thoracic	  aorta.	  
	  
This	  chapter	  serves	  as	  an	  important	  proof	  of	  concept	  that	  BOEC	  can	  be	  used	  to	  phenotype	  a	  
patient	   with	   a	   genetic	   disorder	   and	   retain	   differences	   in	   key	   pathways	   associated	   with	  
disease.	  In	  terms	  of	  endothelial	  cell	  function,	  loss	  of	  a	  key	  enzyme	  in	  prostacyclin	  synthesis,	  
like	  cPLA2	  provides	  a	  gold	  standard	  research	  tool	  to	  investigate	  the	  function	  of	  this	  pathway	  
is	  endothelial	  cell	  biology.	  Understanding	  the	  pathways	  that	  drive	  prostacyclin	  synthesis	   in	  
endothelial	  cells	   is	  essential.	  We	  have	  previously	  shown	  that	  COX-­‐1,	  and	  not	  COX-­‐2	  drives	  
prostacyclin	  release	  from	  vessels	  (Kirkby	  et	  al.,	  2012;	  Kirkby	  et	  al.,	  2013).	  Using	  BOEC	  from	  a	  
cPLA2α	   deficient	   patient	   and	   healthy	   donors	   I	   have	   shown	   that	   cPLA2	   contributes	  
significantly	   to	   prostacyclin	   production	   in	   endothelial	   cells.	   Clearly	   with	   this	   data	   it	   is	  
reasonable	  to	  speculate	  that	  similar,	  less	  obvious,	  disease	  phenotypes	  impact	  on	  endothelial	  




As	   a	   second	   outcome	   I	   was	   able	   to	   use	   these	   cells	   to	   test	   directly	   the	   role	   of	   PLA2	   in	  
prostacyclin	   release	   by	   vascular	   cells.	   This	   is	   important	   to	   address	   and	   conflicting	   reports	  





Summary	   Figure	   6.	   Endothelial	   cells	   express	   G-­‐protein	   coupled	   receptors	   (GPCRs)	   which	  
respond	   to	   physiological	   levels	   of	   agonist	   such	   as	   thrombin	   or	   acetylcholine	   (Ach).	   These	  
receptors	   activate	   Gq	   which	   activates	   phospholipase-­‐Cγ	   (PLCγ)	   which	   cleaves	   membrane	  
bound	  Phosphatidylinositol	   4,5-­‐bisphosphate	   (PIP2)	   to	   liberate	   inositol	   1,4,5-­‐trisphosphate	  
(IP3)	   and	   diacylglycerol	   (DAG).	   IP3	   subsequently	   results	   in	   an	   increase	   in	   intracellular	   Ca2+	  
concentration	  which	  activates	  cytosolic	  Ca2+-­‐dependent	  PLA2	  (cPLA2).	  cPLA2	  then	  cleaves	  the	  
sn-­‐2	   ester	   bond	   of	   membrane	   bound	   phospholipids	   to	   liberate	   the	   cycloxgenase	   (COX)	  
substrate	   arachidonic	   acid	   (AA)	   which	   through	   the	   concerted	   actions	   of	   COX-­‐1	   and	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The	  data	  presented	  in	  this	  chapter	  are	  limited	  in	  a	  number	  of	  ways,	  which	  are	  outlined	  and	  
discussed	  below:	  
	  
As	   data	   presented	   in	   this	   chapter	   were	   gathered	   in	   the	   latter	   stages	   of	   my	   PhD	   time	  
constraint	  became	  apparent.	  It	  would	  have	  been	  valuable	  to	  run	  repeat	  experiments	  as	  well	  
as	  further	  experiments	  including	  the	  iPLA2	  inhibitor,	  bromoenol	  lactone,	  in	  BOEC	  protocols.	  
This	  would	  address	  whether	  thrombin	  is	  in	  fact	  signalling	  via	  iPLA2	  in	  BOEC	  similar	  to	  Ach	  in	  
vessels.	  
	  
I	  also	  acknowledge	  that	  only	  BOEC	  from	  the	  cPLA2	  deficient	  patient	  was	  carried	  out	  without	  
comparison	  with	   family	   relatives	   including	  a	   sibling	  with	   the	   same	  mutation	  and	  a	  parent	  
with	  a	  heterozygote	  mutation.	  
	  
Whilst	  this	  approach,	  using	  pharmacological	  inhibition	  of	  cPLA2	  was	  valuable	  it	  would	  have	  
also	   been	   of	   interest	   to	   use	   gene	   knock	   down	   approaches	  where	   cPLA2,	   iPLA2	   and	   sPLA2	  
could	  have	  been	  targeted.	  Other	  inhibitors	  also	  include	  commercially	  available	  inhibitors	  of	  
Gq	  and	  Gs	  proteins	  which	  are	  thought	  to	  activate	  cPLA2.	  This	  would	  provide	  some	  elucidation	  
of	   the	   mechanism	   by	   which	   physiological	   agonists	   activate	   cPLA2	   and	   subsequent	  
prostacyclin	  release.	  	  
	  
Whilst	   it	   would	   have	   been	   valuable,	   in	   this	   chapter,	   it	   was	   not	   possible,	   due	   to	   time	  




Indeed,	  the	  expression	  of	  different	  PLA2	  isoforms,	  and	  pathways	  regulating	  their	  expression	  
and	   function	   is	   now	  under	   investigation	  by	   our	   group.	   Furthermore,	   as	   the	  BOEC	  derived	  
from	  the	  cPLA2α	  mutant	  patient	  in	  this	  chapter	  clearly	  represent	  a	  valuble	  tool	  to	  study	  PLA2	  






















































Figure	  6.1	  Characterisation	  of	  blood	  outgrowth	  endothelial	  cells	  (BOEC)	  from	  a	  patient	  with	  
a	  homozygous	  deletion	  of	  cPLA2α.	  (A)	  Images	  of	  BOEC	  from	  a	  cPLA2α-­‐deficient	  patient	  (top)	  
and	  healthy	  donors.	   (B)	  Number	  of	   colonies	  emerging	   from	   successful	   isolations	   (healthy;	  
n=4,	  cPLA2α	  deficient	  patient	  n=1).	  Images	  in	  panel	  A	  were	  captured	  using	  a	  light	  microscope	  
with	  a	  Nikon	  VR	  ISO3200	  camera	  attachment.	  Contrast	  and	  brightness	  enhancements	  were	  






















































Figure	  6.2	  Characterisation	  of	  blood	  outgrowth	  endothelial	  cells	  (BOEC)	  from	  a	  patient	  with	  
a	  homozygous	  deletion	  of	  cPLA2α.	  BOEC	  from	  (A)	  healthy	  donors	  and	  (B)	  a	  cPLA2α-­‐deficient	  
patients	  were	  cultured	  for	  4	  days	  shear	  stress	  conditions.	  Images	  were	  taken	  at	  the	  edge	  of	  
the	  well	  of	  cells,	  where	  shear	  stress	  is	  unidirectional	  and	  cells	  align	  and	  at	  the	  center	  of	  the	  
well	   where	   shear	   stress	   has	   no	   preferred	   direction	   and	   cells	   appear	   cobblestone	   in	  
morphology.	  Cells	  were	  stained	  for	  CD31	  (green),	  and	  VE-­‐cadherin	  (red)	  and	  imaged	  using	  a	  








































	   	  
	  
Figure	  6.3	  Effect	  of	  homozygous	  deletion	  of	  cPLA2α	  on	  prostacyclin	  release	  from	  BOEC.	  BOEC	  
from	  healthy	  patients	  (n=2-­‐4)	  and	  a	  cPLA2α-­‐deficient	  patient	  (n=1)	  were	  pre-­‐treated	  for	  24h	  
with	  IL-­‐1β	  (1ng/ml)	  followed	  by	  30	  min	  treatment	  +/-­‐	  thrombin	  (1	  unit/ml),	  A23187	  (50μM)	  
or	   arachidonic	   acid	   (AA;	   30μM)	   Data	   are	   mean	   ±	   SEM.	   Statistical	   significance	   between	  


















































Figure	  6.4	   Lipid	   release	  profile	  measured	  by	  LC-­‐MS/MS	   from	  blood	  outgrowth	  endothelial	  
cells	   (BOEC)	  from	  healthy	  (black;	  n=3)	  or	  a	  cPLA2α-­‐deficient	  patient	  (pink;	  n=1)	  pre-­‐treated	  


























































































































































































Healthy volunteers IL-1β (1ng/ml; 24 hrs) +



































	   	  
Figure	  6.6	  Effect	  of	   inhibition	  of	  cPLA2	  on	  A23187	  induced	  prostacyclin	  release	  from	  blood	  
outgrowth	   endothelial	   cells	   (BOEC).	   Concentration	   response	   curve	   for	   the	   effect	   of	   the	  
cPLA2	   inhibitor,	   pyrophenone	   (10μM-­‐	   0.1μM),	   on	   6-­‐ketoPGF1α	   production	   from	   BOEC	  
following	  24h	  pre-­‐treatment	  with	  IL-­‐1β	  (1ng/ml)	  then	  30min	  treatment	  +/-­‐	  A23187	  (50μM).	  
Data	  are	  mean	  ±	  SEM	  (n=4).	  Statistical	  significance	  was	  determined	  by	  one-­‐sample	  t-­‐test	  vs.	  













































Figure	  6.7	  Effect	  of	  inhibition	  of	  cPLA2	  on	  thrombin	  induced	  prostacyclin	  release	  from	  blood	  
outgrowth	   endothelial	   cells	   (BOEC).	   Concentration	   response	   curve	   for	   the	   effect	   of	   the	  
cPLA2	   inhibitor,	   pyrophenone	   (10μM-­‐	   0.1μM),	   on	   6-­‐ketoPGF1α	   production	   from	   BOEC	  
following	   24h	   pre-­‐treatment	   with	   IL-­‐1β	   (1ng/ml)	   then	   30min	   treatment	   +/-­‐	   Thrombin	  
(1unit/ml).	   Data	   are	   mean	   ±	   SEM	   (n=4).	   Statistical	   significance	   was	   determined	   by	   one-­‐


















































Figure	   6.8	   Effect	   of	   inhibition	   of	   cPLA2	   on	   AA	   induced	   prostacyclin	   release	   from	   blood	  
outgrowth	   endothelial	   cells	   (BOEC).	   Concentration	   response	   curve	   for	   the	   effect	   of	   the	  
cPLA2	   inhibitor,	   pyrophenone	   (10μM-­‐	   0.1μM),	   on	   6-­‐ketoPGF1α	   production	   from	   BOEC	  
following	  24h	  pre-­‐treatment	  with	  IL-­‐1β	  (1ng/ml)	  then	  30min	  treatment	  +/-­‐	  AA	  (30µM).	  Data	  
are	  mean	   ±	   SEM	   (n=3).	   Statistical	   significance	  was	   determined	   by	   one-­‐sample	   t-­‐test	   vs.	   a	  


















































Figure	  6.9	  Effect	  of	   inhibition	  of	  cPLA2	  and	  iPLA2	  on	  Ach	  induced	  prostacyclin	  release	  from	  
mouse	   aorta.	   Concentration	   response	   curves	   for	   the	   effect	   of	   the	   cPLA2	   inhibitor,	  
pyrrophenone	   (10μM-­‐	   0.1μM)	   or	   the	   iPLA2	   inhibitor,	   bromoenol	   lactone	   (BEL)	   (10µM-­‐
0.1µM),	   on	   prostacyclin	   production	   (measured	   as	   6-­‐ketoPGF1α)	   from	   mouse	   aortic	   ring	  
preparations	  pre-­‐treated	  with	   inhibitors	  for	  30	  minutes	  followed	  by	  30min	  treatment	  with	  
with	  Ach	  (1μM).	  Data	  are	  mean	  ±	  SEM	  (n=6	  per	  group).	  Statistical	  significance	  for	  the	  effect	  
of	  the	  individual	  inhibitors	  was	  determined	  using	  a	  Kruskal-­‐Wallis	  test	  for	  non-­‐normal	  data	  
































Table	  6.1	  Summary	  of	  history	  and	  characteristics	  of	  patient	  with	  homozygous	  mutation	  of	  







• Sex:	  Female	  born	  1966.	  
• Presented	  at	  2	  years	  of	  age	  with	  peptic	  ulceration.	  
• Gastrieiunostomy	  in	  1980	  for	  further	  peptic	  ulceration	  and	  duodenal	  stenosis.	  
• Diagnosed	  with	  pernicious	  anaemia.	  
• Surgery	  in	  2000	  for	  ileal	  perforation	  with	  Salmonella	  enteriditis	  infection.	  
• Renal	  biopsy	  in	  2000	  and	  following	  two	  episodes	  of	  Campylobacter	  enteritis	  lead	  to	  diagnosis	  
of	  xanthogranulomatous	  pyelonephritis;	  patient	  continues	  with	  chronic	  renal	  failure.	  
• In	   2001,	   patient	   experienced	   another	   ileal	   perforation	   and	   ileoileal	   fistula	   complicated	   by	  
Candida	   septicaemia,	   resistant	   staphylococcal	   chest	   infection,	   acute	   respiratory	   distress	  
syndrome	  and	  acute	  renal	  failure	  requiring	  haemofiltration.	  
• In	  2009,	  patient	  underwent	  transverse	  colon	  resection	  for	  volvulus.	  
• In	  2010,	  patient	  presented	  malnourished	  with	  hypoalbuminaemia	  and	  oedema,	  and	  started	  
total	  parenteral	  nutrition.	  
• In	   2010,	   patient	   developed	   biliary	   reflux	   with	   severe	   oesophagitis	   and	   structures	   and	  
required	   repeated	   oesophageal	   dilatation	   in	   2010–2011,	   but	   developed	   bronchiectasis	  
secondary	  to	  recurrent	  aspiration	  pneumonia.	  
• Further	   complications	   include	   endometriosis	   (1990),	   gall	   stones	   (2006),	   left	   ventricular	  
concentric	  hypertrophy	  with	  a	  small	  cavity,	  and	  a	  fibrotic,	  unstable	  bladder	  with	  carbapatite	  
stones,	  requiring	  ureteric	  stents	  (both	  2009)	  and	  infertility.	  
• Based	  on	  this	  presentation,	  she	  was	  diagnosed	  in	  2012	  with	  cryptogenic	  multifocal	  ulcerating	  





























Stem	  cell	  research	  is	  changing	  the	  way	  we	  think	  about	  and	  treat	  human	  disease.	  Stem	  cells	  
have	   applications	   that	   pervade	   all	   areas	   of	  modern	  medicine,	   and	   in	  many	   cases,	  will	   be	  
critical	   for	   success	   in	   the	   ongoing	   quest	   to	   treat	   human	   diseases.	   Stem	   cells,	   and	   cells	  
derived	  from	  stem	  cells	  can	  be	  used	  to:	  
• Engineer	  tissues	  and	  organs	  for	  transplant,	  thus	  overcoming	  the	  ‘organ	  waiting	   list’	  
problem.	  In	  fact,	  many	  stem	  cell	  approaches	  will	  allow	  for	  personalised	  organs	  to	  be	  
engineered	  in	  the	  laboratory.	  
• To	  develop	  regenerative	  cell	  therapies,	  whereby	  cells	  can	  be	  injected	  to	  reverse	  cell	  
dysfunction.	  
• Study	   disease	   in	   vitro	   as	   cells	   can	   be	   grown	   from	   individual	   patients	   and	   used	   to	  
phenotype	  cells.	  This	  ‘disease	  in	  a	  dish’	  concept	  sits	  at	  the	  core	  of	  translational	  and	  
personalised	  medicine	  whereby	   in	  vitro	  studies	  can	  be	  related	  directly	  to	  the	  clinic,	  
and	  indeed	  to	  individual	  patients	  or	  groups.	  
	  
In	   line	  with	  all	  of	  these,	  and	   in	  particular	  the	  concept	  of	   ‘disease	   in	  a	  dish’,	  stem	  cells	  can	  
also	  be	  used	  to	  develop	  translational	  in	  vitro	  assays	  to	  assess	  the	  safety	  and	  efficacy	  of	  other	  
therapies	   in	  modern	  medicine,	  such	  as	  biologics,	  gene	  therapies,	  and	  even	  autologous	  cell	  
therapies	  for	  individual	  patients.	  Studying	  stem	  cells	  has	  already	  resulted	  in	  paradigm	  shifts	  
in	   how	  we	   think	   about	   disease.	   Extensive	   examples	   exist	   in	   the	   literature	   illustrating	   the	  
application	  of	  different	   stem	  cells.	  Many	  of	   these	  will	  be	  discussed	   later	   in	   the	  context	  of	  





In	   my	   PhD,	   I	   have	   explored	   some	   of	   these	   applications	   and	   performed	   characterization	  
studies	  which	  will	  be	  essential	  for	  their	  use	  in	  the	  areas	  outlined	  above.	  
	  
As	  discussed	  in	  detail	  in	  Chapter	  1,	  three	  key	  families	  of	  stem	  cells	  exist	  each	  with	  benefits	  
and	   limitations.	   These	   include	  human	  embryonic	   stem	  cells	   (hESC),	   adult	   progenitor/stem	  
cells	   and	   induced	   pluripotent	   stem	   cells	   (iPSC).	   HESC	   have	   largely	   been	   considered	   as	   a	  
cornerstone	  of	  stem	  cell	   research.	  These	  cells	  have	  applications	   in	  organ	  engineering,	  and	  
have	  been	  used	  to	  study	  developmental	  aspects	  of	  human	  biology.	  In	  this	  regard,	  hESC	  have	  
also	  been	  critical	  to	  our	  knowledge	  of	  stem	  cell	  phenotype	  and	  ‘pluripotency’	  which	  is	  the	  
property	  assigned	  to	  cells	  that	  are	  able	  to	  differentiate	  in	  to	  any	  cell	  in	  the	  body.	  Using	  this	  
new	  knowledge	  of	  stem	  cells	  it	  is	  now	  possible	  to	  grow	  a	  plethora	  of	  cells	  and	  tissues	  in	  the	  
lab.	   In	   my	   PhD	   I	   have	   acquired	   or	   isolated	   these	   cells	   and	   differentiated	   them	   in	   to	  
endothelial	   cells.	   This	   gives	   rise	   to	   stem	   cell	   derived	   endothelial	   cells,	   which	   are	   truly	  
revolutionising	  cardiovascular	  disease	  research.	  In	  fact,	  given	  the	  importance	  of	  endothelial	  
cells	  in	  the	  vasculature	  of	  any	  organ,	  stem	  cell	  derived-­‐endothelial	  cells	  will	  be	  critical	  in	  any	  
and	  all	  organ	  regeneration	  programmes.	  	  
	  
As	   discussed,	   endothelial	   cells	   are	   critical	   mediators	   of	   cardiovascular	   health	   whilst	  
dysfunctional	  endothelial	  cells	  result	  in	  disease.	  It	  is	  now	  thought	  that	  endothelial	  cell	  health	  
in	  the	  body	  can	  also	  be	  regulated	  by	  adult	  stem	  cells	  (Hill	  et	  al.,	  2003;	  Timmermans	  et	  al.,	  
2009)	  and	   in	  particular	  endothelial	  progenitor	  cells.	  A	  caveat	   to	  success	   in	  using	  stem	  cell	  
derived	  endothelial	  cells	  in	  the	  future	  has	  been	  the	  need	  to	  characterise	  them	  as	  ‘authentic’	  




	  Indeed,	  any	  stem	  cell	  derived	  endothelial	  cell	  used	  in	  therapy	  or	  in	  assays	  must	  be	  able	  to	  
perform	   as	   a	   healthy	   endothelial	   cell	   and	   display	   cardinal	   hallmarks	   of	   endothelial	   cell	  
phenotype.	  Looking	  at	  some	  of	  these	  pathways	  can	  also	  reveal	  differences	  in	  phenotype	  of	  
endothelial	  cells	  between	  patient	  groups.	  This	  improves	  our	  understanding	  of	  cardiovascular	  
disease	  as	  well	  as	   serves	  as	  a	   safety	   screen	   to	  ensure	  cell	   functions	  are	  preserved	   for	  cell	  
therapy.	  
	  
In	  my	  PhD,	  I	  set	  out	  to	  study	  stem	  cell	  endothelial	  cells	  in	  terms	  of	  some	  cardinal	  endothelial	  
cell	  functions.	  These	  were	  ability	  to	  align	  under	  complex	  shear	  stress,	  respond	  to	  pathogen	  
associated	  molecular	  patterns	   (PAMPs)	  and	  release	  endothelial	  cell	  hormones	  prostacyclin	  
and	  endothelin-­‐1	  (ET-­‐1).	  I	  have	  therefore	  split	  my	  discussion	  in	  to	  characterisation	  followed	  
by	  applications	  of	  stem	  cell	  derived	  endothelial	  cells,	  namely	  blood	  outgrowth	  endothelial	  














PART	  I:	  CHARACTERISATION	  OF	  STEM	  CELL	  DERIVED	  ENDOTHELIAL	  CELLS	  
	  Alignment	  of	  endothelial	  cells	  is	  the	  result	  of	  the	  exposure	  of	  endothelial	  cells	  on	  vessels	  to	  
shear	  stress	  exerted	  by	  the	  flow	  of	  blood	  against	  the	  endothelial	  cell	  surface.	  These	  forces	  
have	  profound	  effects	  of	  the	  morphology	  and	  function	  of	  endothelial	  cells.	  This	  was	  studied	  
extensively	  in	  the	  PhD	  thesis	  of	  my	  colleague	  Dr.	  Claire	  Potter.	  In	  my	  PhD,	  I	  have	  applied	  this	  
knowledge	   to	   ensure	   that	   stem	   cell	   derived	   endothelial	   cells	   display	   the	   same	   pattern	   of	  
responses	   to	   shear	   stress,	   and	   thus	   validate	   them	  as	   endothelial	   cells.	  Modeling	   of	   shear	  
stress	  in	  vitro	  can	  be	  achieved	  using	  a	  system	  previously	  developed	  by	  our	  group	  (Potter	  et	  
al.,	  2011).	  In	  this	  model,	  endothelial	  cells	  are	  grown	  on	  6-­‐well	  culture	  flasks	  and	  placed	  on	  
an	   orbital	   shaker.	   This	   creates	   a	   wave	   of	   media,	   which	   flows	   over	   the	   endothelial	   cell	  
monolayer.	   Cells	   grown	   at	   the	   centre	   of	   the	   well	   experience	   oscillatory/non-­‐directional	  
shear	   stress	  whilst	   cells	   at	   the	   edge	   experience	   laminar/uni-­‐directional	   shear	   stress.	   Cells	  
grown	  under	  non-­‐directional	  shear	  stress	  have	  cobblestone	  morphology	  whilst	  those	  under	  
uni-­‐directional	   shear	   stress	   are	   elongated	   and	   aligned	   (see	   Chapter	   2:	   General	  Methods).	  
Indeed,	  this	  replicates	  the	  types	  of	  shear	  stress	  that	  occur	  in	  vivo,	  which	  are	  typified	  in	  the	  
aortic	   arch	   (Suo	   et	   al.,	   2007).	   In	   the	   lesser	   curvature	   of	   the	   arch,	   shear	   stress	   is	   non-­‐
directional,	  cells	  are	  cobblestone	  in	  appearance	  and	  prone	  to	  atherosclerotic	  lesions.	  In	  the	  
outer	  curvature,	  endothelial	  cells	  are	  aligned	  and	  elongated	  and	  atheroprotected	  (Suo	  et	  al.,	  
2007).	  	  
	  
This	   kind	  of	   characterisation	   is	   highly	   relevant	   to	   the	  use	  of	   stem	  cell	   derived	  endothelial	  
cells.	  Particularly	  in	  vessel	  and	  organ	  engineering	  since	  in	  the	  short	  term	  organs	  will	  need	  to	  
be	   coated	   with	   endothelial	   cells	   that	   can	   align	   under	   shear	   stress	   and	   assume	   an	  
atheroprotected	   phenotype.	   Notably,	   stem	   cell-­‐derived	   cells	   have	   already	   been	   used	   in	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vessel	  engineering.	  These	  include	  autologous	  bone	  marrow	  derived	  mononuclear	  cells	  being	  
seeded	  on	  to	  biodegradable	  scaffolds	  and	  implanted	  in	  to	  patients	  requiring	  cavopulmonary	  
connection	  grafts	  (Matsumura	  et	  al.,	  2006;	  Matsumura	  et	  al.,	  2003).	  At	  a	  median	  follow	  up	  
of	  16.7	  months,	  no	   thrombosis	  or	   restenosis	  was	   reported.	  Whether	   the	  efficacy	  of	   these	  
grafts	   is	  attributable	   to	   the	  ability	  of	  bone	  marrow	  derived	  cells	   to	   form	  endothelial	   cells,	  
which	   subsequently	   align,	   or	   whether	   flanking	   vasculature	   coats	   the	   graft	   in	   vivo	   is	  
unknown.	   In	   other	   studies,	   it	   has	   been	   shown	   that	   bone	  marrow	   derived	   cells	   can	   form	  
endothelial	   cells	   and	   smooth	  muscles,	   and	   so	   it	   appears	   likely	   that	   there	   is	   some	   role	   of	  
endothelial	   progenitor	   cells	   early	   after	   surgery.	   Patients	   at	   high	   risk	   of	   atherosclerosis	  
however	  may	   require	   ‘enhanced’	   endothelial	   cell	   functions	   and	   these	  may	   include	   grafts	  
with	  pre-­‐aligned	  stem	  cell	  derived	  endothelial	  cells.	  In	  the	  case	  of	  whole	  organ	  engineering,	  
and	  with	  the	  fact	  that	  post-­‐transplant	  atherosclerosis	  is	  a	  major	  problem,	  it	  is	  reasonable	  to	  
speculate	   that	   endothelial	   cell	   alignment	   might	   be	   critical	   to	   success.	   Indeed,	   the	  
importance	  of	  vascularisation	  of	  engineered	  tissues	  has	  been	  recognized	  (Chen	  et	  al.,	  2009),	  
and	  is	  currently	  a	  limitation	  in	  the	  organ	  engineering	  field.	  Equally,	  in	  patients	  with	  profound	  
endothelial	   cell	   dysfunction,	   including	   dysfunction	   in	   bone	  marrow-­‐endothelial	   progenitor	  
cell	  pathways,	  the	  ability	  of	  cells	  to	  align	  under	  shear	  stress	  might	  be	  compromised.	  In	  many	  
ways	  therefore,	  assessment	  of	  the	  ability	  of	  stem	  cell	  derived	  endothelial	  cells	  to	  align	  under	  
shear	  stress	  is	  important.	  
	  
Human	  embryonic	   stem	  cell	  derived	  endothelial	   cells	   (hESC-­‐EC)	   can	  now	  be	  derived	  using	  
established	   protocols.	   These	   cells,	   as	   in	   other	   fields,	   have	   been	   used	   to	   study	   the	  
development	  of	  the	  vascular	  system,	  and	  guided	  are	  understanding	  of	  adult	  progenitor	  stem	  
cells.	   In	   this	   regard,	  hESC-­‐EC	  are	  useful	  models	  of	  vasculogenesis	  and	  have	  applications	   in	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therapy	  and	   in	  vitro	   assays	   for	  assessment	  of	  drugs	  effecting	  endothelial	   cells.	  These	  cells	  
have	  been	  characterised	  as	  expressing	  CD31,	  VE-­‐cadherin	  and	  being	  able	   to	   form	  vascular	  
networks	   in	   vivo.	  One	  advantage	  of	   these	  cells	  has	  been	   the	  ability	   to	  grow	   these	  cells	   in	  
large	  numbers	  as	  hESC	  have	  unlimited	  self-­‐renewal	  capacity.	  In	  my	  PhD,	  I	  have	  shown	  that	  
CD31+	   hESC-­‐EC,	   unlike	   endothelial	   cells	   from	   vessels;	   do	   not	   align	   under	   shear	   stress.	  
However,	   these	   cells	   appear	   to	   already	   express	   an	   elongated	   phenotype	   under	   normal	  
culture	   conditions.	   This	   elongated	   phenotype	   is	   typically	   associated	  with	   endothelial	   cells	  
exposed	  to	  laminar/uni-­‐directional	  shear	  stress,	  which	  are	  protected	  from	  atherosclerosis.	  It	  
is	   conceivable	   therefore	   that	   these	   cells	   might	   already	   express	   a	   protected	   phenotype,	  
which	  would	  be	  useful	  in	  organ	  engineering	  for	  the	  reasons	  already	  outlined.	  To	  assess	  this	  
fully,	  an	  animal	  model	  of	  post-­‐transplant	  atherosclerosis	   in	  which	  stem	  cell	  derived	  organs	  
have	   been	   transplanted,	   would	   be	   needed,	   and	   this	   is	   currently	   not	   available.	   More	  
knowledge	  on	   the	   fate	   and	   function	   of	   injected	   stem	   cell	   derived	   endothelial	   cells	   is	   also	  
required	  and	  this	  was	  beyond	  the	  scope	  of	  my	  PhD.	  Conversely,	  the	  inability	  of	  hESC-­‐EC	  to	  
align	   under	   shear	   stress	  might	   raise	   some	   questions	   regarding	   their	   true	   endothelial	   cell	  
phenotype.	  Again	  further	  investigation	  of	  how	  manipulation	  of	  the	  differentiation	  of	  hESC	  in	  
to	  hESC-­‐EC	  might	  affect	  this,	  whilst	  interesting,	  was	  beyond	  the	  scope	  of	  my	  PhD.	  	  
	  
Others	  have	  also	  investigated	  the	  importance	  of	  eNOS	  expression	  and	  function	  in	  stem	  cell	  
derived	  endothelial	  cells	  (Ward	  et	  al.,	  2011)	  and	  expression	  by	  hESC-­‐EC	  has	  been	  illustrated.	  
Since	  NO	   release	  by	   endothelial	   cells	   in	   vitro	   is	   low	  and	   typically	   requires	   highly	   sensitive	  
assays	   employing	   mass	   spectrometry	   for	   NO	   to	   be	   detected	   (Palmer	   et	   al.,	   1987),	  
characterisation	  of	  this	  pathway	  and	  making	  comparisons	  with	  endothelial	  cells	  from	  vessels	  
is	  therefore	  more	  difficult	  but	  will	  be	  important	  to	  investigate	  in	  future	  studies	  in	  this	  field.	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In	  my	  PhD	  however,	  I	  chose	  to	  focus	  on	  the	  pathways	  and	  functions	  described	  as	  these,	  at	  
the	  time,	  can	  be	  measured	  in	  in	  vitro	  assays.	  
	  
In	  terms	  of	  innate	  immunity,	  and	  as	  we	  have	  previously	  shown	  (Földes	  et	  al.,	  2010),	  hESC-­‐EC	  
also	   expressed	   some	   differences	   versus	   endothelial	   cells	   from	   vessels.	   As	   discussed	   in	  
Chapter	  1,	  endothelial	  cells	  are	  critical	  sensors	  of	  pathogens.	  PAMPs	  on	  or	  in	  pathogens	  are	  
recognised	  by	  pattern	  recognition	  receptors,	  and	  in	  endothelial	  cells	  TLR4	  and	  NOD1	  are	  the	  
best	   studied.	   HESC-­‐EC,	   unlike	   endothelial	   cells	   from	   vessels	   did	   not	   respond	   to	   the	   TLR4	  
agonist	   LPS	   to	   release	   inflammatory	   cytokines	   that	   mediate	   immune	   reactions,	   and	  
expressed	   lower	   levels	  of	  TLR4	   than	  HUVEC.	  This	  again,	   could	  call	   to	  question	   to	  maturity	  
and	   ‘endothelial-­‐ness’	  of	   these	   cells,	   certainly	   in	   the	  particular	   cell	   line	   studied.	  However,	  
and	  as	  suggested	  in	  the	  summary	  of	  Chapter	  3	  and	  4,	  a	   lack	  of	  TLR4	  might	  afford	  hESC-­‐EC	  
some	  further	  protection	  from	  atherosclerosis.	  As	  discussed,	  TLR4	  expression	  and	  activation	  
is	  now	  centrally	  implicated	  in	  atherosclerosis	  (Edfeldt	  et	  al.,	  2002;	  Paul-­‐Clark	  et	  al.,	  2012).	  In	  
line	  with	  this,	  kidney	  transplants	  of	  patients	  with	  an	  Asp299Gly	  mutation	  in	  the	  TLR4	  gene	  
which	  confers	  reduced	  TLR4	  function	  have	  been	  found	  to	  be	   less	  prone	  to	  post-­‐transplant	  
atherosclerosis.	   Whether	   this	   is	   a	   result	   of	   circulating	   cells	   expressing	   Asp299Gly	   TLR4	  
entering	   the	   graft	   or	   endothelial	   cells	   with	   Asp299Gly	   colonizing	   the	   graft	   is	   unknown.	  
Indeed,	  TLR4	  on	  endothelial	  cells	  has	  been	  directly	  linked	  with	  atherosclerosis	  and	  inhibition	  
of	  TLR	  in	  endothelial	  cells	  can	  explain	  some	  of	  the	  atheroprotective	  effect	  of	  statins	  (Yang	  et	  
al.,	  2010).	  However,	  a	  lack	  of	  TLR4	  in	  any	  cell	  type	  could	  result	  in	  immune-­‐compromise,	  and	  
in	  the	  case	  of	  hESC-­‐EC	  when	  used	  therapeutically,	  post-­‐transplant	  infection	  and	  graft	  failure	  
could	   occur.	   I	   therefore	   looked	   at	   another	   pattern	   recognition	   receptor	   expressed	   by	  
endothelial	  cells,	  NOD1.	  NOD1,	  like	  TLR4,	  orchestrates	  responses	  to	  Gram-­‐negative	  bacteria	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as	  well	  as	  some	  Gram-­‐positive	  bacteria.	  My	  group	  has	  previously	  described	  the	  role	  of	  NOD1	  
in	  endothelial	  cells	  from	  vessels	  (Gatheral	  et	  al.,	  2012).	  HESC-­‐EC,	  like	  endothelial	  cells	  from	  
vessels	   expressed	   NOD1,	   and	   responded	   to	   NOD1	   agonists	   to	   release	   inflammatory	  
cytokines.	   This	   raised	   the	  question	  as	   to	  whether	  hESC-­‐EC	  were	   immune-­‐compromised	  or	  
able	   to	   sense	   Gram-­‐negative	   bacteria	   through	   NOD1.	   To	   investigate	   this,	   I	   developed	  
protocols	   with	   the	   support	   of	   Dr.	   Aurica	   Telcian	   and	   Dr.	   Mike	   Edwards	   in	   the	   Dept.	   of	  
Respiratory	  Medicine,	   Imperial	   College	   London.	   In	   these	   protocols,	   hESC-­‐EC	   responded	   to	  
the	  Gram-­‐negative	  bacteria	  Haemophilus	  influenzae	  to	  release	  the	  ubiquitous	  inflammatory	  
cytokine	  CXCL8.	  As	  with	  other	   types	  of	  Gram-­‐negative	  bacteria,	  Haemophilus	   influenzae	   is	  
reportedly	  sensed	  by	  cells	  via	  TLR4	  and/or	  NOD1	  PRR	  pathways	  (Hirano	  et	  al.,	  2009;	  Ratner	  
et	   al.,	   2007).	   Taking	   a	   pharmacological	   approach,	   using	   selective	   inhibitors	   of	   NOD1	   and	  
RIP2,	   and	   a	  molecular	   approach,	   using	  NOD1	   targeting	   siRNA,	   I	  was	   able	   to	   demonstrate	  
that	  this	  response	  was	  driven	  by	  NOD1	  activation.	  Interestingly,	  knockdown	  of	  50%	  of	  NOD1	  
mRNA	  was	  sufficient	  to	  result	   in	  an	  almost	  complete	   loss	  of	   function	  of	  NOD1	   in	  terms	  of	  
response	  to	  the	  NOD1	  agonist,	  C12-­‐iE-­‐DAP	  and	  Haemophilus	  influenzae.	  	  This	  is	  likely	  to	  be	  
due	  to	  the	  dynamic	  relationship	  between	  the	  agonists	  and	  the	  NOD1	  receptor	   in	  terms	  of	  
affinity	  and	  efficacy.	  It	  is	  conceivable	  that	  when	  an	  agonist	  binds	  its	  receptor	  this	  might	  not	  
translate	   in	   to	  measurable	   responses	   and	   so	   loss	   of	   50%	   of	   the	   binding	   sites	   (by	   loss	   of	  
expression)	   results	   in	   apparently	   greater	   loss	   of	   function.	   In	   any	   case,	   these	   data	   clearly	  
demonstrated	   that	   in	   TLR4-­‐deficient	   hESC-­‐EC,	   NOD1	   was	   able	   to	   support	   inflammatory	  
responses	  in	  vitro	  to	  Haemophilus	  influenzae.	  	  
	  
It	  was	  also	  determined	   that	  hESC-­‐EC	  do	  not	   release	   the	  endothelial	   cell	  hormone	  ET-­‐1.	   In	  
our	   group,	   we	   have	   since	   go	   on	   to	   show	   that	   the	   low	   ET-­‐1	   release	   from	   hESC-­‐EC	   was	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reflected	  by	  relatively	  low	  levels	  of	  gene	  expression	  when	  compared	  to	  HUVEC	  (Reed	  et	  al.,	  
2014).	   ET-­‐1	   is	   typically	   released	   by	   endothelial	   cells	   from	   vessels	   under	   basal	   culture	  
conditions,	   which	   in	   vivo	   is	   inhibited	   by	   interactions	   with	   other	   cells	   including	   vascular	  
smooth	   muscle	   and	   fibroblasts	   (Stewart	   et	   al.,	   1990).	   High	   levels	   of	   ET-­‐1	   however	   are	  
associated	   with	   cardiovascular	   disease.	   Thus,	   lack	   of	   ET-­‐1	   release	   under	   basal	   conditions	  
might	  give	  hESC-­‐EC	  a	  further	  therapeutic	  advantage.	  Conversely,	   low	  levels	  of	  prostacyclin	  
release	  seen	  in	  hESC-­‐EC,	  which	   is	  protective,	  could	  render	  these	  cells	  a	  potential	  adherent	  
surface	   for	  platelets	  and	   leukocytes	  and	  result	   in	  graft	   failure.	  All	  of	   these	   features	   tested	  
will	  be	  critical	   to	  success	  of	   stem	  cell	  derived	  endothelial	   cell	   therapy,	  and	  may	   represent	  
bioassays	  to	  ensure	  safety	  and	  efficacy	  of	  stem	  cell	  therapies	  as	  they	  become	  established.	  	  
	  
Responses	   to	   shear	   stress,	   TLR4	   function	   and	   vasoactive	   hormone	   release	   also	   represent	  
pathways	  that	  can	  be	  manipulated	  to	  improve	  therapeutic	  utility.	  As	  discussed,	  the	  idea	  of	  
engineering	  cells	  in	  vitro	  to	  improve	  therapeutic	  utility	  is	  not	  new	  (Reed	  et	  al.,	  2012;	  Ward	  
et	   al.,	   2011).	   It	   is	   conceivable,	   that	   the	   most	   useful	   therapeutic	   stem	   cell	   is	   one	   that	   is	  
resistant	  to	  atherosclerosis	  and	  able	  to	  release	  high	  levels	  of	  protective	  hormones	  including	  
prostacyclin.	   Assays	   to	   test	   the	   phenotype	   of	   these	   cells	   for	   individual	   patients	   will	   be	  
equally	  critical	  to	  success.	  
	  
Endothelial	  cells	  grown	  from	  adult	  progenitors,	  so	  called	  blood	  outgrowth	  endothelial	  cells	  
(BOEC),	  did	  respond	  to	  shear	  stress.	  The	  ability	  of	  BOEC	  to	  align	  under	  shear	  stress	  has	  been	  
shown	   previously	   as	   this	   is	   important	   for	   vessel	   engineering	   (Ensley	   et	   al.,	   2012).	  
Nonetheless,	   given	   that	   the	   protocols	   to	   derive	   BOEC,	   and	   the	   definition	   thereof,	   are	  
inconsistent	  across	  publications,	  it	  was	  important	  that	  I	  demonstrate	  this	  in	  BOEC	  grown	  for	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my	   PhD.	   It	   has	   also	   been	   recognised	   that	   basic	   science	   studies	   on	   the	   biochemical	   and	  
biomechanical	   signaling	   involved	   in	   endothelial	   cell	   alignment	   will	   be	   critical	   to	   our	  
understanding	  of	  vascular	  disease	  (Glynn	  and	  Hinds,	  2013).	  This	  is	  a	  research	  direction	  being	  
pursued	  in	  the	  group	  and	  as	  BOEC	  can	  be	  derived	  from	  patients,	  these	  cells,	  when	  used	  in	  
this	   shear	   stress	   model	   are	   an	   ideal	   tool	   to	   study	   endothelial	   cell	   alignment	   signaling	   in	  
health	  and	  disease.	  It	  is	  conceivable,	  that	  BOEC	  derived	  from	  some	  patients	  have	  differences	  
in	   the	   ability	   to	   align	   under	   shear	   stress	   and	   this	   will	   be	   important	   to	   recognise	   when	  
considering	  use	  of	  autologous	  cells	  in	  vessel	  and	  organ	  engineering.	  
	  
BOEC	  also	  responded	  to	  the	  TLR4	  agonist	  LPS	  and	  the	  NOD1	  agonist,	  C12-­‐iE-­‐DAP	  suggesting	  
a	   fully	   mature	   innate	   immune	   phenotype	   comparable	   to	   endothelial	   cells	   from	   vessels.	  
BOEC	  also	  released	  ET-­‐1	  and	  prostacyclin	  at	   levels	  at	   least	  comparable	  to	  endothelial	  cells	  
from	   vessels,	  with	   a	   tendency	   for	   greater	   release.	   IPSC-­‐derived	   endothelial	   cells	   (iPSC-­‐EC)	  
also	  responded	  to	  PAMPs	  and	  released	  prostacyclin	  and	  ET-­‐1,	  although	  I	  was	  unable	  to	  test	  
the	  ability	  of	  these	  cells	  to	  respond	  to	  shear	  stress.	  Nonetheless,	  my	  PhD	  represents	  the	  first	  
comparative	  study	  of	  responses	  of	  different	  stem	  cell	  derived	  endothelial	  cells	  to	  in	  terms	  of	  
these	  key	  endothelial	  cell	  hallmarks.	  
	  
Indeed,	   iPSC-­‐derived	   cells,	   like	   BOEC,	   can	   also	   be	   used	   to	   study	   patient	   cells	   and	   model	  
‘disease	  in	  a	  dish’.	  IPSC-­‐derived	  cells	  however	  have	  been	  through	  genetic	  manipulation	  that	  
arguably	   takes	   them	  another	  degree	  of	   separation	   from	  the	   in	  vivo	   situation.	  Unlike	  adult	  
progenitors,	   IPSC	   are	   also	   derived	   from	   somatic	   cells	   and	   are	   artificial.	   Using	   adult	  
progenitor	  cells	  might	  be	  preferable	  to	  study	  vessel	  biology	  as	  these	  are	  derived	  from	  a	  cell	  
type	  that	  exists	  putatively	   in	  vascular	  physiology.	  One	  major	   limitation	  of	  adult	  progenitor	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cell	  studies	  and	  particularly	  for	  BOEC	  however,	  is	  that	  these	  cells	  are	  low	  in	  number	  in	  the	  
circulation	   and	   are	   difficult	   to	   expand	   from	   blood.	   IPSC-­‐EC	   however	   can	   be	   expanded	   in	  
large	   numbers	   because	   of	   the	   highly	   pluripotent	   nature	   of	   IPSC	   in	   vitro.	   This	   has	   been	  
addressed	   in	   the	   literature	   in	  a	  pioneering	   study	  by	  Geti	   et	   al.	   (Geti	   et	   al.,	   2012)	  wherein	  
iPSC	  were	  derived	  from	  BOEC.	  This	  overcomes	  some	  of	  the	  limitation	  of	  BOEC	  but	  might	  also	  
ensure	   that	   iPSC-­‐EC	   retain	   representation	  of	   the	  vasculature.	  The	   requirement	   for	  genetic	  
manipulation	   however	   remains	   an	   issue,	   and	   as	   discussed,	   transgene	   free	   approaches	   to	  
engineering	   iPSC	  are	  being	   investigated.	  With	   this	   knowledge	   in	  mind,	   I	   choose	   to	  pursue	  
BOEC	  as	  a	  tool	  to	  study	  endothelial	  cells	  and	  apply	  them	  to	  a	  pharmacological	  assay	  in	  which	  
an	  endothelial	  cell	  interface	  is	  critical,	  and	  to	  phenotype	  a	  patient	  with	  a	  mutation	  in	  cPLA2α	  
















PART	   II:	   APPLICATION	   OF	   BLOOD	   OUTGROWTH	   ENDOTHELIAL	   CELLS	   IN	  
PHARMACOLOGICAL	  BIOASSAYS	  
	  
Testing	  the	  potential	  of	  biologics	  to	  cause	  cytokine	  storm	  responses	  
The	  case	  for	  the	  requirement	  of	  improved	  human	  tissue	  bioassays	  to	  detect	  cytokine	  release	  
syndrome	  was	  emphasised	  by	  the	  unexpected	  and	  life	  threatening	  cytokine	  release	  caused	  
by	   the	   CD28	   superagonist,	   TGN1412	   (Suntharalingam	   et	   al.,	   2006).	   This	   occurred	   despite	  
TGN1412	   passing	   the	   required	   preclinical	   safety	   tests.	   Importantly,	   these	   tests	   not	   only	  
included	  the	  use	  of	  standard	  laboratory	  animals	  and	  primates	  but	  also	  human	  T-­‐cells	  in	  vitro	  
(Stebbings	  et	  al.,	  2007)	  which	  were	  the	  target	  cell	  for	  this	  therapy.	  It	  was	  therefore	  not	  clear	  
how	   TGN1412	   could	   appear	   innocuous	   in	   animal	   models,	   and	   target	   human	   cells,	   but	  
precipitate	  such	  rapid	  and	  profound	  side	  effect	  in	  humans.	  In	  this	  way,	  TGN1412	  defined	  an	  
urgent	   unmet	   clinical	   need	   for	   improved	   human	   cell-­‐based	   bioassays	   to	   detect	   cytokine	  
storm	  in	  response	  to	  biological	  therapies.	  
	  
We	  now	  know	  that	  TGN1412	  does	  not	  activate	  PBMCs	  to	  release	  cytokines	  when	  antibodies	  
are	  added	  in	  aqueous	  phase,	  unless	  there	  is	  an	  endothelial	  cell	  interface	  present	  (Findlay	  et	  
al.,	  2011b;	  Stebbings	  et	  al.,	  2007).	  The	   interaction	  with	  endothelial	   cells	  and	  PBMCs	   likely	  
contributes	  receptor	  interactions,	  co-­‐stimulatory	  signals	  and	  immobilisation	  of	  the	  antibody,	  
which	   in	   turn	   activates	   cytokine	   release.	   This	   can	   be	   mimicked	   when	   TGN1412	   is	  
immobilised	  by	  non-­‐specific	  binding	  to	  a	  solid	  phase	  platform	  such	  as	  plastic	  (Findlay	  et	  al.,	  
2010;	  Findlay	  et	  al.,	  2011b).	  Whilst,	  immobilising	  biologics	  to	  plastic	  has	  its	  advantages	  and	  
provides	   a	   simpler	   solution	   than	   combining	   PBMCs	   with	   endothelial	   cells,	   it	   is	   well	  
recognised	  that	  this	  represents	  a	  non-­‐physiological	  system	  (Bugelski	  et	  al.,	  2009;	  Findlay	  et	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al.,	   2011a).	   In	   fact,	   the	   extent	   to	   which	   a	   test	   antibody	   or	   other	   biologic	   undergoes	  
‘immobilisation’	   in	   vivo	   might	   be	   a	   physiological	   pathway	   and	   a	   determining	   factor	   in	  
whether	  a	  cytokine	  storm	  occurs	  and	  this	  may	  occur	  differentially	  in	  different	  patients.	  	  
	  
Pioneering	  studies	  by	  Stebbings	  et	  al.	  were	  the	   first	   to	   illustrate	  that	  endothelial	  cells	  and	  
PBMCs	  in	  co-­‐culture	  detect	  cytokine	  storm	  responses	  to	  TGN1412	  (Stebbings	  et	  al.,	  2007).	  It	  
is	  now	  known	  that	  like	  immobilised	  antibody	  assays,	  endothelial	  cell	  co-­‐culture	  assays	  also	  
sense	  other	  cytokine	  storm	  causing	  drugs	  including	  Campath	  and	  OKT3	  to	  release	  IL-­‐2,	  IL-­‐8,	  
IL-­‐6,	  TNFα	  and	  IFNγ.	   	  As	  our	  group	  (Bailey	  et	  al.,	  2012)	  and	  others	  (Wolf	  et	  al.,	  2012)	  have	  
recently	   described,	   an	   alternative	   approach	   is	   to	   test	   therapeutic	   antibodies	   for	   cytokine	  
storm	  responses	  using	  undiluted	  human	  whole	  blood.	  Human	  whole	  blood	  responds	  readily	  
to	   TGN1412-­‐like	   antibodies	   in	   a	   way	   that	   does	   not	   require,	   and	   is	   not	   enhanced	   by,	   co-­‐
culture	   with	   endothelial	   cells	   (Bailey	   et	   al.,	   2012).	   However,	   whole	   blood	   assays	   have	  
recently	  been	  criticised	  (Thorpe	  et	  al.,	  2013a)	  are	  less	  sensitive	  (Bailey	  et	  al.,	  2012;	  Thorpe	  
et	   al.,	   2013a),	   do	   not	   discriminate	   between	   mild	   and	   severe	   cytokine	   storm	   inducing	  
therapeutics	  (Bailey	  et	  al.,	  2012)	  and	  thus	  do	  not	  adequately	  recapitulate	  the	  full	  extent	  of	  
cytokine	  storm	  responses.	  	  
	  
Accordingly,	   a	   fundamental	   requirement	   for	   any	   cytokine	   release	   assay	   is	   that	   it	   can	  
delineate	  mild	   and	   severe	   cytokine	   storm	   causing	  drugs	   from	  non-­‐cytokine	   storm	   causing	  
drugs	  (Thorpe	  et	  al.,	  2013a).	  The	  extent	  to	  which	   in	  vitro	  cytokine	  release	  should	  correlate	  
with	  absolute	  values	  detected	  in	  serum	  has	  also	  been	  debated	  widely	  (Thorpe	  et	  al.,	  2013a,	  




Whilst	  endothelial	  cell	  co-­‐culture	  assays,	  as	  well	  as	  other	  assays,	  have	  been	  used	  to	  study	  
some	  of	  the	  potential	  mechanisms	  associated	  with	  TGN1412	  induced	  cytokine	  storm,	  these	  
assays	  have,	  to	  date,	  not	  been	  applied	  directly	  to	  study	  patient	  responses	  and	  patterns	  of	  
cytokine	  release	   in	  patients.	  However,	  current	  endothelial	  cell:PBMC	  assays	  where	  human	  
umbilical	  vein	  endothelial	  cells	  (HUVEC)	  are	  grown	  in	  co-­‐culture	  with	  the	  PBMCs	  of	  another	  
donor,	  inevitably	  rely	  on	  mixing	  of	  heterologous	  cells,	  and	  so,	  in	  fact,	  cannot	  be	  applied	  to	  
personalised	   medicine.	   Furthermore,	   heterologous	   mixtures	   of	   cells	   may	   be	   prone	   to	  
inflammatory	  activation,	  which	  may	  interfere	  with	  cytokine	  storm	  detection.	  Indeed,	  recent	  
data	   from	  our	   group	   showed	   that,	   in	   a	  whole	  blood:	  HUVEC	  mixed	   tissue	  bioassay,	   there	  
was	   an	   inflammatory	   activation	   caused	  by	  mixing	   of	  HUVEC	   and	  blood	   in	   at	   least	   10%	  of	  
blood	   donors	   (Bailey	   et	   al.,	   2012).	   It	   is	   also	   known,	   for	   example,	   that	   lymphocytes	   from	  
different	   donors	   differentially	   regulate	   inflammatory	   pathways	   in	   co-­‐culture	   with	  
endothelial	  cells	  from	  human	  aortic	  endothelial	  cells	  (Morris	  et	  al.,	  1994).	  In	  line	  with	  this,	  
and	   more	   recently,	   key	   opinion	   leaders	   in	   field	   have	   also	   suggested	   that	   the	   use	   of	  
heterologous	  co-­‐culture	  assays	  might	  be	  a	  potential	   limitation	  in	  endothelial	  cell:	  PBMC	  o-­‐
culture	  assays	  used	  to	  test	  for	  cytokine	  storm	  responses	  (Finco	  et	  al.,	  2014).	  
	  
Clearly	  and	  logically,	  the	  best	  form	  of	  endothelial	  cell:	  PBMC	  bioassay,	  where	  mixed	  donor	  
immune	   responses	   could	  be	  avoided,	  would	  be	  one	   that	  uses	   cells	   from	   the	   same	  donor.	  
Such	   an	   assay	   could	   then	   be	   used	   to	   study	   patient	   responses	   to	   biologics	   and	   yield	   new	  
knowledge	  on	  cytokine	  release	  syndrome	  and	  how	  to	  use	  and	  develop	  biologics	  optimally.	  
PBMCs	  are	  easy	  to	  obtain	  from	  blood	  donated	  by	  volunteers,	  but	  adult	  endothelial	  cells	  on	  
blood	  vessels	  are	  inaccessible	  and	  can	  only	  be	  obtained	  from	  tissue	  removed	  in	  surgery	  or	  




With	  the	  advent	  of	  stem	  cell	  technology	  and	  its	  application	  in	  translational	  and	  personalised	  
medicine	  research,	  I	  sought	  to	  apply	  endothelial	  cells	  derived	  from	  adult	  progenitors	  (BOEC)	  
to	  an	  endothelial	  cell:	  PBMC	  co-­‐culture	  bioassay.	  As	  BOEC	  are	  derived	  from	  PBMCs,	  taking	  
this	  approach	  uniquely	  allows	  both	  cell	  types	  to	  be	  derived	  from	  the	  same	  donor.	  
	  
I	  chose	  to	  apply	  BOEC	  in	  this	  assay	  not	  least	  because	  they	  have	  a	  phenotype	  consistent	  with	  
endothelial	  cells	  from	  vessels	  but,	  as	  discussed,	  can	  also	  be	  derived	  from	  patients.	  It	  is	  fully	  
conceivable	   that	   differences	   in	   phenotype	   or	   target	   expression	   on	   BOEC	   could	   result	   in	  
variation	  in	  susceptibility	  to	  cytokine	  storm	  as	  well	  as	  efficacy	  of	  the	  biologic	  being	  tested.	  In	  
support	  of	   this,	  we	  have	   recently	   shown	  that	  BOEC	   from	  patients	  with	  pulmonary	  arterial	  
hypertension	  have	  an	  increased	  inflammatory	  response	  to	  interferons	  (George	  et	  al.,	  2013).	  
Others	   have	   shown	   that	   disease	   phenotype	   is	   retained	   in	   BOEC	   from	  patients	  with	   COPD	  
(Paschalaki	  et	  al.,	  2013).	  I	  have	  also	  shown	  in	  this	  thesis	  (Chapter	  6)	  that	  BOEC	  can	  be	  used	  
to	   phenotype	   patients	   with	   genetic	   mutations	   affecting	   cardiovascular	   pathways.	   Using	  
autologous/same	  donor	  BOEC:PBMC	  co-­‐culture	  assays	   in	  preclinical	   testing	  has	   its	  obvious	  
advantages	   however,	   the	   ultimate	   use	   of	   this	   approach	   will	   be	   in	   personalised	  medicine	  
where	  drugs	  can	  be	  tested	  for	  safety	  and	  efficacy	  in	  individual	  patients	  with	  target	  disease.	  
	  
For	  autologous	  BOEC:PBMC	  co-­‐cultures	  to	  be	  useful,	  I	  first	  sought	  to	  ensure	  that	  autologous	  
BOEC:PBMC	  co-­‐cultures	  respond	  avidly	  to	  more	  classical	  inflammatory	  insults.	  As	  discussed	  
at	   length,	   endothelial	   cells	   and	   PBMCs	   respond	   to	   pathogen	   stimuli	   and	   cytokines	   to	  




On	   the	   whole,	   CXCL8	   release	   stimulated	   from	   PBMCs	   was	   less	   than	   seen	   for	   BOEC	   in	  
response	  to	  PAMPs	  and	  this	  is	  expected	  for	  these	  cell	  types.	  When	  cells	  were	  stimulated	  in	  
co-­‐culture	  CXCL8	  release	  was	  essentially	  equivalent	  to	  the	  release	  from	  BOEC	  alone,	  except	  
for	  experiments	  with	  LPS	  where	  there	  was	  a	  tendency	  to	  a	  greater	  than	  additive	  effect.	  This	  
is	   consistent	   with	   what	   is	   known	   for	   endothelial	   cell	   interactions	   with	  monocytes	   where	  
cells	  in	  co-­‐culture	  are	  known	  to	  bi-­‐directionally	  regulate	  responses	  to	  TLR4	  ligands(Ward	  et	  
al.,	  2009).	  
	  
As	  discussed,	  to	  validate	  this	  same	  donor	  BOEC:PBMC	  co-­‐culture	  assay	  as	  a	  cytokine	  storm	  
assay	  the	  following	  criteria	  where	  tested:	  
• Ability	  to	  sense	  TGN1412	  to	  release	  IL-­‐8,	  IL-­‐6,	  IL-­‐2,	  IFNγ	  and	  TNFα.	  
• To	   delineate	   severe	   (TGN1412)	   and	  mild	   (Campath)	   cytokine	   storm	   causing	   drugs	  
from	  non-­‐cytokine	  storm	  causing	  drugs	  (Herceptin,	  Avastin	  and	  Arzerra).	  
Given	   restrictions	   on	   the	   availability	   of	   original	   TGN1412	  material,	   in	  my	   initial	   validation	  
experiments	  for	  this	  assay	  I	  used	  a	  TGN1412-­‐like	  anti-­‐CD28	  superagonist	  (ANC28)	  which	  can	  
be	  used	  to	  model	  TGN1412	  responses	  (Waibler	  et	  al.,	  2008).	  
	  	  
When	  CXCL8	  was	  measured	   as	   a	   read	  out	   PBMC	  or	  BOEC	   cultures	   alone	  did	   not	   respond	  
appreciably	   to	   any	   of	   the	   antibodies	   tested	  when	   treated	   as	  mono-­‐cultures.	   Similarly	   co-­‐
cultures	  of	  PBMCs	  and	  BOEC	   incubated	  with	  Herceptin,	  Avastin	  or	  Arzerra	  did	  not	   release	  
increased	   levels	  of	  CXCL8.	  However,	  co-­‐cultures	  of	  same	  donor	  PBMCs	  and	  BOEC	  released	  
increased	  levels	  of	  CXCL8	  in	  a	  concentration	  dependent	  manner	  when	  stimulated	  with	  the	  
TGN1412-­‐like	   anti-­‐CD28	   superagonist,	   ANC28,	   or	   with	   Campath	   where	   ANC28>Campath.	  
This	  correlates	  with	   the	  expected	  severity	  of	  cytokine	  storm	  for	   these	  drugs	   (Eastwood	  et	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al.,	   2010;	   Suntharalingam	   et	   al.,	   2006).	   Although	   CXCL8	   is	   key	   cytokine	   associated	   with	  
cytokine	   storm	   (Suntharalingam	   et	   al.,	   2006),	   vascular	   inflammation	   (Sprague	   and	   Khalil,	  
2009)	  and	  sepsis	  (Gatheral	  et	  al.,	  2012),	  accordingly,	  in	  order	  to	  fully	  characterise	  this	  assay	  I	  
measured	  a	   full	   range	  of	   cytokines.	  Using	  an	  MSD	  multi-­‐plex	  platform	   I	  was	  able	   to	   show	  
that	   in	   addition	   to	   CXCL8,	   other	   obligatory	   members	   of	   the	   ‘cytokine	   storm’	   response,	  
including,	  GM-­‐CSF,	  IL-­‐6,	  IL-­‐1β,	  IL-­‐10,	  IFNγ	  and	  IL-­‐2	  were	  significantly	  increased	  in	  response	  to	  
the	  TGN1412-­‐like	  anti-­‐CD28	  superagonist,	  ANC28.	  In	  addition	  to	  these	  standard	  cytokines,	  I	  
also	  measured	  release	  of	  8	  chemokines	  by	  cells	  stimulated	  with	  ANC28.	  Of	  the	  chomokines	  
measured	  ANC28	   stimulated	   release	   of	   eotaxin,	  MIP-­‐1β,	   TARC	   and	   IP10	   by	   co-­‐cultures	   of	  
BOEC	  and	  PBMCs.	  	  Interestingly,	  for	  both	  IL-­‐1β	  and	  MIP-­‐1β	  release,	  PBMCs	  did	  not	  require	  
an	   endothelial	   cell	   interface.	   With	   the	   exception	   of	   eotaxin	   and	   MIP-­‐1β,	   less	   cytokine	  
release	  was	  detected	  in	  response	  to	  Campath	  than	  seen	  with	  ANC28.	  It	  is	  also	  important	  to	  
note	   that	   the	  absolute	   levels	  of	  cytokines	   induced	  by	  ANC28	   in	   this	  autologous	  co-­‐culture	  
system	  were	  relatively	  high	  and	  much	  greater	  than	  seen	  in	  whole	  blood	  assays	  (Bailey	  et	  al.,	  
2012).	  	  
	  
Given	  the	  number	  of	  cytokines	  and	  chemokines	  measured	  in	  the	  different	  assay	  conditions,	  I	  
considered	  it	  important	  to	  analyse	  this	  data	  using	  an	  unbias	  approach	  to	  visualize	  the	  data.	  
Furthermore,	  for	  TGN1412,	  as	  for	  new	  biological	  drugs,	  it	  is	  critical	  to	  assess	  any	  generic	  as	  
well	  as	  drug	  specific	  pattern	  of	  cytokine	  release	  and	  to	  analyse	  this	  in	  an	  unbiased	  manner	  
in	  order	  to	  confirm	  safety	  and/or	  efficacy	  principal	  components	  analysis	  allows	  for	  complex	  
data	  with	  multiple	  groups	  and	  variables	   to	  be	   transformed	   in	   to	  a	  coordinate	  system	  that	  
reveals	   clustering	   of	   groups	   of	   data.	   Principal	   components	   analysis	   confirmed	   that	   for	   17	  
cytokine/chemokine	  readouts	  in	  the	  ANC28	  treated	  BOEC:PBMC	  co-­‐cultures	  group	  clustered	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distinct	   from	   control	   antibodies	   and	   Campath,	   which	   clustered	   away	   from	   control	  
antibodies.	   The	   loadings	   plot	   indicated	   positive	   correlations	   between	   all	   cytokines	   and	  
chemokines	  measured	  as	  a	  source	  of	  variation	  and	  clustering.	  	  
	  
In	   separate	  experiments	   it	   seemed	   logical	   to	   consider	  whether	  mixed	  donor	  BOEC:	  PBMC	  
co-­‐cultures	  gave	  results	  similar	   to	  HUVEC:	  PBMC	  co-­‐cultures	  which	  are	  mixed	  donor	  assay	  
by	   definition,	   and	   compare	   these	   with	   same	   donor	   co-­‐cultures.	   Heterologous	   (or	   mixed	  
donor)	   BOEC:	   PBMC	   co-­‐culture	   assays	   appeared	   to	   give	   more	   variable	   results	   similar	   to	  
HUVEC:	   PBMC	   co-­‐cultures.	   Indeed,	   the	  effect	   of	  mixing	   endothelial	   cells	   and	  PBMCs	   from	  
the	  different	  donors	  has	  been	  reported	  previously	  to	  influence	  immune	  signaling	  (Morris	  et	  
al.,	   1994).	   The	   reason	   for	   variation	   in	   HUVEC:	   PBMC	   co-­‐cultures	   and	   whether	   other	   cell	  
types	  are	  required	  for	  clearer	  responses	  has	  been	  investigated	  (Findlay	  et	  al.,	  2011b).	  It	  has	  
not	   been	   considered	   until	   recently	   (Finco	   et	   al.,	   2014)	   and	   as	   hypothesized	   in	   my	   PhD	  
whether	   this	   is	   due	   to	   mixing	   of	   donors.	   The	   ultimate	   use	   of	   this	   approach	   will	   be	   in	  
personalised	   medicine	   where	   drugs	   can	   be	   tested	   for	   safety	   and	   efficacy	   in	   individual	  
patients	  with	  target	  disease.	  
	  
Using	  BOEC	  to	  phenotype	  patients:	  cPLA2	  function	  in	  endothelial	  cells	  
The	  study	  of	  BOEC	  in	  patients	  with	  cardiovascular	  disease	  and	  cancer	  represents	  an	  exciting	  
area	   of	   research	   that,	   as	  with	   other	   stem	   cell	   research	   programs,	  with	   inevitably	   change	  
how	  we	  treat	  disease	  and	  develop	  personalised	  medicines.	   In	   the	   later	  stage	  of	  my	  PhD,	   I	  
applied	  BOEC	  to	  phenotype	  a	  patient	  with	  a	  rare	  disease	  driven	  by	  a	  mutation	  in	  the	  gene	  
encoding	  cPLA2α.	  This	  served	  not	  only	  to	  support	  the	  rationale	  that	  including	  patient	  specific	  
endothelial	   cells	   in	   bioassays	   allows	   one	   to	   capture	   patient	   specific	   phenotypes,	   but	   also	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address	  important	  questions	  relating	  to	  cPLA2α	  and	  arachidonic	  acid	  pathways	  in	  endothelial	  
cells.	  	  
	  
It	   is	   generally	   accepted	   that	   cPLA2	   is	   the	   dominant	   isoform	   responsible	   for	   prostaglandin	  
production.	   However,	   it	   has	   been	   suggested	   that	   iPLA2	   is	   important	   for	   prostacyclin	  
production	  by	  endothelial	  cells	  on	  vessels	  (Rastogi	  and	  McHowat,	  2009;	  Sharma	  et	  al.,	  2011;	  
Sharma	  et	  al.,	  2010)	  and	  prostaglandin	  production	   in	  cancer	  (Sanchez	  and	  Moreno,	  2002).	  
Given	   the	   reported	   role	   of	   iPLA2	   in	   cancer,	   PLA2	   inhibitor	   drugs	   have	   been	   advocated	   as	  
potentially	  beneficial	   in	  cancer	   (Sharma	  et	  al.,	  2010).	   Indeed,	   it	  will	  be	   important	   that	   the	  
role	   of	   cPLA2	   and	   iPLA2	   in	   cardiovascular	   health	   and	   cancer	   be	   unpicked	   to	   ensure	  
therapeutic	   targeting	   of	   certain	   tissues	   and	   minimal	   side	   effects	   to	   the	   cardiovascular	  
system.	  Using	  BOEC	  derived	  from	  a	  patient	  lacking	  cPLA2	  function,	  I	  was	  able	  to	  show	  that	  
these	  cells,	  unlike	  healthy	  BOEC,	  did	  not	  respond	  to	  thrombin	  to	  release	  prostacyclin.	  This	  
suggests	  that	  the	  pathway	  activated	  by	  thrombin	  results	  in	  activation	  of	  cPLA2	  which	  in	  turn	  
drives	   prostacyclin	   production.	   I	   was	   able	   to	   validate	   these	   findings	   using	   an	   inhibitor	   of	  
cPLA2,	   pyrophenone,	   in	   both	   healthy	   BOEC	   and	   mouse	   thoracic	   aortic	   tissue	   in	   culture.	  
Taken	   together,	   these	   data	   suggested	   that	   cPLA2	   and	   not	   iPLA2	   is	   the	   dominant	   isoform	  
responsible	  for	  the	  production	  of	  prostacyclin	  in	  endothelial	  cells.	  This	  provides	  support	  to	  
the	  idea	  that	  inhibition	  of	  iPLA2	  might	  be	  beneficial	  in	  cancer,	  and	  importantly	  suggests	  that	  
such	   a	   strategy	   might	   not	   result	   in	   cardiovascular	   side	   effects.	   Drugs	   that	   targets	   cPLA2	  
however,	  may	   result	   in	   cardiovascular	   toxicity	   and	   this	  will	   require	   careful	   consideration.	  
Further	  to	  this,	  these	  data	  provide	  a	  proof	  of	  concept	  that	  BOEC	  can	  be	  grown	  from	  patients	  




Summary	  and	  future	  directions	  for	  stem	  cell	  derived	  endothelial	  cells	  
Stem	  cell	  derived	  endothelial	  cells	  have	  tremendous	  potential	  in	  cardiovascular	  research.	  As	  
advocated	   throughout	  my	   thesis,	   the	   characterisation	   of	   any	   stem	   cell	   derived	   cell	   as	   an	  
authentic	  phenotype	  will	  be	  essential	  to	  ensure	  safety	  of	  therapy,	  and	  usefulness	  in	  assays.	  
Such	   characterisation	   can	   also	   reveal	   important	   differences	   in	   key	   pathways	   that	   might	  
advance	   our	   understanding	   of	   disease.	   In	   my	   thesis,	   hESC-­‐EC	   were,	   like	   endothelial	   cells	  
from	  vessels,	  found	  to	  be	  innate	  immune	  replete.	  hESC-­‐EC	  however	  express	  lower	  levels	  of	  
TLR4	  compared	   to	  endothelial	   cells	   from	  vessels	  and	  do	  not	   respond	   to	   the	  TLR4	  agonist,	  
LPS.	   Given	   the	   role	   of	   TLR4	   in	   cardiovascular	   disease	   this	   might	   afford	   these	   cells	   some	  
protection	   from	   inflammation	   when	   used	   therapeutically.	   Indeed,	   cells	   engineered	   to	   be	  
‘TLR4-­‐deficient’	  ‘aligned’	  ‘protective	  hormone	  releasing’	  endothelial	  cells	  may	  one	  day	  be	  a	  
possibility	  and	  useful	   for	   therapy.	  Future	  research	  along	  these	   lines	  could	  also	   lead	  to	   the	  
discovery	   of	   additional	   pathways	   that	   could	   be	   engineered	   in	   vitro	   to	   enhance	   the	  
therapeutic	  application	  of	  stem	  cells.	  
	  
Stem	  cell	  derived	  endothelial	  cells	  when	  studied	  in	  vitro	  will	  also	  improve	  our	  understanding	  
of	  endothelial	  cells	  in	  health	  and	  disease	  and	  enable	  new	  drug	  targets	  to	  be	  identified.	  This	  
is	   true	   for	   all	   avenues	   of	   stem	   cell	   research.	   In	   particular,	   I	   have	   applied	   BOEC	   to	   a	  
pharmacological	   bioassay	   to	   detect	   cytokine	   storm	   responses	   to	   biological	   drugs.	   This	  
bringing	  together	  of	  stem	  cell	  technology	  to	  guide	  biological	  therapy	  is	  a	  powerful	  example	  
of	  the	  applications	  of	  stem	  cell	  derived	  endothelial	  cells	   in	  vitro.	   I	  have	  also	  demonstrated	  
that	  BOEC	  can	  be	  used	  to	  phenotype	  patients	  with	  vascular	  disease,	  thus	  providing	  a	  proof	  
of	  concept	  of	  how	  BOEC	  could	  be	  used	  to	  define	  new	  drugs	  targets	  and	  used	  in	  personalised	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medicine.	   The	   	   application	   of	   stem	   cells	   in	   translational	   research	   and	   their	   clinical	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hESC-­‐EC;	  n=8	  from	  4	  experiments	  in	  duplicate	  
BOEC;	  n=8	  from	  4	  experiments	  in	  duplicate	  
iPS-­‐EC;	  n=2	  from	  1	  pilot	  experiment	  in	  duplicate	  
HUVEC;	  n=8	  from	  4	  experiments	  in	  duplicate	  
HMVEC;	  n=6	  from	  2	  experiments	  in	  duplicate	  
B:	  
hESC-­‐EC;	  n=6	  from	  3	  experiments	  in	  duplicate	  
HUVEC;	  n=6	  from	  3	  experiments	  in	  duplicate	  




hESC-­‐EC;	  n=8	  from	  7	  experiments;	  1	  in	  duplicate	  and	  6	  in	  singlicate	  
BOEC;	  n=8	  from	  6	  experiments;	  4	  in	  duplicate	  and	  2	  in	  singlicate	  
iPSC-­‐EC;	  n=2	  from	  one	  pilot	  experiment	  
HUVEC;	  n=6	  from	  6	  experiments	  in	  singlicate	  
HAEC;	  n=3	  from	  1	  experiment	  in	  singlicate	  
HLF;	  n=2	  from	  1	  experiment	  in	  duplicate	  
	  
Figure	  3.10	  
hESC-­‐EC;	  n=5	  from	  4	  experiments;	  1	  in	  duplicate	  and	  3	  in	  singlicate	  
BOEC;	  n=9	  from	  4	  experiments;	  4	  in	  duplicate	  and	  1	  in	  singlicate	  
iPSC-­‐EC;	  n=2	  from	  one	  pilot	  experiment	  in	  duplicate	  
HMVEC;	  n=5	  from	  3	  experiments;	  2	  in	  duplicate	  and	  1	  in	  singlicate	  
	  
Table	  3.1	  
hESC-­‐EC;	   n=8-­‐10	   from	   5	   experiments	   in	   duplicate;	   PolyIC	   was	   run	   in	   singlicate	   in	   two	  
experiments	  
BOEC;	  n-­‐14	  from	  7	  experiments	  in	  duplicate	  
HMVEC;	  n=4	  from	  2	  experiments	  in	  duplicate	  
iPSC-­‐EC;	  n=2	  from	  one	  experiment	  in	  duplicate	  
	  
Table	  3.2	  
hESC-­‐EC;	  n=6	  from	  3	  experiements	  in	  duplicate	  
BOEC;	  n=6	  from	  3	  experiments	  in	  duplicate	  
iPSC-­‐EC;	  n=2	  from	  one	  experiment	  in	  duplicate	  
HMVEC;	  from	  one	  experiment	  in	  duplicate	  
	  
Table	  3.3	  
hESC-­‐EC;	  n=6	  from	  3	  experiments	  in	  duplicate	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HUVEC;	  n=6	  from	  3	  experiments	  in	  duplicate	  
BOEC;	  n=6	  from	  3	  experiments	  in	  duplicate	  
iPSC-­‐EC;	  n=2	  from	  1	  experiment	  in	  duplicate	  
	  
Figure	  4.1	  –	  4.9	  
hESC-­‐EC;	   n=	   3	   from	   3	   experiments	   in	   duplicate.	   Due	   to	   expense	   of	   the	   MSD	   platform,	  
duplicate	  wells	  were	  combined	  by	  mixing	  and	  added	  as	  singlicate	  samples	  to	  the	  assay	  
HUVEC;	   n=	   3	   from	   3	   experiments	   in	   duplicate.	   Due	   to	   expense	   of	   the	   MSD	   platform,	  
duplicate	  wells	  were	  combined	  by	  mixing	  and	  added	  as	  singlicate	  samples	  to	  the	  assay	  
	  
Figure	  4.10	  
hESC-­‐EC	  TLR4	  and	  TLR4;	  n=3	  from	  3	  experiments	  in	  singlicate	  	  
HUVEC	  TLR4	  and	  TLR4;	  n=3	  from	  3	  experiments	  in	  singlicate	  
hESC-­‐EC	  TLR4	  and	  NOD1;	  n=4	  from	  4	  experiments	  in	  singlicate	  	  
HUVEC	  TLR4	  and	  NOD1;	  n=3	  from	  3	  experiments	  in	  singlicate	  
	  
Figure	  4.12	  
A:	  n=6	  from	  3	  experiments	  in	  duplicate	  
B:	  n=7-­‐8;	   for	  media	  and	  HIN;	  n=	  8	   from	  2	  experiments	   in	   triplicate	  and	  1	   in	  duplicate.	  For	  
C12-­‐iE-­‐DAP	  n=7	  from	  2	  experiments	  in	  duplicate	  and	  1	  in	  triplicate.	  	  
	  
Figure	  4.13	  
Media	  and	  0.1ng/ml;	  n=	  8	   from	  2	  experiments	   in	   triplicate	  and	  1	   in	  duplicate.	  0.01ng/ml;	  
n=6	  from2	  experiments	  in	  duplicate	  
	  
Figure	  4.14	  
N=4	  from	  2	  experiments	  in	  duplicate	  
	  
Figure	  4.15	  
N=4	  from	  2	  experiments	  in	  duplicate	  
	  
Table	  4.1	  
N=3	   from	  experiment	  which	  had	  a	  CXCL8	  profile	  consistent	  with	   that	  of	  pooled	  data.	  This	  
suggests	  the	  effects	  of	  the	  agonists	  tested	  were	  not	  due	  to	  cell	  death	  
	  
Table	  4.2	  
SB203580	  and	  BIRB0796;	  n=4	  from	  4	  experiments	  in	  singlicate.	  	  
SC-­‐514;	  n=3	  from	  3	  experiments	  in	  singlicate	  
	  
Table	  4.3	  
N=3	  from	  one	  pilot	  experiment	  in	  triplicate	  
	  
Figure	  5.1	  
A:	  n=5	  from	  5	  experiments	  in	  singlicate	  






A:	  n=8	  from	  8	  experiments	  in	  singlicate	  




N=3	  from	  one	  pilot	  experiment	  in	  triplicate	  
	  
Figure	  5.4	  –	  5.11	  
N=5	  from	  5	  experiments	  in	  singlecate	  
	  
Figure	  5.12	  –	  5.13	  
N=3	  from	  3	  experiments	  in	  singlicate	  
	  
Table	  5.1	  
N=6	  from	  6	  experiments	  in	  singlicate	  
	  
Figure	  6.3	  
Control	  (healthy	  cells);	  n=2-­‐4	  from	  2-­‐4	  experiments	  in	  singlicate	  
Patient	  cells;	  n=1	  from	  1	  pilot	  experiment	  in	  singlicate	  
	  
Figure	  6.4	  
Healthy;	  n=3	  from	  3	  experiments	  in	  singlicate	  
Patient;	  n=1	  from	  1	  pilot	  experiment	  in	  singlicate	  
	  
Figure	  6.6	  –	  6.7	  
N=4	  from	  4	  experiments	  in	  singlicate	  
	  
Figure	  6.8	  
N=3	  from	  3	  experiments	  in	  singlicate	  
	  
Figure	  6.9	  















APPENDIX	   II:	   Supplementary	   figure	   for	   secondary	   control	  





Supplementary	   Figure	   1.	   Secondary	   control	   antibody	   (Alexa	   Fluor	   594)	   staining	   for	   VE-­‐
cadherin.	   Left;	   blood	   outgrowth	   endothelial	   cells	   (BOEC)	   were	   incubated	   with	   primary	  
antibodies	  for	  VE-­‐cadherin	  followed	  by	  incubation	  with	  secondary	  control	  antibodies	  (Alexa	  
Fluor	  594;	  red).	  Right;	  BOEC	  were	  incubated	  with	  vehicle	  only	  without	  primary	  antibody	  (3%	  
BSA/PBS)	  followed	  by	  incubation	  with	  secondary	  control	  antibody	  (Alexa	  Fluor	  594).	  Images	  
were	  captured	  using	  a	  Cellomics	  VTi	  Arrayscan	  at	  10x	  magnification.	  
